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ABSTRACT
Acute subaraclmoid haemorrhage (SAH) is a devastating event prevalent mostly in adult 
life. The vast majority occur from structural defects on major arteries vdthin the basis 
cerebri called berry aneurysms. Apaid fi’om rare exceptions, there are no definite 
conditions—inherited or acquired—that predispose to these. Sudden death may 
accompany the impact, and up to a half of patients do not reach neui'osurgical units alive.
Of those that do, technical improvements in definitive surgery and interventional radiology 
have largely obviated the risk fi'om secondary haemorrhage. However, a tliird of patients 
sui'viving intact to convalescence instead succumb to another process which mysteriously 
develops with some delay. In spite of considerable efforts, both clinical and experimental, 
there continues to remain no wholly satisfactory account for either the mechanism, or the 
treatment, of the stroke that frequently results. The current consensus, however, is that the 
basic mechanism involves an increasingly severe local aiterial spasm (‘vasospasm’, VSM) 
that causes increasing focal cerebral ischaemia (‘delayed cerebral ischaemia’, DCl); and 
that VSM is caused purely as a result of subarachnoid clot lysis.
Although vessel-smface clot can, experimentally, simulate many of the appearances of 
VSM, such studies (i.e. ‘clot-VSM’ models) rarely elicit DCl. Moreover, none of the 
results of ‘clot-VSM’ studies have led to the development of efficacious treatment 
strategies (apart, that is, from the conti oversial exception of the calcium antagonist 
nimodipine). Such a failuie in extrapolation suggests that either DCl is primarily a species- 
specific phenomenon, or that such models are fundamentally flawed (in either design or 
application). Since most current ‘SAH’ models are in reality only models of VSM 
(i.e.‘clot-VSM’ models), one obvious potential design flaw is their implicit assumption that 
‘VSM = DCr. The fact that, clinically, VSM occurs with twice the frequency of DCl 
might suggest to many that other factors are operative. Such factors could relate to 
generalised reductions in cerebral perfusion pressures, a generalised dysautoregulation 
within the cerebrovasculature, or to electrolyte disturbances. However, they could also 
relate to factors long since forgotten associated with the acute ictus. Such factors could 
conceivably include the central physiological distmbance (i.e. systemic and intracranial 
pressor effects) associated with the acute ictus, as well as the properties of the ruptured 
vessel per se. Perhaps related to both of these would also be the conjectured occurrence of
acute VSM as distinct from delayed VSM. The potential gravity of the central 
physiological distmbance is reflected by the fact that sudden death occurs in up to a half of 
SAH patients; whilst many of the remainder are rendered comatose. By ignoring such 
potentially key ‘early’ factors—and, in consequence, by potentially over-emphasizing the 
importance of later ‘clot-VSM’—the failure of most current ‘SAH’ models in adequately 
accounting for DCl might therefore be potentially explained.
In particular, and as implied by proponents such as Nagai, it is possible that the acute ictus 
‘primes’ the larger basal arteries within the subarachnoid space such that they might be 
more—or even less—susceptible to the later effects of chronic clot lysis. If this is so, then 
an analysis of cerebrovascular reactivity in the acute phase following a physiologically 
representative SAH—an area that has been overwhelmingly under-explored—might 
yield important clues: particularly in the form of subtle differences between post-SAH 
vessels and controls. Such differences, if found, might therefore be a factor in explaining 
why current ‘clot-VSM’ SAH models fail to elicit clinically useful results: because, in such 
latter studies, subarachnoid clot is clnonically applied to vessels that are, in fact, 
indistinguishable from controls. In reality, however, it could be that ‘clot lytic’ effects 
ought to be superimposed upon cerebral vessels that have already been rendered 
significantly different from controls by ‘acute ictal’ effects.
The principle hypothesis of the current study is that events associated with the acute 
ictus of SAH elicit changes in cerebrovascular physio-pharmacology that are 
independent of any subsequent effects of chronic clot lysis. As a result, such changes 
might interact with the effects of chronic clot lysis in a way that may, in consequence, 
ultimately explain why currently favoured ‘clot-VSM’ fail to adequately explain delayed 
VSM and DCl. The principle aim of the current thesis was to formally categorize 
cerebrovascular physio-pharmacological properties in sham and non-operative 
controls, and to compare these with those obtained in the acute period after SAH in a 
model more representative of the true clinical scenario. Clearly, the most ideal SAH 
model would be one in which arterial rupture is created inside a closed skull, since only 
here will the acute intracranial pressure changes be faithfully recreated. Ironically, the 
earliest SAH models came close to such an ideal: nevertheless, all utilized a prior 
craniotomy. More recently, endovascular filament (EF) models have instead gained
credence. Because, in such models, intracranial arterial rupture is created in small animals 
by EF advancement through the intracranial internal carotid artery from an extracranial 
source in the neck, the potential disadvantages associated with a prior craniotomy are 
avoided. However, to date no EF-SAH model has yet been used to study 
cerebrovascular reactivity: this thesis is the first to do so.
Hypothetically, however, two sources of ‘side bias’ potentially thwart the application of 
EF-SAH cerebrovascular study. One source relates to the manipulation and temporary 
ischaemia suffered duiing EF insertion (in particular, with prolonged cai'otid clamping). 
Another relates to relative uncertainty regarding the precise site of intracranial rupture. A 
secondary aim of the thesis, then, was to formally assess the hypothesis that EF-SAH 
introduce procedural ‘side bias’ by comparing cerebrovascular responses ipsilateral 
and contralateral to EF insertion using a range of constrictory and dilatory 
agonists—conceivably all relevant to SAH. The successful exclusion of ‘side bias’ would 
be important to any friture study of delayed (i.e. chronic) VSM because, should any side 
differences be subsequently found in such delayed studies, then these could be attributable 
to focal factors—such as thickened clot lateralization—with somewhat greater confidence.
Another potential flaw with cuii'ent ‘clot-VSM’ models, however, resides not in their 
design but in their application. Thus, many do not use as substrate for cerebrovascular 
study vessels from the anterior cerebral circulation—where both VSM and DCl are most 
frequently apparent. Instead, most choose vessels fr om the posterior circulation: in 
particular, the basilar artery. Fmthermore, many do not appear to restrict study to 
particular' segments of specific arteries, and thus potentially thwart ‘like-with- 
like’comparisons. Most studies also do not quote vessel diameters in relation to sub­
groups and their responses: in this regard, most assume that randomisation for vessel side 
would make up for any ‘size effects’ on vessel responses. And finally, most ignore a 
principle implied by Brandt, that variation in vasoreactivity in individual arteries might be 
discontinuous—and not continuous—and so therefore not amenable to routine statistical 
analysis. It was therefore considered critical in this thesis to assess and limit such 
potentially confounding factors by fully reviewing what is already known about cerebral 
vessels before and after SAH, by critically reviewing all experimental models used to
derive such data, and by assiduously analyzing normal vessel responses in a standard small 
vessel study model before progressing to their ultimate study post-SAH. To this end, 
middle cerebral arteries (MCA) medial to the olfactory tract were analyzed by ‘wire 
myography’.
Whilst the ultimate aim of all DCl research must clearly be in the effects of delayed VSM 
on a post-ictal brain, it is a scientific duty to delineate cerebrovascular reactivity at all 
stages prior to this. Unfortunately, it is not possible to apply the methodology of this 
current thesis to assess all of the 192 hours that pass between the acute ictus and the 
typically delayed start of VSM: instead, restriction of study to a shorter time interval would 
only be possible in one thesis. As a result, the current thesis was restricted to an 
analysis of the first three hours of EF-SAH for the following reasons:
1. To assess the principle hypothesis that events associated with acute SAH elicit changes 
in MCA physio-pharmacology that are independent of any subsequent effects of 
chronic clot lysis
2. To assess the secondary hypothesis that EF-SAH models introduce a procedural ‘side 
bias’ by comparing constrictory and dilatory MCA responses ipsilateral and 
contralateral to EF insertion
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ABBREVIATIONS
AC Adenylate Cyclase
ACommA Anterior communicating artery
ARDS Adult respiratoiy distress syndrome
ATP Adenosine triphosphate
AT Agonist-induced Tone
BBB Blood-Brain Barrier
Ca Calcium
CA Catecholamines
cAMP Cyclic Adenosine-3’, 5’-Monophosphate
CBF Cerebral blood flow; Regional CBF; and Local CBF
CCA Common Car otid Artery
cGMP Cyclic Guanosine-3’, 5’-Monophosphate
CHR Cushing Hypertensive Response
CM Cisterna magna
CMRO2 Cerebral Metabolic rate for Oxygen uptake
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CSF Cerebrospinal Fluid
DCl Delayed Cerebral Ischaemia
D ID Delayed Ischaemic Deficit
DSS Denervation Super-Sensitivity
EC50 Mean Effective concentration producing 50% maximal response (i.e 
response potency or affinity)
eCa ExU^acellular Calcium
ECA External Carotid Arteiy
EDCF Endothelial-derived constricting factor
EDRF Endothelial-derived relaxing factor
EEL External Elastic Lamina
EF Endovascular filament
Emax Efficacy of agonist response (i.e. mean maximal response)
GC Guanylate Cyclase
HA Histamine
H b Haemoglobin
5HT 5-Hydroxy Tryptamine (Serotonin)
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zCa Intracellular Calcium
IC A  Internal Carotid Artery
ICP. Intracranial Pressure.
AICP ICP2-ICP1 where ICP2N CP1 (hence AICP is always positive—i.e. an
elevation) 
lEL Internal Elastic Lamina
/NOS Inducible Nitric Oxide Synthase
K Potassium
L-ARG L-Arginine
L-NAME Nm-Nitro -L-Arginine Methyl Ester
MAP Mean Arterial Pressure
AMAP MAP2-MAP1. MAP2>MAPi (+AMAP) = hypertension, MAP2<MAPi
(-AMAP) = hypotension, MAP2=MAPi (zero) = invariant 
M CA Middle Cerebral artery
M T Myogenic Tone
NE Norepinephrine (Noradrenaline)
NO Nitric Oxide
PGF2a Prostaglandin F2a
PKC Protein Kinase C
PPV Papaverine
PSC Potential specific channel
RSP Reserpine
SAH Subarachnoid Haemorrhage
SAS Subarachnoid Space
SIADH Syndrome of inappropriate anti-diiuetic hormone secretion
SIT Subintimal tliickening
SNP Sodium nitroprusside
SNS Sympathetic Neivous System
UTP Uridine-3’, 5’-triphosphate
Vg Volume of blood extravasated (i.e. extent of SAH)
VSM  Vasospasm
VSMC Vascular Smooth Muscle Cell
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NB
1. The notation [substance] cgp- or [substance] will be used to denote the 
concentration of a substance in either the CSF or plasma respectively.
2. All values for continuous data ar e represented as mean+SE (standai d error of the mean) 
except functional vessel diameters which are represented as meanlSD (standard deviation 
of the mean).
3. Maximal agonist responses will generally be denoted as [substance symbol] Emax, e.g. 
KCl Emax- This is because the maximal response is the efficacy (E). However, sometimes 
the notation will be shortened to [substance synibol]max, e.g. Kmax- Since there is no agonist 
used with a symbol E, no undue problems are envisaged.
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Chapter 1
Historical background. Current theoretical and therapeutic
perspectives
1.1 Introduction
Subarachnoid haemorrhage (SAH) is, in large part, a consequence of the unusual 
anangement of the cerebral vasculature. The usual angiology in an organ involves the 
major arterial supply entering at the hilum, with successive ramification then occmring 
within the organ. The only ‘exposed’ region of the supply is therefore at the hilum, 
although even here extra support is still often afforded. For example, the splenic artery 
gains further protection within the lienorenal ligament; the hepatic arteiy within the lesser 
omentum; and the pulmonary artery within the pulmonary ligament. The cerebral 
vasculature, however, eontiasts in both aspects. Its major supply, fi’om two sources 
bilaterally, ramifies over the surface of the brain prior to entering it; whilst the major 
divisions are poorly protected by little—if any—connective tissue. These somewhat 
exposed cerebral vessels thus pulsate freely within the clear CSF of the subarachnoid space 
(SAS)—the latter providing ambient pressui'es for them of around 12 mmHg^^^: their major 
support, in fact.
To make an already precarious situation somewhat worse, the major cerebral arteries are 
frequently defective in their most structurally important layers: the internal elastic 
lamina^^  ^ and the smooth muscle of the tunica media^ ^^  253,385 fact, the cerebral 
vasculature abounds in all sorts of anomalies^'^’ 3%, 592  ^but it is such 
defects—characteristically occurring at points of bifurcation—that are related to the 
precipitation of acute SAH. Nevertheless, it is not until early adult life (especially over 30 
years253) that problems usually arise: eventually bulges form at such points. Since velocity 
of flow must necessarily slow as the lumen suddenly widens, kinetic energy must also fall. 
Potential energy must therefore increase, in order to compensate: the total energy must be 
conserved. Increased potential energy is absorbed by further increases in wall tension, at 
sites already structurally weakened (Part 2, 1.4.3). Once started, a vicious cycle may thus 
ensue, the bulging wall becoming forever larger. These bulgings ai’e refeiTed to as berry 
aneurysms. Some attempt at compromise is reached by successive clot formation and 
calcification, the result of slower and turbulent sac flow. But eventually the equilibrium 
may fail. Blood at systemic arterial pressure then bursts out into the SAS of the 
craniospinal axis—characteristically following a surge in physical activity '^^’ 315,396
Thus is the case with the single most important cause of SAH: a ruptured berry aneuiysm 
(at least 75% cases^^^). However, numerous other causes also abound, and are listed for
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convenience in Table 1. Some of these, especially arterio-venous malformations (AVMs), 
may strike in adolescence or childhood: but SAH is essentially an affliction of adult life. 
This may possibly relate to increasing levels of MAP^ '^ > Furthermore, SAH frequently 
follows heavy lifting, bending, coughing, straining at stool, head injury, and orgasm at 
coitus^ 396. The common denominator in all of these are acute surges in systolic 
pressure cranially.
Table 1. The causes of SAH_____________________________________________
Common Beny Anemysm
Arterio-venous malformation 
Unknown
Rare Non-saccular aneuiysms 
Atherosclerotic 
Mycotic 
Oncotic 
Dissecting 
Traumatic 
Blood dyscrasias 
Coagulopathy
Disseminated intravascular coagulopathy 
Anticoagulants 
Myeloproliferative disorders 
Drugs 
Vasculopathies
Connective tissue disorder 
Henoch Schonlein purpura 
Rheumatic fever 
Drugs
Amphetamines 
? Anabolic steroids 
Eclampsia
SAH is a serious condition, affecting young and old adults alike, in at least 15 per 
100 000 population'^7' .^ With a demonstrable berry aneuiysm, mpture will occur' in 0.05- 
0.5% per amium*^ '^^ . Although Quincke introduced lumbar punctuie in 1891, the diagnosis 
of SAH was probably rarely made in the patient’s own lifetime until only the latter half of 
this century656. SAH is still, in fact, a notable cause of occult sudden death (Part 6 , 
Section III). Thus, it was responsible for 5% of sudden deaths in one study^^o- this rising to 
18% in a group of young soldiers undergoing strenuous physical activity^?^. Because SAFI 
may be misdiagnosed failing an autopsy, decreased autposy-rates following sudden death 
necessarily under-estimate its true incidence.
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1.1.1 Immediate effects of subarachnoid haemorrhage
Blood at systemic MAP suddenly gushes into the subarachnoid space, where the pressure is 
usually less than 15 mmHg. There is, naturally, a limit to the amount of extra fluid that can 
be suddenly accommodated here—particularly within a rigid cranium. With the brain 
parenchyma itself virtually incompressible, the ICP must suddenly rise. This is probably 
the cause of severe headache: the worst, in fact, of that person’s lifetime396. However, 
because extravasation occui's into the subarachnoid space, the AICP is conducted pari passu 
over the entire parenchymal smTace and major cerebral vessels. Venous and capillary beds 
aie soon shut down^^^>2 i2  ^and transmuml vessel pressures (and functional diameters) are 
effectively reduced. In consequence, the CBF becomes drastically reduced (Part 2, 2.4). 
Brain homeostasis is thus soon compromised, this resulting in an abrupt loss of 
consciousness. Unless the CBF can be quickly restored, brain death will soon follow.
Although the initial SAH can rarely—if ever—be monitored clinically, the effects of a 
secondary haemorrhage have frequently been recorded. Such studies have confirmed the 
above reasoning. Thus, the AICP occurs rapidly over one or two minutes such that ICPmax 
~ MAP^ "^^ ' 453,454,632 Howcver, the volume extravasated (Ve) often bears little relationship 
to the ICPmax^ ^^ ’ 453,561 Thereafter, the ICP soon falls^^  ^to a new plateau within 
minutes, usually only slightly above that of the baseline value^^ ,^ 632^  The bleeding is 
probably stopped by a combination of tamponade and acute spasm in the ruptured artery. 
The CBF falls acutely to critically low levels, before slowly rising to regain previous 
values^This,  however, is sometimes delayed, even where ICP values have normalized*^. 
(Persistently low values, of cour se, invariably result in brain death*^). Widespread 
perfusion defects are prevalent in these latter cases (no-reflow phenomena: NRP*^), and 
resemble those seen following cardiac aixest^^o. in others CBF recovery is rapid, with even 
a temporary overshoot (“hyperaemic overshoot”)360,632 jh is  may prove detrimental, 
serving to disinrpt the BBB as it may also do post cardiac arrest* *5,116,285,36o
Yet other findings appear less explicable. For example, the cerebral blood volume (CBV) 
is frequently increased^'^’^"'^ '^  ^after SAH; whilst cardiac arrhythmias abound in up to 91% of 
cases within 48 hours of SAH* .^ Similarly, a persistent state of cardiac dysfunction may 
pertain, the co-development of ARDS often serving as a harbinger of imminent d e m i s e *  ^ 9
1.1.2 Natural history of subarachnoid haemorrhage
Acute SAH therefore clearly represents a profound pathophysiological insult, causing both 
gross central and systemic derangement. It is all the more suiprising, therefore, that most 
current experimental studies choose to ignore this insult (Part 6, Section III), concentrating 
instead on the effects of the blood clot {see below). Although most statistics naturally 
pertain to survivors, anything up to 40-50%477 may never reach hospital at all, these
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suffering sudden death. Even with recent cases benefiting Jfrom efficient emergency 
services, probably less than 60% of those reaching neur osurgical units alive eventually 
return to normal life^^?.
The natural course in those not operated on is necessarily based upon older studies where 
operation was not available. Most agree that there is a high risk of re-rupture over the 
ensuing six weeks: however, this is highest early on. It is especially high in the first 24-48 
hours following initial rupture, and thereafter falls over the first one or two weeks. It 
becomes less likely over the following four weeks. After this crucial period (i.e. the first 
six weeks), the risk falls dramatically such that it soon approaches 0.5% per amium^^? 
However, there is a progressive increase in mortality with each successive re-rupture^^Q.
Perhaps the majority of patients, then, that survive make at least some degree of recovery. 
They thus enter the critical period of the first six weeks. Their major complaints at this 
time centre around a profound headache and photophobia. The latter, coupled with varying 
degrees of nuchal rigidity, provide evidence of meningeal irritation (meningism). The 
MAP is often elevated, along with a central elevation in core t e m p e r a t u r e *^ 3, sis 
some, a mixed peripheral leucocytosis occurs^^ .^ Many also appear drowsy*^3,396 All of 
these signs may correlate with eventual outcome396  ^but most neurosurgeons especially 
rank the latter^^ As a result, stiict bed rest is frequently encouraged; but this and opiate- 
based analgesia encour age constipation—a potent precipitant of re-ruptuie in many cases 
{see below).
1.2 Delayed cerebral ischaemia
With improved safety in definitive smgery, the excess morbidity and mortality (it was 
hoped) would be largely eradicated. Nevertheless, those sui'viving both primary SAH and 
definitive surgery may still instead succumb to yet another process. In fact, the major 
factor now influencing outcome is attributable to this rather nebulous condition that 
characteristically appears in the post-acute recovery phase3*6. Only recognised as a distinct 
entity since the 1950s, it classically evolves several days after SAH, and is thus referred to 
as Delayed Cerebral Ischaemia (DCl). It results in the formation of Delayed Ischaemic 
Deficits (DID) Like secondary haemorrhage, it often strikes in a patient having initially 
made a complete recovery from the primary episode. Although most prevalent 
synchronous with maximal risk from re-haemorrhage, it contrasts markedly from the latter 
both in being more gradual in evolution; and by the absence of fresh bleeding on a CT 
scan. Drowsiness becomes increasingly heightened, and cerebral infarcts eventually arise 
in the same territory in which rupture had occurred (see below). Such infarcts 
predominantly occur within the internal carotid ai’tery (ICA) territoiy : posterior circulation 
infarcts appear especially rai'e^ ^^
20
It is difficult to put a precise figui'e on the proportion succumbing to this syndrome, there 
being large variations reported (from 5% to 90%!)*34 amongst different series. But in a 
recent overview of 10,445 cases amongst 297 studies'34, DCl occurred in 33%. Its timing 
varied from 2-4 days to over 14 days, but the mean time suggested an onset at around 8 
days after SAH. Thereafter, DCl steadily attained a zenith over 1-4 days; following 
which, should the patient have survived, some degree of recovery was the rule.
Once established, DCl appears to possess the same natural history as that associated with 
any other stroke. Thus, death occurs in 30%, whilst a permanent neurological deficit 
occurs in a further 34%. Ultimately, only 36% achieve a good outcome *34. in 
consequence, DCl often serves to thwart the effort and progress made with early aneurysm 
surgeiy, blighting otherwise promising recoveries. It is hardly surprising, then, that most 
current research in SAH has focussed on DCl.
1.3 Delayed vasospasm
In spite of considerable efforts, the precise cause of DCl continues to remain elusive. This 
is reflected in the relative failure of treatment stiategies over the past 20 years^o, *34. Any 
proposed mechanism must adequately explain the temporal delay in onset of neurological 
deficit. Certain associations have accrued. For example, there is frequently a de novo 
reduction in the CBF prior to the onset of DCl, both globally and regionally^32-224,413,632 
There is also a frequent reduction in cerebral metabolism (reduced CMROa)^^ ’^ ^ 4^,632^  as 
well as reduced arterio-venous oxygen differences (AVD02)^32 across the brain. The TCP, 
where monitored, often shows secondaiy elevation454,632- and the CSF classically reveals 
the presence of a lactic acidosis*95.487,632
But without doubt, the most vivid association—and certainly the most tangible—is that 
found on cerebral angiography. In a landmark paper in 1951, Ecker and Riemenschneider 
documented the angiographic occurrence of severe arterial narrowing occur ring in 
association with recently-ruptured cerebral a n e u r y s m s *46. Since that time, this 
phenomenon—forever after referred to as cerebral vasospasm (VSM)—has become 
increasingly established as playing a major, if not indispensable, role in the development of 
both DCl and DIDs. There are, in fact, several reasons for arriving at this conclusion:
• DIDs suggest that a poor local blood supply (ischaemia) has accrued.
• The severity of the angiographic narrowing often appear s proportionate to both the 
clinical grade and the extent of resultant DIDs<*32.
• The timing of angiospasm fr equently appears concurrent with both clinical and 
radiological onset of DIDs. (In a recent overview, Dorsch and King found that across 
12 series and 481 cases, the mean onset was around 7-8 d a y s *34).
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• The location of VSM is usually close to the aneurysm and normally within the 
vascular territory of infarcted a r e a  *46.
* An increased velocity of flow is characteristically registered on Doppler studies 
concurrent with the onset of DCl (at 7-12 days^^s) in 30% of individuals^^*, this bemg 
assumed reflective of an acute narrowing.
* SAH-CSF is vasoconstrictory (see below)
• SAH-CSF produces equivalent angiospasm and vessel wall pathological change
Thus, the development of VSM appeared inextricably linked with DCl; coinciding both in 
time and space. This is so much the case that, until quite recently, possibly the majority of 
neurosurgeons universally diagnosed “DCl” interchangeably with “VSM” 3^2 yfrig process 
appeared, teleologically, to reflect an extended post-haemorrhagic vascular spasm, that 
served to reduce CBF in an area likely to re-rupture*46. It thus appeared—at least to its 
original discoverers—to reflect a fundamentally protective p h e n o m e n o n * 4 6 .  However, 
even at this stage the authors acknowledged that “unfavourable effects” could accrue when 
VSM was either severe or extensive *46.
The concept of blood vessels going into spasm and causing distal ischaemic necrosis is a 
common one both physiologically and pathologically. For example, a purely physiological 
form occurs in women at the time of the meuses. Here the long spiral arteries of the 
uterine stratum spongiosum develop a functional spasm cyclically eveiy 28 days—tliis 
causing infarction of the inner lining (Part 3, 1.5.3). The latter is then shed through the 
vagina as the next menstrual flow. Another example—occurring both physiologically and 
pathologically—concerns the arterial sphincters of the dermal glomus bodies during 
hypothermia. Here, blood is indiscriminately shunted away from the skin in order to 
prevent unnecessary heat loss during drastic reductions in the ambient temperature. When 
extreme, however, this can result in dermal necrosis, ulceration and in the acropathological 
tissue losses of frostbite^^^.
A pui'ely pathological vasoconstriction and, moreover, one occurring within the 
cerebrovasculature, is that associated with migraine. Here, the aura of the attack may be 
associated with a VSM of larger cerebral arteries winch can be appreciated on angiography. 
Such VSM, however, is normally short-lived. The resultant throbbing headache possibly 
reflects gioss metabolic dilation (Paid 2, 2.5) following the ischaemia necessarily incurred. 
Wliilst probably over-simplistic, the latter mechanism appears particularly attractive in that, 
where excessive, local cerebral infarcts can result (hemiplegic migraine)^  ^589 
Furthermore, the arteries involved may, in long-standing cases, show precisely the same 
changes (medial myonecrosis and SIT, see below) as those seen with VSM^^9. This,
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therefore, hints that fundamentally similar processes may be involved in both pathologies; 
functionally and structurally. Particularly interesting from the point of view of universality 
is the increased fi'equency o f migraine with menstruation, since both conditions 
fundamentally reflect vasoconstrictory phenomena.
VSM following SAH, then, could easily be construed as a ‘percentage error’ of a 
physiological mechanism ‘designed’ to prevent the catastrophe of a secondary 
haemorrhage. Clearly there was a need to know the determinants of VSM’s severity, since 
certainly no other artery after haemorrhage exhibited such sustained c o n t r a c t i o n ^ ^ e ,  527 
Clues were initially sought on histological analysis of such vessels harvested from teiminal 
cases, or from patients dying later from some other complication.
1.3.1 Vasospasm pathology
Pathologically, there was no doubt that the vessels associated with VSM were clearly 
abnormal. This was perhaps a little smprising since, on first principles, such vessels 
ought to represent otherwise normal vessels ‘held’ in a state of sustained spasm^^^. 
Nevertheless, such abnormal vessels certainly corresponded both to the vascular territory of 
the resultant 275  ^ as well as to the region of VSM seen angiographically^^'^’ 265,554
In some studies a positive correlation was demonstrated between the degree of angiospasm 
and the extent o f  D C P ^ ^ ,  362 Furthermore, such changes were little apparent within the first 
week of SAH^^o, 107 all cases, the lumen of vessels with documented angiospasm 
appeared narrowed at fixation relative to controls^^c, 554 Thus, the first major conclusion in 
the study of DCI was that vessels in VSM were definitely not normal. Changes could, in 
fact, be present in all three layers (Part 2, 1.2):
1.3.1.1 Vasospasm pathology: tunica intima
In truth, frank endothelial changes are uncommonly reported in SAH patients: they are 
more frequent in experimental models. Intimai changes may be more frequently infened 
than observed. For example, the presence of contrast-enhancement in close proximity to 
the source of haemorrhage on a CT (computerized tomogram) scan^^^ suggests empirically 
that BBS breakdown has occurred. Since the BBB predominantly relates to the endothelial 
lining, it is assumed ipso facto that there has been a derangement in this layer.
Nevertheless, some authors have reported a denuded endothelium in cerebral vessels after
SAHk 170, 178.
In contrast, there frequently are abnormalities reported in the subintimal layer. In 
particular, a marked corrugation is frequently reported in the internal elastic lamina 
(lEL)^^^’ 465, which resembles the appearance of normal vessels when previously
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constricted^^^. Other abnormalities in the lEL—such as fragmentation or, even, 
duplication—may also be seen in such cases. The major change, however, is that of a sub­
intimal swelling. This has been presumed to be the result of fluid transudation and, 
therefore, a BBB defect^’ 398,584,587. since frank structural endothelial change is a rarity, 
BBB disruption is probably the consequence of a functional abnormality However, the 
appearance of intramural red and white blood cells, in addition to a frankly “oedematous” 
picture, tends to suggest somewhat more than this^?  ^ Later on, subintimal thickening 
(SIT) becomes associated with the apparent migration of cells with staining characteristics 
of m yofibroblasts^^. 555. The latter cells are ordinai'ily encountered with either skin 
wounds healing by second intention, or with vascular tears. As they proliferate, 
myofibroblasts deposit copious amounts of giuimd substance and collagen of varying 
maturity.
1.3.1.2 Vasospasm pathology: tunica media
Although, eai’ly on, a slight thickening in this layer may be appaiunt^^^  ^the outstanding 
featine is eventually one of a gradual decrease in medial thickness, accompanied by 
scattered foci of frank myonecrosis^ 7^0,584,587 many studies, this somewhat 
devastating pictme is lai'gely apparent only in the outer layers of the media^^ .^
1.3.1.3 Vasospasm pathology: tunica adventitia
The major abnormality reported is that of the presence of blood elements in the adventitial 
layer after SAH. It is possible that these could either be in consequence of an inflammatoiy 
response, or the result of their being pressure-driven there at the time of rupture362.
1.3.1.4 Vasospasm pathology: vessel injury
The major changes are therefore SIT, lEL disruption, and medial myonecrosis. This, in 
principle, is quite similar to that which results from vessel injury following a variety of 
stimuli399. It is, however, rather more extensive following SAH, and occurs at some 
distance fr om the rupture site^ <^ .^ In many ways the changes resemble those of 
atherosclerosis399^ and both VSM and atherosclerosis may therefore represent final 
common reparative pathways. Other authorities, however, have likened appearances to an 
endarteritis obliterans similar to that seen with either meningitis or Buerger’s disease^^s. 
Interestingly, experimental models of atheroma have shown that such changes are maximal 
at around 7 days399; this concurs with the timing of SIT observed after endothelial 
denudation469. Such results obviously concur not only with epidemiological estimates in 
VSM timing {see abovey^"^, but also with the intensity of the meningeal inflammatory 
reaction eventually seen^^ .^ The concept of VSM occurring as a consequence of vascular
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“injmy” thus began to materialize (see below)^^^. Some, in fact, have even employed direct 
vascular injury as an experimental model for VSM^^v (Part 4, 2.4)
1.3.1.5 Vasospasm pathology: vasospasm is reversible
Perhaps surprisingly, all pathological changes eventually ameliorate—as both VSM and 
DCI ameliorate—with time. Thus, there is eventually a regression in the degree of SIT 
and, in consequence, an increase in the luminal diameter. Such resolution occurs at any 
time between 2 weeks398,424,669 and 6 months^^s. However, a generally “fibrotic” 
histological picture continues to remain, with collagen deposition apparent in all three 
vascular' layers^^s. Remodelling back to a state of normality may take anything up to two 
years5S4 However, that resolution does eventually pertain underscores that VSM is an 
essentially transient phenomenon. This implies that with other processes, such as 
atheroma, it is merely the persistence of the injurious stimulus that distinguishes it from 
VSM. The fact tirat C-type natriuretic peptide has been shown to inhibit SIT following 
vessel injury—and that it is predominantly present within cerebral vessel 
walls —suggests that CNP could be one possible agent that mediates ultimate 
resolution^
In summary, at a fairly early stage in VSM study, two schools of thought concerning the 
possible mechanism of VSM began to emerge;
• Functional (physiological) factors; unopposed vasoconstriction.
• Structural (anatomical) factors; proliferative angiopathy.
Of course, there were also those already proposing that both schemes were correct^^ .^
1.3.2 Functional spasm
Certain changes—intimai corrugation^^s, 467 and medial myonecrosis^?^—immediately 
appeared to confirm an excessive and unopposed vasoconstriction as the underlying cause 
of VSM. For example, the thickened wall and reduced luminal diameter vividly 
suggested—to some—a state of “frozen” vasoconstriction. Perhaps, then, the rest of the 
pathological changes necessarily followed on from this^? .^ Studies continue, in fact, to 
propose a functional spasm as the fundamental mechanism^?^.
1.3.2.1 Functional spasm: sympathetic tone
An obvious first choice as mediator in this scheme was the sympathetic nervous system 
(SNS)24?o. It had been known for some time that cerebral vessels possessed a fine network 
of such fibres on their adventitiae, sometimes even down to the c a p i l l a r i e s 5 0 4 .  Furthermore, 
an excessive SNS discharge had long been implicated with other systemic 
pathophysiological effects of SAH. For example, the Cushing hypertensive response is
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the consequence of both increased total peripheral resistance^s^^ and increased cardiac 
output2i3 Similarly, following Aschenbrenner and Bodechtal’s first report of 
electrocardiographic changes i n  193821, clear examples of frank cardiac injury became a 
popular subject for case reports following SAH218. Furthermore, catecholamines (CA) 
quickly became connected with this^58,380,485, 602 Ttiat reserpine (RSF) antidepressive pre­
treatment obviated these changes (RSP depletes neuronal CAs producing a functional 
denervation), substantiated the case further still255.
I t  seemed reasonable, therefore, to link such a SNS “storm” with a sustained and, 
ultimately, harmful spasm of cerebral vessels. Certainly, acute bursts of circulating CAs 
can follow abrupt AICPs^58,552. whilst high local CSF CA concentrations have recreated 
both angiographic and pathological VSM?» 669 this regard, some have demonstrated that 
NE accumulates within smooth muscle cells of various organs following previous CA 
o v e r l o a d ? ^ .  462 The characteristic histological finding of sympathetic terminal boutons 
apparently depleted of n e u r o t r a n s m i t t e r ^ ^ ® ’ 483 further corroborates such a SNS “storm”.
The problem with the latter concept is that a continuous state of contraction spanning 
several days from the acute ictus does not appeal’ to be the case64?. Certainly a Tucid 
interval’ usually separates any eai’ly VSM from the delayed VSM associated with DCI 
(although some may disagree^^z). Although VSM may represent an attempt to divert blood 
away from a dangerous area, the concept that it is a direct extension of any acute 
vasospastic process appeal’s somewhat untenable. This is particularly pertinent when one 
considers that tachyphylaxis, as a consequence of agonist-induced desensitization, is rather 
a feature of the CAs acting at adrenoceptors (Part 3, 3.2).
In an alternative scheme, Alksne and Greenhoot suggested, in 1974, that the initial intense 
vasoconstriction might then itself initiate a self-propagating, self-destructive mechanism in 
adjacent cells, as a chain reaction spanning several weeks^. Exactly how this might be 
achieved, however, could not be elaborated upon. Another possible mechanism instead 
proposed that VSM resulted from a gradually-developing Denervation Super-Sensitivity 
(DSS) phenomenon?^ (Part 3, 3.3). Thus, following on from the SNS neuronal ‘burn-out’, 
such a DSS could accrue several days hence2. i^5,162,367,368,435 (Part 3, 3.3).
1.3.2.2 Functional spasm: local effects of the blood clot
Attention soon turned, however to blood, and blood products, as possibly containing the 
appropriate vasoconstrictory stimulus. Blood ectopically located within the usually clear 
CSF had long been implicated as the cause of the irritation^the ‘chemical (aseptic) 
meningitis’ ^ 64,232,288—associated with ‘post SAH meningism’. Similai’ degrees of
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inflammation were also apparent with major vessels after acute bacterial m e n i n g i t i s 489, 
5 9 3 ,6 7 0  or head injuiy^s?, 580 both cases, a comparable VSM may also be seen. That this 
can be non-specific is demonstrated by similar appearances following either the addition of 
talc440 or vessel trauma^?^. However, intracerebral bleeding—whilst presumably causing 
comparable ICP-loading—rarely results in either VSM or DCP?5. In consequence, blood 
ectopically located within the subarachnoid space might serve as a non-specific irritant to 
the exposed vasculature. That blood application could also, however, result in an acute 
vasoconstriction was not shown until 1971, when Echlin demonstrated this 
a n g i o g r a p h i c a l l y i 4 8  Numerous factors subsequently supported an aetiological role for clot 
in VSM:
• The laterality of the VSM: VSM often occurs adjacent to the clot^ ?^> ni, 275.
• The size of the clot often appears proportional to the extent of both VSM and the DCI 
induced. In fact, clot size (assessed by CT scan) is often used as a prognostic 
indicator for VSM development^??» 675.
(Both of these points better fit the localized nature of the VSM in a way that a generalized 
SNS over-response can not).
• Conceivably, a poor washing action of the CSF in the vicinity of the clot might allow 
for sustained agonist effect6i4. The fact that hydrocephalus invariably complicates 
SAH52 might also, as a result of poor CSF drainage, elevate effective agonist 
concentrations (Part 1,2.5).
• Owing to the abnoimal anatomy of the tunica adventitia in cerebral arteries (Part 2,
1.2), agonists have been shown to penetrate the wall more easily from the abluminal 
border^'o 468.
• Blood clot contains most of the agents (e.g. 5HT, NE, and UTP) that are incriminated 
in other vasoconstrictory phenomena, such as with Raynaud’s disease and migraine.
• Blood clot also contains elements known to be associated with sub-intimal proliferative 
phenomena such as platelet-derived growth factor (PDGF). Such agents are known 
to be involved with the formation of similar degrees of SIT in other disease states.
• An abundance of experimental studies has confirmed that the pathological, 
physiological and angiographic featui'es of VSM can be reproduced by the local 
application of autologous blood. That these changes were effectively abolished by RSP 
pre-treatment in the blood-donor implies that the agent required was platelet-borne 
(and therefore possibly 5HT, NE or UTP)584.
• The apparent effectiveness of clot removal in alleviating VSM by i r r i g a t i o n 4 5 ? ,  
f i b r i n o l y s i s ^ 23,540 qj- F y  operation425,465,526,570 implicates the clot as the major offender.
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# Conceivably, the application of thick clot to the precaiious adventitia may interfere 
with vessel wall metabolism^^^, 5 4 8 ,6 7 6  (Pait 2,1.2).
In summaiy, an abundance of evidence appear ed to correlate VSM directly to the presence 
of CSF clot. In fact, to many authors, subarachnoid clot continues to represent the conditio 
sine qua non of VSM and DCF39. Certainly, the presence of subarachnoid clot satisfies 
two minimal requirements in causing cerebral vasoconstriction observable 
angiographically, and in causing a representative vessel morphological change.
It is worth mentioning, however, that VSM can occur' in the presence of clear CSF^is, 265 
Although rarely reported, such occurrences must be awarded due regard when attempting 
to delineate the mechanism involved. Furthermore, almost all of the above points have, 
over the years, suffered some degree of detriment under the scrutiny of closer re­
examination. For example, VSM may not always correspond to the site of the clot, and any 
prognostication based upon its size is often erroneous^^o, 583 n  jg questionable that a major 
source of nutrition derives from the CSF^^s, whilst agonists are frequently more effective 
zM/rnluminally than ex tr a-luminally^^^. Moreover, the vessel wall itself metabolizes many 
agonists, and a persistent supply could, conceivably, be quite easily metabolized^*^. 
Following clot removal, both VSM and vessel morphological change can continue on 
unabated^; whilst non-physiological doses of catecholamines alone can cause a 
myonecrosis and a widespread meningeal fibrosis?.
1.3.3 Structural spasm: proliferative angiopathy
By 1974, the importance of the structural changes in the vessel wall had begun to be 
stressed?. Not only important as a possible manifestation of generalized inflammation, the 
extensive cellular-proliferative and noncellular changes gradually became accepted in their 
ovm right as possibly being causal to VSM and DCM Thus, proliferative change can 
result in a non-compiiant fixity of contracted staters. *oo, 668 gy resultant loss of 
normal elasticity at normal pressui'es—it was argued—the necessarily the less would be the 
effective functional diameter^s. In fact it has been estimated that by the latter mechanism, 
such a reduction in effective luminal diameter could amount to anytliing up to 40% fi'om 
that of normal*9*. This, of course, bears strikingly close agreement to that seen 
a n g i o g r a p h i c a l l y 5 S 4  Furthermore, increased rigidity has been shown to be present even 
upon the total abolition of all myogenic tone from the vessel walP26. Thus, it may be that 
the ‘aseptic meningitis’ principle is in fact the more important one; with inflammatory 
changes throughout the subarachnoid space affecting the mechanical properties of the 
major cerebral vessels^^ Such reasoning explains several short-comings of the 
“vasoconstrictor” hypothesis:
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•  The decreased number o f  vascular smooth muscle cells (VSM Cs) in the timica media 
o f  vessels in VSM  suggests that such a vessel would be less able to maintain 
vasoconstriction: this is directly evidenced by studies that have demonstrated reduced
contractile responses^^, 289,472,598.
•  The migratory cells present in the subintima as part o f  the process o f  VSM  resemble the 
myofibroblasts seen in wounds healing by second intention. The latter function to 
contract and then bold together the margins o f  the wound, by the deposition o f a 
collagen matrix?^» 554 The presence o f  these cells could easily explain VSM.
• Although, without doubt, SAH-CSF samples are definitely vasoconstrictory5?» 64^  the 
vasoconstrictory profile does not correspond temporally to either VSM  or DCI52?. 
However, SAH-CSF can promote the transition o f  SMCs to myofibroblasts, at least 
in tissue culture^^s. This suggests that a proliferative angiopathy might predominate.
• Many studies have demonstrated a distinct lack of efficacy o f common vasodilators to 
reverse VSM623.655.
•  The apparent effectiveness of trans-luminal angioplasty (TLA) in the treatment o f  
VSM  and DCI is a strong argument in favour o f  the fact that the major 
pathophysiological change is that o f  a vessel wall ‘fibrosis’449.
•  A  myonecrosis can occur without a persistent vasoconstriction having been in 
evidence?. This is so where no intimai corrugations were in evidence following 
application o f  blood, 5HT and barium chloride^^s.
•  There is abimdant evidence that has demonstrated immunological change with in the 
vessel wall. Thus, there is leucocyte adherence at sites o f  intimai conugatioM^^, 
endothelial expression o f  intercellular adhesion molecule 1 (IC AM-1) 3^5, and class II 
antigens, and the presenee o f  interleukin 1 (IL-1) within the vessel wall555. hr 
particular, myonecrosis has been shown to be associated with an immunopathy235 for 
which cytokines have been heavily implicated?94-206 Furthermore, there is evidence o f  
a generalized systemic inflammatory reaction, with systemic activation o f  
complement439 and a peripheral leucocytosis^^s.
Nevertheless, vasodilator therapy— paiticularty when given locally— can successfully  
reverse angiospasm in approximately 50% cases^^o. In fact, there has been a recent 
renaissance in local papaverine therapy-particularly at angiography^^» 102, 319, 400, 60s, 622 
Furthermore, an increased rigidity per se does not rule out a functional constriction in 
aetiology, since the latter can be a feature o f  other diseases also characterized by persistent 
constriction (such as Hirschprimg’s disease o f  the rectosigmoid— Part 2, 3.4). Moreover, 
the aforementioned Toss o f  elasticity’ principle cannot adequately explain reduced 
diameters in cerebral arteries because the development o f  myogenic tone to distension
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would tend to offset elastic distension (Part 2, 2.2). In consequence, a proliferative 
angiopathy may not successfully explain every case of VSM or DCI. Instead, a 
combination of factors may be implied.
1,4 Red blood cell lysis and free radicals
The effects of subarachnoid clot continue to appear integral, in the majority of cases, to the 
development of VSM. Several constituents of the clot may contribute in this fasliion. The 
contribution of platelets (containing NE, 5HT, UTP and PDGF) have already been alluded 
to. Most current hypotheses on VSM, however, concentrate upon the effects of red blood 
cells (RBC) and their contained haemoglobin (Hb). In particular, they centre upon the 
effects of substances released by RBC lysis over ensuing days.
1.4.1 Haemoglobin and its derivatives: contractile effects
Initially, the oxyhaemoglobin (HbOi) released after SAH becomes desatuiated and, within 
a first few hours, deoxyhaemoglobin begins to accumulate. The process is probably 
complete within about 72 hours, but this clearly depends upon clot size. That both agents 
can potentially cause cerebral arterial constriction was initially an exciting discovery *48; 
unfortunately, contractile effects appear greater in animals than in humans^ **?. Hb/HbOi 
can cause vasoconstriction directly by P I P 2  activation and the release of I P 3  (Pard 2, 3.5.2): 
however, this is probably more slower than with other agonists. Nevertheless, the 
contraction can be a prolonged one, spanning several d a y s  *^6 Hb/HbOi can also inhibit 
the transfer of EDRF^^ô by extracellular scavenging of NO (Paid 3, 1.8). Perhaps the 
major mechanism of Hb/HbO] action, however, involves the enhancement (or the de novo 
release) of other agonists, from the vessel wall. Thus, Hb/HbOz can release endothelial 
prostanoids *^** and stimulate endothelin b i o s y n t h e s i s 4 6 6 .  Hb/HbOz can also potentiate the 
activity of other agonists^?^; for example, it directly potentiates a 5HT c o n s t r i e t i o n ^  *^ 3 3 8 ,  
650 as well as that of NE and PGF2a3*6,338 (although in all three cases only with intact 
endothelia). Therefore, several of these mechanisms show that Hb/HbOi particularly 
works by the enhancement of pre-existing vascular tone
1.4.2 Free radical formation
With prolonged application of Hb/HbOi, however, different variables arise. Hb/Hb02 is 
eventually decomposed into methaemoglobin (methHb) over several days. Not only is the 
latter prolonged exposure related to the prolonged production of eicosanoids, it is also 
related to increased release and activity of free radicals. The problem is that when Hb02 is 
converted to methHb superoxide anion is fonned423. This, in turn, either directly (or 
indirectly via hydroxyl ion, singlet oxygen, or alkoyl radical) initiates free radical 
reactions, such as the peroxidation of polyunsaturated fatty acids (PUFAs) within the 
b i o m e m b r a n e 5 2 7 .  Furtheimore, some degradation products of Hb such as haematin, iron
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ions and metHb, in turn powerfully catalyze PUFAs to their peroxide forms (hydro- and 
endo-peroxides); and nearby leucocytes also release superoxides^??. Thus, the degradation 
of Hb is instrumental to the release of many deleterious agents.
1.4.3 Vasospasm as a deficiency syndrome
Normally, however, superoxide dismutase (SOD) converts superoxide to H2O2 , which is 
then inactivated by either glutathione peroxidase or catalase^^?. SOD, glutathione 
peroxidase and catalase aie all anti-oxidants, and tend to stabilize membranes which have 
been exposed to free radicals in a fashion similar to that with either NADPH or vitamin E. 
They thus function as free radical scavengers. Anti-oxidants are normally present in 
significant concentrations within the serum and parenchyma of body tissues, but for some 
unknown reason appear particularly sparse centrally^??, hi fact, vitamin E and catalase are 
undetectable in the CSF, whilst glutathione peroxidase is barely detectable at alP??. Some, 
then, have proffered the interesting concept that VSM may be a consequence of such 
central deficiency of anti-oxidants, the detiimental effects of blood degradation being 
poorly contained here^^?. Such effects can be appreciated with the cellular damage 
apparent in hereditary acatalasia*6*. However, CSF anti-oxidant concentrations usually rise 
after SAH and, indeed, some have demonstrated that the cytokines so liberated by SAH 
(especially IL-1 and TNF) fruther induce their e x p r e s s i o n ^ ^ s .  in addition, glucose-6- 
phosphate dehydrogenase (G6PD) is also increased?**, whilst many patients with acatalasia 
experience no untoward consequences tliroughout their entire lives*^*.
Nevertheless, lowered basal anti-oxidant levels (or interference by iron complexes within 
the vessel wall) may conceivably allow superoxide or H2O2 to produce singlet oxygen or 
hydroxyl ion via the Haber-Weiss reaction^^?. Superoxide also reacts with PUFA- 
hydroperoxides (impurities) to form the alkoyl radical. All of these free radicals combine 
with PUFAs to produce organic (free fatty acid) radicals which react with O2 to produce 
lipid peroxides—thus producing a chain of lipid peroxidation. Lipid peroxides can cause 
both a potent vasoconstriction and, ultimately, endothelial dismption^^?.
Thus, a large number of potentially deleterious agents accumulate several days after Hb 
degradation. Additionally, some have found significant levels of detergent-like ampiphiles 
(such as lyosophosphatidylcholine) peaking at around 10 days: these are very effective at 
damaging membranes (paiticularly myelinated ones)*43. Furthermore, aracliidonic acid 
itself also causes detergent-like effects^ ^ ^ . This is important because not only do 
detergents threaten endothelial breakdown, they also cause v a s o c o n s t r i c t i o n ^ ^ ,  320,321 ■ 
this being necessarily delayed. Both vascular damage and vasoconstriction may therefore 
be explained by the effects of clot lysis over ensuing days.
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1.5 Caveat: Vasospasm qua delayed cerebral ischaemia?
The structural-functional debate over the mechanism of VSM has somewhat detracted 
attention away from questioning the place of VSM qua DCI. Indeed, anecdotal clinical 
evidence has increasingly questioned this association. In a recent overview of 13,490 cases 
(across 223 studies) by Dorsch and King*34, 43% of patients overall developed VSM. This 
frgui'e, although quite close to that of DCI (33%), is still in excess of it. However, studies 
that have additionally focussed angiography into the second week after SAH (2738 cases 
across 38 studies) have inadvertently increased the proportion to 6 7 % * 3 4 .  Thus, although 
the initial figure for VSM more closely resembled that of DCI, this may have been due to a 
gross under-reporting in angiograpliic documentation.
The importance of correct timing in angiography (i.e. into the second week) has previously 
been stressed^^s. Some have even—somewhat rashly—extrapolated the conclusion that 
daily angiographic studies would reveal that the proportion developing VSM approaches 
100% *.653. Nevertheless, since the majority appear to develop VSM at the begimiing of the 
second w e e k  *34, it would seem likely that studies based on a single first-week angiogram 
have inadvertently lowered the true estimate. Under-reporting could, of course, also be 
applied to DCI figures tending to restore the initial association. In fact, a whole range of 
confounding factors could thwart statistical analysis in these matters. These would include 
the lack of agreed narrowing considered representative of angiospasm; and the frequency of 
excluding groups from study (especially those of poor clinical grade).
Nevertheless, the best data available tends to support anecdotal clinical impressions that 
VSM does not invariably equate with DCI*?**—VSM appears the more common. 
Moreover, whilst most experimental models have successfttlly demonstrated a comparable 
VSM few, if any, have managed to recreate a corresponding DID, This may just be 
because only VSM of a certain degree causes DCI, as Ecker and Reimenschneider 
originally p o s t u l a t e d * 4 6 .  The latter is suggested in some studies that have demonstrated a 
correlation between severity of narrowing and DCI632. However, perhaps a more sensible 
policy is to accept that other factors may contribute to the effects of VSM to appear 
collectively responsible for DCI4*3, To emphasize this, there have been repeated 
appellations in recent times to clearly dichotomize VSM and DCI, and to cease the 
hitherto practice of using both terms i n t e r c h a n g e a b l y 4 * * 9 .
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Chapter 2 
Contributory factors to delayed cerebral ischaemia
2.1 Introduction
Several factors may contribute toward DCI development. When considered pmely as an 
ischaemic phenomenon, the most important would be the effective circulatory delivery of 
oxygen and glucose to the cerebral parenchyma. Assuming adequate lung function, this 
depends upon the cerebral perfusion pressure, (CPP). This is the mean aiterial pressure 
minus the intracranial pressure:
CPP = [MAP] -  [ICP]
2.2 Gradually decreasing cerebral blood flow
The acute falls in CBF (Part 1, 1.1.1) experienced with the acute ictus usually quickly 
recover *8» 222-224,454. However, secondary falls in CBF may follow in the ensuing days^^ .^ 
One cause is certainly cardiogenic dysfunction. The latter seems distinct from that which 
causes arrhythmias in the immediate post-SAH period^^i, and may eventually prove 
terminal not only for the patient but also for any potential recipient, should transplantation 
subsequently take place. In fact, donor heart dysfunction is a major scourge of cardiac 
transplantation, often occurring along with ARDS458-461, 552
Nevertheless, a gradually decreasing CBF may occur without any overt cardiovascular 
dysfunction, this being a peculiar feature of SAH. In documenting this fact, Meyer and his 
colleagues assessed CBF in the post-SAH period by the use of the *33Xe inhalational 
method4*3. fo a now classical study, they demonstrated the astonishing fact that the global 
CBF gradually falls in all cases following acute SAH during the first two weeks, this 
occurring as a secondary phenomenon over that of the acute episode^*^. This fall was 
particulai'iy greater in patients in the poorer clinical grades and with older age, and 
tended to reach its nadir at around 14 days post ictus. Thereafter it gradually commenced 
its rise back up to normal values^* .^ Similai' findings have been reported by others^^?. 
Clearly, this mysterious process will only serve to worsen any relative ischaemia already 
being experienced at local levels (i.e. VSM)^^^.
The precise cause of this confoimding process may, however, vaiy between individuals. 
For example, in addition to possible cardiac causes, hypothyroidism (which may be in 
evidence in up to 45% patients following SAFU? )^ is associated with a definite decrease in 
circulating v o lu m e^ ^ ^  Since some 23% may also suffer Adreno-corticotrophin hormone 
depletion after SAH^?  ^this factor may become ever more important. Furthermore, many
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patients in this condition appear decidedly drowsy*63= 396^  and slow wave sleep is associated 
with significant CBF reductions^*?» 663. But it is the disturbances in plasma sodium levels, 
and their associated syndromes, which appear particularly linked to this process {see 
helow).
2.3 Decreased cerebral metabolism
The insidious development of global cerebral hypoperfusion is often accompanied by a 
diminution in cerebral m e t a b o l i s m * ^ 3 2 - 2 2 4  (Part 1, 1.2). The two processes are, of course, 
directly linked, this denoting metabolic regulation^* * (Part 2, 2.5). It is uncertain which of 
the two processes represents the primary disturbance. Some studies have shown that the 
reduction in the CMRO2 after SAH is in excess of the CBF. This indicates global “luxury 
perfusion”—a CBF in excess of apparent requirements. Luxury perfusion is more 
apparent in the better clinical grades632 The correlation between a poor CMRO2 and a 
poor CBF is much closer in the poorer clinical grades632. Perhaps, then, the fall in the 
CMRO2 is the primary distmbance—the fall in CBF merely following on. Certainly the 
frequent drowsiness seen396^  the frequently retarded electro-encephelogram, the observed 
reductions in A - V D O 2632,  and a CSF lactic a c i d o s i s ‘^ 5,4 8 7 , 6 3 2  perhaps tend to support the 
view that the primary disturbance is with cerebral metabolism. Nevertheless, there is 
ample evidence that the circulating volume is frequently reduced after SAH559^  {see below).
2.4 Electrolyte disturbance
Disturbances in plasma sodium levels frequently occur in the post-SAH period. Their 
importance resides not only in their frequent association with the onset of DCI, but also in 
the way they are treated. Although the predominant cause of hyponatraemia was formerly 
held to be the syndrome of inappropriate anti-diuretic hormone (SIADH) secretion, this is 
probably the rarer cause283,448,646 Thus, the major causes of both hypo- and hyper- 
natraemia involve a relative loss of circulating volume, therefore linking in with the 
process of Meyer a b o v e * * 3 . In support of this, more than one study has shown evidence of 
lowered central venous pressures (CVPs) indicating lower circulating volumes553, one also 
showing increased plasma levels of atrial natriuretic factor concurrent with reductions in 
ADH283.
2.4.1 Hypernatraemia
This is most often due to a failure of posterior pituitary secretion of ADH. It results in the 
loss of excess water in the urine (Diabetes Insipidus), and a decrease in the circulating 
volume. It is therefore associated with an increased plasma osmolality and increased 
viscosity. In the former capacity it may offset cerebral oedema formation, but in the latter 
capacity it may worsen any ischaemia whilst also promoting intravascular coagulation. A
34
massive depletion in this agent often accompanies the agonal period of brain death, so 
much that ADH administiution is often required to restore circulatory stability, particularly 
pending a potential transplantation^^?.
Table 2 Contributory factors to the development of DCI
Pulmonary dysfunction
1. Central factors
Decreased conscious level 
Direct brainstem factors
2. Pulmonary factors
Pneumonia - decreased conscious level 
ARDS
Cardiac failure
Cardiovascular dysfunction
1. Circulating volume
Decreasing CBF
Natriuresis
Hypothyioidism
Ant pituitaiy dysflmction
Diuretics - antihypertensives
Fluid overload - SIADFI
Hypervolaemic hypertensive therapy
2. Cardiac Function.
Acute dysfunction - catecholamines 
Chronic dysfunction - others 
Hypervolaemic hypertensive therapy
3. Systemic blood pressure
Hypervolaemic hypertensive therapy
Cerebrovascular dysfunction
1. Dysautoregulation
2. Diminished CO2 regulation (and /.metabolic regulation)
3. Hypervolaemic hypertensive therapy
Hydrocephalus
2.4.2 Hyponatraemia
This is often synonymous with plasma hypo-osmolality since [Na+]piasma the major 
determinant of the latter^^. Hypo-osmolality thi'eatens cerebral oedema formation. It is 
most likely due to the secretion of a natriuretic factor possibly from the CNS i t s e l f * 3 3 , 646 
It is thus often referred to as the syndrome of Cerebral Salt Wasting (CSW). It results in 
the excess loss of salt and water from the body and in a decreased circulating volume553. 
Numerous substances liberate atrial natriuretic peptide (ANP) such as catecholamines,
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endothelin and calcitonin gene related p o l y p e t i d e ? * * 0 ; whilst calcium channel blockers 
inhibit ANP^i^. The fact that there are increased circulating catecholamine levels five days 
after SAH may be relevant in this setting*^  ^ Interestingly, the most recent member of the 
natriuretic peptide family, C-type natriuretic peptide (CNP), is most frequently found 
within the CNS. This agent may have especial relevance to VSM since it decreases 
myoproliferation within the vessel wall*^ .^ Thus, it is conceivable that CNP remodels the 
structural changes wrought by acute SAH (Part 1, 1.3.1.5); in addition to explaining why 
hyponatraemia occurs as a side effect from the second week onwards.
SIADH, by encouraging excess water-retention at the distal renal tubule, will cause the 
opposite effect. Thus, a significant prevalence of SIADH would be expected to inversely 
relate to the ‘Meyer’ effect. However, both SIADH and CSW may contribute to the 
worsening of DIDs by diminishing plasma osmolality and, thus, by encouraging 
osmotically-driven cerebral oedema. It is important to exclude the (probably) rarer SIADH 
as a cause for hyponatraemia, since the treatment here is primarily one of fluid restriction. 
As aformentioned, the majority of patients after SAH develop a relative cerebral 
hypoperfusion: fluid restriction could, thus, prove calamitous.
2.5 Hydrocephalus
Although the AICP experienced acutely after SAH soon falls to near-normal levels, there is 
often a secondary rise that commences some hours (or even days) later?^ ?» 453 q  jg 
important that the cause of this AICP be documented since this may not necessarily be due 
to hydrocephalus. For example, Hayashi et al—whilst noting that patients with poorer 
clinical grades tended to have higher ICPs—concluded that this resulted from a 
dysautoregulation and a subsequent cerebrovascular paralysis?^?. Nornes and Magnaes had 
also previously noted the latter which, when acute and severe, often served as a harbinger 
of récurrent haemorrhage453.
Neveidheless, hydrocephalus fi-equendy does complicate acute SAH. This may be purely 
obstructive, the result of thick basal clot disrupting CSF flow; but it may also be 
‘communicating’ and develop after some days. The latter is most likely the result of a 
relative failure of normal CSF outflow mechanisms via the arachnoid granulations. The 
mechanism is often held to relate to blood debris plugging the CSF outlet: however, this 
may be far too simplistic. For example, in Cushing’s studies, mercury globules released 
into the CSF easily found their way across this barrier (Part 6, Section I, 1.4.2). Returning 
to the “irritative” principle of ectopic blood^^^» 232  ^inflammatory changes have been 
observed to red blood cells trapped in arachnoid villi one week after experimental SAH543. 
That an inflammatory component may be involved is further suggested by the improvement
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in hydrocephalus with low dose methylprednisolone^^o. The risk of hydrocephalus appears 
greater with a larger amount of clot.
Notwithstanding the precise cause. Black has estimated that the majority (70%) of patients 
experience some degree of HC following SAH^^; others concur^^z. However, in only 15- 
20% does a state of “normal pressui'e” hydrocephalus (NPH) eventually supervene as a 
chronic p r o b l e m ^ ^ .  By increasing still further the ICP, the effective CPP is reduced with 
hydrocephalus, this aggravating fuifher any CBF compromise that is already extant. But 
hydrocephalus may be doubly harmful where it relates to diminished CSF drainage, since 
this will result in an increased effective spasmogen concentration, with increased risk of 
VSM.
2.6 Cerebrovascular dysfunction
This has already been alluded to in the previous section. Several non-invasive studies of 
CBF have demonstrated anomalies in both auto- and metabolic- regulation at the time of 
D C p 2 2 - 2 2 4 ,257,453 sincc both proccsses are crucial to matching CBF with metabolic 
requirements, such disturbances may both prove critical under even normal circumstances. 
However, they would cleaiiy seive to amplify any disturbance that has already occuired in 
regional CBF as a result of VSM.
Although the two processes are entirely different in the way that they affect CBF 
regulation, metabolic regulation is often confused with autoregulation in the literature, 
C02-regulation often being referred to as ‘C02-autoregulation’2S9. Their differences, 
however, become even more apparent pathologically, since one is often affected more than 
the other. Thus, whilst autoregulation may be lost early*?**, and be globally impaired 
irr espective of the clinical grade^^ ,^ alterations in CO2 regulation are usually more mild 
and local, and correlate more closely with clinical grade590,632. fo consequence, 
metabolic regulation appears somewhat more robust*^*5. This is perhaps not too surprising, 
since metabolic regulation is a basic one—and absolutely essential for survival. For 
example, the tissue acidity seen around the time of DCI should result in a paralysis of 
pressure autoregulation*^^, this representing at least one possible mechanism for 
dysautoregulation after SAH. It is also possible, however, that SAH may dismpt both 
autoregulation and metabolic regulation, since both are similarly affected after cerebral 
i s c h a e m i a ^ ^ 5  Clearly, a failure in both may significantly contribute to a failure of ‘supply’ 
to satisfy ‘demand’.
2.7 Summary
Those sinviving either primary or secondary SAH may still succumb to the syndrome of 
Delayed Cerebral Ischaemia. The cause of this has, ever since its original discovery, been
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considered due to a vasospasm of major cerebral arteries associated with the clot. 
However, since DCI is probably much less common than VSM, the latter must either be 
particularly severe or be associated with other factors, in order to result in DIDs. Such 
factors could include global reductions in CPP—in turn related to decreases in global CBF 
and increases in ICP—since these both occur in the majority of patients. Cerebrovascular 
dysautoregulation and altered plasma osmolality could also contribute. The cause of VSM 
itself is divided between those believing in a persistent vasoconstriction, and those 
believing in a proliferative angiopathy shrinking the vessel as in a wound healing by 
second intention. In the following chapter we will review various treatment policies that 
have been devised to combat some or all of the aforementioned and putative contributor 
factors, and discuss their relative efficacy.
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Chapter 3 
Treatment policies for delayed cerebral ischaemia
General
Circulating Volume Hypervolaemia 
Hydrocephalus External ventricular drain
Specific
F unctional V asodilation
Structural Transluminal Angioplasty
Blood clot Clot removal
Free radicals Antioxidants
3.1 General treatment policies
Certain basic aspects of management such as optimization of oxygenation, analgesia, 
laxatives, and shade from bright lights, will all be assumed. This section is a necessarily 
brief review of treatments designed specifically to combat DCI and VSM.
3.1.1 Hypervolaemic hypertensive therapy (HHT)
In view of the findings presented in Part 1, 2.1 above, hypervolaemic hypertension would 
seem a sensible, albeit empirical, policy. Yet in spite of probable widespread use over 
several years, broad statistical analysis has failed to show that it has had any obvious 
influence on either morbidity or mortality?**» *?4 Some have advocated that HHT actually 
works by principally improving haemorrheology via decreased viscosity: particularly 
when Dextran is used as an expanding agent. However, one can identify several areas 
where HHT may prove counter-productive:
• Given the prevalence of dysautoregulation post SAH, high levels of MAP may threaten 
oedema formation and, possibly, capillary damage* *5,285,360
• Unless early surgery is undertaken, such therapy risks re-mptmo.
• There is a high risk of cai'diac an'hythmias in the eai’ly post-SAH period. In patients in 
the poorer clinical grades, with high circulating catecholamine levels, this may become 
associated with a frankly dysfunctioning heart. “Donor heart dysfunction” is a major 
cause of subsequently failed heart transplants in patients dying of brain-stem deatM^s- 
461,548; a high fluid load here risks exacerbating this state.
• An abnormal Teakiness’ of the pulmonaiy microvasculatm'e—resulting in 
ARDS—complicates a certain proportion post SAH.
• A state of fluid overload can accompany volume expansion with SIADH.
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• Many patients develop SAH in older age where there are ordinarily higher risks of both 
cardiac and cerebrovascular disease.
3.1.2 External ventricular drain
From first principles, it would seem sensible to reduce the ambient ICP in order to facilitate 
a greater CPP. This may be paiticularly the case around DCI, where global falls in CBF 
appear concurrent with secondary AICPs. Because of the nature of the fluid to be drained 
(contaminated as it is with blood and proteinaceous debris) a standard ventriculo-peritoneal 
shunt would be unwise, given the risk of coagulum obstruction. Fmthermore, as only a 
small proportion of patients subsequently proceed to develop NPH, a non-permanent 
procedure would seem even more justified. Some have demonstrated clinical improvement 
by the use of an external ventricular drain^^?. Against this, however, must be balanced the 
risk of precipitating secondary haemorrhage in consequence of increased pressure- 
differentials across the sac walB^ ?» 632. Furthermore, infection also becomes an ever­
present risk, particularly after 5 days. This is precisely the time when both VSM and DCI 
are likely to materialize. As a result, EVD insertion could profitably be deferred until the 
end of the first week.
3.2 Specific treatment policies
3.2.1 Systemic vasodilation
Early attempts to influence VSM centred upon reversing a supposed vasoconstriction.
Thus, drugs used to treat conditions such as Raynaud’s phenomenon were initially 
considered: Table 3 lists some of those commonly tried. The use of CO2 i n h a l a t i o n 4 3 6  was 
probably more theoretical than practical: for example, it would be contraindicated with 
pulmonary dysfunction. Furthermore, as we have already seen, metabolic regulation is 
often disturbed after SAH—particularly in the poorer grades, where both VSM and DCI are 
more likely. Nimodipine was originally developed as a calcium channel blocker, with 
vasodilatory action specific to the cerebrovasculature: however, it is likely that other of its 
effects are more pertinent in the sphere of DCI {see below).
The major problem with all vasodilators, when given systemically, is that they all risk CBF 
compromise by virtue of induced systemic hypotension. Whilst MAP values of 65 mmHg 
may not ordinarily be a problem??^, the dysautoregulation apparent after SAH {see above) 
renders such hypotension problematic. This should rarely apply to nimodipine, however, 
since its action is specific to the cerebrovasculature: but it is an ever-present risk with PPV 
or SNP. Furthermore, systemic vasodilators dilate the cerebrovasculature indiscriminately: 
as a result, they risk vascular “steal” fiom areas not able to respond—such as vessels in 
the region of VSM (Part 6, Section II, 3.7).
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3.2.2 Local vasodilation
Because of the risks associated with systemic hypotension, there has been an increase in the 
use of local therapy in order to obviate systemic side effects. Although most of the drugs 
listed in 3.2.1 above could be applied, in practice only PPV tends to be given. This can be 
administered extraluminally via an in-dwelling catheter exteriorized following 
craniotomy?*^, or intraluminally via the catheter used at angiography. Encouraging 
clinical responses appear to be obtainable in up to 50% cases*****.
Table 3. Vasodilators used to reverse VSM____________________________________
Systemic
CO2 Inhalation
5HT antagonists
Sodium nitroprusside (SNP)
Papaverine (PPV)
Nimodipine
Angiotensin converting enzyme (ACE) inhibitors 
Local
Papaverine (PPV)
Lignocaine
 P receptor agonists (e.g. isoprenolol)_______________________________________
3.2.3. Anti-oxidant therapy
This is a relatively new concept which targets the deleterious effects of the degradative 
products that accumulate during clot lysis (Part 1, 1.4). It is still a mainly theoretical 
therapeutic option, but some have gained ethical clearance for their use clinically. For 
example, Asano et al have used the free radical scavenger “Nicaraven” and noted improved 
outcome at one month after SAH?**. In this context, the use of non-steroidal anti­
inflammatory agents (such as indomethacin) may also be described, since they may 
reduce the ultimate production of prostaglandins and leukotrienes^*.
3.2.4 Nimodipine
This agent must be briefly discussed separately. Although primarily used as a vasodilator, 
its major action is probably as a neuro-protective agent. One cellular event associated 
with the terminal stages of ischaemia is that of extiacellular calcium influx: nimodipine can 
prevent this. Furthermore, nimodipine can also prevent atrial natriuretic peptide (ANP)
41
release, thus potentially also limiting the risk of CSW. The effectiveness of nimodipine 
has been established clinically, in a multi-centre trial*^?.
3.2.5 Trans-luminal angioplasty
When VSM is considered as largely a more fixed ‘fibrotic’ state, somewhat similar to 
atheroma, trans-luminal angioplasty (TLA) has a clearly defined role. Its increased use 
underscores the concept of a proliferative angiopathy with VSM** .^ Its use, however, 
highlights many of the paiadoxes associated with VSM and DCI. For example, the tiauma 
of TLA should, in principle, act as a trigger toward the fiuther development of VSM (Part 
4, 3.1). That DCI, however, only occur s with VSM in the subacute stage of SAH, suggests 
that VSM must be linked to some other process in order to prove critical (Part 1, Chapter 
2).
3.2.6 Clot removal
If VSM and DCI are primarily due to the presence of the clot, then its prompt removal 
should effect adequate prophylaxis. This, however, may have other fortuitous effects, since 
the hydrocephalus that complicates so many cases may also be fundamentally due to the 
presence of clot debris. Certainly, the ICP can be lowered by such intervention*^?. 
Conceivably, clot removal can be achieved by operative evacuation, saline iiTigation via 
cisternal camiula, or fibrinolysis (again by cisternal cannulation).
Operative removal, to some extent, probably occurs in most operations for securing the 
aneurysm neck. However, its specific performance has been advocated in many studies; 
particularly within 48-72 hours post ictus*? ,^ *65,526,570 Nevertheless, the practical problem 
of picking away all of the clot, in piecemeal fashion, is Ifaught with dangers all of its own. 
These include fmfher vessel trauma, brain swelling and the need for repeated craniotomies. 
Furthermore, an early operation specifically performed with this as its major aim will be 
doubly confounded upon its failui'e, since fibrinolytic therapy—the current vogue—will 
then be obviated {see below).
To improve upon the dangers and failure of operative clot removal others have resorted to 
the insertion of cisternal cannulae, and the subsequent use of saline irrigation, over the 
ensuing days. The efficacy of this manoeuvre was mostly demonstrated in animal 
models**  ^where the critical time for this was again established as being within the first 48 
hours*??. In truth, however, saline irrigation is often combined with prior operative 
removal. This means that such cases are, in reality, statistically ones of combined 
therapeutic intervention. Fmfhermore, in most animal studies the ‘SAH’ produced is not 
always representative of the clinical situation, the experimental clot being far easier to
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remove. Perhaps it is not too surprising, therefore, that several groups have since reported 
upon the lack of efficacy of clot removal??*» ???» ?66= 4so.
At first glance, fibrinolysis appears to be a manoeuvre somewhat fraught with risk since, 
after all, the rupture site is probably only secured by the very clot to which this therapy may 
be directed. Nevertheless, fibrinolysis has been increasingly—and successfully—used 
without this logically-perceived danger being realised*??» ?***. Ordinarily, copious amounts 
of plasminogen are co-released into the clot at the site of vessel trauma, where they quickly 
bind to the fibrin polymers. However, in order to effect a subsequent fibrinolysis these 
amounts of plasminogen need to be activated by a ‘plasminogen activator’. Whilst this is 
the rate-limiting step in most clots, it must be particularly so after SAH, since the CSF is 
deficient in these ‘activator’ molecules*??. The most suitable agent in this regard is that of 
the genetically-engineered tissue plasminogen activator. This is not only because of the 
latter’ considerably diminished antigenic properties, but also because it is reasonably “clot- 
specific”. Thus, some have argued that it may predominantly dissolve neothrombus 
formation: in particular that present extraluminally. It certainly seems that tissue 
plasminogen activator is much less likely to provoke a systemic fîbrinogenolysis^?^. Of 
couise, its use would be contraindicated following any recent surgical procedure.
Notwithstanding the resurgence in clot removal, a strong cautionaiy note is proffered by 
Alexander and Black. These authors have demonstrated that, in spite of successful clot 
irrigation, neither the course nor the severity of either angiospasm or morphological 
change, was altered as a result?» 6.
3.3 Summary and Concluding Remarks
Most treatment policies are empirically geared towards increasing the flow of oxygenated 
blood to the brain by generally improving the CPP. Some are specifically geared towards 
improving flow locally through the VSM territory. This is achieved either by clot removal, 
or by attempting to dilate the consti’icted region—mechanically or pharmacologically. 
However, apart fiom possibly the singular use of nimodipine, there is scant evidence that 
either the prevalence, or the outcome, of DCI has been modified as a result of the use of 
any such regimen. Even with nimodipine, there continue to emerge conflicting reports. 
This, therefore, suggests that factors other than those discussed in the cunent and 
preceding chapters might be operative. Perhaps because of this, there has been a renewed 
focus upon VSM qua DCI, with increasing numbers o f ‘clot-VSM’ studies employed to 
potentially reveal the missing clues {see Part 4). Notwithstanding, other factors potentially 
exist that are regularly overlooked by clinical and experimental studies. These relate to 
events associated with the acute ictus, and conceivably include the central physiological
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disturbance (i.e. systemic and intracranial pressor effects), as well as the properties of the 
ruptured vessel per se. Such factors could, hypothetically, set in train processes that might 
prove critical to the subsequent development of VSM and DCI. For example, the 
assumption made in ‘clot-VSM’ studies—i.e. that delayed VSM merely results from the 
clironic effects of clot lysis upon otherwise normal vessels—might not be sound, should it 
subsequently transpire that the acute ictus itself actually alters cerebrovascular reactivity. 
This is important, because none of the results of ‘clot-VSM’ studies have so far led to 
efficacious treatment strategies. Before testing such a hypothesis, however, a full review of 
the anatomical, physiological and pharmacological properties of cerebral vessels (i.e. Parts 
2&3) is required before an appropriate means of small vessel study is conceived that 
complements a representative model of SAH (i.e. Part 4).
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PART 2 
CEREBRAL VESSELS
Chapters 1-4
45
Chapter 1 Anatomy of cerebral arteries
1.1 Introduction 48
1.2 The singular structure of cerebral arteries 49
1.2.1 Tunica intima 49
1.2.2 Tunica media 49
1.2.3 Tunica adventitia 50
1.3 The Blood-Brain Barrier (BBB) 50
1.4 Aneuiysm formation 51
1.4.1 Inheritable factors 51
1.4.2 Deficiencies in the wall 52
1.4.3 Infhndibnla 52
Chapter 2 Physiology of cerebral arteries
2.1 Resistance vessels in the cerebral circulation 55
2.2 Pre-capillary sphincters: myogenic tone 56
2.3 Capillary regulation 57
2.4 Autoregulation 57
2.5 Metabolic regulation 58
2.6 Sympathetic regulation 59
2.6.1 Role of the sympathetic nervous system in cerebral blood flow 60
2.6.2 Ischaemic preconditioning? 62
Chapter 3 Smooth muscle cell physiology
3.1 Introduction 63
3.1.1 Plastic compliance and myogenic tone 63
3.1.2 Vascular smooth muscle cells 63
3.2 Mechanism of contractile force 64
3.3 Muscle energetics 65
3.4 The implications of intensive and prolonged constriction: 
physiological sphincters
66
3.5 Second messenger systems 67
3.5.1 Vasoconstriction: Calcium 67
3.5.2 Vasoconstriction: Phosphatidylinositol system 68
3.5.3
3.5.4
Vasodilation: Cyclic Adenosine 3’, 5’ Monophosphate (cAMP) 69 
Vasodilation: Cyclic Guanosine 3’, 5’ Monophosphate (cGMP) 71
46
Chapter 4 Cerebrospinal fluid and its properties after 
subarachnoid haemorrhage
4.1 Normal cerebrospinal fluid 73
4.1.1 Sampling errors 73
4.2 Post sub arachnoid haemorrhage cerebrospinal fluid 73
4.2.1 Vasoconstrictory phenomena 74
4.2.2 Myofibroblasto-proliferative phenomena 75
47 I
Chapter 1 
Anatomy of cerebral arteries
1.1 Introduction
The cerebral circulation is fed from two sources bilaterally, each source being sunounded 
by sympatho-adrenergic fibres principally emanating from the neck. Thus, the two internal 
carotid arteries (ICAs), both directly deriving from the aortic arch, enter the cranium after 
passing tln ough the carotid sinus below the floor of the middle eai\ They are then 
intimately related to the VI cranial nerves below the cavernous sinuses, and the II cranial 
nerves above them. In the neck they are intimately related, at inteiwals, with the IX, X and 
XII cranial nerves; and are constantly suiTounded by fibres from the SNS. It is a fact that 
the ICAs conduct the major share of the CBF, this being >70% of the totaP^^
The vertebral ar teries (VAs), branches of the subclavian arteries, enter the cranium thr ough 
the foramen magnum after having ascended the neck within the foramina transversaria of 
the cervical vertebrae. They, again, are intimately associated with fibres from the (cervical) 
SNS. After a short course on the basi-occiput, they unite to form the basilar artery (BA) at 
the lower border of the pons. Less than 30% of the CBF is conducted through the VAs^^ .^
These four sources are normally interconnected by a curious structure found only in the 
brain, called the Circle of Willis (CoW). Although it must have evolved as a means for the 
rapid redistribution of arterial input following unilateral neck vessel occlusion, its relative 
significance in this regard has been in question {see below). Issuing from the CoW are 
three major vessels on each side, the cerebral arteries, which finally supply blood to the 
region of the brain indicated by their names: anterior, middle and posterior. By far the 
largest flow occurs within the middle cerebral arteries (MCAs), this reflecting the greater 
role of the ICAs in determining the CBF.
This circle is frequently (50%) incomplete, however, and these anomalies are more 
frequent in patients who suffer fr om cerebrovascular accidents^^’ In approximately 
30% there is significant hypoplasia of a major vessel associated with it ?^. Such hypoplasia, 
occurring in the anterior circle, may be especially apparent in patients harbouring an 
aneurysm of the anterior communicating arteiy (ACommA), occurring in as many as 85%
cases87
As described in Pail 1, 1.1, the major cerebral vessels ramify over the surface of the brain 
before entering it. An extensive collateral circulation is possible through anastomoses 
between suiface pial vessels. These constitute the leptomeningeal arteries of
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Heubnerioo. However, the vessels distal to this network, which penetrate the cortex in the 
Virchow-Robin spaces, have little communication with one another. Apart from possible 
“shunts” occurring in pre-capillary arterioles there is little potential for anastomosis at the 
intraparenchymal leveP" .^
The cerebral venous drainage is via imiumerable cerebral veins pooling into the cerebral 
venous sinuses. These, then, drain mainly into the internal jugular system in man. In rats, 
however, drainage is mainly via the vein of Labbé to the external jugular system^39 
Although the cerebral venous sinuses ar e often considered ‘incollapsable’, they in fact only 
prevent ‘suction-collapse’. Certainly they cannot prevent collapse from externally-applied 
pressure. Thus, Cushing in his classical cranial window study of 1901, vividly described 
the ready collapse of the superior sagittal sinus in even the initial phase of AICP, in either 
dogs or rabbits^ 15.
1.2 The singular structure of the cerebral arteries
In general, this is similar to that seen in ‘resistance vessels’ throughout the body. However, 
there are important differences. The most abnormal layer histologically is that of the tunica 
adventitia. Deficiencies in each of the thr ee wall layers may, however, play a role in each 
aspect of SAH. The increased presence of mast cells (MCs) within the vessel wall in cases 
of aneurysm rupture might possibly suggest their role both in the development and rupture 
of beiiy aneurysms. This is currently considered the case with the rupture of coronary 
artery atherosclerotic p l a q u e s ^ o f
1.2.1 Tunica intima
This consists of the endothelium, the internal elastic lamina (lEL), and the sub-intima. The 
endothelium is the predominant site of the blood-brain barrier (BBB) {see below). 
Deficiencies in the lEL may represent the conditio sine qua non of aneurysm development. 
The sub-intima is normally thin and insignificant: however it thickens in response to 
nonspecific vessel trauma (Part 1, 1.3.1.4).
1.2.2 Tunica media
This predominantly consists of vascular smooth muscle cells (VSMCs) aiTanged in (> x6) 
concentric layers^^ .^ Approximately 70% of this layer may be composed of VSMCs^59_ 
However, the arrangement of these cells becomes haphazard in regions of acute 
bifurcations: regions, in fact, where aneuiysms abound. A possible helical arrangement of 
VSMCs 5^9^  however, may contribute both physiologically and pathologically (Part 2,
3.1.2). It is often held that this layer is thinner than would be expected, in consideration of 
the active tone and intraluminal pressures normally experienced. However, if Laplace’s
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law for hollow sh'uctures does essentially apply (Part 2, 2.1), the contracted state 
necessarily signifies wall tensions experienced to be conespondingly the lesser, by virtue 
of both reduced luminal diameter and correspondingly increased wall thickness. In other 
words, by virtue of the property of myogenic tone (Part 2, 2.2), cerebral vessels can afford 
to possess somewhat slender wall mass, because the operating wall tensions would 
necessarily be the less.
1.2.3 Tunica adventitia
This layer is normally thick in systemic vessels. However, it is extraordinarily thin in 
cerebral vessels. In fact, it essentially disappears altogether in pial arteries with increasing 
cortical depth^29 Furthermore, there is no external elastic lamina (EEL) present in the 
major vessels of the SAS. This is a marked departure from normal structure, which, by 
placing more responsibility on the lEL, may be of the utmost importance in aneurysm 
development and rupture499. Normally, similar-sized vessels possess fuither tiny 
vessels—the vasa vasora—that course through this layer, supplying blood to the energetic 
media. However, even the most major branches of the CoW are conspicuously lacking in 
t h e s e ^ 5 , 101,275 instead, there ai*e numerous micropores present—the ‘rete 
vasorum’—which suggest, to many, a significant role for the CSF in both nutrient supply 
and waste disposaP®' ’^ ^ 76
The latter feature (rete vasorum) lead to one hypothesis that the presence of the thick 
subarachnoid clot might, by micropore occlusion, disrupt a significant component of vessel 
wall metabolism. However, Ohta et al subsequently demonstrated that horse-radish 
peroxidase not only continued to permeate the wall following clot application, but also 
appeared able to do so more readily^^L That the addition of powerful vasoconstrictoiy 
agents such as barium chloride, also achieved enhanced ‘uptake’ suggested that blood acted 
in the same way. That is, vessel wall constriction per se appears to effectively open up 
these micropores. Thus, rather than limiting CSF metabolite exchange, blood may even 
increase this. However, by increasing micropore patency, the further penetration of vaso­
active agonists into the vessel wall would be facilitated, thus promoting VSM92,3io, 468
1.3 The Blood Brain Barrier (BBB)
The BBB essentially derives from the presence of tight junctions {zonula occludens) 
between the endothelial cells. Thus, the BBB is mainly due to the membrane properties of 
this cell, as suggested by its oil-water immiscibility^^^. Such an endothelial cell may often 
form a complete tube in the capillary, and is itself enveloped by out-projections (“feet”) of 
large nearby astrocytes^^^. The presence of the BBB, by preventing the transudation of 
plasma under the balance of hydrostatic and osmotic pressure, is the reason why there are
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no lymphatics present within the CNS. In likewise fashion, the subarachnoid space is 
similarly sealed-off from the dura, as both the pia and the arachnoid layers also possess 
tight junctions536. Thus, both CSF and the cerebral blood are very separate from the rest of 
the brain; and from each other.
The presence of an excessively large number of mitochondria within endothelial cells hints 
at their intense metabolic properties'^M olecules can permeate the barrier by crossing the 
luminal membrane, traversing the cytoplasm, and finally crossing the abluminal membrane. 
That such passage exhibits saturation, stereospecificity and competition implies it to be 
governed by receptor and carrier-mediated m e c h a n i s m s ^ ^ ^ .  Such molecules are often seen 
to be conducted transcellulaiiy, within intracytoplasmic vesicles^^^. Some have shovm that 
high levels of hypertension, for example, can effectively increase BBB “permeability” by 
increasing the rate of this vesicular transport mechanism^^^
The most crucial molecules for cerebral metabolism me oxygen and glucose, the latter 
being transferred as the D-isomer536. Amino acids, however, are transported in three 
essential categories: acidic, basic and neutraF^s. That the transfer of L-tyi’osine, for 
example, competes with that of phenylalanine, was an important discoveiy in elucidating 
the mechanism of hyperaminoacidaemia-induced CNS disease. Such is the case with 
phenylketonuria and hepatic disease, for example, where relative excesses of certain amino 
acids starve the brain from others by virtue of carrier-mediated saturation.
1.4 Aneurysm formation
Although considered ‘congenital’, aneurysms rarely occur in childhood. In this sense, 
beriy aneurysms are not truly congenital.
1.4.1 Inheritable factors
It is clear that some aneurysms do appear associated with clemly-recognisable genetic 
disorders such as Ehlers-Danlos syndrome, coarctation of the aorta, and polycystic kidney 
disease^^b 396 Nevertheless, few in the past have genuinely felt that aneurysm probands 
regular ly denote familial clusters. However, recent studies have again returned to this 
theme, one even suggesting that at least 1:5 SAH probands will have an affected first or 
second degree relative^^f Most others have found the proportion to be lower^53 However, 
a preponderance of fertile women has also been noted in such cases^53, this suggesting 
underlying genetic heterogeneity^^!.
Notwithstanding, the vast majority of cerebral aneurysms do not appear truly ‘inheritable’. 
Furthermore, that aneurysms mainly tend to develop in the third decade^^r jji tui"n strongly
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implicates environmental factors, of which hypertension appears p r e d o m i n a n t ^ 3 2  
Certainly, some have experimentally created cerebral aneurysms by such MAP 
elevations33o. Nevertheless others have singularly failed in this regard, even with pressures 
up to 600 mmHg!556.
1.4.2 Deficiencies in the wall
Some consider the tunica media to represent the most structurally important layer. Yet, 
even if this were so, some 31% of 157 random autopsies show major vessels associated 
with the CoW conspicuously lacking VSMCs at the apex o f  b i f u r c a t i o n s ^ ^ s  T J i i g  tends to 
support a “congenital” background to the process of medial deficiencies, but it does not 
explain why only a few actually succumb to aneurysm formation. Quigley et al noted that 
the lEL was frequently damaged in regions of aneurysm formatioM^? (^ see also references in 
Ref 385). Since the adventitia routinely lacks an EEL in cerebral vessels (see above), they 
postulated that such lEL defects were at least as important as those in the media, the 
presence of the two compounding each other. Quigley et al, in fact, managed to produce 
aneurysms by laser coagulation in some 30% of cases which, by causing such defects in 
both layers, resulted in aneurysm-formation without the pre-requisite of increased MAP"!^ .^ 
There has been a recent proliferation of reports relating lEL defects to abnormally elevated 
activities of elastase in cerebral vessel walls. However, whilst some demonstrate 
convincing evidence, many appear experimentally flawed^^O; and
all—uniformly—suspiciously fail to quote Hassler’s landmark stiidy^^  ^which categorically
refuted such a m e c h a n i s m ^ ^ s
Another possible factor may relate to the presence of MCs within the arterial wall. Their 
presence not only within cerebral blood vessel walls o r d i n a r i l y !  54^  but also more 
specifically in relation to berry aneurysm rupture^ )^' have long been documented.
Recent interest in their putative role in the “rupture” of a coronary vascular atheromatous 
plaques^oi raises analogous possibilities with aneurysm rupture. MCs are, of course, 
pregnant with vasoactive compounds—however, it is with regard to lytic agents that may 
cause structural weakening of the vessel wall that interest is now being turned to^oi.
1.4.3 Infundibula (References in tliis section are contained in Ref 385)
Infundibula (IF) are conical, triangular or funnel-shaped widenings that occur at branch 
points of major cerebral aiteries. Although they rarely occui* at other sites, they principally 
occur at the ICA-PCommA junction. At this location, the IF base—normally defined at a 
maximum of 3 mm—faces the ICA, whilst the PCommA arises from its apex. IF thus 
appear as a symmetric bulge without a neck, in marked contrast to an intracranial aneuiysm
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which bulges asymmetrically from a well-defined neck. They are seen in 7-25% of normal 
angiograms, although their incidence may be greater in cases of either multiple or familial 
intracranial aneurysms.
Hassler & Saltzmann were amongst the first to suggest that IF might be precursors of 
cerebral aneurysms. This was based on the presence of ‘aneurysm histology’ in IF 
obtained from seven necropsies following SAH. In these, foui* IF exhibited lEL 
fragmentation, one had no lEL at all, whilst five exhibited significant medial defects. 
Stehbens also demonstrated lEL fr agmentation in five out of seven IF, whilst Archer and 
Silbert demonstrated complete lEL absence in one case with bilaterally symmetrical IF 
(one having been deemed the site of rupture). However, ‘aneuiysm histology’ is not 
invariably present in IF. Two in Hassler and Saltzman’s series showed no abnormality at 
all, whilst Sahs demonstrated only one IF with an lEL defect in his extensive series. 
Furthermore, Epstein et al demonstrated no structural defect at all in all seven of their 
cases. Based on such findings, numerous authors have denounced the ‘pre-aneurysm 
hypothesis’, describing IF instead as merely normal anatomical ‘variants’.
Notwithstanding, Endo et al found atypical bulgings on IF strongly suggestive of early 
aneurysm progression. Indeed, a total of eleven cases have now been reported 
documenting frank IF-aneuiysm progression^^s. Since at least some IF clearly are pre- 
aneurysmal, one possibility is that such progression only occurs in those with underlying 
‘aneurysm histology’. Whether this may be congenital or acquired is, of course, the same 
dilemma that applies to berry aneurysms in general. But it may be the case, however, that 
IF configurations are hydraulically more disposed toward fuither dilation. On Bernoulli’s 
principle, sudden decreased velocity— and, therefore, kinetic energy—at IF, necessarily 
result in increased wall tensions since:
p  + + pgh = constant
where p  = fluid pressure, v = velocity of flow, p -  blood density, g  = acceleration due to 
gravity, and h = height above ground level (the latter three are effectively constants). In the 
normal situation, flow is of course directed from the ICA into the PCommA: however, this
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can be reversed during carotid compression so long as the PCommA is patent. 
Conceivably, repeated distensions could trigger lEL fragmentation which, in the presence 
of frequent medial defects, could lead to aneurysm fomiation. It is interesting that Endo et 
al found early IF-aneurysm progression to be more likely with enlarged PCommAs.
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Chapter 2 
Physiology of cerebral arteries
2.1 Resistance vessels in the cerebral circulation
The major level of resistance to flow within the cerebral circulation continues to remain in 
dispute. That major anomalies in the CoW do not necessarily equate with CBF 
compromise, particularly following carotid ligation^^i, suggests that whatever its 
teleological function the CoW does not appeal' crucial toward a collateral circulation^^*.
The major resistance appears therefore to lie distal to this point, with deficiencies in the 
aforementioned leptomeningeal anastomosis being largely responsible for CBF 
compromise following carotid ligation^^*. In fact, at least 50% of the cerebrovascular 
resistance may be contained within these vessels^^z. Nevertheless, it is of interest that CCA 
ligature results in a 50-60% stroke incidence in animals such as gerbils which completely 
lack a CoW379; and that pressure-falls of up to 30 mmHg have been recorded in human 
subjects across the circle^^*. Fui’thermore, the subclavian steal syndrome shows that the 
CoW may redistribute away fr om the brain when carotid pressure gradients become 
reversed*!**.
Earlier studies repeatedly suggested that the major level of cerebral resistance resided in the 
arterioles, at diameters less than about 60 p m * 5^,378 Increasingly, however, more recent 
studies have shown significant contributions from larger vessels, these at least including 
vessels between 120 and small arteries of 200 pm outer diameter*^^. An important
feature of these vessels is their extent of wall thickness in relation to their luminal 
diameters, and in the degree to which the medial SMCs function in controlling wall 
tension. The basic properties may be largely explained by the law of Laplace, which 
governs the properties of elastic cylinders in response to luminal (radial) pressures. Thus:
^  P.a1 — --------------th
Where T is the wall tension; P is the pressuie differential across the vessel wall (this is the 
MAP minus the cranial CSF pressure); and where th is the wall thicloiess.
However, one must accept the major limitation of this equation in assuming a cylinder 
containing elastic walls. This, in fact, may not necessarily apply to cerebral vessels as 
myogenic tone (MT) effectively reduces elastic effects (Part 2, 2.2). Other systemic 
conduit vessels, however—particularly the pulmonary vasculature—much more closely 
resemble the ‘passive’ Laplace requirements (Fig 13). Notwithstanding, it is a useful 
relationship to bear in mind, if anything because of its simplicity. Thus, a vessel in a
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smaller contracted state will necessarily experience smaller wall tensions, therefore they do 
not need to be ‘built’ as thick as conduit vessels.
2.2 Pre-capillary sphincters: myogenic tone
The further distally within the microvascular bed, the gieater the relative resistance to flow 
offered. In fact, at some point, arterioles exhibit essentially “sphincteric” function. Such 
vessels ultimately control both pressure and volume of flow to the vulnerable capillaiy bed 
(capillary regulation'***'^ ). At this extreme level, the major factors that should dictate flow 
ought largely to be either metabolic or protective. Thus, an increase in tissue metabolism, 
through the build up of waste products, should be able to dictate conesponding increases in 
local flow (capillary ‘recruitment’'***^). In turn, dangerous levels of MAP breaking 
through proximal resistance vessels should be stopped at the pre-capillary stage, by 
sphincteric activity.
The latter protective mechanism reflects the innate ability of the contractile machinery of 
the vessel to respond to luminal distension as a stimulus, it being totally independent of 
neurogenic controF^  ^ This, in fact, is a major property of all resistance vessels, but it 
particularly applies to pre-capillary sphincters. Such vessels can be anything up to 70 to 
100 pm in diametert**?, and this property is referred to as myogenic tone (MT). Such 
vessels chai'acteristically exhibit MT spontaneously, and not just in response to stretch.
This is evidenced by a continuous, rhythmic, oscillation in vessel tone in isolated segments 
@ 3/min in the larger vessels, to 12/min in the smaller ones^ .^ It is possibly due to 
spontaneous electi'ical activity within the VSMC membrane, and it results form the overall 
integration of numerous, isolated, phasic contr actions occuiTing throughout a functional 
VSMC syncitium'***^ . Therefore, the SMCs in these vessels possess fundamentally different 
properties to those elsewhere in the vasculature {see below).
Within the systemic circulation, it has been estimated that such MT may amount to up to 
70% of the total resting peripheral resistance'***'^ . Thus, the background “noise” of 
sympathetic tone is probably less than that of MT. SNS tone is revealed following spinal 
cord transection above the level of the thoracolumbar" outflow, or following the 
administration of ganglion-blocking drugs, and results in falls of MAP of 40-60 mmHg^^  ^
However, the SNS becomes more prominent with extremes of MAP within the 
cerebrovasculature {see below). The resting MT within cerebral vessels has been assessed, 
by some, to represent somewhere between 20%'*  ^to 40%'*5'5 of the total tone possible. 
However, this clearly depends upon the degree of distension present and, therefore, upon 
the intraluminal pressme. It may also depend on the level in the microcirculation, it being
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greater the more distally^ ***?, 6is consequence, any further agonist-induced 
vasoconstrictory tone (AT) must be super-imposed upon MT.
2.3 Capillary regulation
Thus precapillary sphincters serve to maintain capillary pressmes within a more or less 
constant range, this being approximately 15-16 mmHg. Without this protective 
mechanism, and by maintaining MAPs of 125 mmHg for only 15 mins, 50% of the 
circulating plasma may be lost into the interstitium, this clearly resulting in circulatory 
collapse'***'^ . Thus, such vessels offset deleterious sudden surges in MAP. However, they 
also dilate in response to falls in MAP. Thus, at the capillary level, the majority of tissue 
beds appear equivalent. Yet in some organs, this property is also apparent in the small 
arteries as well. As a result, total organ blood flow itself remains regulated to optimum 
levels, in spite of large MAP var iations.
2.4 Autoregulation
The innate ability of some vessels to spontaneously maintain flow to certain regions of the 
systemic circulation was initially implied by Ostromnoff in 18684^ .^ Unfortunately, he 
could not come to the conclusion that both sensor and effector actually resided within such 
vessels, although this was implicit in his findings. Instead, it was Sir William Maddock 
Bayliss35 who first explicitly reported this fact in 1902 (the same year*, in fact, that 
Cushing’s Mutter lecture**5 was published—Part 6, Section I, 1.3 ). Although more 
famous subsequently for his joint discovery (with Starling) of the first hormone, secretin, 
his role in developing the concept of autoregulation has become increasingly appreciated, 
particularly within renal and cerebral beds. The “Bayliss effect” thus serves to maintain 
organ blood flow itself at more or less constant levels, in much the same way that pre­
capillary tone maintains capillary flow.
In consequence, CBF is maintained ordinarily at around 750 ml/min**53. This is 
approximately 13% of the cardiac output, yet the brain only represents about 2% of the 
total body mass^ *53 Xhus, normal levels of CBF approximate to 50 ml/lOOg/min, being far 
greater within the grey than white matter^53 Similaiiy, in the other major autoregulatory 
organ, renal blood flow is maintained at levels of 1 200 ml/min: this being some 20% of 
the cardiac output*^ ^^  Clearly, these are organs with large metabolic activities. It has 
been estimated that values between 10-20 ml/lOOg/min become critical to cerebral 
metabolism, and that values <10 ml/lOOg/min result in the onset of ischaemic necrosis592.
In the presence of autoregulation basal CBF can only be increased by extreme surges in the 
MAP; or by increases in cerebral metabolism'*!!. Thus, only with acute severe hypertension
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aie cerebral vessels passively dilated and the brain exposed to dangerously increased 
CBF33- 428 Flow itself is approximately governed by the Poissieulle equation;
V ------------------%rji
Where V is the volume of fluid flowing per unit time; AP is the pressure gradient along the 
vessel length; a is the luminal radius; p is the viscosity coefficient of the fluid; and i is the 
length of the tube considered. Once again, as with the Laplace relationship, limitations 
abound in its translation to the physiological milieu. Thus, it strictly relates only to the 
continuous laminar flow of homogenous fluids, flow within rigid tubes, and tubes with 
wettable walls. All of these requirements are regularly not met within the systemic 
vasculature.
Attempts have been made to establish the precise range of MAP values over which 
autoregulation works. The upper limit has been assessed at around 160 mmHg by 
Hernandez et afi64. In consequence, MT must increase proportionately throughout this 
range in order to maintain functional diameters. Any further AT must, therefore, be 
superimposed upon this MT. Beyond this limit, then, the eerebrovasculature will be 
expected to passively dilate. However the upper limit may be ‘up-regulated’ in essential 
hypertension.
The lower limit, in turn, has been estimated at around 60 to 69 mmHg by MacKenzie et 
aP78. However, this value was derived from haemorrhagic hypotension where reflex 
sympathetic tone is necessarily induced within larger ai’teries {see below). In consequence, 
the true value is even lower, as evidenced within the pial vessels within MacKenzie’s 
study; and as produced by various forms of sympatholysis'*^*. Thus, CBF can be 
maintained at least down to MAP levels of 50 mmHg in clinical studies using sodium 
nitr"oprusside (SNP)^ **^ . In similar fashion, the lower limit may be up-regulated in 
hypertension. Therefore, between these two extremes of 50-160 mmHg, the CBF is 
maintained remarkably constant.
2.5 Metabolic regulation
Neither can an increase in MAP, nor a release of background sympathetic tone increase the 
CBF in anticipation of increased levels of demand. The mechanism that can is associated 
with increased metabolic activity. Thus a dramatic increase in CBF can be witnessed, for 
example, during an epileptiform convulsion^^. In consequence, metabolic regulation can 
readily overcome autoregulation: an important principle {see below). Lassen stated, in
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1968, that metabolic regulation constituted the most important regulator of CBF, achieving 
this largely by way of increased tissue acidity352.
Metabolic regulation is effected by the relative build up in ‘waste products’ of tissue 
metabolism. Such products include potassium (K+) ion, hydrogen (H+) ion, carbon dioxide 
(CO2), and adenosine compounds*]*) .^ However, it is also effected by a relative lack in 
certain agents. Thus, cerebral blood vessels are extremely sensitive to local pOa, and any 
hypoxia will result in vasodilatation. Such substances, individually, can powerfully dilate 
the vasculature, offsetting autoregulatory tone. Perhaps their effects may even synergize 
together, since all are likely to accumulate s i m u l t a n e o u s l y * ^ 3 6  metabolic regulation 
does not merely represent vasodilation. For example, an increase in pFI (increasing 
alkalinity) can actually produce a vasoconstriction* 29. This will happen when the local 
cellular metabolism becomes decreased.
Pharmacological agents can mimic the effects of metabolic regulation. Thus papaverine, 
for example, can dilate pre-capillaiy vessels in the systemic circulatioM**2. it can thus also 
abolish autoregulatory MT, and is used as such experimentally. Under these conditions, 
the microcirculatory bed behaves passively to increases in pressure and flow. Thus, 
intracapillaiy pressures of up to 36 mmHg can be experienced, this damaging the capillary 
bed and resulting in excessive oedema formatioM** ,^
This is not just the case in cerebral vessels, however. Metabolic regulation is, of course, 
the major influence on increasing tissue blood flow thi'oughout the entire systemic 
circulation. It has been estimated, for example, that, should all the capillary beds within 
the systemic vasculature become maximally dilated with maximal metabolic activity, the 
heart would be required to maintain the impossible output of some 40 L/mirri**2_ With 
maximal muscular' exercise, for example, this output can increase to 25 L/min*^ 3^ with 
temperatures of 44°C at over 85% humidity, levels of 20 L/min can be reached^^^ The 
combination of excessive muscular exercise in a hot, humid climate may, ultimately, 
threaten cardiovascular collapse. Clear ly, the development of a mechanism to not only 
limit the extent of this response, but also to reduce flow to non-vital areas, would be an 
extremely felicitous one.
2.6 Sympathetic regulation
A major fimction of the SNS within the systemic circulation is in the redistribution of the 
cardiac output to various tissues and organs under varying conditions. Another major role, 
however, may arise under conditions of excessive metabolism. Firstly, by increasing tone 
in ‘non-vital’ regions, it can effectively divert more blood to regions of intense metabolism.
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In fact it can increase the total peripheral resistance by a factor of five here4**2. This not 
only increases the head of pressure to those beds still dilated but, by reducing intracapillary 
pressures in non-active beds to minima of around 7 mmHg, it can also effectively ‘suck- 
back’ extracellular fluid from the interstitium^ ***?. This therefore augments the circulating 
volume. Secondly, there is evidence that sympathetic regulation may be more potent in 
those beds most metabolically active. Thus, at the upper level of autoregulatory 
breakthrough, pre-capillary vessels can be x3 as sensitive to NE when maximally dilated 
metabolically***?.
Therefore, it appears reasonable that the thr ee regulatory mechanisms (autoregulation, 
metabolic regulation, and sympathetic regulation), work together in concert at the 
microcirculatory level; in order to control both the distribution, and the redistribution, of 
the cardiac outpuf*? .^
2.6.1 Role of the sympathetic nervous in cerebral blood flow
Most small arteries and arterioles throughout the systemic circulation possess a dense 
supply of adrenergic nerwe fibres, including even that of the other major autoregulatory 
organ, the kidney. Although, in comparison, the cerebral circulation is much less densely 
innervated^53  ^^ reasonable supply is extant to the adventitia of pial vessels in humans and 
other species* 5**, 2 4 9 ,4 6 4 ,4 8 3  _ some this was in evidence even down to the level of the 
capillaries5**4. However, this is heterogeneous, and maximal only at the level of the 
CoW^20 Both innervation and NE-responsiveness fall off markedly within the 
intraparenchymal vasculature'*^.
However, although the cerebral SNS classically ascends the neck from the cervical ganglia, 
reaching the intracranial cavity upon the large cervical arteries, it also derives If om a 
complicated and largely unknown intracranial source. This involves a source in the locus 
coeruleus which may be activated during stress^ *^  ^ The latter nucleus is located 
dorsomedially in the floor of the rostral part of the IV ventricle. Catecholamine containing 
neurones thence project via the dorsal tegmental bundle to the hypothalamus, cortex and 
hippocampus5?5. But they also project caudally to the nucleus tractus solitarius (NTS), and 
the spinal cord^? .^ More importantly, they project directly to the microvessels of the pial 
circulation^?^. The comiexions to the NTS certainly seem to mediate systemic MAP via the 
thoracic intermediolateral columns. Afferent stimuli, coming from the trigeminal system 
seiwing the meninges, may stimulate this system.
Yet several authors have commented upon the relative lack of influence of the SNS within 
the cerebral circulation*'***, with even bigger doubts about the cholinergic contribution23. *22,
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•27. Thus, most have found relatively poor NE responses w i^thin cerebral vessels525,588,600, 
650. Although recent comparisons between wire-mounted and pressure-cannulized vessel 
studies have highlighted important areas of recording bias with adrenergic responses?^, *67^  
this only refers to response potency. Since efficacy, therefore, remains unaffected this 
cannot account for the lack of effect seen. Moreover, such reduced effectiveness is also 
observed in v i v o * *9. it is possible that this is a feature only with non-human animal 
vessels. Thus, several authors have noted larger NE responses within human cerebral 
arteries^oo, 607^  some suggesting this to relate to a predominance of a l  receptors, a2 
receptors allegedly mediating weaker responses. This is a fascinating proposition which, if 
so, might be explained by the adoption of the upright posture. But a far more likely (and 
certainly more prosaic) explanation may also relate to a differential responsiveness between 
the BA and the other cerebral vessels. Thus, the BA tends to be the more frequently used 
in experimental studies, and yet is known to demonstrate a sparse response to NE29**.
Even so, some have estimated that the cerebral SNS contributes only 5% toward overall 
cerebrovascular tone normally'*^*. This is in marked contrast to its role systemically, where 
acute falls in MAP of 40-60 mmHg may be observed following sympatholysis^^s. fr may 
be, then, that the cerebral SNS only really comes into play under more extreme 
circumstances. Thus, in addition to its gi'eater role with metabolic dilation, it may also 
exert a much greater effect under extremes of systemic MAP. For example, the lower limit 
of cerebral autoregulation following haemonfragic hypotension (at 65 mmHg) is 
significantly higher^?^ than that induced under sympatholysis'*^*. Thus, CBF can be 
adequately maintained down to MAP values of 50 mmHg following SNP administration in 
clinical studies?2, even down to 30 mmHg in experimental ones^o .^ Haemorrhagic 
hypotension is therefore accompanied by a reflex cerebral SNS-activation^^s. Some have 
estimated its contribution toward overall cerebral vessel tone to be increased fourfold to 
around 20% under such circumstances'*^*.
Similarly the cerebral SNS may exert a greater influence with increases in MAP, with 
several docmnenting increased recruitment here. This may serve to offset dangerous surges 
in CBF5*.260,428_ Therefore, with systemic hypertension the cerebral SNS appears to 
augment the underlying protective autoregulatory mechanism. In contrast, under 
hypotensive conditions, it appears counterproductive to this mechanism. Perhaps this is 
because the SNS must necessarily be brought into play as part of a generalized response to 
circulatory shock: a primitive reflex to generally maintain systemic pressure.
Wliatever its role there is much evidence suggesting this to be largely experienced upon the 
larger extra-parenchymal cerebral vessels within the subarachnoid space. Thus, cerebral
61
angiography undertaken during periods of SNS activation frequently show larger arteries to 
be constricted222, 223 concunent with pial dilation^?^. This is compatible with a greater 
extraparenchymal adrenergic innervation*53. This observation has given rise, then, over the 
years, to the “Dual effects” hypothesis^^^usi
2.6.2 Ischaemic pre-conditioning?
An interesting alternative role for the SNS may be implied from consideration of its effects 
within the myocardium. Thus, by a l  adrenoceptor activation594  ^(or by somehow 
increasing stimulation relative to NE at especially high levels around 56
appears able to lengthen the ischaemic tolerance of cardiac muscle to subsequent decreases 
in coronary blood flow*35, 612 ^  may be that a similar role for the cerebral SNS pertains 
within the eerebrovasculature since, teleologically, the cerebrum is particularly prone to the 
occurrences of decreased blood flow. The fact that this may be particularly so with the 
upright posture of humans, may possibly reflect its greater role here^ **?. It is interesting, 
however, that nitric oxide (NO) has also been implicated in ischaemic pre-conditioning. In 
one study, NO produced fr om cNOS mediated ischaemic pre-conditioning by a mechanism 
that did not alter mitochondrial hyperoxidation induced by subsequent r e p e r f r i s i o n ^ 5
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Chapter 3 
Smooth muscle cell physiology
3.1 Introduction
SMCs are spindle-shaped, 50-400 pm long, and 2-10 pm thick^* .^
In general there are two types of SMCs defined by their responses to stretch or to neuronal 
input.
3.1.1 Plastic compliance and myogenic tone
After an initial rise in tension following stretch, due to inherent visco-elastic properties, 
most SMCs exhibit plastic compliance. In the post-stretch phase, tension decreases 
abruptly at first, and then ever-more slowly. Thus, such types can be completely relaxed in 
both the shortened and stretched states, and featuie largely in structures required for 
storage, such as the urinaiy bladder^*^. However, some SMCs also respond with a stretch- 
activated contraction, this being superimposed onto the aforementioned visco-elastic 
properties. Thus such SMCs behave similarly to cardiac and skeletal muscles, and are 
prevalent within the ‘autoregulatory’ vasculature. Intriguingly, the two types may not be 
fixed. For example the urinary bladder, following cord transection, can change from 
having one having distinctly visco-elastic/plastic properties, into one with a stretch- 
activated response over a period of several days. Hence the ‘automatic-emptying’ of the 
bladder in the acutely paralyzed patient^* .^
Some SMCs in the body are spontaneously active and do not require any stretching. Thus 
the ureter, the intestine and the uterus spontaneously contract in rhythmic fashion (e.g. 
Braxton-Hicks contractions within the uterus). This is truly myogenic, as in the heart. 
Excitation can rapidly spread from “pacemaker” regions throughout the muscle due to 
electrotonic spread across low-resistance tight junctions at intercellular nexi (i.e. a 
functional syncitium^*^). in many ways, autoregulatory vessels resemble these tissues, with 
spontaneous rhythmic activity of between 3 and 12/min22. However, even with such 
myogenic SMCs some degee of plastic compliance is still apparent, as is reflected during 
the mounting procedure of cerebral arteries in wire myography (Part 4, 5.2.1).
3.1.2 Vascular smooth muscle cells
It is not known where the stretch sensor or effector resides within the autoregulatory 
mechanism. Some empirically accept that the sensor must represent stretch-sensitive ion 
channels within VSMC membranes^**?. However, others have demonstrated the 
endothelium to be necessary, certainly within cerebral a r t e r i e s ^ ^ ^ ,  240, 320,321 This is also in 
evidence in experiments where vessel compliance was greater following endothelial
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denudatioii326. Although the latter authors assumed that all MT had been abolished with 
100 pM PPV, this is not invariably the case (Part 5, Section II, 3.8); and, thus, the greater 
compliance seen with endothelial denudation may have been due to a “release” of MT. 
Thus, the endothelium not only may sense the degree of luminal stretch, it may also enact 
the VSMC response via an endothelial-dependent contracting f a c t o r ^ ^ ô ,  240 , 320,3 2 1 (EDCF). 
Such endothelial-VSMC electi'omechanicai coupling is a common event physiologically. 
Thus, there is a similar release of an endothelial derived relaxing factor (EDRF) in 
response to a shear stimulus (Part 3, 1,8). Whilst the EDCF is probably a prostanoid, the 
EDRF can be either prostacyclin, nitric oxide (NO) or, even, some other substance with 
hyperpolarizing properties (see below). There is some reason to believe that the 
endothelium and the VSMCs, by virtue of tight nexi between them, act as a kind of 
functional syncitium^oo. Certainly, this would explain their tightly linked functions.
Based upon a circumferential arrangement of VSMCs in arteries, Walmsley et aF^  ^have 
assessed that a 58% decrease in length of the cells would be required in order to afford 
luminal closure. Whilst this is possible, a dual-assumption of a helical VSMC arrangement 
of along with essentially fixed vessel lengths, much better explains vessel closure^^ .^ In 
this hypothesis, much less than a 58% degree of VSMC shortening would be required.
Even based upon a helical arrangement, it seems likely that the inner layers of VSMCs 
only contribute to the initiation of contraction, with the outer layers the maintaining 
this639. If so, it may be that this is the reason why medial myonecrosis largely appears 
within the outer layers post SAH669^  as this would represent the most physiologically 
active.
3.2 Mechanism of contractile force
The actual contractile mechanism within SMCs is probably fundamentally that as described 
for skeletal muscle^^o. Thus, it is essentially due to the flexing and rowing movements of 
myosin (thick filaments) along a double strand of actin (thin filaments). However, in 
SMCs the actomyosin filaments are not arranged as regularly as in skeletal muscle, and so 
lack the striations which are so much a featur e of skeletal muscle^* .^ The rate of filament 
sliding is, furthermore, approximately xlOO to xlOOO slower, so allowing for prolonged, 
maintained contractions without fatigue, and with little energy consumption^*^. The 
contractile tension per unit area is, nevertheless, of the same order as that of skeletal 
muscle (about 30-40 N/m^), So, in the long term, VSMCs can support as great a load. Yet 
the energy consiuned in the process is some x 100 to x 500 smaller. This is an important 
point to bear* in mind when considering persistent vasoconstriction as a cause of VSM.
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The elastic “pull” of an acto-myosin flexing movement, however, can actually generate a 
force without any sliding, this constituting isometric tension (see below). It has been 
estimated that a billion of these actomyosin-induced elastic tensions, arranged in parallel, 
would constitute a 1 mN force in that muscle^*^. But each is not an isolated and fixed 
reaction. In reality, there is a continuous ‘attacliment-release’ cycle of these bonds @ 5- 
50Hz (with attachments lasting only i/ioo or i/io second). Therefore, so long as there is a 
normal level of cellular metabolism (see below), acto-myosin bonds are being continuously 
made and dissociated following activation by the appropriate switch mechanism (see 
second messenger systems). Yet, overall, the contraction itself appears smooth because, 
statistically, a certain number of units will be attached at any one time: the actual number 
being dependent upon the extent of the stimulus^* .^ Because of these repeated cycles, a 
certain amount of energy is lost as heat: the maintenance heat of contr action. This is 
essentially because only about 40-50% of the chemical energy associated with ATP can 
actually be converted into mechanical energy^* ,^
3.3 Muscle energetics
A major finding was that the addition of ATP to a solution of actomyosin resulted in the 
dissociation of actin from myosin^^^. That is, ATP is required to separate these two 
structures. Thus, when the two are connected there can be no relaxation of tone unless 
ATP is present564. This is, in fact, the situation in rigor mortis. Thus, if there had been, 
for example, an excessive amount of muscle activity pre-mortem (as in a violent struggle), 
then rigor mortis will occur all the more sooner post-mortem, as all the ATP may have 
been used up. This can prove important forensically. It may also be relevant to the 
possible mechanism of VSM (see below).
Thus, in the first “act” of the cycle, the ATP molecule separates the two filaments. Since a 
flexing movement had already occurred in the previous cycle, this release allows the 
myosin head to ‘spring back’ to its resting position. Almost immediately thereafter, the 
ATP-cleavage reaction commences, but it only remains half-complete:
MyATPase + ATP + HgO-^ MyATPase-[ADP + P/]
this is because although the myosin ‘head’ region actually functions as an ATPase, it can 
only function as such by a subsequent re-attachment to actin (with Mg^+ as cofactor)^* ,^ 564 
Thus the ADP molecule effectively obstructs the catalytic centre of the MyATPase, thus 
preventing it from completing its task. Subsequent fusion with actin, by allowing for the 
discharge of the [ADP + P/] bundle, thus permits the reaction to go to completions*^, 564 
The stored energy is, then, only released at this stage, and is reflected in the ffirther flexing
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of the myosin head upon its necks *9. Thus the stored energy is released only with the 
‘power stroke’. Another molecule of ATP may then come in order to commence another 
cycle. If the muscle as a whole is allowed to change its length, then this will result in a 
progressive shortening with each cycle. If, however, this is prevented, then tension will be 
maintained without shortening: an isometric contraction.
3.4 The implications of intensive and prolonged vasoconstriction: 
physiological sphincters
It would be prudent at this stage to consider the possible effects of prolonged 
vasoconstriction, as this represents to many the major mechanism behind VSM qua DCI. 
What is the evidence that such a profound and prolonged state is, actually, detrimental? 
Certainly, the complete physiological closure of a major vessel for any significant length of 
time would be, in the limit, terminal for the tissue supplied. However, is it necessarily so 
for the vessel wall itself? As already explained, SMCs are by nature able to maintain 
prolonged states of contraction with minimal energy consumption. Indeed, the pre­
capillary spliincters, to which MCAs bear many functional resemblances, are quite clearly 
able to maintain prolonged constrictions particularly with hypertension. But perhaps the 
SMCs that display this camel-like endurance par* excellance must be the sphincters of the 
urinaiy and gastro-intestinal tracts. Here, apart from brief episodes of relaxation, a 
continued state of near-maxhnal contraction can be maintained, it would seem, indefinitely.
However, even here there are degrees. Thus, although seemingly maximal, both urinary 
and anal sphincters can be voluntarily ‘squeezed’ by superadded contractions. It would 
seem that in the latter, at least, complete obstruction of the lumen is effected by expansion 
of the haemorrhoidal cushions. Indeed, in certain conditions such as anal fissure, an 
abnormally increased resting tone is the rule: tliis sometimes resulting in a lack of 
compliance known as anal stenosis. It would seem that in these cases the neuional input is 
predominantly present to afford a relaxation from this natural constrictory tendency. This 
is evidenced both in Hirschprung’s disease of the recto-sigmoid, and in achalasia of the 
cardia^ '^ 4^**. Indeed, achalasia means “failure to relax”. In both conditions, there is an 
aganglionosis of gut wall plexi, this permitting the development of pathologically- 
increased tone^^’ 4^**. Interestingly, with Hirschprung’s disease there is both an increased 
wall rigidity as well as a failure to relax with smooth muscle dilating agents'*^ ** This is 
clearly an analogous state of affairs to that seen with VSM. Yet, in contrast, a myonecrosis 
is not in evidence. In fact, at least with achalasia of the cardia, a SMC hypertrophy is 
apparent^^.
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Perhaps because major cerebral vessels are conspicuously lacking in vasa vasora (Part 2,
1.2), the limiting factor is dependent upon luminal diffusion to the vessel wall. Such a lack 
of vasa vasora seems surprising, as one might expect myogenic SMCs to be more energy- 
requiring. Nevertheless if the major energy source then derives from the lumen, such 
prolonged luminal narrowing may indeed result in medial ischaemic change.
3.5 Second messenger systems
These are agents that act as intermediaries relaying the membrane-signal to the active 
intracellular mechanism. They are thus membrane-transduction agents, acting as 
switches to the contractile m e c h a n i s m ^ 6 4  phey were first identified as intermediaries in the 
actions of hormones. In the same way, they are now established as the major 
intermediaries in the action of drugs. Probably only one, however, mediates the neurogenic 
skeletal muscle response: calcium (Ca).
In spite of there being an enormous variety of drugs and honnones, and therefore in their 
corresponding receptors, there are only a few  types of second messenger^^^. This is an 
important principle because the second messenger is usually a common and ubiquitous 
molecule, capable of being present in large supply at short notice. Clear ly, an infinite 
variety of second messenger would be unfeasible in this context. Because of this, one 
hormone combining with one receptor, for example, can result in the liberation of many 
more molecules of second messenger intracellularly. In tur n, the latter may activate many 
other messenger molecules, so resulting in a cascade reaction. This greatly amplifies the 
cellular response. For example, the concentration of many hormones in the plasma is 
around the 10-*** M level, yet intracellular Ca and cAMP are both considerably higher at 10" 
 ^M364. But not only must there be a large potential pool of second messenger at hand, 
there must also be efficient mechanisms for either its removal or de-activation. After all, 
a switch must be able to be turned-off as quickly as it is turned-on.
3.5.1 Vasoconstriction: Calcium
The essential “switch” to elicit neurogenic contraction is, classically, due to elevations in 
intracellular calcium (/Ca) levels. Thus, transient elevations fiom the resting 
intracytoplasmic level of 10 * M to that of over 10-6 effectively switch-on the conhactile 
machinery3*9,564 fact, there appears to be a dose-dependent effect of graded elevations 
in /Ca with contractile force generated, and with levels of ATPase activity^ *^ . Furthermore, 
if the level is maintained multiple single twitches will fuse into a tetaniform spasm, this 
maintained as long as the increased /Ca is maintained. Such contraction is maximal at /Ca 
levels o f  1 0 “5 M 5 1 9 ,5 6 4 .
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Precisely how /Ca switches the mechanism on, however, remains in dispute. With skeletal 
muscle, it involves conformational changes in troponin molecules which somehow force 
movements in long tropomyosin molecules lying parallel to actin filaments. Since 
ti'opomyosin ordinarily overlies SI myosin filament binding sites, such movement 
therefore exposes the ‘active’ region, so allowing acto-myosin bonds to form. In SMCs, 
however, another structure—Calmodulin— is involved in the Ca switclF*^, 564
Although the resting /Ca is around 10’^  M, skeletal muscles actually contain considerably 
more. In fact, they contain about 1 pM Ca per gm weigl#*9. Therefore, in order to prevent 
continual (tetaniform) spasms, this excess of second messenger requires ordinarily to be 
locked away. The major way by which this is achieved is by an active pumping of Ca ions 
across various membranes. The latter include not only the plasma membrane itself, but 
also membranes associated with intracellular storage: (the endoplasmic reticulum, 
mitochondria, and possibly others). The pump itself is a Ca-ATPase complex attached to 
the intracellullar membrane in question, and it is this complex that maintains /Ca
homeostasis^*^, 564
Thus, when the cell is appropriately stimulated, the /Ca rises. This may simply be achieved 
by a reversal of the above /Ca-extruding mechanisms. However, the major mechanism is 
via the influx of extracellular Ca (eCa) across the plasma membrane. There are many ways 
that this can be achieved. There are potential-specific Ca channels (PSCs) within the 
membrane, for example: these can open upon depolai'ization of the membrane. Similarly, 
there are receptor operated channels (ROCs), which can either themselves affect the 
membrane potential, or even open Ca channels directly. It is also possible that other 
second messengers can cause eCa influx, such as perhaps PKC. Rapid release of Ca from 
intracellular stores may be an important feature of action of various agonists (see below). 
Finally, there may be reciprocal interactions between these mechanisms: that is, between 
eCa influx and /Ca release. Thus, the initial release of /Ca pools may then trigger eCa 
influx; the eCa influx may simultaneously maintain actomyosin activation at the same time 
as replenishing the /Ca pools; some ER stores may directly communicate with the plasma 
membrane (and so become directly replenished along with eCa influx); there may even be 
present Ca-stimulated Ca membrane channels; and it is also possible that eCa influx itself 
may release /Ca stores?*» ??» 4^ *, 5i9,564_
3.5.2 Vasoconstriction: Phosphatidylinositol system
However, a SMC contraction can also be stimulated by another process completely 
independent of the Ca-calmodulin mechanism. This is achieved by Protein Kinase C 
(PKC), which works largely by an unknovm mechanism. It is quantitatively and
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qualitatively different from a “classical” Ca contraction^*^, 564_ Thus, it is slower to build 
up yet more persistently maintained. It also uses much less energy in the process^^s 
Some recent findings have suggested that receptor-mediated contractile (RMC) agents, 
such as nor-epinephrine (NE), can ‘reset the bias’ in the Ca-calmodulin mechanism^^^. 
Thus, for example, NE may serve to ‘up-grade’ the ca/calmodulin mechanism at each 
particular level. This could possibly be due to a direct effect of PKC upon the Ca- 
calmodulin mechanism *3 8.
However, whatever its precise mechanism, this represents a major way by which receptor- 
mediated contr actile (RMCs) agonists work. The receptor itself is largely biased toward 
the outer side of the plasma m e m b r a n e ^ 6 4  its inner aspect it is associated with a G 
protein, so-named because it can split guanidine ti'iphosphate^^^ (GTP). The agonist- 
receptor complex, by a conformational change, activates the G protein. This then 
phosphoiylates phosphatidylinositol diphosphate (PIP2) within the plasma membrane, 
generating both inositol triphosphate (IP3) and diacylglycerol (DG). Both of these 
agents subsequently play a crucial part in activating the intracellular contractile
machinery364,
IP3 liberates of /Ca from inti’acellulai' stores: therefore, this pathway activates the Ca- 
calmodulin mechanism (see below). Since IP3 may, in turn, become successively 
dephosphorylated into IP and IP2, and since these also achieve /Ca release, the effect may 
be perpetuated. Fui'thermore, IP4 may similarly be formed as a result of a further 
phosphorylation, and this effects an elevation in the /Ca by encouraging eCa influx^* ,^ 564
However, DG—by combining with a membrane associated phorbol ester—activates 
protein kinase C (PKC). This effects the phosphorylation of numerous intracellular 
proteins in the same way that all protein kinases do {see below). In this context it also 
activates the actomysosin mechanism, but by a process not involving Ca-calmodulin. It is 
also possible that an amount of /Ca released (perhaps by the IP3 pathway) which also serves 
to liberate the PKC pathway. Therefore, the phosphatidylinositol system potentially has 
much greater scope to effect vasoconstriction than the Ca-calmodulin pathway alone^ *^ » 364
3.5.3 Vasodilation: Cyclic Adenosine 3%5’ Monophosphate (cAMP)
cAMP was first discovered in association with its role as second messenger to several 
hormones (particularly the catecholamines). It developed phyllogenetically as a “hunger 
signal”. Thus in bacteria, it signals a relative ‘glucose lack’ to the cell, and thus triggers 
the de novo production of other enzymes, more suitable for the catabolism of alternative 
food substrates364. Whilst continuing to mediate this signal in mamalian cells (for
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example, epineplnine p-mediated hepatic glycogenolysis), it does so by the 
phosphorylation of protein kinases rather than by genetic transcriptioii364, ft is formed by 
the reaction catalyzed by the enzyme adenylate cyclase (AC):
ATP cAMP + PP/ +
Thus, cAMP derives from a potentially large source since ATP is a ubiquitous molecule. 
Though derived from a substance at the centre of cellular* metabolism cAMP has nothing 
further to do *with this process, and so can be independently controlled340,564 Moreover, it 
has a number of functional groupings capable of binding numerous protein kinases, so 
allowing for their activation. It functions by activating the normally unstable Protein 
Kinase A (PKA). This molecule consists of two regulatory subunits (R) and two catalytic 
subunits (C), and these are cleaved by cAMP in the following reaction, at cAMP 
concentrations around 10"^M340,564.
R2C2 (unstable) R2 + 2.C
Thus one molecule of cAMP liberates two catalytic subunits from PKA upon activation34o, 
364. These then phosphoi*ylate cellular proteins, thus activating them.
Adenylate cyclase is activated in similar fashion to that described for PIP2 {see below). 
Thus an agonist-receptor coupling results in the activation of an inner membrane-bound Gs 
protein, which then cleaves GTP. It is this latter reaction that activates AC: again on the 
inner membrane wall. However, AC may also be directly inhibited by an analogous inner 
membrane-bound Gi protein (which again acliieves this effect by cleaving GTP). Thus (3 
adrenoceptor stimulation characteristically elevates cAMP levels by way of Gs -->AC 
activation, whilst a2 adrenoceptor stimulation, on the contrary, decreases cAMP levels by 
Gi -> AC inhibition {see below).
cAMP itself can be switched-off by hydrolysis in the reaction catalyzed by 
phosphodiesterase (PDE):
cAMP + H2O AMP + H+
The activity of both AC and PDE can be subject directly to negative feedback 
mechanisms34o, 564 jftjg j^^y play a major role in agonist-induced desensitization.
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The mamalian brain has a enormous capacity for the metabolism of cAMP343 Thus, levels 
of both AC and PDE are considerably higher in the CNS than they are within most other 
tissues3?9. Almost certainly, it plays a major role in mediating cerebral metabolism, 
irrespective of its role in mediating cerebral vasodilation. Thus cAMP may cause an 
increase in the CBF both directly—by vasodilation, and indirectly by stimulating 
CMRO2 (metabolic regulation)'***» 379_ cAMP achieves vasodilation largely by enhancing 
the clear ance of /Ca. One possible mechanism proposed is by stimulation of membrane 
Na/K“ATPase339. By decreasing /Na levels, lesser amounts are then available for Na/Ca 
exchange; and thus /Ca levels become diminished in consequence^^^.
3.5.4 Vasodilation: Cyclic Guanosine 3’,5’ Monophosphate (cGMP)
In similar fashion, cGMP is formed by receptor-Gj* stimulation of the membrane-bound 
enzyme guanylate cyclase (GC): this then catalyzes the reaction
GTP -> cGMP + PP/ + H+
In similar fashion, cGMP exerts its effect intracellularly by the activation of a protein 
kinase: in this case, by activation of Protein Kinase G (PKG)34o. VSMC relaxation is 
achieved as with cAMP, by decreasing myofilament sensitivity to calcium344 and by 
decreasing /Ca levels344. However, PKG is activated without necessitating its dissociation 
into R and C subunits340. Whereas PKA is a ubiquitous enzyme, present throughout most 
species and phyla of the animal kingdom34o PKG, by contrast, is scarce in mamalian 
tissues, although comparable concentrations exist in the brain (cerebellum) and VSMCs340. 
Nevertheless, it has otherwise similar molecular and catalytic properties to that of PKA, 
and this suggests a similar phyllogenetic ancestry34o. Perhaps not surprisingly there is 
much evidence to suggest the two systems, cAMP and cGMP, to interact at various levels. 
Thus cAMP and its derivatives are capable of maximally-stimulating PKG activity34o. 
Similarly NO (cGMP) and PGI2 (cAMP) synergize markedly in platelets to inhibit 
aggregation^oo at doses where both agents alone are completely without effect. More 
specifically, it has been reported that stimulation of cAMP in VSMCs augments the 
response to NO^so. Recently, it has been shown that cGMP and cAMP may directly 
interact to produce vasodilation via a common mechanism, with both agents potentiating 
one anothei'666, cGMP (e.g. via NO release from SNP) can elevate levels of cAMP by 
inhibition of Phosphodiesterase IIP9?.
It is important to note the other cellulai* mechanisms which cGMP mediates at this stage. 
Thus decreased levels of cGMP, for example, are associated with the stimulation of 
myoproliferation in the vessel walP****. Therefore, decreased EDRF-NO, for example
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resulting from endothelial denudation, may result in the development of SIT. Whilst the 
administration of sodium nitroprusside, for example, can inhibit this response (see below)
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Chapter 4 
Cerebrospinal fluid and its properties post subarachnoid 
haemorrhage
4.1 Normal cerebrospinal fluid
The CSF is largely formed by the choroid plexus, where fenestrated endothelial cells 
abound. Thus the BBB is relatively ‘deficient’ here. However, a significant proportion 
(perhaps 30%) derives Jhom the ependyma, and interstitium, of the brain^^ .^
Ordinarily, there is a gradient for amino acids which favours flow from the plasma and the 
interstitium, toward the CSF. The CSF, therefore, acts as a ‘sink’ for these molecules.
This is because the choroid plexus constantly extrudes these against an ‘uphill’ gradient in 
addition to limiting entry from the plasma. Thus the concentration of, for example, L- 
arginine is around the 20 pM level within the CSF, but yet is considerably higher within 
the serum at up to 50 p,M. Similarly, the CSF protein and glucose levels are considerably 
lower than in the plasma. However, this was not always the case ontologically, since foetal 
CSF protein levels are up to x 40 that experienced in adult life^ ^^ ’ Contrary to early reports 
this is unlikely to be due to developmental differences in the BBB, but more likely instead 
to the rapid development of aforementioned ependymal protein-uptake mechanisms, thus 
forming a ‘CSF-brain’ barrier^^ .^
4.1.1 Sampling errors
It is important, however, to note that various CSF concentrations vary fi'om the site of 
CSF sampling. Thus protein levels progressively increase from the ventricles to the 
lumbar CSF^^e is also important to note that measurements of CSF pH are poorly 
representative of that pertaining in the immediate neuronal environment: (the latter being 
more acidic than the former). In this context, it must also be stressed that the assessment of 
neuronal metabolism based upon CSF sampling may also be fallacious: spinal CSF 
sampling, therefore, merely reflecting spinal neuronal m e t a b o l i s m ^ ^ ô
4.2 Post subarachnoid haemorrhage cerebrospinal fluid
The CSF of patients following acute SAH (SAH-CSF) is considerably different from that 
of normal. This fact has been used both diagnostically and prognostically. Thus, a CSF 
lactic acidosis^^  ^and fall in glucose leveP^o g^e often apparent at around the time of DCI. 
Although both may be epiphenomena, they may both directly impair cerebral function and 
thus cause further deterioration^^?. However, aforementioned sampling enors must also be 
borne in mind. Furthermore, temporal factors also introduce further sampling errors, the 
CSF varying with the time interval post SAH. As a result, this aspect of VSM-DCI study,
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as with so many others, has not always been a very precise science; the comparison of Tike 
with like’ frequently being called into question (Part 6, Section III). Nevertheless, several 
interesting findings have accrued.
4.2.1 Vasoconstrictory phenomena
Many authors have shown, for example, that SAH-CSF is vasoconstrictory. Some have 
shown that this is associated with massive influxes of extracellular Ca^^?’ (eCa) into 
VSMCs^^2,438 Yhat eCa influx can also be achieved by the mere application of surface 
blood^ "^^  might suggest the substance to be blood-borne. Bilimbin, for example, can also 
causes eCa influxi44. Another mechanism relates to the SAH-CSF breakdown of natural 
inhibitoiy mechanisms favouring vasoconstriction: for example, by inhibition of EDRF 
PGIi^^. A similar proposition was mae by Kanamura et aP^ ,^ who also noted that tliis 
effect was indistinguishable from that of the addition of mere surface blood. Nevertheless, 
studies that have specifically measured Hb levels in SAH-CSF have shown that these do 
not correlate with VSM^ s^ The overall consensus, therefore, is that the ‘unknown 
substance’ is merely that of Hb, and that this per se does not directly correlate with VSM or 
DCI—although it certainly causes vasoconstriction.
In a slightly more ordered experiment, Sasaki et al (1984) systematically added various 
antagonists to canine basilar strips pre-constricted with SAH-CSF (Type V VSM model; 
Part 4, 2.5)528 gg doing, they seemingly eliminated agonists such as 5HT and NE in this 
search, finally concluding the vasospastic substance to be either a “....prostanoid or a lipid 
peroxide”. Several others have arrived at similar conclusions^^, 509,539 yet many have 
shown the presence of 5HT and NE—in addition to prostanoids—within SAH-CSF'f’^ ; and 
VSMC culture with catecholamines has also resulted in the aforementioned iCa 
overload257. Furthermore, HbOs can also enhance agonist responses (Part 1, 1.4).
Hardly surprisingly, then, there is much non-uniformity in the literature regarding the 
characteristics of the SAH-CSF vasoconstrictory response. For example, SAH-CSF may 
cause an abrupt response when applied, or cause one only after temporal delay^?, 4^ The 
response obtained may exhibit rapid decay, or be somewhat more s u s t a i n e d ^ ^ s  Such 
variation strongly suggests a failure to compare Tike with like’ (Part 6, Section III). In 
summary, there appears to be no strong correlation between SAH-CSF vasoconstrictory 
activity and the development of VSM. Indeed, the former is often maximal earlier on 
when the incidence of VSM is remote^^?. Even if there were a strong correlation, it would 
be hard to deny that such enhanced tone ought to generally persist throughout the 
cerebrovasculature; throughout the post-SAH period. This, however, is clearly not the 
case.
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4.2.2. Myofibroblasto-proliferative phenomena
In marked contrast to the aforementioned, Yamamoto et aF^  ^demonstrated the intriguing 
finding that SAH-CSF could cause the de-differentiation of human SMCs in culture into 
myofibroblasts. This is both interesting and important because it suggests that agents 
acting as cytokines are present. Such results endorse the ‘structuralist’ hypothesis of VSM. 
For example, both of the cytokines interleukin 1 a  and p (IL-1 a  and IL-1 p) can induce 
fibroblastic proliferation in culture^^, and there is evidence accumulating indicting 
interleukins to be present within the SAH-CSF (Part 6, Section I, 1.6).
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Chapter 1
Agonists to be used and their properties
1.1 Introduction
It is proposed to use a combination of physiological and pharmacological agents in order to 
obtain an aiTay of MCA attributes in controls, shams and after SAH. Thus, certain 
physiological agents will be chosen that are either explicitly, or implicitly, connected with 
either VSM or DCI. Similarly, certain agents used therapeutically will be used to gain 
further characterization. It will be pointed out from the outset that there are severe 
practical limitations to the number of agonists that can be studied or their combination 
(Part 3, Chapter 2).
1.2 Potassium Chloride (KCl)
KCl is regularly used in small vessel agonist studies to primarily ‘test’ initial vessel 
viability—and at intervals thereafter. In low dose (up to about 10 mmol) KCl acts as a 
v a s o d i l a t o r ^ 2 5  this regard, KCl functions as an important mediator of metabolic 
regulation (Part 2, 2.5). With increasing concentration (>20 mM), KCl causes an ever- 
increasing VSMC depolarization and v a s o c o n s t r i c t i o n ^ ^ ^ s  most excitable membranes, 
the potential across them is largely dictated by an asymmetrical K distribution^^, si9 This is 
because greater amounts of K+ ions must accrue intracellularly to balance an excess 
organic cations. A negative transmembrane potential ai’oimd -94mV is created^'^^ this 
approximating to the overall membrane p o t e n t i a l  Thus, increasing the eK+ will reverse 
transmembrane polarity. However, only a small change in this potential is required to 
activate smooth muscle tension. For example, there can be a 30% increase in tension 
consequent upon only a 4 mV change in potential, and an 80% increase can follow a 
depolarization of 14 mV^? .^ Such a depolarization may be apparent following either 
denervation or acute SAH {see below).
The K+ contraction characteristically consists of two components: a peak (phasic), 
followed by a plateau (tonic) response usually smaller in magnitude (Fig 15). It is 
thought that both responses are largely due to the opening up of potential-specific charmels 
(PSCs) within the VSMC membrane (Part 2, 3.5). Thus KCl’s action is totally dependent 
upon the presence of adequate amounts of external Calcium (eCa). However, unlike the 
case with receptor-mediated contractions, the K response is independent of the 
endothelium and the co-release of any EDRF'^?’ ^ 26
Although producing reliable and characteristic vasoconstrictions there are several reasons 
for not wishing to use KCl as a pre-constrictor of vessels for a subsequent vasodilator
78
study. Thus a prolonged KCl depolarization can be irreversibly detrimental to vessel 
function. As a result, endothelial-dependent vasodilations may be less efficacious 
following KCl vasoconstriction^^?. Indeed, KCl can cause significant endothelial 
damage542. Because some vasodilator studies require over half an hour, such prolonged 
KCl contact could be detrimental. Moreover, the KCl response may be affected by SAH^? .^ 
635,641 KCl was not to be used as the pre-constricting agent in vasodilator studies in
this thesis.
1.3 Norepinephrine (NE)
The catecholamines epinephrine and norepinephrine (NE) have widespread effects 
thi'oughout the body. NE, in particular, may be important after SAH, as not only is it a 
prime neurotransmitter within the SNS, but it also present in significant amounts within 
platelets. The latter are, of coui'se, in plentiful supply within the SAH clot. NE is 
synthesized intraneuronally fiom the substrate tyrosine. This is first hydroxylated into 
DOPA (dihydroxyphenylalanine), and then subsequently decaiboxylated into dopamine (3- 
hydroxytryptamine). The latter is then finally (3-hydroxylated into NE^ .^ NE, in turn, may 
be catabolized by two major mechanisms. One involves catechol-o-methyl transferase 
(COMT) extraneuronally; the other, a mono-amine oxidase (MAO) largely found 
intraneuronally23. Even so, the vascular endothelium can also take up and destroy both NE 
and 5HT by MAO mechanisms'll^ Although most NE released (probably up to 90%) is 
subject to re-uptake into the SNS neurone, and thus made available for re-use?^; this does 
not appear to be the case with cerebral vessels^o.
Adrenoceptors hold a classical place in pharmacology in that they were the first to be 
studied and classified. The first major categorization was by Ahlquist in 1948 who 
suggested the classical division into a  and (3 adrenoceptors. The p receptor was clearly 
distinguished by its insensitivity to the ergot alkaloids and, ultimately, by its selectivity to 
isoprenaline. Therefore, Ahlquist’s classification was based pur ely upon drug sensitivity 
and not physiological effect. As a result each receptor could, depending on the tissue, still 
actually mediate stimulatory or inhibitoiy effects—it was only the drug-binding character 
of the receptor that mattered in this classification. The throe major physiological agents 
epinephrine, norepinephrine and dopamine could, however, be effective at both receptor 
types, with different potencies? f ?^, 42
A further contribution came in 1967, when Lands et al showed that there were two 
subtypes of p receptor. These were distinguishable by their different tissue distributions; 
and by their differing affinities to NE. Thus the p i receptor was found mainly in the heart 
and adipose tissue, and appeared equally sensitive to both agents. However, the p2
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receptor was mainly associated with the smooth muscle of the blood vessels, the airways 
and the uterus; and was considerably more sensitive to epinephrine than to NE. In 1974 
Langer subdivided a  receptors into a l  and a2 subtypes, initially based on anatomical 
grounds (a I receptors were mostly post-synaptic, a2 receptors pre-synaptic). However, 
this was soon extended into a physiological subdivision, the drug prazosin specifically 
combining with a l  receptors (a2 receptors could also be post-synaptic). More recently, the 
p3 receptor has also been identified, this being associated with neonatal brown fat 
stimulation'll > 77,421
However, it soon became clear that the a  receptor heterogeneity represented no mere 
subdivision as with p receptors. Thus the a l  and a2 receptors were as distinct from each 
other as they were from the p receptors. In consequence, it is far more useful nowadays to 
classify the adrenoceptors into three main groups a l ,  a2 and p, for three main reasons:
• Differences in agonist affinity vary most between these groups, rather than within 
them.
• The second messenger systems differ only between these groups.
• Amino acid sequencing suggests three groupings rather than two.
In fact, this has now set the precedent for the classification of all receptor types: namely 
drug-related properties, signal transduction mechanisms, and finally genetic/amino 
acid profile?! ??’ 42i.
1.3.1 a l  receptors
Responses can be summarized as?*’ ?7 42! ;
• Epinephrine and NE equally effective.
• All labelled with ^H Prazosin.
• Tend to mediate SNS responses.
• All associated with increased iCa.
The mechanism of action may actually vary between agonists. The most established 
mechanism is that of activation leading to IPs-zCa release fiom intracellular stores, and 
PKC activation. Additionally there are direct G protein linkages to membrane PSCs, thus 
causing eCa influx. There may, in fact, be two G proteins associated with a l  receptors. 
One links to PIP2, the other to PSCs. It may be that only activation of both reflects full 
agonist activity at these receptors. Activation of only one (the PSC) is indicative of 
partial agonist activity. The fact that low dose (<10'^ M) NE vasoconstriction is not 
associated with a membrane depolarization., whereas higher doses are indicate such 
channels to not be opened at lower doses. However, the situation may be more
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complicated as stimulation of cyclic nucleotides, phospholipase A2 or even 
phospholipase D may also result form a l  activation?f ?"^ ' 42
1.3.2 a2 receptors
Responses can be summarized as' i^’ 42 u
• Epinephrine and NE equally effective.
• All labelled with Yohimibine.
• Tend to mediate circulating catecholamine responses.
• All associated with inhibition of adenylate cyclase: (i.e. ‘anti-P’ effect).
The major mechanism of action here is Gz (inhibitory) activation inhibiting AC, this 
depressing intracellular cAMP. It is unlikely, however, that there is a basal cAMP release 
in resistance vessels for which to inhibit. Therefore, other mechanisms are required to 
explain the pressor effects of a2 stimulation here. Thus, a2 receptors may also be directly 
linked to PSCs, a2 stimulation thus enhancing eCa influx. Again, the situation may be 
complicated further still by activation of K channels, phospholipase A2 and increased 
Na/H exchange?!’ 77, 421 _
1.3.3 Preceptors
Responses can be summarized as'^ !’ 421.
• Epinephrine xlOO selectivity at P2 receptor
• NE more potent at p3 receptor
• Propranolol p i, P2 »  P3 receptors
• All activate adenylate cyclase
The common mechanism here is straightforward G.y activation of AC with elevation of 
cAMP. Again, there may also be direct connexions to membrane PSCs, especially in 
cardiac muscle.
It is laiown that all three receptor types can be present upon the same cell, but that usually 
one predominates in any particular tissue??. The permutations increase even fmther when 
we contemplate that all tliree types can appear in all three major locations (VSMC 
membrane, pre-synaptic SNS membrane, and endothelium). Such receptor combinations 
could mediate opposing (a2 versus p); redundant (pi versus p2); or synergistic (a l and 
P especially in the heart)??. There is some evidence that the a2 receptor is both more 
common in the non-human animal kingdom, and that it mediates less potent 
vasoconstrictoiy responses^!!?. However, the apparent association between the a2 receptor 
diminished responses may well be because of a2 endothelial presence^ü^. Here a2
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stimulation results in simultaneous EDRF release: either PGÏ2^^f or N0^43-245,679 
Jones et al noted that, within the coronary circulation, a l  receptors predominated on the 
small arteries, whereas the a2 receptors were more present upon the arterioles^^^. They 
noted a significant EDRF component to NE agonist tone associated with a2 endothelial 
receptors, this being ‘unmasked’ by L-NAME. This explains why NE responses are 
diminished in certain locations (e.g. the coronary circulation) where it would be 
undesirable to have adrenergic influence. Perhaps this is also the case, then, within the 
cerebrovasculature^!!?
The NE response, like KCl, is composed of phasic and tonic components. However, the 
phasic response is neither as abrupt nor as large. Although it has always been hoped that 
clearly-defined mechanisms would explain these two components, no such clarity exists. 
Certainly in some vessels, the phasic response appears more dependent upon eCa; yet in 
others the converse is true?!» ??= 421 _
1,4 5 Hydroxy Tryptamine (5HT) (Serotonin)
1.4.1 Introduction
5HT is a widespread physiological agent; with widespread functions. Probably its most 
important is as a neurotransmitter within the brain. But it also has widespread effects 
upon smooth muscle thr oughout the body. Of particular’ relevance are its cerebrovascular 
effects, its release from mast cells, and its release from platelets. It has long been 
considered to be instrumental in the development of VSM. This is probably because it has 
been similarly implicated in various other ‘vasospastic’ states such as Raynaud’s 
phenomenon, Prinzmetal’s angina and migraine. It is also present in the CSF of patients 
following SAH^ '^ Virtually all of the circulating 5HT is locked up in p l a t e l e t s ^ ^ ô ,  3 2 3 ,6io 
Since reserpine also depletes 5HT from both p l a t e l e t s ^ 4 9  and n e u r o n e s 4 0 5 ^  it is possible that 
reserpine exerts its VSM-protective effects by 5HT inhibition in addition to NE 
inhibition555,584 (Part 1, 1.3.2.2). More interesting still, 5HT possesses VSMC myo- 
proliferative effects^^  ^ Thus, 5HT may play a role in both str’uctural and functional 
mechanisms associated with VSM.
1.4.2 Receptor heterogeneity
With NE one may reasonably derive the impression that adrenoceptor subtypes developed 
as genetic polymorphisms, which subsequently became established as the result of 
evolutionary pressures. If so, then the situation with 5HT denotes an extreme one. Thus, 
in excess of fifteen receptor subtypes have evolved to cater for— seemingly—one 
agent^? .^
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Three major 5HT receptor divisions contain further subtypes. The first major division 
(5HTi) has five subtypes: SHTia-e- This first grouping is quite a heterogeneous one. 
Certainly the 5HTic receptor appears to have more in common with the second gr oup 
(5 HT2), and there have been some calls to re-classify it as such. But as a group, their 
common feature is their transduction of decreased intracellular cAMP levels via a 
negative (G-protein adenyl cyclase) coupling. Cerebral vessels contain 5HT]-like 
receptors in the MCA, BA and pial vessels. These may be directly linked to PSCs as with 
a  receptors: certainly this may explain their strong contractions. Sumatriptan acts as an 
agonist, and methiopin as a non-specific antagonist, at these receptors '^^ .^
5 HT2 receptors activate platelets, and mediate bronchoconstriction and non- 
cerebrovascular function (5HT2a). They commonly transduce by stimulating PIP2 
breakdown. The 5HT2c receptor has also been shown to mediate the composition and 
volume of CSF. Ketanserin effectively antagonises at these receptors, and was formerly 
used therapeutically in the treatment of another ‘vasospastic’ condition (Raynaud’s 
phenomenon)
5 HT3 receptors mediate cellular depolarization and therefore eCa influx: this is 
important in triggering the Ca-calmodulin dependent nitric oxide system, and can result in 
vasodilation via increased cGMP {see below). They do not couple to membrane G 
proteins. Ondansetron (a potent anti-emetic) is the antagonist at these receptors^?^.
5 HT4 receptors stimulate adenyl cyclase and elevate intracellular cAMP levels.
Metoclopromide can exert agonistic effects at these receptors. The transductional 
characteristics of the 5HTs receptors are unknown: these receptors mediate the effects of 
LSD (lysergic acid diethylamide), for example^?^.
1.5 Prostaglandin F2a (PGF2a)
1.5.1 The prostaglandins
The biochemical activity ultimately associated with prostaglandins (PGs) was actually 
discovered as long ago as 1930 in a sample of human seminal fluid. It was not until 1957, 
however, that Bergstrom and Sjovall successfully purified and isolated the first of these 
lipid acids! Ü5. Thus, PGE and PGF were identified based upon whether they were 
exti'actable from ether (E) or not (F). Von Euler later coined the term “prostaglandin” in 
reverence to the organ of their original discoveiy (prostate gland). The chemical structures 
of these two agents were not elucidated, however, until 1962. They were then formerly 
identified as PGE] and PGF2a: lipid acids with peculiar cyclopentone rings. Since then the 
main family has been designated alphabetically fiom A2 to H2. The letter characterizes the
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ring structure; the numerical subscript the number o f double bonds in the side chains^^^. 
This classification has now been extended, to include two rather unstable compounds with 
prostaglandin-like activity: the “prostanoids” thromboxane (TXA2) and prostacylcin 
(PGI2). Both are vitally important to haemodynamics. PGs are synthesised by the action of 
cyclo-oxygenase on the precursor polyunsaturated fatty acid (PUFA): 5,8,11,14 
eicosatetraenoic acid: arachidonic acid. At an early stage, an alternative reaction pathway 
can lead to the formation of leukotrienes'^^5.
A feature of PGs and receptor-interaction is that the latter ‘autoregulate’. Thus, high local 
concentrations of agonists result in rapid ‘down-regulation’ of transduction mechanisms, 
or in decreased receptor binding s i t e s T h i s  resembles the tachyphylaxis of CAs. The 
second messenger mechanisms vary between each group: these will be discussed with each 
subtype. PGs can be released in vivo by both NE acting at a l  adrenoceptors, and by 
Hb0 2 !^ ’^ 601 acting on the endothelium.
1.5.2 Prostaglandin receptors
The action of the five naturally occurring prostanoids, PGD2, PGE2, PGF2c(^  PGI2 and 
TXA2, are now known to be mediated by complementary receptors thus designated DP, EP, 
FP, IP and TP. Therefore, PGE has its greatest affinity at EP receptors; PGF at FP 
receptors; and so on. As might be anticipated, there can be cross-reactions within this 
scheme. Yet in comparison to other hormones receptor-selectivity is impressively 
conserved. This is in marked contrast to the catecholamines, tachykinins, and even the
related leukotrienes^^^.
DP receptors are present on platelets, VSMCs and in the CNS. Apart from mediating 
painful stimuli (hyperalgesia), they are generally ‘inhibitory’ in nature. Thus, they are anti­
aggregatory and vasodilatory agents. The transduction mechanism involves a Gs protein 
mediated elevation of cAMP by the stimulation of AC’^ .^
The E P  receptors are the most complicated. The most relevant are the E P 3 receptors which 
mediate VSMC contraction and aggregate platelets. They interact with two G proteins. 
Thus Gz coupling decreases intracellular levels of cAMP by the inhibition of AC, and G^ 
coupling induces the breakdown of PI?2 ^^ .^
The IP receptors are mainly associated with VSMCs and blood platelets. They mediate a 
profound hyperalgesia, but otherwise are quite ‘inhibitory’. Thus, they mediate 
vasodilation and aie anti-aggregatory. They are present mostly on aiteries: rarely on veins. 
The transduction mechanism involves G5 stimulation of AC to elevate intracelullar cAMP.
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However, it has become apparent recently that, in some cases, they can mediate a 
vasoconstriction: in this case they elevate zCa levels by some unknown m e c h a n i s m !
TP receptors are predominantly present upon platelets and VSMCs: they are thus the most 
‘specialized’ of the series. TXA2 acting on these does so in an opposing fashion to that of 
PGI2 at the IP receptors. Therefore they tend to elicit vasoconstrictory and platelet 
aggregatoiy phenomena. TP receptors are far more widely distributed in the vasculature 
than IPs, and may play a major role in pathophysiology. With perhaps particular reference 
to the process of VSM, there are TP receptors present upon myofibroblasts: thus, TXA2 
ordinarily mediates the process of wound healing !ü5.
1.5.3 PGF2a
Whilst PGF2a is a potent FP receptor agonist, analogues were not formerly particularly 
selective, there being appreciable agonistic activity at both EP and TP receptors. However, 
current PGF2a analogues are increasingly selective, with little or no ‘cross-reactivity’. 
Moreover, the FP receptor itself is ‘pure’ in that there have been, as yet, no subdivisions of 
this receptor found. FP receptors are widespread throughout the body, but are especially 
present upon VSMCs!ü5. PGF2a may mediate uterine contractions, as well as the 
constriction of the long spiral arteries of the uterine wall causing menses (Part 1, 1.3). The 
transduction mechanism is predominantly via Gq membrane protein activation of PIP2ü!^ . 
Thus, PGF2a results in contraction by both PKC and zCa mechanisms. In addition, there is 
some evidence that a second and separate phase of Ca elevation occurs as a consequence of 
eCa influx. Thus, PGF2a produces reliable and prolonged contractions for indefinite 
periods, it therefore being the ideal contractile standard in most agonist studies^?!- ^ 52 jg 
one of the strongest vasoconstrictors known, and can maintain constriction even in a Ca- 
free medium.
1.6 Uridine 3% 5’ Triphosphate (UTP)
The major nucleotides usually studied are the purines, in paificular adenosine. Adenosine 
is a significant vasodilator within the microcirculation which, as a ‘waste product’ of tissue 
metabolism, functions in metabolic regulation (Part 2, 2.5). However, UTP, a pyrimidine, 
acts as a vasoconstrictor in cerebral arteries and, therefore, is not likely to play a role 
comparable to adenosine. Whatever its precise role, this remains relatively unexplored 
within the CNS. This is in spite of the fact that the brain represents a rather rich source of 
this nucleotide (30p,M/100g tissue)^!^. The apparent disregard for UTP becomes more 
surprising when one considers that UTP may be relatively specific in function toward the 
cerebrovasculature. Thus, systemic injection fails to elicit any pressor response at all !^4,
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whilst negligible conti’actile responses are achieved in isolated coronary or mesenteric
vessels^ !4
The attraction of UTP to the current experiment becomes heightened upon consideration of 
its contractile attributes. For example, UTP produces a prolonged vasoconstriction of 
cerebral arteries that lasts up to 7 hours dogs, or 20 hours in humans^!4 Such a result can 
also be achieved in vivo, thus defying the principle that most spasmogens are rapidly 
inactivated in free-form within most biological fluids^ This relative absence of 
tachyphylaxis distinguishes UTP from other VSM contenders such as 5HT ’^52-6S5^  and is in 
marked contrast to the often rapid tachyphylaxis seen with catecholamines (Part 3, 3.2). In 
addition, its immediate metabolite, midine diphosphate (UDP) may share similar 
properties^!4 uxP  is, of course, stored in significant amounts witliin blood platelets, along 
with serotonin (5HT) and norepinephr ine (NE)
There are specific receptors for the pyrimidines^!4 although these remain under-explored. 
Such pyrimidoceptors would provide as targets for therapeutic antagonism should UTP be 
shown to influence VSM. However, UTP may exhibits receptor heterology, cross-reacting 
with purinoceptors^!4. This must be taken into account when developing the appropriate 
antagonist.
hi cerebral arteries, UTP also produces phasic and tonic responses. The intracellular 
‘second messenger’ systems ar e probably similar to those of other receptor mediated 
agonists. Thus, it has been concluded that UTP can result in the opening of both ROCs and 
PSCs in the cellular membrane, as well as the quick release of membrane-associated zCa !^4. 
The latter may quickly trigger the former, and tliis may be the mechanism behind both the 
rapidity, and the increased magnitude of the phasic to the tonic response^!4.
1.7 Papaverine (PPV)
Papaverine (PPV) is an example of a pharmacological agent to be used in this study. It is 
an opiate alkaloid, with potent vasodilatory actions in a wide range of vascular beds!^. 
However, it can also dilate other smooth muscles, and may cause a mydriasis if infused 
close to the origin of the opthalmic arteiy^^ .^ It is thought to act directly on VSMCs by 
inhibiting phosphodiesterase in the sarcoplasm: the build-up cyclic adenosine 
monophosphate (cAMP) then reduces /Ca by a number of mechanisms'!'^. However, it also 
may directly interfere with the Ca-calmodulin machinery. Because it is moderately 
lipophilic it should be able to exert its effects both intra- and extra- luminally; as is indeed 
clinically apparent. However, PPV may have a longer half-life when administered 
extraluminally into the cerebrospinal fluid (CSF)463,537,634^  and it may be even longer in the
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region of a clot where the ‘washing-action’ of CSF may be deficient^!4 jg frequently 
used extraluminally at craniotomy by topical application onto vessels within the operative 
field. The intraluminal route is used more specifically to reverse angiospasm following 
SAH. Maximally effective concentrations are in the 10"^  M region^o .^
1.8 L-arginine (L-ARG)
The importance of the endothelium with vasodilation by agents such as acetylcholine 
(ACh), was first hinted at by Furchgott in 1980. By 1984, evidence for a diffusible 
substance that passed from the endothelium to the VSMCs had been obtained!^^, this agent 
being refened to as an endothelial derived relaxing factor (EDRF)^! .^ It appeared to be 
a very unstable substance, particularly in the presence of superoxide anions, hyperoxia, 
methylene blue, and (of great relevance to VSM) Hb. The latter principle stresses the 
importance of the tight nexi between the endothelium and the VSMC^o .^ By 1987 there 
was much evidence accming identifying nitric oxide (NO) as the EDRF4?s, it soon was 
demonstrated that NO was produced from L-arginine within the endothelial cell by the 
activity of the enzyme nitric oxide synthase (NOS)4? .^ It was evident that, at least with 
systemic vessels, NO was constantly released under basal tonic conditions in vivo, this 
sometimes amounting for up to 20-40% of the total NO-release possible?^—a shear stress 
representing the stimulus required for its release.
NOS was soon found in other tissues such as in the brain (where it could also function as a 
neurotransmitter), and within platelets. It only required NADPH as cofactor, and released 
NO in picomolar amounts. However, this process was dependent upon the activation of the 
intracellular calcium/calmodulin system^^ .^ It was found to be a constitutive enzyme 
(cNOS), present in fixed amounts within tissues, the cNOS present within neurones and 
blood vessels being distinguished as type I and type II respectively^!^, xhus:
L-ARG —> NOS -A  NO 
Upon diffusion to adjacent VSMCs, NO then becomes the substrate for GC to produce 
cGMP426. Thus, all NO-forming agents—such as the organo-nitrates—similarly function 
by the formation of intracellular cGMP.
However, it had been known since 1983 that rats treated with E.Coli lipopolysaccharide 
(LPS) had a high urinary nitrate output which correlated with the degree of the pyrexia426. 
Even further back, it had been known that macrophages stimulated by cytokines (from 
sensitized lymphocytes) exhibited non-specific cytotoxicity toward micro-organisms426.
In fact, they were also cytotoxic to neoplastic cells. In neither case, however, was this 
dependent upon phagocytosis426: rather it involved target cell inhibition of DNA 
replication426. Granger and Lehninger then showed^!^ that such non-specific cytotoxicity
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involved an inhibition of target eell mitochondrial respiration at the levels of complex I 
and II in the electron transmitter system. Others, in turn, showed that the eitric acid 
cycle enzyme aconitase was similarly inhibited by a soluble factor from appropriately 
stimulated macrophages^^^. Formerly identified as NO, potent inliibition of cytochrome 
oxidase was obtainable in the (higher) nanomolar range^^s. Biochemically, NO appeared to 
combine with (non-haem) iron-sulphui* gi'oupings at the catalytically active site, foiming 
iron-nitrosoyl complexes which inactivated the enzyme^^ .^ This effectiveness clearly 
varied between cells, with some being cytotoxic and others cytostatic.
A clue to this ‘other side’ to NO came from Rees et al in 1990503. They showed that 
endothelium-depleted rat vascular rings incubated with lipopolysaccharide (LPS) 
produced de novo NOS, predominantly within the VSMCs503. This, therefore, tied in with 
the findings of Wagner et al 1983, and appeared inextricably linked with the ‘macrophage’ 
findings. Thus, NO could also be formed by other cells in response to “infection risk” 
stimuli. It was soon apparent that this de novo NOS differed markedly from its 
constitutive relation (cNOS):
• It was Ca/Calmodulin independent.
• It could be induced either by LPS or directly by cytokines.
• It requires NADPH, tetrahydrobiopterin, flavine adenine nucleotide, and reduced 
glutathione.
• It was not subject to any cellular control mechanisms: i.e. it will continue to form NO 
from L-ARG unless either the substrate runs out, or the cell dies426.
The distinct form of NOS was therefore referred to as /NOS: {inducible NOS). It may be 
of supreme importance to the CNS as the appropriate cytokines can be stimulated, in great 
quantities, by processes as seemingly umelated as acute bacterial meningitis and SAH. 
Thus, widespread release of excess NO in these circumstances can be cytotoxic both to 
foreign cells as well as to host cells; zNOS producing indefatigable amounts of this 
cytotoxic agent. For example, IL-1 p has been shown to stimulate /NOS production in 
VSMCs, endothelial cells, microglia, astrocytes, and f i b r o b l a s t s ^ ^ o ,  443
As aforementioned, Hb has a strong affinity for NO: a fact known since 1865263. In 1957 it 
was shown that Hb combines with NO with xl500 greater affinity than with carbon 
monoxide (00)269. It has also been shown that topical application of blood to cerebral 
vessels effectively inhibits tonic NO activity, leading to vasoconstriction. This has 
therefore been proposed as a mechanism for VSM. However, Hb predominantly inhibits 
extracellular NO since Hb cannot gain easy access to the intracellular milieu^! !. A priori
Hb may not readily affect a VSMC source /NOS. Hb may, in turn, actually augment IL 
Ip production of more 573
NO has more diverse effects still. Its role as a neurotransmitter has already been 
mentioned—particularly when released from nitroxidergic neurones^^^. It also has 
important anti-platelet and anti thrombotic properties, which it shares with PGI2 {see 
below). It may even interact with PGI2 in this r e g a r d N O  particularly appears 
protective against injury-induced arterial thrombosis426. It is also mast cell stabilizerioi 
389; and, as such, would be expected to possess marked anti-inflammatory properties, 
especially in the context of ischaernia-reperfusion irrjury3ii, 34i particularly important in 
this regard would be the preservation of the BBB in the presence of platelet activating 
factor release from endothelial cells^^fi and from mast cells^oi. In fact NO has been shown 
to be positively beneficial in stroke^??.
Finally, NO has potent anti-proliferative effects. Basally released NO is essential not 
only for counteracting vessel tone but also for damping down the release growth factors^o .^ 
Chr onic administration of L-ARG effectively reduces the SIT that develops in response to 
non-specific vessel trauma263,234  ^whilst impairment of EDRF release correlates with the 
degree of SIT286. In this context, basic fibroblast growth factor (bFGF) appears 
important in restoring any endothelial damage and increasing NO production, following 
vessel trauma4i4.
It should be pointed out that “EDRF” is now known to actually be more than one agent. In 
fact, it is probably at least three. For example, prostacyclin, PGI2 {see below?), is also an 
EDRF which shares many of NO’s other properties {see below): the two agents possibly 
interacting in some of these aspects. Another EDRF is associated with hyperpolarization 
of the VSMC membrane (endothelial dependent hyperpolarizing factor, EDHF). However, 
there is some evidence that NO itself may be associated with a hyperpolarization of the 
V SMC membrane.
There may be bountiful amounts of the substrate L-arg in the blood in certain conditions 
(up to 45-148 p,M)426. Its concentration within the CSF is normally around 20 nmol/L: but 
this may increase to 80 pmol/L with the presence of subarachnoid blood^o ,^ as do most 
amino acids except taurine.
1.9 Nco-Nitro-L-Arginine Methyl Ester (L-NAME)
Nco-nitro-L-arginine methyl ester (L-NAME) acts as an analogue of L-ARG which 
competitively interacts with NOS. Instead of forming NO, however, it results in the
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formation of an inactive complex. Thus, it antagonises NOs effects^o .^ When injected 
systemically into normal rats, it causes an elevation in MAP concurrent with a marked 
decrease in VSMC cGMP^^. This, therefore, suggests that NO is ‘basally’ released within 
the systemic circuit, tending to constantly counteract background tonic activity {see above). 
Such basal release may also be present within the cerebrovasculature, at least within the 
BA. Thus, addition of L-NAME in vivo diminishes CBF, at least transiently563. L-NAME 
is, therefore, predominantly used to assess ‘basal’ release: either in vitro or in vivo.
1.10 Sodium Nitroprusside (SNP)
Sodium Nitroprusside is another example of a pharmacological agent to be used in this 
study. It is an ‘organo-nitrate’ like isosorbide nitrate (ISN) and glyceryl trinitrate (GTN), 
and is thought to produce its effect primarily by the ‘spontaneous’ liberation of NO within 
VSMCs. This concept derives from the practical observation that solutions of the 
compound aie very unstable experimentally, particularly in the presence of light^^J?, 
Perhaps it is too simplistic then to refer to such ‘spontaneous’ liberation. Nevertheless, the 
presence of reducing agents do greatly promote this effect (even the presence of red cell or 
VSMC membranes achieving this)^!. Whatever the precise mechanism, somehow integral 
to this process is the simultaneous release of cyanide within VSMCs^ f  Although cyanide 
potentially accumulates as NO is released, this is not ordinarily a problem as NO is so 
potent it is effective at lower concentrations where little cyanide toxicity would accme^^J?, 
426. But with higher doses, and particularly following prolonged usage, this becomes an 
ever-present d a n g e i ’426. Such toxicity could also he a theoretical problem within the 
context of the cuirent experiment. Because of this, the duration of exposure at each dose 
was kept to a minimum, and the bath copiously washed out with saline solution at the end 
of each study.
Therefore most of SNP’s effects ought to resemble those of NO or other NO-donors {see 
above), hnportantly, this does not require the presence of the endothelium. Therefore,
SNP assesses NO activity independently of endothelial release. There is some confusion as 
to whether Hb may actually interfere with NO release fr om SNP (or with other 
nitrosovasodilators). Kim et al found that Hb in CSF could inliibit the effect of the 
nitrosovasodilators, by suppressing GC activity32s. Feelisch and Noack, however, found 
the opposite result!69. The situation may be different with the cerebral vessels: particularly 
in vivo within the CSF.
SNP is most often used in neurosurgical practice to obtain controlled systemic 
hypotension immediately prior to aneurysm manipulation. However, it has also been 
used to directly reverse clinical and angiographic VSM^^s. Natur ally, the risk of an acute
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fall in MAP has tended disfavour such use. Nevertheless, some have found that this need 
not necessarily occm’û!?, whilst others suggest that regional CBF may only suffer in the 
telencephalic or neocortical regions^o?.
1.11 Histamine (HA)
A major source of HA is within mast cells (MCs). MCs are present within the systemic 
and cerebral vasculature! 12, 154,202 However, they are said to be more prevalent in 
association with vessels having ruptured from a berry aneurysm^o !66. Thus, they may 
have been present in increased amounts prior to SAFI (Part 2, 1.4.2). HA may, however, 
also be associated with non-MC sources. There have been several allusions to these^o?, 
some authors demonstrating MCs to be present within medial VSMC layers!59. HA is also 
an important neurotransmitter^^o, 259
There are non-uniform reports in the literature as to the type of response that HA effects 
within the cerebral vasculature. Ultimately, HA responses may depend upon the 
concentration used, the systemic vascular bed, or the species: the latter being particularly 
important. Thus, many have found HA to be vasoconstrictory in dogs, cats or rabbits! !’ 44?, 
568. I n  contrast, in mice HA may have no obvious effect5!2, whilst in p r i m a t e s 5 0 9 , 643 and 
humans595 HA is a cerebrovascular dilator. HA is also a cerebrovascular dilator in rats.
Whatever its ultimate cellular response, HA achieves this effect via three different kinds of 
membrane receptor: HAl, HA2 and HA3. The HAl receptor classically mediates capillary 
Teakiness’ via endothelial receptors and cGMP mechanisms. However, HAl-mediated 
vascular permeability is conspicuously absent in the CNS, even when applied topically^s». 
This may result from the fact that although the capillary endothelial cells take up HA from 
both sides the vessel wall, HA is subsequently released only on the luminal side^??. The 
HAl receptor may be blocked by agents such as chlorpheniramine.
HA2 receptors mediate gastric acid secretion and can be blocked by cimetidine or 
ranitidine. However, they also appear to mediate most o f  HAs effects within the 
cerbrovasculature, this being achieved via cAMP mechanisms288,452 HA can also release 
EDRF via endothelial H A l receptors, thus effecting vasodilation via cGMP 
mechanisms569. Cerebrovascular responses in most cases are HA2-mediated259
1.12 Hypoxia
Hypoxia can be achieved in in vitro studies by bubbling a mixture of 95% N% and 5% CO2 
over several minutes. The effective p02 can then be directly ascertained fr om the saline 
bath. CO2 responses are more commonly used in cerebral vessel studies, since CO2 is
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ultimately a therapeutic weapon. Nevertheless, it is difficult with in vitro studies to isolate 
the effects of CO2 from that of the acidosis necessarily created. Furthermore, hypoxia is 
able to dilate MCAs from baseline MT without any preconstriction being required, this 
being achieved via non-NO EDRF release^^  ^ Hypoxia may thus serve the dual function of 
measuiing MT as well as confirming endothelial function. The EDRF released is probably
a prostanoid!93.
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Chapter 2 
Permutations and combinations
It is important to appreciate that agonists do not, of course, work in isolation within the 
physiological milieu. This may be considered both a limitation as well as an advantage of 
in vitro models (Part 4, 4.2). Thus, agonists occur physiologically in combination with 
others with which they may ordinarily interact^? ,^ 655 Such interactions may be either 
additive, synergistic, inhibitory, or non-existent. Furthermore, effective agonist 
concentrations may vary dependent upon local concentrations of catabolic enzymes, for 
example. Even the ambient temperature may vary in vivo between regions. Thus, in 
cooler regions (e.g. fingers and toes) agonists may effect different responses, such 
temperature-dependence explaining the distribution of diseases such as cryoglobulin- 
induced Raynaud’s phenomena and Leprosy, for example. Fmthermore, although 
homeostasis ultimately supervenes in vivo, this is often only after significant local 
fluctuations.
In vitro studies therefore circumvent these problems by, as far as is reasonably possible, 
controlling all such variables (Part 4, 4.2). This allows for the identification of isolated 
vessel properties. Between the two extremes of in vivo and in vitro there are obviously a 
vast number of intermediate agonist permutations possible, all potentially analyzable in 
vitro. Thus, although one must start by noting isolated characteristics, one must, 
ultimately, build up a picture of how these may interact cumulatively.
The problem is, of course, that the number of possibilities is prohibitively vast. For 
example, in the cuirent study it is proposed to analyze the isolated properties of up to 10 
agonists: a mixture of vasoconstrictory and vasodilatory substances. Since each requires, 
following suitable periods of wash-out and equilibration, about one hour in order to be 
completed, up to 10 hours (Part 4, 7.4) would be required to study all 10 agonists. This, in 
turn, would be additional to the time taken to obtain the vessels (VA hours in controls, and 
up to 6 hours following operation!). Since all current in vitro studies follow directly on 
from any operative model—no vessels were fridge-kept for use on subsequent days—this 
all has, therefore, to be accomplished within the confines of one day. As a result, this 
obviously places a great limitation upon any proposed further study of agonist 
combinations.
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Such agonist combinations can be numerized. For example, the choice of r items from a 
total of n possibilities (where the order is unimportant, i.e. a combination) is governed by 
the equation:
n!nQr — (n-r)!  r!
the sign ! denoting the factorial of that integer chosen (i.e. 4! = 4x3x2xl).
This would apply to combinations such as [NE + PPV], [HA + SNP], [5HT + L-NAME] 
etc. Therefore, if we were to repeat the study using two agonists at a time (from a total of 
ten), instead of using each in isolation, then one could do this in:
10! 10x9 -  45 ways8!2! 2x1
Similai’ly, one could choose a combination of three agonists in 120 ways; four agonists in 
210 ways; and five agonists in 252 ways.
Thus, although conceptually attractive, the concept of using sequential agonist 
combinations in vitro is not really tenable. One combination that is necessarily used in the 
current study is, of course, that of [vasodilator + PGF2a] (see Part 5, Results). 
Nevertheless, other combinations were attempted, in pai’ticular that of PPV with SNP (see 
below). The concept of permutations and combinations will be referred to again later, in 
the assessment of the nature of receptor-mediated responses. It is quite likely that VSM 
may be much better explained by such i n t e r a c t i o n s ^ ^ s
94
Chapter 3 
General properties of agonists relevant to vasospasm
3.1 Introduction
Here we discuss the effects of an abnormal increase or decrease in the amount of agonist 
upon ‘end-organ’ responses. The main example is that of NE acting as neurotransmitter 
between the SNS and VSMCs, but the principle may be more widespread. Such 
consideration leads us frequently to regard the relationship as one of a ‘homeostasis of 
effector-cell function’.
3.2 Agonist-induced desensitization
A feature of some agonist-receptor interactions is that of a rapidly-developing 
tachyphylaxis. Tliis is a particular property of catecholamines, particularly when acting in 
a hormonal capacity: but it may also be appai'ent with PGs^^s. It is particularly well 
developed within the pineal g la n d   ^f  In some cases agonist incubation for only 30 mins 
or so will result in an 80% loss of effect. This is not completely explained by a decreased 
receptor density as decreases here may only amount to 17%664. in many cases the 
subsequent recovery of normal responsiveness requires de novo protein synthesis. 
Alternatively, de novo protein synthesis may be required to effect receptor ‘down- 
regulation’ in the first place. Whatever the mechanism, adenyl cyclase alone is a 
prerequisite664. Ultimately it entails two processes separated by time. The acute 
desensitization is effected by receptor uncoupling. Up to 50% can be uncoupled in this 
way, this being achieved by a disconnection of the receptor from the membrane G protein. 
Thus, any agonist-receptor combinations are functionless. Eventually in the chronic 
situation, however, the receptor number itself becomes reduced664.
3.3 Denervation Supersensitivity (DSS)
Denervation can have many differing effects, this dependent upon the particular nerve, its 
situation, and transmitter substance released. It also depends heavily upon the 
completeness of the denervation. The main principle to be discussed here is with regard to 
VSMCs and transmitters such as NE, 5HT and UTP. In 1949, Cannon and Rosenbleuth 
formally described the gradual development of a supersensitivity of the skeletal muscle 
membrane following acute denervation^^. This was particularly so to the corresponding 
transmitter, acetylcholine, and it involved an increased number and distribution of 
nicotinic receptors, as well as diminished transmitter degradation within the synaptic 
cleft^ .^ But it also involved a certain non-specific increase in membrane sensitivity. This 
is clearly apparent with the endless fibrillations observable in the deneivated muscle
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clinically!! .^ The latter principle is even more apparent with smooth muscle denervation 
(see below).
In theory, there are two basic kinds of DSS^^!. Following denervation where neuronal 
reuptake foims a major route of transmitter ‘disposal’, maximal concentrations of 
transmitter may therefore pertain within the synaptic cleft. This constitutes deviation 
supersensitivity. Here there is no genuine increase in the efficacy of the response, the 
latter being maximal merely because of maximal agonist concentrations. However, 
within the CNS, there are ample means with which to dispose of this accumulated 
transmitter, so this may be of limited potential in this situation. In any case, continued 
maximal NE would soon lead to agonist-induced desensitization (see below). Therefore 
the other major type of DSS, adaptive supersensivity, will be the one considered instead.
In this “truer” form there is a genuinely increased target cell responsiveness (see below).
3.3.1 Optimum level of target cell activity
Here the target cell appear s to possess some form of homeostatic ‘set-point’. Thus, the 
target cell possesses a certain level of optimal function to which, following under­
stimulation, it strives to return to^^i. Following skeletal muscle denervation any form of 
electrical activity within the sarcolemnal membrane will maintain the functional integrity 
of that muscle: hence the use of faradic stimulation in states of reversible paralysis. This 
suggests that membrane stimulation is the only requirement here. But the organ that 
demonstrates homeostasis of fimction par excellance, however, is that of the pineal 
gland!8!, 664 Here, following any apparent increase in glandular stimulation mechanisms 
are immediately set in motion to decrease the target cell response. Alternatively, periods of 
decreased stimulation result in the gland developing a supersensitivity to subsequent 
stimulation. The target cell appears to largely achieve these aims by variations in p 
adrenoceptor density, variations in the degree of adenyl cyclase activity, and variations in 
the levels of cellular phosphodiesterase activity. Whatever the case, it would appear’ that 
some tar get cells appear to possess ‘memory’ of optimal activity levels required!
3.3.2 Inhibitory trophic substance
In other cases it appears as if some substance—either co-released with the 
neur otransmitter or actually that of the neurotransmitter itself—acts as a continuous 
inhibitor of maximal target cell function!8!, Thus, following removal of 
neurotransmitter from the scene, the target cell response becomes ‘up-graded’ to any 
subsequent stimulation. For example, the injection of high doses of botulinurn toxin (BT) 
into skeletal muscle results in a complete denervation and, therefore, in a full DSS.
Modest doses of BT, however, result in much lesser degrees of DSS. Modest doses are
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used clinically to suppress the over-stimulation of certain muscles, such as the facial 
muscle in hemi-facial spasm. In moderate dose, BT still allows the basal release of 
neuronal quanta in order to maintain background levels of MEPPs (miniature end-plate 
potentials). Since DSS Is less pronounced, tliis therefore implies that basal amounts of 
trophic inhibitor ai’e continuously delivered. In another example, following adrenergic 
denervation of the cat nictitating smooth muscle membrane, the status quo can 
subsequently be restored upon re-inneiwation with even cholinergic neurones! Thus, any 
transmitter will suffice in this case! Such a promiscuity of effector cell sensitivity 
following deneivation is a frequent finding in VSMCs^^!.
In other situations the ti'ophic substance is clearly not the neurotransmitter released. The 
application of either colchicine or vinblastine to a neurone, for example, specifically 
inhibits axonal transport without affecting transmitter release. The DSS that subsequently 
occurs, then, is clearly independent of neurotransmitter release. An interesting analogue of 
this that of hepatic function following adrenalectomy. Normally, epinephrine stimulates 
hepatic glycogenolysis via p receptor-adenyl cyclase activity. Adrenalectomy results in an 
increase in receptor density and in enzyme activity. However, in order to decrease the 
latter back to normal, one has to administer cortisone and not epinephrine. Thus, adrenal 
steroids act as the trophic substance in this case. This is not as fanciful an analogy as it 
might seem as the adrenal medulla is, in reality, an extremely enlarged and elaborated 
synaptic bouton within the SNS^^^’ 664
The latter example reflects an important principle because, theoretically, denervation will 
result in the gradual development of DSS in spite of the continued presence of the 
‘transmitter’ from an ectopic source. Such a situation may pertain following SAH: here 
denervation occurs in the presence of copious platelet-derived NE. Should a DSS 
subsequently pertain, then this would occur' in the presence of large amounts of transmitter.
3.3.3 Membrane meehanisms for DSS
The development of non-specific DSS in VSMCs involves membrane depolarization in 
addition to increases in the /Ca pooE®!. There are also increases in intracellular IP3 
present, and the Ca-calmodulin system appears ‘up-graded’. In some situations, there is 
increased cell-cell coupling present. Normally any agonist will only simultaneously affect 
a few cells due to the constraints of diffusion, but in some cases an enhanced synchrony of 
contraction is apparent due to the presence of increasingly efficient tight junctions. 
Following DSS, VSMCs characteristically become sensitive to many agonists 
indiscriminately!^!. As a result, the process of DSS appears attractive in explaining VSM; 
particularly with regard to its temporal delay {see below).
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3.3.4 Time course of DSS
Whatever the case, DSS characteristically develops some days after the denervation^^h A 
good example follows the chemical destruction of rat forebrain serotonergic neurones. 
Here, there is a specific DSS to 5HT within the first week, this coinciding with the 
disappearance of serotonergic histology. After this time a non-specific increase in 
sensitivity develops, eventually developing into a promiscuity to other agonists such as NE 
and y-amino butyric acid (GABA)
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Chapter 1 
Experimental models for the production of acute 
subarachnoid haemorrhage
1.1 Introduction
Apart from the controversial discovery of the calcium antagonist nimodipine, none of the 
results of current ‘clot-VSM' studies have so far led to the development of efficacious 
treatment strategies in clinical DCL Such a failure suggests that either DCI is primarily a 
species-specific phenomenon, or that such models are flmdamentally flawed (in either 
design or application). Since most cuirent ‘SAH’ models are in reality only models of 
VSM (i.e.‘clot-VSM’ models), such models overlook: 1) the central physiological 
disturbance (i.e. systemic and intracranial pressor effects) associated with the acute ictus, 
and 2) the properties of the ruptured vessel per se. The potential gravity of the acute ictal 
disturbance is reflected by the frequency of sudden death and coma clinically.
The purpose of this Part of the thesis is to critically review all experimental models that 
have been used to derive data for either SAH, VSM or DCL The review will include both 
aspects of the thesis: i.e. the animal model used to create a representative SAH, as well as 
the small vessel study model used to subsequently assess cerebral vasoreactivity. The aim 
will be to delineate each model’s assets and deficits: however, particulai* attention will be 
paid to identifying any potential flaws in design or application which may explain the 
model’s failure to yield clinically-useful results. In light of this knowledge, a means of 
small vessel study of MCAs following a representative SAH will be conceived which, it is 
hoped, will overcome many— if not all—of the pitfalls thus identified. In consequence, the 
hypothesis will be formally tested that events associated with acute SAH elicit changes in 
MCA physio-pharmacology that are independent of any subsequent effects of chronic clot 
lysis—thus undermining the assumption implicit in ‘clot-VSM’ models that delayed VSM 
and DCI merely result fr om the chronic effects of clot lysis upon normal cerebral vessels.
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1.2 Type I: Rupture of cerebral artery within a ‘closed’ skull
Vessel rapture can conceivably be achieved from within vessels (endovascular) or without 
(extravascular). The fact that not only is the former more physiological, but also an ever­
present risk from such procedures as angiography, may make it seem somewhat surprising 
that no such model had hitherto been referred to^^L Most efforts instead have involved 
some form of craniotomy or craniectomy. Whilst often only being carried out on larger 
animals such as primates and dogs, this does not necessarily have to be the case^ ®.
By far the most common route taken for such access is the trans-orbital route. By such 
means, the MCA, PCommA and the distal ICA have all been accessed. This procedure 
necessarily involves exenteration of the orbital contents and, therefore, adds in the further 
variables of surgical mutilation and immunological effects. Nevertheless, extremely useful 
models of SAH have been achieved and, where performed following healing around the 
rupture-device, within an essentially ‘closed space’. All studies have usually documented 
well the acute changes in ICP, MAP, and CBF. Most have, additionally, studied some 
other area. For example, Nagai et al studied neur onal histopathological changes and 
ischaemic tliresholds in monkeys following PCommA rupture^^s  ^whilst Shigeno et al 
studied cerebral oedema formation following ICA rupture in the cat^ '*^ . Kamiya et al 
documented changes in metabolic regulation and autoregulation in primates after PCommA 
rupture whilst Clower et al directly assessed isolated cerebral vessel compliance 
following MCA rupture in monkeys
Avoidance of orbital exenteration has been achieved by alternative approaches. For 
example, Asano and Sano achieved an extensive and detailed study of acute 
pathophysiological changes via temporal craniectomy and ICA rupture in dogs^^: 
unfortunately, this was not accompanied by any vessel study. Toda et al, in contrast, did 
study vessel responses following ICA rapture in the dog^^ :^ however, they employed the 
helical strip method—a decidedly unphysiological model {see below). Others have utilized 
a fronto-temporal craniectomy. For example, Mendelow studied in vivo responses 
several days following MCA rupture in monkeys^ ^^ :^ however, specific vessel 
responsiveness was not examined in this study (this being inferred instead from overall 
CBF effects). In an interesting alternative, Barry et al used a midline clival craniectomy 
anteriorly to directly study in vivo BA responses, in rats^ .^
Although all of the above models have successfully reproduced the circumstances 
associated with the acute ictus, they have all the potential setbacks associated with 
craniectomy. Since most necessitate the prior placement of the rupture device, they impose 
the superadded variables of inflammatory reaction and infection over a period of several
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days. Probably because of the belief that such models could only be performed in larger 
animals, their use has subsequently fallen into decline. However, Barry et al have clearly 
shown that small animals can be used^o
Vessel rupture models closely represent the physiological ‘ideal’. It is therefore surprising 
that most current models specifically avoid arterial rupture as the source of SAH.
Although it may be the case that such avoidance relates to perceived cost and efficiency 
considerations in model requirements, it is probably more likely that most current 
researchers appear content to attribute DCI solely to VSM; and to attribute VSM to merely 
the prolonged surface contact of autologous blood with cerebral vessels. The cuiTcnt 
author regards this trend as a most disturbing one.
1.3 Type II: Artificial injection of autologous blood into the 
subarachnoid space
With the need to achieve increased efficiency in all aspects of SAH-VSM research, there 
has been a vastly increased tendency to use autologous blood injection to simulate SAH. 
After all, when reduced to first principles, this is exactly what SAH appears to represent: an 
injection of blood into the subarachnoid space (SAS).
1.3.1 Type Ha: with ICP-rise
In most cases, blood-injection models are achieved by injections posteriorly, via a cisterna 
magna (CM) catheter. A good example is that of Peterson and Car doso who produced 
BBB disturbances by autologous blood injection into the CM. It is pertinent, however, that 
the latter authors specifically avoided steep ôlCP/ôts in their study'^^  ^(see below). In one 
sense, CM injection models feasibly represent posterior CoW SAH such as may occur, for 
example, with rupture from a posterior inferior cerebellar artery aneurysm. However, since 
80% of aneurysmal SAH actually derives ftom the anterior CoW, posterior injection 
studies represent the considerably rarer clinical scenario.
In principle, the rapid injection of any fluid into the SAS ought to achieve hydraulic effects 
equivalent to those observed with autologous blood injection or SAH. Several 
experimenters have, indeed, confirmed analogous ôlCP/ôts, ôBP/ôts, cardiac arrhythmias 
and pupil abnormalities to those seen with SAH clinically with CM saline injections^^^’
444. Such studies, in fact, formed a considerable part of Cushing’s original studies^ 
Nevertheless, equivalent ‘hydraulic’ effects between blood and saline are not invariably 
witnessed in experimental studies. For example, Lacey and Earle found that a rapid 
injection of blood into the CM of Sprague-Dawley rats elicited a much greater AICP than 
that observed with either saline or Dextran 40^ 43,344 jj^  another study, blood was more
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efficacious at reducing CBF for the same AICP as that seen with sal ine^Moreover,  CM 
saline injections do not result in VSM: blood is definitely required for this444. Indeed, 
saline injections may even elicit a v a s o d i l a t i o n ^ 48 possibly by diluting the [ K + ] c s f -
The recreation of more representative anterior SAHs have been made by some 
investigators. In one model, autologous blood injection was performed trails- 
hemispherically into the basal cisterns of rats via long plastic cannulae inserted through 
convexity burr h o l e s ^ 4 4 , 345 an interesting variant, Yamashima and Yamamoto injected 
autologous blood via the optic canal into the chiasmatic cistern of dogs, along with various 
“test” agents such as epinephrine and In the latter study, injections were made
rapidly and under pressure in order to mimic the clinical scenario. As a result, these 
authors produced vessel morphological change in addition to the expected acute hydraulic 
effects. In some cases the authors injected the “test” agent alone, this constituting a Type 
III VSM model {see below). The authors showed that injections of “test” agents alone 
could produce vessel change as well as a meningeal reaction^^^.
One setback with all of the above models, however, is that autologous blood must be 
withdrawn from a peripheral vessel (or, even, in one case by direct caidiac puncture!) prior 
to its subsequent i i ^ e c t i o n ^ 4 4 , 345 _ xhus, haemolysis of the sample may introduce fuither 
variables, such as the injection of free haemoglobin and, potentially, high K+ 
concentrations. Furthermore, systemic hypotension and sympathetic activation may also 
follow venesection '^^^’ 481, particularly in a smaller laboratoiy animal. A final problem 
relates to the fact that most aliquots aie heparinized. Since heparin can clearly interfere 
with vascular remodelling469  ^this could be of crucial importance in a model that was 
promulgated to produce chronic VSM.
An ingenious way to overcome at least some of these setbacks was described by Steiner et 
al in 1975^^f These authors used direct shunts of blood from extra-cranial vessels to the 
SAS. Usually blood was shunted, via a tap and tubing, from the femoral arteiy (FA); and 
the SAH produced terminated by its own tamponade within the SAS. By such means, 
blood was shunted to several sites; and not just into the CM. By droplet-flow 
measurement, it was shown that—more, or less—the same volume of blood (Vy: 20 mis) 
was passed irrespective of the site: although maxima and minima were obtained in the 
spinal canal and brain parenchyma respectively. Furthermore, the V e was similar even 
when blood was shunted into a container; this implying that haemostasis was not 
dependent upon acute vasospasm in vivo (at least in dogs). Unfortunately, a considerable 
column o f ‘dead-space’ blood is apparent in such models; this possibly proving critical in 
the smaller laboratory animal. Yet, in spite of this (and other) shortcomings; and in spite of
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laying dormant for many years; this model has recently been revived—once more in 
dogs402. In this latter study, it was demonstrated that SAH lasted in excess of 4 mins: this 
emphasizes the occasionally prolonged duration of SAH^o .^
1.3.2 Type lib: without ICP-rise
The premise that the mere surface contact of autologous blood causes VSM (and ipso facto 
DCI) has reached its nadir in type II SAH models. At present, such studies represent the 
majority of SAH-VSM investigations. In these studies, sometimes great lengths are made 
to avoid steep ôlCP/ôts. The more usual involve the slow injection of small quantities of 
blood over relatively prolonged periods*^ ^^ . However, many also remove an aliquot of CSF 
equivalent to the V e immediately prior to blood in je c t io n 6^8,304,3Js, 362,635 Some have 
also simultaneously measured the ICP in order to ensure that no AICP actually o c c u r s ! ^^8 
Because most of these studies involve an unpressurized injection into the CM posteriorly, 
all of these animals are required to be tilted head-down in order to allow the blood to re­
distribute anteriorly304,3is Furthermore, as aforementioned, posterior blood injections 
denote the least common clinical analogue (see 1.2.1 above).
In order to allow for gieater Ves to be applied, some models have incorporated the use of 
in-dwelling catheters over a period of several days. Such models, however, superimpose 
the significant risk of bacterial infection; although this is claimed, naturally enough, to be 
“negligible”’2^ . The possibility of super-added bacterial infection is exti'emely important to 
the study of VSM, because VSM angiographically and morphologically indistinguishable 
from SAH-VSM is frequently obseiwed with bacterial meningitis (Part 1, 1.3.2.2). 
Nevertheless, and in spite of this risk, the “double haemorrhage” model (and, more recently 
the “triple haemorrhage” model) are both, cunently, the most popular SAH model in 
existence^^^.
In order to improve upon some of the aforementioned short-comings, other groups have 
recently returned to the production of craniotomies. However, such craniotomies have not 
been made to allow access for vessel rupture as in a type I model. Instead, they have been 
used merely to permit gi'eater quantities of blood (V e) to be placed, under direct vision, 
around pai'ticular vessels, unilaterally (the MCA being the most f i ' e q u e n t ) ’ '^4,494 
Impressive Ves can be applied by such means—yet all without steep ôlCP/ôts ^ 99. Such 
models require especial mention because, by such means, the contralateral vessel is often 
considered the paired ‘control’. The latter form of study is, usually, the biostatistical 
ideal; and usually permit a reduction in experimental numbers. However, with SAH-VSM 
paired-control studies are maiTed by the fact that clot-product diffusion may also affect the 
contralateral vessel. Such studies, therefore, may not truly create an isolated control.
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Moreover, there are other reasons—discovered and emphasized in the current study—why 
‘paired-control’ studies may not be appropriate with cerebral vessels (Part 6, Section II,
1.1).
1.4 Summary of subarachnoid haemorrhage models
The earlier models of acute SAH that produced SAH by arterial rupture were, ironically, 
the closer to the physiological ideal. Although they served largely to document acute 
physiological disturbances—systemic and intracranial—that accompanied SAH, at least 
some also attempted to study VSM-in-evolution. In contrast, more recent SAH models 
have increasingly focused only upon ‘clot-VSM’. The premise in such studies is that VSM 
is caused by surface blood ‘irritation’ following chi'onic clot lysis; and that VSM, in turn, is 
the cause of DCL However, since VSM qua DCI is not axiomatic, a clear dichotomy 
between the two processes should be maintained and emphasized in experimental 
studies—in the same way that has been proposed c l i n i c a l l y ^ 82 (p^rt 1, 1.5).
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Chapter 2 
Experimental models for the production of vasospasm
These models are required to be distinguished from SAH models. They are concerned only 
with the faithful reproduction of analogous vessel morphological change; and the 
production of angiographic constriction. They assume that VSM is the conditio sine qua 
non of DCI. Conceivably, then, there are thi'ee main types:
2.1 Type I: Activation of the cerebral sympathetic nervous system
In practice, probably no such model has successfully been developed. This is because most 
attempts to activate the cerebral SNS have, thus far, only activated the ascending cervical 
supply by way of the stellate ganglion. This, of course, supplies only a part of the total 
cerebral SNS (Part 2, 2.6). For example, D’Alecy and Feigl stimulated the stellate 
ganglion in ventilated dogs and noticed CBF reductions” 9. However, these authors also 
noticed that, rather incongiuously, the ICP became elevated! A recent study by Pilati et al 
came closer to the ideal: the authors injected veratrine or citrate directly into the CM493.
By such injections, these authors created a systemic sympathetic “storm” by an activation 
of the medullary vasomotor centre. Such a study would be clinically representative 
because the cerebral SNS is probably only influential at higher MAPs (Part 2, 2.6). 
Unfortunately, the authors in this study did not simultaneously study the cerebral 
vasculature (their aim being instead to create left ventricular dysfunction and ARDS). 
Because NE and 5HT both function as cerebrovascular neuiotransmitters, the addition of 
these to the CM (Type III below) may prove representative'^-
2.2 Type II: Application of adventitial autologous blood in vitro
Type II VSM studies are, in principle, equivalent to Type Ilb SAH models (see above). A  
good example would be that of Tsuji and Cook (1988), who added blood directly to canine 
BAs in vitro^94
2.3 Type III: Artificial injection of biochemical agents into the 
subarachnoid space
Such models concentrate upon the effects of blood constituents putatively responsible for 
VSM. In this regard, applications of NE, UTP and 5HT ai e all theoretically feasible. For 
example, NE was injected into the subarachnoid space by Yamashima and Y a m a m o t o ^ ^ g .  
UTP by Urquilla^’3,6i4. ^nd 5HT by Cardoso et artss. Such models may also be used to 
enhance type II SAH models, such as in the studies of Wang et afr^ o or Yamashima and 
Y a m a m o t o ^ ^ 9  above). In another variant, Nagata et aM^ re-created a comparable VSM 
by the addition of talc to the CM of dogs. The latter underscores the “imtative” principle
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of VSM aetiology, and reaches its pinnacle in the next type of VSM model to be described 
{see 2.4 next).
2.4 Type IV: Direct vessel trauma
The main example here is that of Symon et al 1967^“^ .^ hi this study, the authors produced 
VSM in the MCA of baboons by repeated compression with non-toothed forceps.
However, although this was successful at producing acute VSM, a prolonged VSM rarely 
resulted. It is interesting, however, that a recognized treatment for VSM (that of local 
intra-arterial PPV) is also efficacious at reversing traumatic VSM^^2
2.5 Type V: Artificial injection of cerebrospinal fluid from subarachnoid 
haemorrhage patients
CSF obtained from patients after SAH has often been used to supply the putative 
vasospastic agent directly to isolated vessels. For example, Sasaki et al utilized human 
SAH-CSF in an attempt to isolate the nature of the putative vasospastic s u b s t a n c e ^ ^ s  
Yamamoto et al provided indirect evidence that SAH-CSF produced cytokine-like activity 
toward cultured fibroblasts. *^ 8^ The problem with Type V VSM studies is that they include 
errors in both temporal and spatial CSF sampling (Part 2, Chapter 4); as a result, there is 
a great non-uniformity in results obtained.
2.6 Summary
• The majority of cmrent models are of Type lib autologous injection. Such studies 
totally betray the profound physiological disturbance associated with the acute ictus. 
The unphysiological nature of such studies is reflected in their low mortalities, and 
impossibly high sui'vivals (>90%)—a finding clearly incompatible with the high 
incidence o f ‘sudden death’ clinically.
• As well as being easier to perform, the Type Ila model is also more physiologically 
sound: yet is rarely performed. In addition to displaying all the faults associated with 
autologous blood injection {see above). Type Ila studies also betray acute vessel- 
rupture as the all-important source of the haemorrhage.
• In models employing acute vessel ruptuie (Type I) local craniectomies are invariably 
used. The latter may result in a wide array of additional variables being introduced, 
including inflammation and infection. Perhaps because of their complexity, few have 
proceeded to subsequently study isolated cerebral vessel reactivity.
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T able 4. Summary of SAH and VSM models
SAH Model Cerebral vessel 
rupture
ICPt V e
I y / variable
Ila X / variable
lib X X large
Key. I arterial rupture within a closed skull, Ha autologous blood injection into 
subarachnoid space with ICP rise, lib  autologous blood injection into subarachnoid space 
without ICP rise.
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Chapter 3 
Proposed model for the production of acute subarachnoid 
haemorrhage
3.1 The importance of vessel rupture
It is important to consider vessel rupture as this alone has been deemed the major 
differentiating factor between experimental SAH groups.
Most muscular arteries develop a functional spasm following haemon'hage through a 
breach of their walls. Some authors have hinted that such spasm results from a local 
neurovascular reflex^46  ^and Duckies et al have demonstrated alterations in both imieiwation 
and reactivity in monkey cerebral arteries following aiterial rupture’ i4i since SIT 
primarily follows endothelial damage’ and since the latter must necessarily accompany 
r u p t u r e ’"^8^ this hints that vital reparative processes may be triggered by ruptuie that would 
not otherwise be triggered by the mere addition of surface blood. Certainly SIT appears 
intimately linked with vessel trauma per se^ ^^ , 584 (Part 1, 1.3.1.4). Further along these 
lines, an inhibitory heparan-like substance—derived from the endothelium84—has been 
shown to basally suppress VSMC proliferation, the production of which is increasmgly 
released by a rejuvenating endothelium after injiuy469. Interestingly, Clower et al have 
demonstrated that rupture models tend, on the whole, to produce the most extensive 
morphological change of all SAH studies’O”. In addition, rupture models also more 
successfully recreate the decreased cerebral vessel compliance which is so much a feature 
of vessels in VSM’””.
In interpreting the above findings, some have proposed that rupture allows the infiltration 
of blood elements—under pressure—into the vessel walP”^  gy qjjs means, blood and its 
contained agonists—such as platelet-derived growth factor (PDGF)—can, thus, be directly 
applied to target cells with minimal loss of effect. More recent studies have shown that 
vessel trauma results in the expression of c~fos and c-myc proto-oncogenes within 
VSMCs—the increase in c~fos being proportional to the injury s u s t a i n e d ^ ^ z  % u s ,  VSMC 
rupture elicits considerably more SIT than does mere endothelial d e n u d a t i o n ’^ 5,282 
Other groups have shown that the trigger towards SIT involves auto- and para- crine 
cytokine production, in addition to gi’owth factor release^^  ^ a  single transient stimulus can 
result in the considerable expression of local PDGF and FGF (fibroblast growth factor) by 
such mechanisms89.
Whatever the underlying mechanisms, a quite overwhelming case for vessel mptui'e 
appears to be extant for precise SAH study.
I l l
3.2 Proposed experimental subarachnoid haemorrhage model for the 
current study
The main criteria for the production of a representative SAH were set out by Shigeno et al 
in 1982^46 Thus, for any putative model there should be;
• Bleeding from acute vessel-rupture intracranially.
• Acute pressuie-loading (acute ICP rise) within a closed skull.
• A sufficient amount clot produced.
To these one should add;
• Endovascular filament (EF) rupture without craniotomy.
EF rupture without craniotomy was achieved in the current study by simply passing a 
length of fairly rigid 3/0 prolene intracranially within the lumen of the ICA, from a remote 
(extracranial) source in the neck. The thread was then made to ruptme thi'ough the anterior 
CoW with minimal force before being withdrawn, thus allowing abrupt extravasation 
(Plates 5, 7 and 9). The model was essentially that developed in this laboratory”^  ^but with 
important modifications {see below). Other variations on this theme have subsequently 
been described4”- 4i, 236,302^
3.3 Details of the method used for the production of subarachnoid 
haemorrhage
All animals were anaesthetized with 25% urethane [with two exceptions^], injected 
intraperitoneally (Ig/Kg), and then transfen-ed to a hot plate which served as the work 
surface for the entire procedure. A rectal probe was inserted to record the core temperature 
tliroughout, this being kept at around 38°C. The animal breathed spontaneously on air (or 
an air- 0 2  mixture, as required).
Following micro-dissection in the left groin, using small spring-loaded scissors and 
forceps, the left femoral artery (FA) was isolated from its vein and nerve. The distal FA 
was then tied, following which the femoral vein was coagulated: this was because the left 
leg was invariably became ischaemic. Through a small slit in the upper surface of the FA, 
a saline-pressurized cannula was inserted and advanced into the lower abdominal aorta. 
This was then double-tied, and the wound closed with 3/0 silk to obviate fluid loss. 
Through this cannula both MAP and arterial blood gases were continuously monitored, 
with frequent infusions of normal saline being given to maintain hydration. No 
heparinization was used. The technique was perfected so that no haemorrhage occurred 
whatsoever, thus obviating the risk of haemodynamic compromise throughout.
*One animal each from SAH Grp 2 and 3 were anaesthetized with liypiiorm (0.5mg.ml"'hr' fentanyl,
5mg.ml *hi-' fluanisone)/hypnovel (midazolam) — only without paralysis and ventilation.
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After carefully turning the animal prone, a m idline incision was made from the vertex to 
the spine o f  C l . Follow ing careful m icrodissection o f  the suboccipital m uscles, a small 
plastic cannula was inserted into the CM through a nick in the suboccipital membrane. 
This manoeuvre w as carefully performed under m axim um  m agnification, so as to ensure 
cannula positioning
ACA
Circle of 
Willis
PcommA
PCA
Thread
Fig 1. Schematic representation of SAH procedure. The thread is inserted into the 
temporarily clipped-off ICA segm ent, fo llow ing which it is then advanced intracranially to 
rupture (m ost com m only) through the anterior com m unicating artery. Key: CCA com m on  
carotid artery, EC A  external carotid artery, ICA internal carotid artery, V A  vertebral artery, 
BA basilar artery, PCA posterior cerebral artery, PCom m A posterior com m unicating  
artery, PtA ptergypopalatine artery, M C A m iddle cerebral artery, A C A  anterior cerebral 
artery.
at an angle away from the spinal cord, into the lateral subarachnoid space. The cannula 
w as also connected via a colum n o f  saline to the transducer o f  an oscilloscope to thus
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record the intracranial pressure (ICP), a sinuous waveform indicating ideal positioning. It 
was “fixed” in position by pouring dental acrylate into the wound, and by tying-over the 
suboccipital muscles as this ‘sef (Plate 4). Following this the animal was returned to the 
supine position.
A long midline incision was made from the sternal notch to the hyoid region. Following 
tracheostomy (achieved by inserting the cut-off port of a Swan-Ganz® catheter between 
the third and fourth tracheal rings anteriorly), the right common carotid artery (CCA) was 
dissected free from its vagus nerve, with the external carotid artery (ECA) being divided to 
a small stump. The pteiygopalatine branch of the internal carotid artery (ICA) was 
temporarily clipped, as were both the distal ICA and proximal CCA (aneurysm clips), and 
within this isolated segment a small length of 3/0 prolene (about 3cm: wiped with 70% 
alcohol, and allowed to dry) was introduced through the ECA stump (Fig 1). The ICA clip 
was then removed to allow the thread to be advanced intracranially within the ICA lumen 
until, on passing tlnough a small resistance, it ruptured through the wall of the anterior 
CoW, thus causing acute SAH (Fig 1). This was confirmed by a sudden elevation in ICP, 
which then fell to a lower plateau (Figs 8, 10 and 11). Frequently, respiratory irregularities 
occurred at this stage, but these were usually only transient; respiratory support was rai'ely 
required (but hence the prior tracheostomy). Sudden extensor posturing often also 
coincided here, sometimes resulting in the loss of ICP tracing (n = 7: Tables 17-19, 
Appendix: Fig 9 subscript). The tlnead was immediately withdrawn at this stage and, 
following coagulation of the ECA stump, reperfusion attempted by release of the CCA clip.
In most cases (SAH Group 3: n -  17) reperfrision was uneventful. However, in others, 
reperfusion resulted in a significant ICP re-rise. Because this was felt, as a result of 
previous studies^^^, to risk catastrophic secondary SAH, the clip was repositioned in such 
cases so as to ensure adequate haemostasis from the primary SAFI. The rationale was to 
limit study to that of a single primary SAH, In most cases where an ICP re-rise occurred 
(SAH Group 2: n = 13) CCA re-clamping spamied periods of less than 5 mins. In a few 
cases, however, CCA re-clamping was considered necessary for over 1 hour (this 
representing the entire study period in such cases—SAH Group 1, n = 4—because all of 
these animals died prematuiely within the aifritrary three hours [Part 5, 1.4 & 1.5]). The 
possible superposition of unilateral carotid ischaemia in such cases—particularly the 
latter—upon SAH effects is fully discussed later (Pai’t 6, section III). However, it is worth 
noting at this stage that, in a previous in vivo study, pial vasoreactivity remained 
remarkably unaffected by considerably longer periods (2-5 hours) of unilateral carotid
ligation^ 13
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According to protocol (Part 4, Chapter 7), all animals were to be sacrificed by 
exsanguination after an arbitrary period of thi'ee hours following SAH. However, in a 
significant number of cases, a subacute cardiovascular collapse (SCC) ensued at some 
stage within this time scale (Part 5, 1.4; Part 6, Section I, 1.6; Part 6, Section III). If, in 
such cases, haemodynamic stability was not restored by simple oxygenation and repeated 
fluid-challenge, the animal was electively sacrificed by exsanguination at this point within 
the arbritary three houi' period. The rationale behind early sacrifice in these cases was 
to limit the confounding effects of a prolonged hypotensive state upon MCA 
r e a c t i v i t y 3 3 5 .  [Furthermore, it was decided not to restore systemic pressures with inotropic 
agents in these cases because of the risk of metabolic acidosis.] Although such 
methodology necessai'ily gave rise to heterogeneous survival groups (see Tables 20-22, 
Appendix), such methodology was considered to more closely reflect the clinical scenario, 
where sudden death is seen in up to 50%4'7'^ . Indeed, uniepresentatively low mortalities 
reported in the vast majority of experimental SAH studies (in reality, type II VSM models) 
ought to be considered a distinct design weakness rather than—as is usually the case—a 
strength. Similar considerations of 'unrepresentativeness' also resulted in the 
abandonment, in the current study, of the sub-groups previously emphasized in the 
“Sheffield Model” of SAH (see belowf^K
Sham-operative group
8 animals underwent exactly the same procedure as for the SAH groups, but instead the 
thi'ead was not allowed to ruptuie. In all cases, CCA cross-clamping was immediately 
cm'tailed after tliread removal, and full reperfusion subsequently restored. Any deleterious 
effects of unilateral (i.e. right-sided) surgical manipulation, CCA cross-clamping, ECA 
obliteration and thread-insertion, were to be closely looked-for by examining for any 
rightdeft side differences in MCA in vitro responses (Part 5, Section II, Chapter 2). In all 
animals (from both sham and SAH groups) arterial blood gases were monitored 
intermittently. In the vast majority of cases, the animal breathed spontaneously on air 
without any further support of any kind; urethane anaesthesia proved remarkably 
efficacious in this study.
The proceduie described above is essentially that of “The Sheffield model” of SAH^ ^^ s 
However, closed-chest pressure-ventilation (with its deleterious effects upon 
cardiovascular function) was specifically avoided in the current model—the animal 
spontaneously breathing air throughout. Furthermore, no attempt was made to create the 
“differing extremes” of SAH emphasized in the fonner study, since in preliminary 
experiments in the current study, SAH appealed equally as extensive whichever method 
was employed; and because the Tesser’ SAH variety reported in the “Sheffield Model”
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(i.e. with thi'ead left in situ and CCA permanently cross-clamped—causing unilateral MCA 
ischaemia) was considered wholly incompatible with 'pui'e' SAH study.
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Chapter 4
Experimental methods for small vessel study
4.1 In vivo methods
There are several important setbacks with in vivo models for the study of VSM. Perhaps 
the most major is that of the continuing effects of the anaesthetic agent used, and its 
possible interaction. This is clearly not a problem with in vitro studies, excluding any 
permanent effects of the anaesthetic agent used. Nevertheless, the fact that vessels retain 
their natuial systemic connexions, and that they have usually suffered a minimum of 
experimental manipulation, remain attractive featmes of in vivo models.
4.1.1 Angiography
Angiography is so frequently used in SAH studies that no list of examples is a realistic 
possibility. The study of Delgado et al in eighty seven rats represents a good example of its 
detailed use, albeit in a type lib SAH modeP^^. The major advantage of angiography is its 
relative ease of use, its reproducibility over prolonged periods, and the fact that it allows 
a large area of vasculature to be studied. Unfortunately, there is much room for 
obseiver bias, particularly at the stage of film examination where pencil is often used to 
highlight luminal borders’26. There is also a problem over the agreed equation between 
extent of luminal narrowing and its significance. For example, Delgado et al considered a 
change of 8% from baseline to be significant, wliilst Pluta et afi^  ^required 25%. Most, 
however, require this to be > 40-50%. The better studies rank the diameters obseived into 
categories. Thus, Liszczak et aP62 ranked a 10-20% decrease in diameter as 'mild’, 20- 
30% as ‘moderate’, and 30-80% as ‘severe’, following a type lib study in dogs. 
Nevertheless, in spite of these short-comings, angiography remains a frequently used 
device.
4.1.2 Cranial “window”
The technique involves the removal of a small piece of skull, usually over a convexity, and 
the subsequent isolation of a small network of pial vessels for video diameter study. The 
dura is reflected in such studies, and the exposed cortex bathed in a continuous flow of 
paraffin oiP^s. Various complexities of visual mensui ation are utilized in order to assess 
vessel diameter change—these becoming increasingly sophisticated. The best examples 
have not, in fact, followed SAH. Bairy et al have used an ingenious variant of this method 
to study VSM in the BA anteriorly (see below) 36. The cranial window was, of course, 
elegantly used and described by Cushing in his classical study of 1901 ” 3. The latter 
literally was a window: a piece of glass screwed into the skull! Through this window, 
Cushing made careful drawings of the pial vasculature at various increments of AICP.
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In criticising such models, one must consider the detrimental effects of the local 
craniotomy or sui'gical trauma upon the superficial region exposed^?’’. Furthermore, by the 
very fact that the region under examination is being isolated (usually within an oil bath), 
such vessels must also remain as isolated from the CSF as they would be in vitro. 
Therefore, at least some of the theoretical advantage of the in vivo study may be lost. The 
effect of the bathing solution would also remain unknown in such studies.
4.1.3 Cisterna magna (CM) “window”
This is obviously a variant of the above cranial window: however, cleaiiy no extensive 
craniotomy is required as the atlanto-occiptial membrane can itself act as the “window”. 
This is a commonly used method, for both “SAH” and “VSM” models.
4.2 In vitro methods
These models have the distinct advantage in that they directly observe isolated vessel 
characteristics (Part 3, Chapter 2). Not only does this mean complete isolation from other 
important inputs, in particular those relating to sympathetic and metabolic regulation, but 
also the exclusion of other confounding variables such as continuing anaesthesia. Because 
of this it is possible, within reason, to limit many of the variables known to affect vessel 
function, such as pH, CO2 and O2 levels, temperature, agonist concentrations, and so on. 
The control of confounding variables is, of course, the over-riding aim of most scientific 
studies. The major criticism of in vitro studies is, however, that vasoreactivity is not being 
witnessed within its true physiological environs, and that vessel damage may necessarily 
have been incurred dur ing handling^^f
4.2.1. Helical strips
This entails the cutting of a length of cerebral artery diagonally and continuously into a 
helical strip, and then its suspension vertically between hooks, one of which is attached to a 
force transducer. In such a manoeuvre, a concentric array of VSMCs is converted from a 
concentric one into a straight length in parallel. For example, Toda et al obtained MCAs 
from dogs following a Type I SAH model, helical strips being produced by cutting at an 
angle of 45°399 Sasaki et al similarly utilized dog BAs to carry out a Type V VSM 
modeP28. By the use of various antagonists, the latter authors ruled out 5HT, NE, HA and 
acetylcholine as mediators of VSM, concluding instead PGs or leukotrienes to be the 
culprit (Paif 2, Chapter 4).
However, the problem with this technique is that a lot of manipulation is involved, and that 
the normal architecture of the vessel is completely destroyed^ .^ Furthermore, the 
continuity of important layers such as the endothelium is similai'ly deranged, tliis risking
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great departures from normal physiological function' '^ .^ It is therefore a decidedly 
unphysiological form of small vessel in vitro study639.
4.2.2. Ring preparations
The first to study VSM using ring preparations was probably Miller in 197 Although 
many experimenters have utilized either in vivo methods, or ‘helical strip’ in vitro 
methods, for cerebral vessel study in SAH models, a significantly lai'ge number have also 
utilized ‘wire’ (ring) myography’ = 2,3 ,9, 10, 14,46-48,57, ss, 63,64,108, 123, 124, 141-144, 152, 155, i90,192,
254,284, 308, 309, 326, 329, 337, 354, 368, 393, 417, 422, 437, 472, 473, 523, 524, 528, 529, 569, 574, 585, 598, 601, 604, 605, 623,
635,637,650,654,655,661, 662,667,674,682 Such studics liave, witli the advciit of Mulvany 
myography429,430^ become the standard small vessel study research tool. Indeed, recent 
studies from influential centres’-3, ’4,5o, 605 have continued to use this method for SAH- 
VSM study despite some significant shortcomings (Part 4, 5.5). However, when 
myography has been used in SAH studies, it has invariably followed the use of a Type II 
SAH model. For example, Kim et al studied BA responses in the dog after a Type Ila 
SAH326^  whilst Vollmer et al studied BA responses in rabbits after a Type lib SAH 635.
Ring myography will be discussed in more detail later (see below): it represented the 
method chosen in this study.
4.2.3 Pressure-cannulized studies
These, of couise, represent the ideal type of in vitro small vessel study. Thus, radial 
distending pressures are experienced from fluid hydrodynamics, with agonist action being 
separated into intra- and extra-luminal components. Admittedly, some degree of 
manipulation is still apparent, this probably being comparable to that seen with wire 
myography. Nevertheless, this represents an altogether more physiological compromise. 
However, such models aie very expensive and therefore in more limited supply. Because 
of this and other reasons, they are fai’ less frequently used than wire myography. Indeed, 
even in units that possess both pressure and wire myographs, there appears to be a certain 
preference for the continued use of the latter. Furthermore, they are, at present, less 
comparable to the vast amount of studies being performed with ring myography. They 
have been rarely used thus far in SAH study, an example being that in the rabbit BA by 
Vollmer et aF35. Although Tsuji and Cook used this model, they chose the BA for study 
and, worse still, only mimicked SAH by merely adding surface blood in vitro604.
4.2.4 Brain slice microvessel studies
This technique involves the en bloc removal of sections of brain and the subsequent 
videomicroscopic mensuration of vessel diameter-change. However, an important setback 
is that the vessels are not subjected to any form of distension32f Furthermore, they tend to
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be mounted in ambient temperatures of 33°C, which is clearly u n p h y s i o l o g i c a F ^ h  One 
such model is worth especial mention because it was used to demonstrate a paradoxical 
vasoconstriction in pial vessels with 50 pM concentrations of PPV293. This subject will be 
returned to later on in the discussion.
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Chapter 5
Proposed model for vessel study
5.1 Rationale
The purpose of this project was to study the early responses of MCAs immediately 
following acute SAH in a model closely resembling that of the clinical scenario. Thus, 
although both VSM and DCI represent processes essentially delayed in manifestation, it is 
difficult to concede that their seeds are not in some way critical sewn within the acute ictus. 
For example: vessel trauma, an acute SNS storm (see below), and dysautoregulation 
probably all relate directly to the acute impact—distinct from any fuither delayed effect 
consequent upon clot lysis. Furthermore, this crucial period of the first few hours has 
continued to remain relatively under-explored.
It was also necessary to have a model that balanced the needs of physiological 
representativeness with cost efficiency. As a result, the wire myograph was chosen:
1. Several aspects of the study required bilateral responses. This is difficult with most in 
vivo models.
2. It was considered important to confirm not only that SAH had occurred, but also to 
record its extent. The repeated addition of chemicals and saline (PSS) to the SAS 
throughout a study period could seriously interfere with such assessment.
3. The wire myograph is widely used and, in consequence, more comparable to the results 
obtained in other studies. It is also considerably cheaper than the pressure-perfusion 
version.
4. Apart from subtle differences in affinity with adrenergic responses, there have been no 
significant differences reported in response findings between wire and pressui'e- 
cannulized models26. i67 Furthermore, spontaneous myogenic tone—which is both 
characteristic of cerebral vessels and a testimony to the accuracy of the mounting 
procedure—can still be apparent with wire myography, depending upon the handling 
{see below).
5.2 Principles of wire myography
The essential principle is that of distending a fixed length of artery in order to simulate a 
luminal pressure closely resembling that experienced in vivo^ ,^ 429.430 jn consequence, 
changes in wall tension produced by agonist action will be more physiological and 
therefore representative. Since the transducer {see below) can only measiu'e force (mN), 
this level of resting pressure must therefore be extrapolated. This is achieved by the 
assumption of the Laplace relationship (Pai't 2, 2.1), where T oc P 429,430_ Thus, in the case 
of MCAs, the operating internal pressuie will be around 90 mmHg. In order to achieve
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this, the fixed MCA length is progressively distended by two intraluminal wires in small 
increments over a prolonged period, until the desired ‘pressure’ is achieved. A softwai'e 
programme then maintains this level, such that agonist-induced tension changes are 
proportional to diameter changes: i.e. T oc D429,430
5.2.1 Details of myography
The automated myograph (Fig 3) is able to alter vessel diameter according to the force 
recorded by the sensing jaw, through an electrically driven micrometer attached to a mobile 
jaw. Software control automatically pre-tensions vessels to simulate any required resting 
transmural pressure429,430 The vessel diameter is inferred from the vessel 
circumference at this resting pressure: the ‘normalised’ lumen diameter ( F D 9 0 ) .  Thus, 
for a cylinder, the Laplace relationship approximates to^ 63 ;
T = P.a
Since vessel circumference is C = 27ra, we therefore obtain:
P = 2 î ï
C
Now, where F is the force recorded by the tiansducer, and 1 is the segment length (i.e. the 
only viable length between the jaws, 2,3 mm: see Fig 4.3) 429,430.
T = 2^1
Furthermore, for a mounted vessel (Fig 5) the circumference, C’, can be given by:
C’ = (2+7t)d + 2(gap)
where d is the diameter of the moimting wires (40 pm), and the gap is directly measured by 
the micrometer on the moving jaw as the distance moved by the jaw away from the 
point when the wires on the respective jaws touch.
The expressions for C and T can then be substituted into the Laplace equation, so that we 
can develop a relationship between the gap, transducer force, and equivalent pressure:
p = l[(2 + 7i)dH-2(gap)]
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or:
F = — ,(gap) + — .(2 + Jt)n n
F = c.gap + c’
As a result, when the pressure is kept constant within a vessel, there is a linear 
relationship between wall tension and the gap between the jaws (Fig 2). Thus, a linear 
isobar may be plotted on a graph of force on the ordinate against gap on the abscissa, with 
the line having a gradient 2W n  and y intercept Pld(2+7i)/%429,430 (The value 1 remains 
constant as this is the segment length between the jaws that remains viable: i.e. this 
represents the active segment not crushed by the wire assembly against the jaws (see Fig 
4.3).
Tliis can be represented in the isobar for 90 mmFIg in the graph in Fig 2 below:
Wall Tension (mN/mm) 90m m H g isobar
0.6
0.4
0.2
350 400250
Vessel diameter (uni)
300200100 150
wall-lension vs, diameter relationship 
o f  cerebral resistance vessel
Fig 2. Diagrammatic representation of the normalisation routine. The isobar for the 
desired pressure is derived, in this case 90 mmHg. The myograph software then directs 
stretching of the vessel until the wall tension equilibrates at a point on the isobar. The wall 
tension is then equivalent to a transmural pressure of 90 mmHg,
The diameter, D, that the vessel would have had in its native cylindrical state may be 
derived from the equation:
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C = ttD
The myograph software plots the isobar for the required pressure on a graph of wall tension 
against gap. The software is then able to stretch the vessel until the approximately 
exponential relationship between gap and wall tension intersects with the isobar; at this 
point the tension in the vessel wall will be equivalent to the pressui'e of the isobar. Because 
all vessels show some degree of plastic compliance (Part 2, 3.1.1), the gap needs to be 
continually modulated by software control until equilibrium is reached: this takes about 20 
minutes with force increments @ 0.70 mN/min. In the experiments reported here, once 
this loading procedure had been performed the vessels were studied isometrically (Part 2, 
3.2): i.e. by keeping the diameter constant whilst measuring the changes in tension, AT, 
generated in the vessel walB^, 429,430
5.2.2 Automated myograph structure
A major advantage of the automated myograph (Fig 3) is that it is automated by software 
control, thus allowing movement of a mobile jaw to be directed in response to tension 
recorded from the sensing jaw and gap. Thus datum position (the position of the jaws at 
which there is no wire gap), zero tension, equivalent transmural pressure and 
normalised lumen diameter are rapidly established or calculated by the command 
program, allowing uncomplicated, rapid and accurate pre-tensioning of vessels. Digital 
tension data from the entire experiment may be continuously recorded onto the hard disk, 
and the tension-time trace may be displayed on a visual display unit and/or be 
instantaneously printed out onto a hard copy. Instantaneous tension recordings may be 
fi'ozen to aid their recording by hand, in a further manual log of the e x p e r i m e n f ^ ^ ^ ,  430
Each organ bath of the myograph accommodates 2 vessel segments, each one mounted on a 
pair of jaws as a ring preparation (Figs 4.3 & 4.4; Plate 3). The sensing jaw is connected to 
a novel feedback type force transducer, having a resolution of 0.05 mN and drift less than
0.05 mN/hour. The feedback design allows true isometric responses to be measured^^s, 430 
(Part 2, 3.2)
The myograph organ baths were fitted with a temperatuie sensor and heater. The 
myograph software maintained a constant temperature automatically by feedback control. 
All experiments reported in this thesis were performed at 37°C. The vessels were bathed in 
the organ bath in physiological salt solution (PSS) (Part 4, 6.1.1).
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Outflow<J - 
Gas in
To <(- micrometer
Moving jaw
Blood vessel
Stainless steel 
' organ bath
2x40um  
mounting wires
 ^ To force 
transducer
Sensing jaw
Fig 3. Bath of myograph. The left hand jaw can be moved by a motorised micrometer 
screw. The right hand jaw is connected to a force transducer. The bath is filled with 
physiological salt solution maintained at 37°C and bubbled with different gas mixtures.
The situation is reversed in the upper jaws. The actual model used was the Mulvany 
500A®, JP Trading, Aarhus, Denmark.
5.2.3 Calibration and up keep
The force transducer was calibrated at intervals between once per day to once per week. 
This involves mounting a wire on to the transducer jaw, and placing a known weight (2g) 
on a beam and lever assembly to ‘pulT on this. This produced a force of 9.81 mN on the 
transducer. Because of the use of Ca^  ^in the PSS, the frequent build up of Ca deposits 
required the regular clean-out of the bath lining, this being achieved with 50% glacial 
acetic acid at intervals of once-weekly. At all times a sufficient amount of protective 
grease (applied in fresh weekly) was maintained around the force transducer armature, as 
water seepage into the micrometer housing is a potent cause of transducer decay.
5.3 Vessel harvesting and mounting procedure
All animals in all groups were sacrificed by exsanguination under urethane anaesthesia {see 
below). This not only satisfied schedule I (Home office) procedures, but also served to 
obviate any peri-mortem ooze which may hinder analysis of SAH. Following sacrifice, the 
rat was placed prone and a long midline incision made from the fr ontal region to the mid- 
cervical region. Skin and superficial fascia were swept laterally with large scissors, and the 
posterior cervical muscles cleared to reveal the C1-C3 vertebral spines. Using small bone 
forceps. Cl and C2 vertebral aiches were removed, and the spinal cord then transected at 
this level through the clear meninges. By again using the bone forceps, the posterior 
cranium was successively removed, displaying the cerebrum and cerebellum. The brain 
was then lifted gently from the cut cord region, tilting gently anteriorly, with successive
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excision of cranial nerves increasingly facilitating this. Extreme care was taken at the stage 
of excision of ÏCA and VA connexions, and with excision of the optic nerves: the latter 
representing the final resistance to the complete removal of the entire brain.
The brain was then placed basal surface upwards inside a petri dish, with continual PSS 
irrigation throughout (Plate 8). Under maximal magnification with the operating 
microscope (Carl Zeiss®), the proximal portion of each MCA was then removed by picking 
up the CoW on either side proximal to its division and by then cutting away the pia close to 
the vessel on each side. At all stages watchmakers forceps and scissors were used.
Extreme care was taken to:
• Not touch the MCA in any part. The only part of the vessel touched was the CoW at 
either side (Fig 4.1) of the ‘T’.
• Not ‘pull’ on the MCA segment from CoW hold as it was sequentially lifted out.
The removed MCAs were then immediately transferred to the myograph bath containing 
PSS. With a 40 pm wire already partially secured on the transducer side (one end cuiwed 
onto the screw in clockwise fashion, the other free and straight in the PSS: Fig 4.2) one 
MCA was then sleeved over the latter, this being achieved through the V-shaped breach at 
the CoW:MCA T-junction (Fig 4.2; Plate 1). At no point was the wire-tip allowed to snag 
the endothelial lining. Once fully on, the free wire-tip was then finally secured onto the 
transducer jaw by again curving it onto the screw as the latter tightened in clockwise 
fashion (Plate 2). As the MCA length was longer than the vertical gap, it usually curved 
ai'ound the jaw at either end (Fig 4.3; Plate 2): this excess would later be removed. For the 
time being, however, another cut was made in the ante-jaw vessei-wall at one such curve, 
tfirough which another straightened-and-smoothed 40 pm wire was inserted intraluminally, 
along the length of the segment, to thus appear tlu ough a similar breach at the other end 
(Fig 4.3). This was then secured onto the tensioning jaw as before. At all stages extreme 
care was taken:
• Not to ‘pulF on the MCA during second wire insertion.
• Not to snag the second inserted wire-tip on the endothelium.
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Areas handled
Circle of W illis
MCA
Stem
Cut to 
admit
Fig 4.1. Manipulation of MCAs prior to mounting.
V essel pulled 
over partially fixed 
wire through hole 
created in the end
W illisCircle
MCA
Fig 4.2. MCA being sleeved over mounting wire. The only parts touched are those o f  
the bar o f  the ‘T ’: i.e. the CoW . The M CA is not touched in any part.
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Hole cut in 
ante-jaw wall
2.3mm
A new wire is carefully 
p a sse d  through the lumen 
of the partially secured 
v e sse l:  it is crucial not 
to snag  the tip of the wire 
upon the endothelium in 
th is m anoevre.
F ig  4 .3 . MCA secured onto transducer jaw of myograph.
The v e s se l is com pletely fixed and has been 
stretched by the program m e to its functional 
diam eter.
F ig  4 .4 . MCA fully mounted onto myograph jaws.
128
In fact, with practice, it was routinely possible to achieve all of these aims. At all stages 
dming mounting maximal magnification was used with the operating microscope, and 
watchmakers forceps and scissors were used throughout.
After ensuring the two intialuminal wires to appear parallel, with adjustments being made 
as necessary, and following removal of excess tissue at either end (only the length between 
the jaws, i.e. the middle 2.3 mm, would be viable: Fig 4.3), the jaws were brought together 
so that the internal wires ‘kissed’ each other, this registering a negative reading on the force 
transducer. From this position, the movable jaw was then gradually moved away from the 
transducer jaw (in 1 pm increments) until the force recorded stopped increasing 
dramatically in a positive direction: this represented the datum position at which the 
wires were just parted, and could be confirmed visually. From this position the software 
programme could then begin its regime of sequential stretching at predetermined 
increments (usually 0.70 mN), so producing an exponential curve of Tension v gap  (Fig 2). 
From this the desired internal pressure (90 mmHg) could then be extrapolated, and the 
diameter set, by the software programme (Fig 4.4; Plate 3); the diameter thereafter being 
referred to as the FD90. At all stages during this procedure the PSS bath level was kept at 
1 0  mis, and bubbled continuously with 95% O2 and 5% CO2, at 37°C.
The stretch routine was deliberately performed slowly in the current study because cerebral 
vessels develop myogenic tone to distension (Part 2, 2.2). The average length of time taken 
was around 25 mins. The vessels were then left to equilibrate for at least 45 minutes before 
any attempt at constriction was made. The final tensions and FD90 values were obtained 
before attempting agonist study. In some vessels, the distending pressuie was repeated at 
different levels of normalization. Thus fruictional diameters were obtained at extrapolated 
luminal pressures of 70, 90, 110, 130, and 150 mmHg (Fig 31). In these cases, the 
diameter recorded would obviously be FD70, FD90’ FDnoand so on (Part 5, Section II, 3.1).
5.4 Rejected vessels: bifid middle cerebral arteries
There is a lower limit to the vessel size compatible with wire myography. This is not just 
because of technical problems in manipulating and inserting 40 pm diameter wires into the 
lumena: as will subsequently be demonstrated, agonist contractile responses are 
proportional in magnitude to the size of the vessel obtained (Part 6 , section 11, 1.1). As a 
result, the small responses obtained by tiny vessels were generally incompatible with the 
detection of statistical significance. The most common cause for such vessels was the 
presence of bifid MCAs: here the sum of each FD90 branch obtained approached normal 
dimensions, but each itself was small. Such vessels were, in general, rejected from further 
study. Vessels in which KCl constrictions were poor were also rejected from the study.
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Plate 3. M C A  fully mounted on myograph and stretched to an internal ‘pressure’ of 
90 mmHg The diameter obtained is therefore the FD qo- The myograph m odel used  
throughout w as the M ulvany 500A ® — the m ost current m odel. Endothelial function tests 
(L-ARG, L-NAM E and hypoxia) confirm that no endothelial damage has been incurred.
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5.5 Faults with the wire myograph
Apart from the fact that considerable dexterity is required to rem ove and mount the vesse ls  
without com plication, several important criticism s distinguish wire myography from  
pressure-cannulized preparations:
1. The distending pressure is not truly radial (Fig 5).
2. The distending pressure is from 40 pm diameter wires w hich may damage the 
endothelium  during both m ounting and stretching.
3. It is not possible to separate agonist action into intraluminal and extraluminal effects.
4. The distending pressure is inferred, and not directly measured.
N evertheless, wire myography continues to represent the ‘gold standard’ small vessel study 
m odel. It is also w idely used for the study o f  cerebral vessels— including that o f  V SM  after 
SAH {see Part 4, 4 .2 .2  for sixty-one non-exhaustive references). In spite o f  technical 
difficulties, with practice the vesse ls mounted produced m yogenic tone (M T) and EDRF  
production in all cases— this indicating minimal endothelial and VSM C damage.
d/2 gap
Fig 5. Diagram of vessel mounted on wires, show ing gap, segm ent length and derivation  
o f  vessel circum ference. N ote how  the distension produced differs from the radial 
distension achieved in vivo. Any length o f  vessel >1 w ill be crushed against the jaw s, and 
w ill not be viable for study. The circum ference is n/2.d +  2 [d/2 +  d/2] + 2gap +  7i/2.d, 
which is (2 + 7i)d +  2 gap.
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Chapter 6 
Measurement of in vitro agonist activity
6.1 Solutions and drugs
6.1.1 Physiological saline solution (PSS)
One litre of PSS contained, in mM: NaCl 119, NaH2C0 3  25, KCl 4.7, CaCl2.2H20 2.5, 
MgS0 4 .7 H2 0  1.17, KH2PO4 1.18, Na2EDTA 0.026 and D-Glucose 5.5. The CaCl2.2H20 
was only added to the solution following continuous bubbling with 95%02 and 5%C02 for 
> 30mins: tliis was to ensuie its complete dissolution, a constant problem with myography. 
This was kept bubbling at 37°C in a separate container in an immersion bath: failure to do 
this often resulted in Ca^  ^precipitation.
At all times the myograph bath level itself was kept at 10 mis. This was crucial because all 
in vitro agonist concentrations were calculated assuming this as the final bath dilution.
This level was ensured by using a 10 ml syringe for PSS additions, and by keeping the 
perspex roof to the myograph bath in place throughout the entire procedure, so preventing 
evaporation.
Following each agonist study, the myograph bath contents were suctioned out (maintaining 
the perspex roof thr'oughout), and the bath irrigated with fresh PSS at least three of four’ 
times. Following this, a suitable period of equilibration was again allowed. However, with 
repeated study, the vessels frequently became ‘trained’, and soon regained their prior 
baseline values for tension and diameter.
6.1.2 Drugs
KCl solution was made up as a IM stock solution of 1 litre. PGF2a was obtained from the 
Royal Hallamshire Hospital pharmacy depar-tment as prostin®. All other drugs and 
chemicals were obtained from Sigma® Chemicals Ltd, Parkway, Sheffield. PPV and HA 
were obtained as the hydrochloride salts. Each agonist was made up as IM stock solutions
(in distilled water) from which 10 '\ 10'^, 10"^ ........10"^  M solutions were then obtained by
serial dilution (with distilled water). All solutions were kept in light-proof containers, and 
were made up fr’esh weekly. However NE, for example, was also made freshly each day. 
Each was kept refrigerated until the time of use, at which point they were equilibrated to 
37°C.
6.2 Measurement of agonist action
For contractile agonists responses were obtained as increases in either tension or force 
generated in the vessel wall following agonist addition. In some cases this occuned
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quickly (KCl, Fig 15), whilst in others tliis took several minutes (FGF2a, Fig 19). In all 
cases the progressive results obtained were expressed only as AT or AF: absolute values 
not being fruther considered. Usually the AF (mN) was only considered as tension was 
constantly proportional to this: this was because the active vessel length itself was constant 
at 2.3 mm (Fig 4.3).
For vasodilators, responses were measured as the progressive decrease of force (or
tension) following each dose increment given. For most this involved the progressive
dilation of pre-constricted agonist tone, this being achieved by vessel pre-constriction
with 30 pM PGF2a. This is standard myograph procedure. However, with some
(hypoxia) this was achieved by progressive dilation of only baseline tone: thus, no PGF2a
pre-constriction was used here. In all former cases, however, the dilation achieved was
expressed the percentage (%) relaxation o f the preconstricted tonic value achieved, for
that agonist in that vessel. Thus, if a MCA was initially pre-constricted from a baseline of
FI to F2, and then progressively dilated from F2 to a minimum of F3 (where F3<F2), the
maximum dilation then achieved would be:
(F 2 -F 3 )-------------xlOO% of pre-constricted tone (i.e. F2-F1) achieved.(F 2 -F 1 )
In most cases F1>F3<F2: i.e. E^ax vasodilation achieved was <100%. In these cases each 
agonist dilated only a proportion of the PGF2a-induced tone that was additional to baseline 
value. However, in some cases F3<F1 with Emax>100%: in these cases the agonist had 
additionally dilated baseline myogenic tone in addition to that of the superadded PGF2a.
Obviously this could not be the form of expression used for hypoxic baseline dilation.
Here I chose to express this as the decrease of force in mN: i.e. the exact reverse for agonist 
constriction. Others, however, express this as the precentage of myogenic tone achieved.
6.3 KCl responses
Contractile responses to KCl were obtained as abrupt changes to addition of maximal 
agonist concentration. No attempt at progressive constriction was made here. This was 
primarily because KCl was to be used as a marker of vessel viability; both at initiation and 
termination of vessel study. However, it was also because one wanted to obviate any 
endothelial damage resulting from more prolonged exposure (Part 3, 1.2). Thus, only E,nax 
values were expressed: i.e. the efficacy of response.
6.4 Hypoxic responses
Again, only maximal responses were obtained to a Tixed-dose’ as with KCl above. That 
is, no attempt was made to achieve progiessive dilations to incremental ‘doses’ (i.e.
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intermediate pOi values) as in a formal dose-response curve. Thus only Emax values were 
expressed: i.e. the efficacy of response. Hypoxic responses were only recorded in controls.
6.5 Concentration-response (C-R) curves
In all other cases, each agonist was added to the bath in ever-increasing dose increments, in 
order to obtain progressive increases in response up to the maximal value obtainable, this 
being achieved at maximal agonist concentrations (but see PGF2a, Fig 33). Such 
concentration-response curves provide much better characterization of agonist responses, 
this being standardized by the ECso value: the effective concentration at which 50% of the 
maximal response (Emax) would be achieved (Fig 6). This describes the affinity of agonist 
response, a theoretical concept of the degree of
Emax
Response
Ie C50
Concentration
F ig  6. Hypothetical Concentration-response (C-R) curve. Emax and EC50 values.
agonist-receptor interaction. It is a necessarily inferred value, as the C-R curve must itself 
be plotted to determine the dose, or concentration (abscissa), at which 50%Emax occurs. 
The concentration range for each agonist was worked out individually: thus the range for 
5HT, for example, was several orders of magnitude lower than with other contractile 
agonists (Part 5, Results). In occasional cases, in order to save time, complete 
concentration-response curves were not performed: only maximal responses (Emax values) 
were obtained instead. A good example would be L-NAME responses, E C 50  values were 
therefore obviated in such cases and, in these MCAs, n values for ECso< Emax- 
Furthermore, in sporadic MCAs, PGF2a pre-constriction was temporarily inadequate 
enough for some agonists to allow an accurate C-R curve to be determined. NE responses
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were singular in that, for some MCAs, no response at all could be reliably detected: in 
these cases, both Emax and EC50 n values were lower than with other agonists.
6.6 Group comparisons and statistical methods used
Inter-group agonist response analysis was performed by comparing continuous data of 
Emax values and, where appropriate, comparison of EC50 values. This was performed by 
using a one-way analysis of variance (ANOVA). Values of p<0.05 were considered 
statistically significant.
However, in some cases the study of proportions was required. For example, with HA 
responses (Table 6: Part 5, Section II, 3.7) it was required to consider proportions of sub­
responders and responders between each group. In this ease 2 x k  tables were constructed 
(in this case k = 3) with evaluation of y} being obtained. By consideration of the y} 
distribution for the number degrees of freedom permitted ([n - 1] = 2, in this case), values 
of p<0.05 were again considered statistically significant.
All data of continuous variables are stated as mean±SE except F D 9 0  values which 
were expressed as mean±SD.
6.7 Histopathological study
The brain and vessels were occasionally studied at the end of the experiment. The heart 
was rarely considered for study as the time period after SAH was too short for histological 
changes to be incurred^^h
6.8 Choice of vessel for study
Most SAH studies choose the BA. However, there are several setbacks with this. Firstly, 
although the BA may develop VSM, DIDs are raie in its territory^ "^ .^ Secondly, its study 
does not permit the analysis of lateralization with DCI, as the BA is a single midline vessel. 
Thirdly, the BA has decidedly different physiological and pharmacological properties in 
comparison to anterior circulation vessels^^o>
It is also important to analyze a particular length of the branch considered, as properties 
differ markedly between proximal and distal segments^^^. Thus NE activity is greater in 
the proximal MCA^^?, this according with the greater adrenergic imiervation centred on the 
CoW^20 Responses may also differ with age, hence the importance in studying a small age 
range^^o.
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Chapter 7 
Central hypothesis and Experimental protocols
7.1 Central Hypothesis and Aim of Study
The principle hypothesis of the current study is that events associated with acute SAH elicit 
changes in MCA physio-pharmacology that are independent of any subsequent effects of 
chronic clot lysis. In consequence, such changes might potentially explain why currently 
favoured ‘elot-VSM’ fail to adequately explain delayed VSM and DCI—because, by 
demonstrating post-ictal alterations, the assumption of ‘clot-VSM’ models that delayed 
VSM merely results from chronic clot lysis upon normal cerebral vessels is therefore 
undennined. The principle aim of this thesis is therefore to study the physio- 
pharmacological responsiveness of isolated MCAs to an aiTay of conceivably-relevant 
agonists in the acute period (i.e. within tln*ee hours) of a tmly representative SAH (i.e. EF- 
SAH), and to compare these responses with those of sham operative and non-operative 
controls. To this end, it is intended that both MCAs from all animals medial to the 
olfactory tract are subjected to in vitro myography using all of the physiological and 
pharmacological agonists listed in Part 3. No attempt will be made to study the delayed 
effects o f  chronic clot lysis in this thesis.
In each in vitro experiment in the current study, the sequence of agonist responses obtained 
will be relatively fixed as: KCl x2, PGF2a, PPV, UTP, HA, L-ARG, 5HT, SNP, NE, KCl 
(final). It is important to assess the KCl (final) as this confirms vessel viability even after 
10 hours or so of in vitro study. In addition, vessel viability will also be sporadically 
checked throughout the study by analyzing KCl constrictions: poor responses will result in 
premature termination of in vitro myography.
If, as a result of this analysis, no differences are found between SAH vessels and controls, 
the central hypothesis of the current study would therefore have to be rejected. Such a 
finding would, instead, be supportive of the alternative hypothesis: i.e. that the current 
failure of SAH models to elicit clinically useful information most likely results fr om the 
fact that DCI is a species-specific pathophysiological process; and that results obtained 
fi'om one species are not readily translatable to those of another.
A secondary hypothesis of the current thesis is that EF-SAH fundamentally introduce a 
‘side bias’ upon post-SAH vasoreactivity that potentially confounds their use for studying 
delayed VSM. A secondary aim of the thesis, then, is to formally assess for such bias by 
comparing constrietory and dilatory MCA responses ipsilateral and contralateral to EF 
insertion. If, as a result, any significant side differences were found, then this would be
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supportive of the fact that the combination: 1) unilateral carotid manipulation, 2) unilateral 
EF insertion or 2) potentially ipsilateral intracranial rupture introduces a ‘side bias’ on 
MCA reactivity that potentially confounds their continued use in analysing the delayed 
effects of chr onic clot lysis in VSM or DCF
7.2 Experimental protocols and practice
7.2.1 Non-operative controls
A total of 20 animals were used. Animals were anaesthetized with 25% methane 
intraperitoneally (Ig/Kg) and sacrificed by aortic exsanguination. Vessels were 
immediately transferred for myography: no MCAs were fridge-kept for use on 
subsequent days.
7.2.2 Sham operative controls
A total of 8 animals was used. Animals were anaesthetized with 25% urethane 
intraperitoneally (Ig/Kg) and sacrificed by aortic exsanguination. Operating time varied 
between 1.5-3.0 hours. All animals underwent the same procedure as SAH animals except 
that the thread was not allowed to perforate the CoW. After thread withdrawal, all 
animals were kept alive for 3.0 hours. Total anaesthetic time therefore spanned up to 6.0 
horns. Vessels were immediately transferred for myography: no MCAs were fridge-kept 
for use on subsequent days.
7.2.3 Subarachnoid haemorrhage groups
A total of 34 animals were studied. Animals were anaesthetized with 25% methane 
intraperitoneally (Ig/Kg) [except two anaesthetized with hypnorm and hypnovel], and then 
sacrificed by aortic exsanguination. In vivo operating time varied between 1.5-3.0 hours, 
following which SAH was induced. All animals were then to be kept alive for up to 3.0 
hours. However, in those cases in which a subacute cardiovascular collapse (SCC) 
occmred—analogous to cases o f ‘sudden death’ clinically—such animals were electively 
sacrificed within tliree hours (see Results). Total anaesthetic time thus spanned up to 6.0 
hours. MCAs were immediately transferred for myography: no MCAs were fridge-kept 
for use on subsequent days.
7.2.4 Myography
Wire myography was to be used in all MCAs in all three groups as described in Part 4, Ch
5. Adequate KCl constrictions were a condition of vessel viability: repeated poor 
contractile responses resulted in the abandonment of the vessel study at whichever stage 
this occmred. [NB in most cases, poor contractile responses were only a temporary 
phenomena: a brief period o f vessel relaxation usually resulted in a full return of
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normal activity.] The target for vessel study 'was the proximal 3 mm of the MCA, 
proximal to the olfactory tract. Mounting time was approximately 1 hour. In vitro analysis 
took up to 11 hours (approximately one hour for each agonist). Therefore total duration for 
myography was up to 12 hours. Vessels were immediately transferred for myography: no 
MCAs were fridge-kept for use on subsequent days. Myography was performed in all 
animals obtained from shams and controls, and in 30/34 (88%) of animals after SAH. 
Notwithstanding, not all agonists were used in all MCAs in all experimental groups—time 
frequently proved to be of the essence for one researcher in this study, where total 
experimental times frequently exceeded 15 hours in one day!
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S E C T I O N  I  
W h o l e  a n i m a l  r e s p o n s e s  
Chapter 1
Cardiovascular and intracranial pressor responses
1.1 Recording bias with multi-channel flat bed pen recorders
Both arterial and ICP pressure transducers used in this study were doubly connected to both 
a patient monitor (for direct visual and digital display), as well as to a multi-channel flat 
bed pen recorder (Rikadenki®) for permanent graphical print-out of qualitative trends. 
Correlations between sphygmomanometer values, and those displayed on the patient 
monitor, were regularly checked (validation of transducer precision and accuracy). Direct 
callibration of static sphygmomanometer pressui es onto the multi-channel flat bed 
recorder were intermittently performed: however, frequent checks were made (re­
validation) on these values by reference to those displayed on the patient monitor.
Throughout the period of the study, and despite re-validation, it was noted that pen recorder 
BP values were frequently at variance either with directly calibrated pen recorder values, or 
with those displayed simultaneously on the patient monitor. In particular, systolic-diastolic 
BP fluctuations—at times—appeared grossly uncorrelated with calibrated values. Mean 
BP values (MAP), however, appeared to correlate with both pen recorder and patient 
monitor values, as did ICP values (systolic, diastolic or mean). Re-checking static pen 
recorder values against sphygmomanometer values failed to reveal that any “drift” had 
occuiTed when these anomalies were noted. The problem encountered, therefore, did not 
appear to relate to calibration eiTors.
Because the patient monitor (validation of arterial transducer) had faithfully recorded 
absolute pressures, it was initially presumed that possible systolic-diastolic pen recorder 
aberrations could be adequately compensated for. This resulted from the original intention 
merely to use pen printouts to demonstrate qualitative trends in pressure fluctuations. 
However, the (unexpected) acute pressor changes ultimately found clearly revealed a need 
for their accurate quantification {see below). The clue to the solution of the problem, it 
later transpired, lay in the fact that only BP systolic-diastolic fluctuations appeared 
affected: MAP values or [systolic, diastolic and mean] ICP values appeared unaffected,
BP systolic-diastolic fluctuations differ fr om ICP fluctuations on the pen recorder in one 
important respect: they are considerably wider (one can, o f course, make them equal by changing 
the gain on the signal). Thus, whilst ICP systolic-diastolic fluctuations usually extend for less 
than 3 or 4 mmHg, BP fluctuations frequently exceed 30 or 40 mmHg. Such fluctuations
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are represented on flat bed recorders by pen excursions between systolic and diastolic 
extremes. It is not difficult to envisage that a pen, already moving rapidly to and fro 
against resistance in a vertical direction, might become progressively restricted in its aims 
by decreases in the time available for this excursion. Thus, where the pen is required to 
move a set distance with increased rapidity (i.e. with increasing heart rate), there may 
arise a situation, in the limit, where it simply cannot achieve its full excursion in the 
diminished time available. A rapidly supervening diastolic signal could, for example, 
abruptly coerce a pen into its reversed direction before it had reached its systolic height in 
its original direction. Ultimately, one can surmise, the systolic-diastolic bandwidth will 
become increasingly constricted with increased tachycardia, the bandwidth becoming 
increasingly uncorrelated with its true width as extrapolated fiom both static pen recorder 
calibrations and those displayed on the patient monitor.
This hypothesis was directly tested in the present thesis by sending two fixed electrical 
signals to a pen recorder, at variable speeds, in order to create pen excursions mimicking 
systolic-diastolic pressure fluctuations. These (“pressure”) signals were fixed and did not 
vary: only the rate of signal alternation was allowed to vary. The results of the experiment 
are shown in Figs 7a and b. In both Figs, the systolic-diastolic signals were fixed at 30 
mmHg tlrroughout all sequences: only the ‘heart-rate’ (HR) was allowed to vary.
Increasing the HR from 60 b.p.m. on the left hand side, to 300 b.p.m. on the right, in Fig 
7a, cleaiiy caused the systolic-diastolic pen excursion (‘bandwidth’) to contract: exactly as 
hypothesized. As is shown, the contraction was uniform (approximately 50%) about the 
MAP (defined as the mid-point of the systolic-diastolic excursion) which remained 
invariant. Thus, both systolic and diastolic values contracted equally about the MAP at 
higher pen speeds.
In Fig 7b, increasing speeds through 450, 600 and 750 b.p.m produced corresponding 
decreases in bandwidth dimension. Again, the contraction approximated to 50% at each 
level. Because of this approximation, greater magnitude effects are to be expected early on 
in the sequence: i.e. bandwidth contraction probably exhibits exponential decay (Fig 47, 
Appendix). Importantly, significant bandwidth contraction is apparent in the HR range 
300-450 b.p.m.: precisely that of the normal rat 344 possible example from the thesis 
is witnessed in Fig 11, where bandwidth contraction occurred with tachycardia dming a 
CHR: (however, a genuinely decreased pulse pressure could also have occurred here).
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30mmHg
MAP
10 secs
Fig 7a. Pen recorder speed-inertia artefact.
Electrical signals are set to m im ic a constant systolic-diastolic fluctuation o f  30mniHg.
On the left-hand side (A ), the speed ( ‘heart rate’ [HR]) is set at 60 b.p.m. On the right 
hand side (B), HR is increased to 300 b.p.m. Clearly, the bandwidth has contracted from A  
to B. The ‘MAP’ (the m id-point), however, remains invariant under the transformation.
30 mmHg MAP
BVr» ■ c D 1 i E
10 secs
Fig 7b. Pen recorder speed-inertia artefact.
This tracing is continued from Fig 7a, right hand side (m oving L to R). The HR is varied 
through 300 (B ), 600, (C), 450  (D ) and 750 (E) b.p.m. The bandwidth in the normal rat 
HR range (300-450  b.p.m: B -D ) is clearly a considerable fraction o f  its true ‘static’ value 
(left hand scale): the systolic BP has ‘decreased’, the diastolic ‘increased’; the M AP is 
invariant. Dynamic-static correlations are therefore only valid with M A Ps: systolic and 
diastolic BPs becom e increasingly uncorrelated at higher pen speeds (i.e. faster HRs).
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The current findings can be summarized:
# Dynamic systolic and diastolic BP values become uncorrelated with static pen recorder 
calibrations at higher pen speeds (i.e. faster HRs). ICP values—because of smaller pen 
excursions—remain unaffected.
• True dynamic systolic and diastolic BP values can only be reliably documented fi'om a 
patient monitor
An example of the error that can be incuned by using systolic and diastolic values to 
estimate pressure changes is demonstrated in Fig 8. In this tracing, the baseline BP 
appears to be 125/102 (MAP 114) mmHg. In fact, the patient monitor shows that it is 
actually 146/84 (MAP 115) mmHg. Thus, the bandwidth has contracted—by reference to 
static calibrations—by approximately 21 mmHg systolic, and 18 mmHg diastolic. This is a 
symmetric contraction, within the error of the approximations; the difference in the MAPs 
being negligible. Using the contracted bandwidth, 23mm on the graph paper represents 62 
mmHg (on static calibrations). Since the measured -AMAP is 31mm on the paper, this 
translates to a -AMAP of 84 mmHg and a MAPg of only 31 mmHg (on static calibrations). 
In fact, the actual -AMAP is merely 34 mmHg, the MAP2 much greater at 81 mmHg. The 
pen recorder speed artefact tends, therefore, to exaggerate the magnitude of ABPs,
Figs 7a & b—as well as Fig 8— amply demonstrate, however, that the value that can be 
quantified throughout any HR transformation is the MAP: effectively the mid-point of the 
pen excursion. This is important because the MAP correlates directly with static pen 
recorder calibrations as well as to patient monitor displays. It also directly correlates 
with the animal’s aortic MAP, since the MAP here is half the pulse pressure plus the 
diastolic value (i.e. the arithmetic mean of the pulse pressure)^^^. Quantification of all 
pressure changes in this thesis is therefore based upon MAP values.
A problem still remains, however, in how to display pressor fluctuations. Since more 
modern patient monitors are able to store and print out graphical representations of pressor 
values, every encouragement should now be given to their full employment in experimental 
studies, since they obviate the error incurred by a rapidly moving pen. However, where 
these remain unavailable, and where the use of a pen recorder is mandatory, three methods 
are available to display pressor fluctuations—each with their advantages and 
disadvantages:
1. Display pen recorder print out with j-axis respecting MAP values. Advantage: the 
in situ experimental recording is demonstrated, producing ‘hard’ evidence of 
authenticity. Disadvantage: systolic values are ai’tefactually decreased, diastolic values
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artefactually increased, with increasing HR. This leads to inconsistencies between 
patient monitor (or sphygmomanometer) values and those inferred from the graphical 
display.
2. Display MAP values as a ‘straight-line’ graph. Advantage: this allows a true 
representation of the only reliable pressor value, with avoidance of contradictoiy 
systolic-diastolic values on the same graph. Disadvantage: the ‘straight-line’ graph is 
derived, therefore losing the ‘hard’ evidence of authenticity supplied by the in situ 
tracing. (However, one could ‘shrink’ the systolic-diastolic fluctuations by changing 
the gain on the recorder channel).
3. Display pen recorder print out with twoy-axis scales: one respecting MAP values, 
the other respecting systolic and diastolic BPs. Advantage: this is more informative 
than a single-axis scale. Disadvantage: two y-axes are unconventional and therefore 
potentially confusing.
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1.2. Sham operative control MAP and ICP values
Satisfactory MAP and ICP values were obtained in 8/8 rats (Table 16, Appendix). The 
group mean MAP was 112±6 mmHg, the group mean ICP value 7+1 mmHg. However, the 
MAP at the start of the experiment—-i.e. tliat immediately following arterial cannula 
insertion—was usually much lower (97 mmHg). The cause of this elevation was not 
related to inadequate anaesthesia as the animal did not exhibit any response to painful 
stimuli (respiration remained regular, there were no contralateral response to hind-limb 
tweaking, and there were no further MAP increase etc). However, in one or two cases 
where this was performed, concurrent section of the ipsilateral femoral nerve appeared to 
reverse the hypertension.
Mean arterial blood gases are displayed in Table 15, Appendix. At no point was any blood 
observed in the ICP cannula, nor was any formd within the subarachnoid space at post 
mortem (Plates 4, 6 and 8).
1.3 Subarachnoid haemorrhage groups MAP and ICP values
Mean arterial blood gases aie displayed in Table 15, Appendix: these did not significantly 
differ from those in sham operative controls. Satisfactory pen-recorder BP tracings were 
obtained in 33/34 rats (patient monitor and arterial blood gas values confirmed adequate 
perfusion in one animal without a tracing); satisfactory ICP tracings in only 26/34 [see Part 
4, 3.3; also Tables 17-19, Appendix]. Nevertheless, continuous digital read-outs from the 
patient monitor confirmed adequate BPs as well as AICPs upon arterial mptm*e. Mean 
baseline MAP was 123+5 mmHg: this value did not significantly differ fiom that in sham 
operative controls (p»0.2). However, once again the initial MAP had been lower, a return 
to this level possible by sectioning the femoral nerve. The mean baseline ICP was 8±1 
mmHg: after acute SAH, this rose sixfold over 1.8+0.4 secs to 49+4 mmHg, gradually 
falling thereafter to near-baseline values. Respiratoiy irregularities and transient falls in 
pOg occurred at this juncture, but only one animal required respiratory support. There were 
three clearly defined pressor responses concurrent with SAH (Figs 8, 10, 11):-
1.3.1 Type I acute pressor response (acute hypotension)
Acute hypotension was concunent with SAH in 21/33 cases (64%), forming a distinct and 
large sub-group of animals. It resulted in a significant fall of MAP (-AMAP) of 30±4 
mmHg over 2.4±0.3 secs, ftom I28±6 to 98+7 mmHg (p = 0.03); following which the 
MAP gradually recovered pari passu with ICP resolution (Table 17). [This drop is similar 
in magnitude to that seen following sympatholysis (Part 2, 2.6)].
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F ig  9. Correlation between hypotension and hypertension with AlCP after SAH.
Acute hypotension correlates with sm aller AICPs; acute hypertension with higher AICPs 
(i.e. AICP>65 m m Hg) [r =  0 .6 , p<0.01]. The correlation coefficient (r) becom es 0 .77  
(p<0.001) by exclusion  o f  the gross outlier [dICP 41 m m Hg, dM AP -7 1  mmHg]: this is 
highly significant, and suggests that 60% o f  the variance in acute pressor response directly 
relates to SAH -induced AICP.
NOTE: there are only n = 18 pts on the graph. This is because in 4/7 hypotensive-group animals, the ICP 
tracing was lost (Part 4, 3.3; Table 17-19, Appendix). In one other animal the pen-recorder tracing for both 
BP and ICP values was subsequently lost in transit—experimental notes at the time, however, confirmed that 
an acute hypotension had occurred. The total combined number of animals in hypo- and hypertensive groups 
is, o f course, 23.
M AP recovery was som etim es prolonged slightly beyond ICP recovery (Fig 8). The 
ICPmax attained in this group (38±2 mmHg) was significantly lower than that obtained in 
either pressor type II (60+6 m m H g) or HI (83±5 m m Hg) [p<0.001]. Furthermore, the 
change in ICP (AICP: 31 ±2 m m H g) w as also significantly smaller in this group relative 
to that in pressor type II (50±6 m m H g) and III (73+4 m m Hg) [p<0.001]. In fact, a 
significant correlation existed between the type and magnitude o f  the acute pressor 
response and the AICP (r = 0.6, p < 0.01: Fig 9). Fig 9 show s that -A M A P  w as closely  
linked to smaller AICPs: +AM AP to higher AICPs (i.e. AICP>65 m m Hg). [By excluding the 
statistically gross outlier in Fig 9, the significance o f  the correlation is increased by an order o f  
magnitude { r -  0.77, p<0.001)].
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Hypotension associated with modest AICP and ICPmax values after SAH may be more than 
mere coincidence. Hypotension effectively increased the ICPmax:MAP ratio closer to the 
range observed in the other two groups. Thus, the ICPmax:MAP ratio that would have been 
seen had -AMAP not occurred (31+3%) was significantly increased to 41+3% as a result of 
-AMAP (p = 0.02). Importantly, whilst the former ratio (31±3%) differed highly 
significantly from that of either acute pressor response type II (53+8%) or III (57+4%) [p = 
0.001], the latter value after -AMAP (41+3%) was only just significant [p = 0.046]. This 
suggests that relatively modest ICPmax:MAP ratios—perhaps only in the range 40- 
60%—are required to stanch SAH. The rate of ICPmax attainment (AICP/At) also appeared 
more prolonged (2.4+0.3 secs) in Type I compared to that in groups II and III (compare 
Figs 8, l O&l l ) .
1.3.2 Type II acute pressor response (invariant) and Type III pressor response 
(Cushing hypertensive)
In n = 10 (30%) the MAP level was invariant after SAH (Type II, Fig 10); whilst in n = 2 
(6%) the MAP demonstrated a classic Cushing-type response (Type III “CHR”, Fig 11). 
Baseline pre-SAH MAPs did not significantly differ across the tluee pressor groups (128+6 
mmHg, 113±7 mmHg and 128+3 mmHg, p = 0.38). As stated in 1.3.1 above, both the 
ICPmax and AICP were significantly greater in these two gi'oups relative to Type I 
responses (p<0.001 : Tables 17-19, Appendix). Furthermore, the ôlCP/ôt appeared much 
steeper (compare Figs 8, 10 & 11). In pressor groups II and III, the ICPmax represented 
53+8% and 65+2% that of the pre-SAH baseline MAP respectively: however, the ratio in 
group III (CHR response) effectively decreased to 57+4% as a result o f the hypertension 
(+AMAP) that supervened. In this respect the CHR appears paradoxical, offsetting SAH- 
tamponade and courting re-haemorrhage. The progressively higher ICPmax values and 
ICPmax:MAP ratios across the three pressor groups suggest that pressure-venting was 
increasingly less successful across the series: type I—type II—type III acute pressor 
responses. Fig 9 suggests that the CHR is likely to be triggered when AICP exceeds ~65 
mmHg, as a result of inefficient venting.
1.4 Subacute Cardiovascular Collapse (SCC) and ‘Survival’
In n = 14 (42%) animals (Table 20, Appendix), a hypotensive state ensued at some point 
within the arbritary three hours which proved refractory to intravenous fluid challenge and 
100% O2 administi'ation. Its occunence was temporally distinct and unrelated to the 
type I pressor response (which was always transient and spontaneously reversible). The 
decision was made early on in the study to sacrifice any such animal within the arbitrary 
three hour period, the rationale being to limit the known confounding effects of a 
prolonged hypotensive state upon subsequent in vitro MCA r e a c t i v i t y ^ ^ s  [Furthermore, it
154
was decided not to restore systemic pressnies with inotropic agents in these cases because 
of the risk of metabolic acidosis.] Although this methodology necessarily gave rise to 
heterogeneous survival groups, this scenario was considered to be more representative of 
the clinical one (Part 4, 3.3; Pait 6, Section III).
Animals developing subacute cardiovascular collapse (SCC) did so in the and 2"  ^hours 
of SAH: animals surviving into the 3"^  ^hour did not develop SCC (SCC is equivalent to 
mortality in this thesis). SCC ensued in 9/21 (43%) animals exhibiting acute pressor 
Type I responses, 4/10 (40%) exhibiting Type II, and 1/2 (50%) exhibiting Type III 
responses. Thus, to a first approximation, it would seem that SCC was equally likely 
irrespective of the type of pressor response—intracranial or systemic—that preceded it.
This result was not as expected, since SCC is thought to relate a SNS “storm” after SAH 
(and ipso facto to a CHR: Part 1, 1.3.2.1). Therefore, the possibility that SCC could relate 
to the acute pressor response was investigated fuither, with rigour. The results and 
calculations are shown in (Table 20, Appendix): as is appaient, no statistical significance 
was demonstrated (%^  = 1.06, p»0.2). In consequence, any particular acute pressor 
response is not predictive of SCC: SCC is equally as likely whichever acute pressor 
change occurs. (Note that the total number of animals in Table 20 is 33 and not 34: this is 
because in one animal the type of acute pressor response was not recorded on a pen tracing; 
nor could it be stored onto the hard disk of the patient monitor).
1.5 CCA re-clamping and SAH Groups 1-3
As described in Part 4, 3.3, the aim of the study was to produce SAH by endo vascular 
filament ruptine and, then, to immediately restore normal perfusion by CCA clamp release. 
This occurred successfully in n = 17 animals (SAH Group 3). However, in n = 13 an ICP 
re-rise occurred following CCA clamp release. Because an ICP re-rise was felt—as a result 
of previous findings^^^—to represent a re-bleed and, therefore, possibly premature 
mortality; it was decided to re-clamp the CCA in such cases for a few minutes more in 
order to ensure haemostasis (the precise period in all cases being less than five minutes: 
SAH Group 2). The over-riding aim, therefore, was to limit study to that of a single 
primaiy SAH with full reperfusion. Unfortimately, in n = 4 animals, a further ICP re-rise 
followed reperfusion—even after 5 minutes of CCA re-clamping. In such cases, the CCA 
clamp was re-positioned for periods of over 1 hour (SAH Group 1): this, effectively, 
represented permanent CCA re-clamping in such cases, because of this group’s prematuie 
mortality (Table 21, Appendix).
As Table 21, Appendix shows, SAH Group 1 suffered significantly greater mortality
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(100%) than either SAH Groups 2 (39%) or 3 (29%) = 6.76, p<0.05]. Importantly, the
trend clearly suggested that survival improved in the direction Group 1 —> Group2 —> 
Group3. This is interesting because it is exactly the opposite trend to that implied in the 
former study from this l a b o r a t o r y ^ ^ s  [Note that all animals examined in this thesis could 
be incorporated into Table 21, Appendix].
The distribution of acute pressor response with CCA re-clamping is shown in Table 22, 
Appendix. The fact that no statistical difference is demonstrated suggests that the type of 
acute pressor response observed did not significantly influence the occurrence—or repeated 
occuiTence—of an ICP re-rise upon reperfusion, or vice versa. NOTE: the total group 
number in Table 22, Appendix is 29 and not 34. This is because Table 22 was used only to 
provide some explanation for PGF2a and NE EC50 values as discussed in Part 6 , Section 
II, 3.2 & 3.5. In consequence, only ‘acute pressor/CCA re-clamp’ values for which 
myographic data were available were required in this Table. Myography, of comse, was 
only performed in n = 30 animals (Protocols: Paif 4, 7.4). However, in one animal, 
myogi’aphy was performed without knowledge of the acute qualitative pressor response 
(because the pen recorder ti'acing was subsequently lost, and because the ‘patient monitor’ 
values could not be retrieved from a hard disk). Therefore, the myographic denominator 
must be reduced from 30 to 29. Because, however, BP values from the ‘patient 
monitor’—as well as intermittent arterial blood gases—confirmed that the latter animal 
was adequately perfused, its myographic data could still be used elsewhere in the thesis. 
The value was similarly insignificant when n = 33 animals were considered for Table 22
(p>0 .2 ).
1.6 Conclusions: implications of ‘whole animal response’ sub-groups for 
subsequent small vessel study.
Different sub-gioups arose as a result of the acute physiological ictus in this study. Some 
of these related directly to the ictus itself: for example, animals demonstrating a type I 
arterial pressor response had significantly lower ICPmax values than those demonstrating 
type II or III responses; whilst approximately 40% animals dying within the arbitary three 
hour period were distributed across all three ‘arterial presssor’ groups equally. Other sub­
groups arose by virtue of the methodology used: thus, SAH groups 1, 2 and 3 arose solely 
by virtue of the (somewhat arbitary) CCA-clamp duration. The creation of such sub­
groups is important to note because MCA responses may differ significantly between them; 
and, thus, individually account for overall differences in ‘SAH-vessels’ from controls. 
Moreover, in cases where no overall differences are noted in ‘SAH-vessels’ fr om controls, 
isolated sub-group differences (that have thus become ‘submerged’ when considering
156
‘SAH-vessels’ overall) might still prove significantly different from controls, with separate 
implications for later study with chronic clot lysis and delayed VSM.
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SECTION I 
Whole animal responses 
Chapter 2 
Post mortem evidence and extent of subarachnoid haemorrhage
2.1 Confirmation and extent of subarachnoid haemorrhage
The first confirmation of SAH was obtained by the finding of blood issuing along the ICP 
cannula from the CM posteriorly (Plate 5). This was never seen in any control animal, nor 
in any animal prior to SAH induction (Plate 4). Its extent indicated a priori a free 
communication between anterior and posterior subarachnoid space (SAS) cisterns. The 
next indication of SAH was the finding of extensive blood in the cisterna magna (CM) 
(Plate 7) at the commencement of brain removal. This was also found to extend caudally 
along the spinal SAS. Again, such findings were entirely absent in control animals (Plate 
6). Following removal of the brain extensive SAH was often noticed over convexities 
frontally and basally; however, much of this became sepai'ated during removal. As a result, 
the final picture remaining in the basal cisterns following complete removal and petri-dish 
placement, was diminished. Nevertheless, a considerable quantity still remained (Plate 9). 
This contrasts markedly to the rather anaemic picture obtained in control II brains (Plate 8). 
(NB all animals in all groups were exsanguinated at sacrifice).
It soon became apparent that no meaningful categorization of SAFI Ye at post mortem 
could be realizable in this study. This was because in almost every case the 
aforementioned findings pertained: i.e. all cases appeared ‘severe’. Moreover, in contrast 
to Veelken et aF^^—but in agreement with Harada et aP^^—SAH was not found to 
lateralize to either side. Most vaiiability was found in the ‘final’ picture obtained 
following complete brain removal: however, this was merely because of pial tearing during 
removal, and subsequent dispersion of Ye as a result. In consequence, it is strongly 
recommended to not base assessment of Ye upon the ‘final’ picture, as this may be under- 
representativc.
A final assessment of SAH was the thick coating of clot present around the major arteries 
themselves. However, with saline irrigation and increased confidence with operative 
technique, MCAs could be as reliably removed with a ‘no touch’ technique as in sham 
operative and non-operative controls.
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2.2 Position of rupture
The point of rupture can only be determined by leaving the thi ead in situ until sacrifice, 
thus directly noting its point of exit fiom the CoW, as in Veelken et aF^\ This, however, 
was clearly incompatible with the proposed form of study here: (in the previous study, such 
a manoeuvre formed part of the study protocoF^^). As stated in Part 4, 3.3, this aspeet of 
the “Sheffield Model” (i.e. with thread left in situ) was abandoned in the present study, 
partly because of its unphysiological implications; but also because prior studies suggested 
that it did not minimize either Ye or mortality. From prior studies, however, rupture was 
confirmed to occur from the ACommA anteriorly. Although the site of rupture could still 
be approximately ascertained following brain removal by noting a breach in the CoW, 
extensive clot in the basal cisterns often rendered this difficult. As a result, the precise site 
of rupture must remain conjectui’al in the large majority of cases.
2.3 Histopathological examination
Histological analysis confirmed widespread SAH with otherwise normal brain anatomy 
(not shown). There was sometimes blood found within the ventricular system: although 
this may have been due to thread-tracking, no evidence for this was found at histology. 
Pathological analysis of the heaif revealed no abnormality, even in those cases suffering a 
cardiovascular collapse (not shown). The lungs in these cases, however, often showed 
evidence of pulmonary oedema (not shown).
MCAs appeared architecturally unchanged by either sham operation, acute SAH or 
prolonged myography. Plates 10 and 11 overleaf demonstrate this with light microscopic 
power at xlOO. Thus plate 10 denotes MCAs in conti’ol animals that have recently been 
sacrificed but which have not yet undergone myography. Note the thick lEL. Plate 11, in 
turn, demonstrates MCAs following SAH and following 12 hours of myography. The 
apparent discontinuity in the lEL at 6°clock can be shown to be an artefact upon racking 
the microscope up and down. Results obtained with EM again revealed no abnormality 
following acute SAH and up to 12 hours myography (not shown).
2.4 Conclusions: implications of SAH extent for subsequent small vessel 
study
Before this study was undertaken, it was asssumed that differing degrees of SAH severity 
would be reflected in differing amounts of Ye: clearly, however, the current results refute 
this beyond doubt. As a result, similar degrees of Ye appeared to result in all animals 
studied. Furthermore, no lateralization of clot was apparent either. In consequence, ‘blood 
coating’ of MCAs was probably equal amongst all animals. This, coupled with the even 
more important fact that study was restricted to 3 hours post-SAH, implies that MCA
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reactivity study was subsequently restricted overwhelmingly to the effects of the acute ictus 
(rather than to any significant effects of clot lysis); or that any such ‘clot-effects’ were 
equally distributed across all animals.
164
SECTION II 
In vitro vessel responses 
Chapter 1 
Non-operative controls
1.1 Myogenic tone
Spontaneous myogenic tone (MT) was evidenced in all vessels tested (Fig 12) and in all 
study groups. It was indicated by continuous vasomotion with intraluminal distension 
that remained tlii'oughout the period of myography. It occurred at rates of between 3/min 
up to 8/min (Fig 12) and is compatible with previous fmdings^^ (Part 2, 2.2). It strongly 
suggests that MCAs, at least in rats, behave much as pre-capillary resistance vessels (Part 
2, 2.2). However, MT was also indicated by other features found in this study (see relevant 
sections);
• Dilation of pre-constricted tone past baseline (i.e. E^ax >100%: Part 5, Section II, 1.8 & 
1.9; Part 6, Section II, 1.4).
• Direct dilation of baseline tone by hypoxia (Part 5, Section II, 1.13).
• The invariance of the internal diameter to increasing luminal distension (Fig 14).
Thus, increasing distension in MCAs thioughout the working range of MAPs (70-150 
mmHg) invariably resulted in a corresponding increase of MT to counteract it, rendering 
functional diameters more or less invariant (Fig 14). This contrasts markedly with the 
response obtained from pulmonary arteries in their normal pressure range (15-35 mmHg) 
where MT is absent, and where elastic distension is apparent with increased luminal 
pressure (Fig 13, n = 13).
0.3 mlf
1  min
Fig 12. Spontaneous MT in MCA. This may result from pacemaker activity spreading 
tlnoughout a syncitium of VSMCs (Part 2, 2.2). The rate varies from 3-8/min^^.
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Fig 13. The effect of intraluminal pressure on pulmonary arteries, (n = 13). Clearly, 
pulmonary arteries distend passively to luminal pressure, behaving as ‘Laplace’ elastic 
cylinders. The correlation is highly significant (r = 0.98, p«0.001). Results reprinted by 
permission o f Dr J.S. Thompson -  see Acknowledgements, p 8.
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Fig 14. Invariance of functional diameter with increasing intraluminal pressure.
MCAs resist distension with active MT (SAH vessels). No correlation is demonstrated 
between FD and intraluminal pressure, (n ^27,  r = 0.072, p = 0.79).
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1.2 Functional diameters (FD9 0)
Values were recorded in 39 vessels. The normalized diameters achieved by the programme 
were referred to as FD90 values (‘functional diameter at 90 mmHg’). The mean right MCA 
FD90 was 160+31 p,m, the mean left 152+51 pm. The overall control group mean FD90 was 
thus 156+42 pm. The range of diameters (71-237 pm) was large and approximated to 50% 
either side of the mean. However, in n = 10 rats (53%) one vessel was larger than its 
fellow by at least one standard deviation (SD). Thus, significant asymmetry is present in 
individual rat MCAs.
1.3, KCl responses
KCl depolarizing constrictions produced typical phasic and tonic components (Fig 15). As 
the tonic component proved quite variable, only phasic response was considered.
Responses were recorded in n = 34 vessels. The KCl responses (Fig 16) exhibited wide 
variance with an Emax of 5.5+0.3 mN. Thus, the frequency histogram only approximately 
reflects that of a normal distribution (Fig 16), this being due to significant numbers 
deviating from the group mean Emax-
Tracer movement
lOsecs
10 mN
Fig 15. Phasic (P) and tonic (T) KCl constrictions. NOTE: tracing moves from right to 
left. Vertical arrow defines when KCl was added to the bath.
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I
Kmax (mN)
Fig 16. Control Kmax frequency histogram (Non-operative controls). This only 
vaguely corresponds to a normal distiibution. However, it is symmetrical, with similar 
mean (5.5 mN) and median (5.4 mN) values.
FD90/Kiiiax (uni/niN)
Fig 17. Transformed Control Kmax frequency histogram (Non-operative controls).
The transfoiTnation F D 9 0  / K,„ax enhances the normalization. This suggests that F D 90  
significantly influences Kmax-
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It was felt, however, that a large factor involved here was the size of the MCA concerned. 
This was borne out by relating the Kmax to the individual FD90 (Fig 17). Thus, the 
transformed FDgo/Kmax more closely resembles a normal distribution. The diameter 
influence was further confirmed by the regression plot of Kmax v FD90 (Fig 18): here the 
correlation was highly significant with r = 0.75 (p<0.001 : Table 31, Appendix). In fact, a 
linear Emax v FD90 pattern pertained, to greater or lesser degi'ees, with all other contractile 
agonists tested in this thesis {see below).
1.4 PGF2a responses
The PGF2a-induced constriction was distinct fi'om the KCl response. Thus, the slope of 
tension-rise was more gradual, and an acute phasic response was conspicuously absent. 
Furthermore, the contraction displayed continuous vasomotion thioughout its ascent (Fig 
19). Responses were recorded in n = 22 MCAs. The E m a x  was 5.1+0.4 mN and the E C 50
6.4±1.0 pM. As with KCl responses, variance in PGF2a Emax appeared to reflect variance 
in FD90. This was subsequently confirmed by a linear PGF2amax v FD90 regression plot 
(Fig 20: r = 0.45, p<0.05: Table 31, Appendix).
 ^Tracer movement
10 secs
T.OmN
Fig 19. The PGF2a-induced constriction. Note the absence of the phasic component 
and continued vasomotion. Vertical arrow indicates when PGF2a was administered.
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1.5 5HT responses
Responses were recorded in n ^ 24 vessels. The contractile response demonstrated phasic 
and tonic components that more resembled KCl than PGF2a. However, the tension-rise 
was slower, and the Emax (4.4±0.3 mN) less efficacious than KCl (p = 0.019). Again, a 
linear relationship between Emax and FD90 was apparent (Fig 21): however, the correlation 
was less close than with KCl (r = 0.523, p<0.02: Table 31, Appendix). Thus, less than 
30% of the Emax variance could be attributable to diameter variance with 5HT. This 
suggested a degree of heterogeneity in receptor/second-messenger activity also found with 
PGF2a for which the wide diversity of receptors mediating the effects of one agent (Part 3,
1.4) could have possibly accounted for this. The EC50 was 0.09+0.02 pM; this value is 
several orders of magnitude lower than that of any other agonist used. 5HT responses ai’e 
therefore especially potent in rat MCAs.
a  4 a
If) 3
♦ ♦
50
♦ ♦
100 150 200 250
FD90 (um)
Fig 21. Non-operative controls 5HT Emax v FDgg. The linear association is much less 
exact than with KCl, although the correlation remains significant (r ^  0.523, p<0.02). The 
regression equation obeys Emax (0.022). F D 9 0  + 1.06. The value of 0.27 indicates that 
only 27% of the variance in Emax can be accounted for by variance in F D 9 0 .
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1.6. UTP responses
Responses were obtained in n == 17 MCAs. The contractile response demonstrated phasic 
and tonic components that more closely resembled KCl than PGF2a. The UTP Emax was 
3.4+0.4 mN: this was significantly weaker than the control K^ax (p = 0.0001). A 
considerably poorer linear' relationship between E,„ax and FD90 was also apparent with UTP 
(Fig 22: r = 0.31, p>0.10). The poor linearity for UTP responses was distinctly at variance 
with all other contractile agonists used; as well as from UTP responses in shams and after 
SAH (Table 31, Appendix). The E C 5 0  was 16.4+2.8 pM: this value was an order of 
magnitude greater than that of any other agonist used. UTP responses ar e therefore much 
less potent than other agonists in rat MCAs.
0
♦
0 50 100 150 200 250
FD90 (iim)
Fig 22. Non-operative controls UTPmax v FD9 0 . The linear relationship and correlation 
is poor (r = 0.31), and not statistically significant (p>0.10). This was the only example in 
the thesis where a contractile Emax failed to attain a significant correlation with FD90; other 
than NE (uneorrected for ' subrespondersE see below).
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1.7 NE responses
NE responses were attempted in n = 34 MCAs. The greater scatter apparent with 5HT and 
UTP—in contrast to that with KCl or PGF2a—was greater still with NE. In fact, no clear 
linear relationship was initially apparent on the NEmax v FD90 plot, with only 1 0 % of the 
NEmax variance being possibly attributable to diameter variance. Clearly, receptor- 
mediated factors played a greater role here than ‘muscle-bulk’ effects. However, a closer 
look at the plot revealed that many responses clustered in the range 0-1 mN: implying a 
discontinuous distribution (Fig 23). Such values were, in reality, too close to baseline 
vasomotion to be reliably quantifiable in any case (Fig 12). Furthermore, corresponding 
contractions to other agonists were invariably satisfactory (e.g. Fig 24): thus, NE responses 
were specifically poor in these MCAs.
It was therefore decided to separately classify NEmax values <1.0 mN as NE- 
‘subresponders’ and, thus, to distinguish them from NE-‘responders’ (whose values were 
distributed normally and continuously). ‘Subresponders’ were therefore excluded from 
analysis of continuous data, and instead analyzed as categorical data. Upon exclusion of 
‘subresponders’, a linear' relationsliip once again pertained between ‘responder’ NEmax and 
F D 9 0  (r = 0.62, p<0,01: Figs 23; Table 31, Appendix). The NEmax in ‘responders’ was 
3.2+0.3 mN (n = 26): this was significantly weaker than either the KCl Emax (p = 0.0001 : 
Fig 24) or the PGF2a Emax (p ^ 0.0006). The EC50 in ‘responders’ was 2.4±1.0 pM.
1.7.1 NE-‘responders’ (Table 10, Appendix)
These were defined as NEmax ^1.1 mN. A total of 26/34 (77%) MCAs showed an adequate 
NE response. Because in n = 2 animals, one MCA was generally unresponsive to all 
agonists contralateral to a specifically NE-subresponsive MCA (and so excluded from 
study: see Part 4, 7.4), the denominator over which responses are considered must be 
reduced fi'om 18 to 16. Thus, 77% MCAs showed a response in 14/16 (8 8 %) animals. NE 
responses were obtained bilaterally in 12/16 (75%) animals. NE responses were therefore 
recordably asymmetrical (i.e. a ‘subresponder’ contralateral to a ‘responder’) in 2/16 
(12.5%) animals.
1.7.2 NE-‘subresponders’ (Table 10, Appendix)
These were defined as NEmax <11 mN. A total of 8/34 (24 %) MCAs were subresponsive 
to NE in 6/18 (33%) animals. (The denominator is restored to its ‘normal’ value here 
because the two animals with a generally umesponsive MCA contained a specifically
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subresponsive MCA to NE). NE-'subresponders' were obtained bilaterally in 2/16 (12.5%) 
animals. NE responses were recordably asymmetrical (i.e. one ‘subresponder’ contralateral 
to a ‘responder’) in 2/16 (12.5%) animals, because inn ^ 2 animals, one vessel from each 
was excluded from analysis (Part 4, 6.5 & 7.4; Table 10, Appendix).
1.8 HA responses
Responses were recorded in n = 23 MCAs. HA was a potent and efficacious dilator of 
MCAs with an E^ax of 102±5 % and an EC50 of 2.3+0.6 pM. The vasodilation achieved 
often exceeded baseline values (i.e. E^ax >100%, n = 12, 52%): this can be appreciated in 
the right hand tail of the fi'equency distribution shown in Fig 25. Thus, HA must frequently 
dilate MT in addition to AT because it relaxes more vessel tone than the applied agonist 
had been responsible for.
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Fig 25. Non-operative eontrols HA Emax Frequency histogram. Because the mean is 
centred on HA Emax ^  100% (i.e. complete relaxation of AT), the right hand tail must 
reflect additional dilation of backgi'ound MT. In two extreme eases, the MT dilated was 
equivalent to 50 and 90% that of the AT induced—i.e. such MCAs were effectively 
paralyzed.
As more than one receptor may be involved (Part 3, 1.11), it was important to identify the 
major receptor of action. Following pre-constriction with PGF2a, 200 pM ranitidine was 
added to the bath. The resultant HA C-R curve (n = 18 vessels) shows that FIA relaxation 
of AT was severely obtunded (Fig 26). Thus, the Emax obtained following HA2 blockade 
was 18+9%: the HA2 reeeptor therefore mediates approximately 82% of the HA response.
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Fig 26. The effect of HA2 blockade (200 p.M ranitidine) on MCA HA response in n = 
18 vessels (Non-operative controls). The HA2 receptor appears to mediate approximately 
82% of the HA response in rat MCAs.
1.9 PPV responses
Responses were recorded in n = 22 vessels. PPV, like HA, was a potent and efficacious 
dilator of MCAs. Thus, the Emax was 106+9%, and the EC50 2.1+0.6 pM. As with HA, 
PPV frequently dilated MCAs past baseline tone (i.e. Emax >100%), indicating dilation of 
MT (Fig 40; Part 5, Section II). The C-R curve is presented on the combined group graph 
in Fig 39. Frequent abnormalities in the C-R curve were observed in individual MCAs, 
these occurring at the 50 pM level and consisting of a transient loss of relaxation (Fig 41).
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1.10 L-ARG and L-NAME responses
Responses were recorded in n = 23 (L-ARG) and n = 8  (L-NAME) MCAs respectively.
The L-ARG E^ax was 72±4 % and the EC50 5.0+1.3 pM. The C-R curve can be visualized
in the combined graph of Fig 44 (Part 5, Section II). As the combined control frequency
distribution shows in Fig 43, L-ARG rarely dilated baseline MT (i.e. invariably
Emax l^OO%). The L-NAME Emax was 1.3+0.4 mN; no EC50 value was attempted. Thus
‘tonic release’ of NO with PGF2a-induced AT has ‘basally’ reduced AT from 6.4 mN (i.e.
5.1 + 1.3) to 5.1 mN {see PGF2a Emax and L-NAME Emax values, Table 28, Appendix].
From this we can derive the % maximal NO release that ‘basal NO release’ represents.
Thus, L-ARG maximally relaxes AT from 5.1 by 3.67 mN to 1.4 mN (i.e. 72%
relaxation—the mean L-ARG Emax). But we know that ‘basal release’ had already reduced
AT by 1.3 mN prior to any L-ARG. Therefore, basal release represents 
1 3   X100% or 26 %. That is, basal NO release with AT represents 26% of the(1.3 + 3.67)
total NO release possible.
1.11 SNP responses
Responses were recorded in n = 24 vessels. The Emax was 72+4% and the EC50 10.7+4.3 p 
M. The C-R curve is presented on the combined group graph in Fig 46. SNP, like L-ARG, 
clearly acts mainly upon AT: i.e. SNP rarely dilates >100% AT.
1.12 PPV-SNP interaction
Because of the theoretical possibility of an interaction between PPV and SNP, and because 
of their occasional co-administration at aneurysm sui'gery, the combination of PPV and 
SNP was performed in n = 17 MCAs. As a result, the C-R curve (Fig 27) was significantly 
left-shifted with an Emax of 146±12 % and an EC50 of 0.48+0.06 pM. Both values differed 
significantly from either PPV or SNP values alone (p = 0.01 and p = 0.014 respectively). 
Therefore, the significant degree of MT dilation (i.e. Emax >100%) that PPV achieves alone 
is significantly enhanced by its co-administration with SNP, thus supporting a possible 
interaction between the two agents.
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1.13 Hypoxia
Hypoxic responses were only recorded in non-operative control MCAs. Here dilation was 
achieved by replacing the 95%02/5%C02 mixture in the myograph bath by 95%N2~ 
5%C02- This was performed for 15-20 mins at the end of the study period in order to 
obviate metabolic exhaustion of the MCA concerned. Since there had been no prior 
addition of PGF2a, these relaxations were achieved against a baekground only of MT. 
Responses were obtained in n = 14 MCAs: the mean relaxation produced was 3.6+0.6 mN. 
Thus, the total tone possible in normal MCAs is 3.6 + 5.5 mN (i.e. [hypoxic dilation]mN + 
[KCl Emax]mN), which is 9.1 mN. As a result, MT therefore represents (3.6 x 100)/(9.1) = 
40% of the total tone possible.
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SECTION II 
I n  v i t r o  v e s s e l  r e s p o n s e s  
Chapter 2 
Sham operative controls
2.1 Functional diameters (FD9 0 )
Values were recorded in n = 16 MCAs. The mean sham MCA F D 9 0  was 157+41 (SD) pm 
which strikingly resembled the control value (156±42 pm). As with non-operative controls, a 
significant degree of asynunetiy was apparent in MCAs from individual animals (not shown). 
Thus, in 4/8 (50%) of animals the right MCA F D 9 0  differed from the left by at least one overall 
group SD (i.e. approximately 40 pm): this proportion did not differ significantly from that in 
non-operative controls. Nevertheless, no significant overall group mean right:left side 
difference in F D 9 0  was apparent (Table 23, Appendix), suggesting that unilateral CCA 
manipulation and tliread insertion were without ipsilateral effect.
2 . 2  KCl responses
Responses were recorded in n = 16 vessels. The mean KCl Emax was 5.9+0.5 mN which did 
not differ significantly fi’om non-operative conti'ols. As with non-operative controls, a strong 
linear relationship was appaient between Emax and FD90 {r = 0.78, p<0.001 : Fig 28; Table 31, 
Appendix). No significant right:lefi side difference was appaient in either Emax or E C 5 0 ,  
suggesting that unilateral CCA manipulation and thread insertion were without ipsilateral 
effect (Table 23, Appendix).
2.3 PGF2a responses
Responses were recorded in n = 16 vessels. The PGF2a Emax was 5.9+0.6 mN and the EC50 
6.2±1.1 pM. Neither value significantly differed from that in non-operative controls. A 
significant linear relationship was again apparent between Emax and FD90 (r = 0.87, p<0.001 : 
Table 31, Appendix), No significant right:lefi side difference was apparent in either Emax or 
EC50 value, suggesting that unilateral CCA manipulation and thread insertion were without 
ipsilateral effect (Table 23, Appendix). The C-R cui-ve for FGF2a is presented in the 
combination graph of Fig 33.
2.4 5HT responses
Responses were recorded in n = 16 vessels. The Emax was 5.4+0.7 mN and the E C 5 0  0.08+0.02 
pM. Neither value was significantly different from that obtained in non-operative controls.
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As with non-operative controls, a linear relationship was appaient between Emax and F D 9 0 ,  this 
being less strong than with PGF2a or KCl (r = 0.64, p<0.01 : Table 31, Appendix). The C-R 
curve is presented in the combination graph of Fig 35. No significant rightdeft side difference 
was apparent in either Emax or E C 5 0  value, suggesting that unilateral CCA manipulation and 
thread insertion were without ipsilateral effect (Table 23, Appendix).
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Fig 28. Sham operative control K,„ax v FD90. Once again the correlation is extremely close 
with r = 0.78; n = 16 (p<0.001). The value suggests that more than 60% of the KCl Emax 
can be attributable simply to the variance in FD90.
2.5 UTP responses
Responses were recorded in n = 16 vessels. The Emax was 4.7+0.5 mN and the EC50 20.1+1.4 
pM: neither value differed significantly with non-operative controls. Unlike control UTP 
responses, a linear Emax v FD90 relationship was apparent (r = 0.74, p<0.01 : Table 31, 
Appendix). No significant rightdeft side difference was apparent in either Emax or EC50 value, 
suggesting that unilateral CCA manipulation and thi'ead insertion were without ipsilateral 
effect (Table 23, Appendix). The combined C-R cuive is shown in Fig 37.
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2,6 NE responses
NE responses were attempted in n = 16 MCAs: however, as with non-operative controls, a sub 
group of NE“‘subresponders’ was apparent in which effectively no conti’actions were observed 
(NEmax ^1.0 mN: see below). The mean NEmax m responders was 3.3±0.4 mN, the mean EC50
3.1 ±0.9 pM: neither value differed significantly fiom non-operative controls. No significant 
right:left side difference was apparent in either Emax or EC50 value, suggesting that unilateral 
CCA manipulation and thiead insertion were without ipsilateral effect. As with non-operative 
controls, a linear relationship was apparent between Emax and FD90 in ‘responders’ (r = 0.72, 
p<0.001: Table 31, Appendix), therefore justifying the exclusion of discontinuous 
‘subresponders’.
2 .6 .1  NE“‘responders’
These referred to NEmax >E0 mN. A total of 14/16 (88%) of MCAs showed a response in 8/8 
(100%) animals (Table 11, Appendix). NE responses were obtained bilaterally in 6/8 (75%). 
NE responses were therefore asymmetrical (i.e. one ‘responder’ contralateral to a 
‘subresponder’) in 2/8 (25%) animals.
2.6.2 NE-‘subresponders’
These referred to NEmax^l.O mN. A total of 2/16 (12.5%) of MCAs were subresponsive to NE 
in 2/8 (25%) animals (Table 11, Appendix). No animal contained bilaterally subresponsive 
MCAs. NE responses were therefore asymmetrical (i.e. one ‘responder’ contralateral to a 
‘subresponder’) in 2/8 (25%) animals.
2.7 HA responses
Responses were recorded in n = 16 vessels. The Emax was 82±5 % and the EC50 6.8+1.6 
pM. Both of these results were significantly different from non-operative controls (p = 0.0085 
and p = 0.0062 respectively). Furthermore, the HAmax fi'equency distribution was significantly 
left-shifted, resulting in a smaller proportion of MCAs (4/16 = 25%) with an Emax >100%: 
however, the latter was not quite statistically significant (p = 0.56). As Fig 30 shows, the 
effect produced was akin to that of low-dose HA2 blockade (c.f. Fig 26). No significant 
right:left side difference was apparent in either Emax or EC50 value, suggesting that unilateral 
CCA manipulation and thiead insertion were without ipsilateral effect.
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F ig  29 . Combined non-operative controls and shams HAmax frequency histograms.
N ote the marked left-shift fo llow ing sham operation. N ote also that there are fewer numbers 
in the right hand tail (i.e. Emax >100% ) Key: white non-operative controls, grey shams.
2.8 PPV responses
Responses were recorded in n =  16 vessels. The Emax was 107+16 % and the EC50 2 .7+0.5  
pM. Neither value was significantly different from that in non-operative controls. A s with  
non-operative controls, C-R curve abnormalities again occurred at the 50 pM level, amounting 
to a similar transient loss o f  relaxation {see Fig 41). N o significant rightdeft side difference 
was apparent in either Emax or E C 5 0  value, suggesting that unilateral CCA manipulation and 
thread insertion were without ipsilateral effect (Table 23, Appendix). The com bined C-R  
curve is show n in Fig 39.
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Fig 30. Combined non-operative controls and shams HA C-R curves. The significant 
right-shift resembles low-dose HA2 blockade {see Fig 26): both EC50 and Emax values are 
significantly different from non-operative controls (p<0 .0 1 ).
2.9 L-ARG and L-NAME responses
Responses were recorded in n = 16 (L-ARG) and 6  (L-NAME) vessels respectively. The L- 
ARG Emax was 72±5 % and EC50 4.7±1.4 p,M: neither value differed significantly from non­
operative controls. The combined frequency distribution shown in Fig 43 demonstrates that in 
very few MCAs L-ARG Emax > 100%. No significant rightilefr side difference was apparent in 
either Emax or EC50 value, suggesting that unilateral CCA manipulation and thread insertion 
were without ipsilateral effect (Table 23, Appendix).
The L-NAME mean Emax was 2.0±0.5 mN, which did not significantly differ from non­
operative controls. No significant right:left side difference was apparent m either Emax or E C 5 0  
value, suggesting that unilateral CCA manipulation and thread insertion were without 
ipsilateral effect (Table 23, Appendix).
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2.10 SNP responses
Responses were recorded in n = 16 vessels. The Emax 76±3 % was and the E C 5 0  8.8+3.2 p.M: 
neither value differed significantly from non-operative controls. No significant right:left side 
difference was apparent in either Emax or E C 5 0  value, suggesting that unilateral CCA 
manipulation and thread insertion were without ipsilateral effect (Table 23, Appendix). The 
combined C-R curve is shown Fig 46.
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SECTION II 
I n  v i t r o  v e s s e l  r e s p o n s e s  
Chapter 3 
Subarachnoid haemorrhage groups
3.1 Functional diameters
Values were recorded in n = 60 vessels. The overall SAH group mean FD90 was 161±39(SD) 
pm; the mean right MCA being 161+43(SD) pm, the mean left MCA 160+36(SD) pm. None 
of these values differed significantly from shams or non-operative controls. In fact, there was 
a remarkable degree of uniformity across these groups (p = 0.86: see Table 28, Appendix).
This does not merely reflect an overall uniformity in MCA ^anatomical size’: MCA 
dimensions at 90mmHg internal pressure ( F D 9 0 )  are determined by myogenic contraction (MT) 
as well as by anatomical dimensions. Thus, a imiformity in functional activity—at least with 
regard to baseline MT—is also suggested. This possibility is further—and more 
profoundly—suggested by the invariance of FD in n = 27 SAH MCAs tlnoughout a range of 
intraluminal pressures from 70-150 mmHg {see Table 5 and Fig 31).
Table 5. Pressure-FD relationship values for Fig 29. (r = 0.072, p = 0.79,11 = 27)_______
Pressure 70 90 110 130 150
(mmHg)
FD±SE(pm) 157±9________143+9________ 152+9________160+10_______ 150+11
Again, as with shams and non-operative controls, a significant degi'ee of asymmetiy was 
apparent in MCAs obtained from individual animals (not shown). Thus, in 15/30 (50%) of 
animals the right MCA FD90 differed from the left by at least one overall group SD (i.e. 
approximately 40 pm). Because of the Emax v FD90 relationship, this could have implications 
for experimental studies that use the contralateral vessel as the control (Part 6 , Section II,
1.1.4). Nevertheless, as the overall values show, randomization for side, or—in 
pai’ticular—the use of lai'ger experimental numbers, usually overcomes this error. The 
proportion of animals with asymmetrical MCAs (50%) did not differ significantly from either 
shams (50%) or non-operative controls (53%).
3.1.1. SAH sub-group analysis {see Tables 24-30, Appendix)
The striking degree of uniformity apparent in SAH groups overall against shams and non­
operative controls was further endorsed upon SAH sub-group analysis. Thus, the F D 9 0  was
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remarkably similar despite vaiying degi'ees of CCA re-clamping (i.e. SAH Groups 1-3: p
0.85). Furthermore, no significant side differences were apparent in these groups individually 
(p = 0.82, 0,64 and 0.99 respectively).
In marked contrast, the FD90 was considerably lower in the 1 hour survival group after SAH 
(136+31 pm) compared to the 2 or 3 hour group. Nevertheless, this value was not significantly 
different (p = 0.08: Table 29).
The high degree of uniformity in F D 9 0  was once again restored across acute pressor response 
groups after SAH (Table 30).
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
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3.2 KCl responses
Responses were recorded in n = 57 vessels. The overall SAH (i.e. Groups 1-3) KCl Emax was 
5.2+0.3 mN: this did not significantly differ from either control (Table 28). As with shams 
and non-operative conti'ols, a linear relationship between Emax and FD90 was very much in 
evidence, though less close than with shams or non-operative controls (r = 0.52, p<0.001:
Table 31, Appendix). As FD90 values remained remarkably unchanged after SAH (3.1 above), 
this implies that KCl contractions also remained proportionately unchanged. Thus, MCA 
contractile potential (contractility) remains preserved after acute SAH. Furthermore, as with 
shams and non-operative conti'ols, the Kmax remained the ‘gold’ standard against which to 
compare all other contractile responses.
3.2.1. SAH sub-group analysis {see Tables 24-30, Appendix)
The strong degree of uniformity in KCl Emax values across non-operative controls, shams and 
overall SAH groups was also apparent across SAH sub-groups. Thus, the Kmax did not 
significantly differ across SAH Groups 1-3, indicating that varying degrees of CCA re­
clamping were tolerated without overt effect after SAH (Table 27). Moreover, there was a 
striking degree of uniformity m Kmax values between right and left MCAs in SAH Groups 1, 2 
and 3 (Tables 24-26). This was evidenced by p values of 0.90, 0.66 and 0.86 respectively 
which, along with FD90 invaiiance, supports the view that all other responses were essentially 
analyzed against a background compai'ison of ‘like with like’ in this study. It also suggests, of 
course, that CCA re-clamping effects did not singularly affect ipsilateral MCA reactivity: 
however, poor statistical n numbers for SAH Group 1 (n = 4 for each MCA) renders this 
analysis inconclusive.
The mean Kmax was also strikingly invaiiant across 1, 2 and 3 hour sm'vival groups after SAH 
(Table 29).
In marked contrast, the mean Kmax appeared strongly affected by the acute pressor response 
(Table 30). Thus, the mean Kmax with the type II ‘invariant’ pressor response (3.7+0.5 mN) 
almost significantly differed from either type I or type III pressor response (p = 0.0527) of 
which, each in turn, both more closely resembled shams and non-operative controls. In fact, 
the type II Kmax significantly differed from type I when considered in isolation (p = 0.025). 
Furthermore, the type I Kmax also significantly differed fr om the combined type II & III value 
(p = 0.044).
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
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3.3 PGF2a responses
Responses were recorded in n = 55 MCAs. The overall SAH (i.e. SAH Groups 1-3) PGF2a 
Emax was 6.5+0.3 mN—this very nearly differed significantly from shams and non-operative 
controls (p = 0.051 : Table 28). The overall SAH PGF2a EC50 value (5.8+0.6 jaM), however, 
was strikingly similar to shams and non-operative controls (p = 0 .8 8 ): a fact that can be 
appreciated in the combined C-R curve of Fig 33. Also apparent in Fig 33 is a partial loss of 
efficacy at supramaximal (i.e. >50 pM) concentrations. As with shams and non-operative 
controls, a close linear relationship of Emax to F D 9 0  was again apparent (r ^ 0.632, p<0.001 : 
Table 31, Appendix; Fig 34).
- ■ m -  CON 
SHAM 
— •— SAH
BM 0.8iPh% 0.6Io
& 0.4 
&
0.2
0 0.1 0.5 1001 5 10 30 50 70
[PGF2a] M-6
Fig 33. Combined non-operative controls, shams and SAH (i.e. SAH Groups 1-3) 
PGF2a C-R curves. A remarkable degree of unifoimity apparent in each C-R curve. Some 
loss of efficacy is apparent at [PGF2a] >50 pM.
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3.3,1. SAH sub-group analysis (see Tables 24-30, Appendix)
The PGF2a Emax did not differ significantly across SAH Groups 1-3, suggesting that varying 
degrees of CCA re-clamping were tolerated without overt effect within the confines of this 
study (Table 27). This fact is further suggested by insignificant side differences between right 
and left MCAs within each Group—particularly within SAH Group 1 (Tables 24-26). 
However, poor statistical n numbers for SAH Group 1 (n = 4 for each MCA) renders the latter 
analysis strictly inconclusive. Statistical significance was apparent, however, in EC50 values 
between SAH Groups 1-3. Thus, the mean E C 5 0  in SAH Group 2 (3.7±0.6 pM) significantly 
differed fii'om Groups 1 and 2: moreover, it nearly differed significantly from shams and non­
operative controls (p = 0.058).
There appeared to be a progressive increase in mean PGF2a Emax with increased survival after 
SAH (Table 29). Thus, the Emax increased from 4.6+0.8  mN in the 1 hour group, through 
6 .6+0.7 mN in the 2 hour group, to 7.2+0.4 mN in the 3 hour group (p = 0.03). Furthermore, 
the 3 hour value significantly differed from both shams and non-operative controls (p = 0.006). 
However, it has already been noted that the FD90 was considerably smaller in the 1 hour group. 
Although not in itself of statistical significance (Part 5, Section II, 3.1 : Table 29), a smaller 
FD90 could account for a smaller Emax by virtue of the Emax: FD90 relationship (Fig 32). No 
significance was apparent in mean E C 5 0  values across this series: indeed, the mean E C 5 0  
appeared strikingly uniform with survival.
Mean PGF2a Emax and EC50 values did not differ significantly across differing acute pressor 
response sub-groups after SAH (Table 30).
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
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3.4 5HT responses
Responses were recorded in n = 54 vessels. The overall SAH (i.e. SAH Groups 1-3) Emax was 
5.1+0.4 mN, the EC50 0.21+0.06 pM: neither value differed significantly from shams or non­
operative controls (Table 28). A linear relationship between 5HT Emax v FD90 (not shown) of 
similar correlation to that of shams or non-operative controls was again apparent after SAH:
i.e. similar to KCl or PGF2a (r = 0.56, p<0.01; Table 31, Appendix). The combined C-R 
curve suggests approximate conformity across the three main experimental groups (Fig 35).
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Fig 35. Combined non-operative controls, shams and SAH (i.e. SAH Groups 1-3) 5HT 
C-R curves.
3.4.1. SAH sub-group analysis (see Tables 24-30, Appendix)
No statistical significance was demonstrated in 5HT Emax values between SAFI Groups 1-3 
(Table 27): nor were there any significant side differences apparent (Tables 24-26). Varying 
degrees of CCA re-clamping were therefore tolerated without overt effect, although small n
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numbers for Group 1 render this inconclusive. The SAH Group 1 mean EC50 value (0.72+0.31 
pM), however, did signifieantly differ from SAH Groups 2 & 3 (p = 0.0004); as well as from 
shams and non-operative controls (p = 0.0002). No significant side difference, however, was 
demonstrated in SAH Group 1.
No significance was demonstrated in 5HT Emax values between survival gioups after SAH 
(Table 29). However, the 2  houi' EC50 value (0.38+0.17 pM) appeared markedly different 
fi'om the 1 and 3 hour value. Although this did not reach statistical significance (p = 0.06), it 
significantly differed from either shams or non-operative controls (p = 0.012).
No significance was demonstiated in 5HT Emax values between acute pressor response groups 
after SAH (Table 30). The type III (CHR) response EC50 value (0.92+0.64 pM), however, did 
significantly differ from either type I & II response groups (p = 0.002); as well as from shams 
and non-operative controls (p = 0.0003).
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
3.5 NE responses
NE responses were attempted in n = 57 MCAs from n = 29 animals (in one animal, NE 
responses were not attempted due to pressures of time: see Part 4, 6.5). As with shams and 
non-operative controls, however, NE responses were singularly heterogeneous in comparison 
to other contractile agonists: some MCAs effectively demonstrated no response (NEmax 
<1 .OmN) despite adequate constrictions to other agonists. Fig 36 demonstrates this in relation 
to corresponding KCl constrictions per each MCA. As with shams or non-operative controls, 
a linear relationship was appaient in ‘responders’ between Emax and F D 9 0  {r = 0.47, p<0.001 : 
Table 31, Appendix). Again, as in shams or non-operative controls, the overall SAH NEmax in 
‘responders’ (3.1+03 mN) was significantly weaker than the overall mean SAH Kmax (5.2+0.3 
mN, p = 0.000003). However, the overall SAH ‘responder’ NEmax did not differ significantly 
from either shams or non-operative controls (Table 28, Appendix): indeed, all of these values 
were impressively similar (p = 0.90). The E C 5 0  in responders (5.9+1.4 pM) again did not 
significantly differ fiom either control: however, sub-group analysis suggested that SAH 
Group 3 did statistically differ from either SAH Groups 1-2 or shams and non-operative 
controls (see below).
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3.5.1 NE-‘responders’
A total of 34/57 (60%) MCAs showed a response to NE in 22/29 (76%) animals (Tables 12- 
14, Appendix). NE responses were obtained bilaterally in 12/28 (43%) animals [in one animal 
the contralateral MCA was generally unresponsive to all agonists, thus reducing the 
denominator], NE responses were therefore asymmetiical (i.e. one ‘responder’ contralateral to 
a ‘subresponder’) in 9/28 (32%) animals. None of these values was significantly different 
from shams or non-operative controls.
3.5.2 NE-‘subresponders’
A total of 23/57 (40%) MCAs showed no effective NE response in 16/29 (55%) animals 
(Tables 12-14, Appendix) despite adequate responses to other contractile agonists (Fig 36).
The response was bilaterally poor in 7/28 (25%) animals. NE responses were therefore 
asymmetrical (i.e. one ‘responder’ contralateral to a ‘subresponder’) in 9/28 (32%) animals. 
None of these values was significantly different from shams and non-operative controls.
3.5.3. SAH sub-group analysis {see Tables 24-30, Appendix)
Table 27 demonstrates the striking degree of uniformity in ‘responder’ NEmax despite varying 
degrees of CCA re-clamping (i.e. SAH Groups 1-3: p = 0.97). Note also that no significant 
side difference nor trend is demonstrated in any SAH sub-group based on CCA-clamping (i.e. 
SAH Groups 1-3: Tables 24-26): however, poor statistical n numbers for SAH Group 1 [n = 4 
for each MCA] renders this analysis inconclusive. Nevei*theless, the ‘responder’ EC50 in SAH 
Group 3 (9.2±2.3 pM) was significantly different from either SAH Groups 1 or 2, or fr om 
shams and non-operative controls (p = 0 .0 0 2 ) [no E C 5 0  was obtained in Group 1—see Part 4,
6.5]. The degree of heterogeneity (i.e. proportion of NE- ‘ subresponders ’ : ‘ responders ’ ) did not 
vary significantly across SAH Groups 1-3 (38%, 35% and 45% NE-‘subresponders’ : p»0 .2 ).
The mean ‘responder’ NEmax appeared to increase significantly with prolonged survival after 
SAH (Table 29). Thus, the 3 hour NEmax (4.8+0.6  mN) differed significantly from the 1 and 2 
hour values (p = 0.04); as well as from shams and non-operative controls (p = 0.026).
However, the mean functional diameter in the 1 hour- group was considerably lower than the 2 
or 3 hour value and, excluding this group, no significance was apparent between 2 and 3 hour 
values when considered in isolation (p = 0.09). No statistical significance was apparent in 
EC50 values across this series. No significance was apparent in NE heterogeneity with survival 
(33%-Group 1, 38%-Group 2, 48%-Group 3 NE-‘subresponders’ : p»0 .2).
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The mean ‘responder’ NEmax was strikingly invaiiant across acute pressor response groups 
after SAH (Table 30). In contrast, an equally striking degree of statistical significance was 
apparent in EC50 values across the same series: the ‘invariant’ type II acute pressor response 
gi’oup appeared distinctively abnormal here. In fact, type II acute pressor response EC50 values 
were significantly different from both type I & III acute pressor response groups (p = 0.004 and 
p = 0 .0 2  respectively), as well as from shams & non-operative controls (p = 0 .0 0 0 1 ).
However, poor statistical n numbers for type II and III pressor groups (n = 4 EC50 values in 
each case) renders this analysis inconclusive. In similar fashion, the degree of heterogeneity in 
type III acute pressor responses was significantly lower than that in type I or type II pressor 
groups (39%-type I, 60%-type II, and 0%-type III NE-‘subresponders’, p<0.05): however, the 
statistically small group number in the type III pressor group once again precluded this from 
being conclusive. Furthermore, no statistical significance was apparent in the degree of 
heterogeneity between the type I acute pressor response group (39%) and type II & III pressor 
groups (47%: p>0.2) when the latter were grouped together based upon their significantly 
higher AICP values [Part 5, Section I, 1.3.2].
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
3.6 UTP responses
Responses were recorded in n = 55 MCAs. The overall SAH (i.e. Groups 1-3) Emax was 
3.7+0.3 mN, the overall SAH E C 5 0  21.3+1.3 pM: neither value significantly differed from 
either control (Table 28, Appendix). The uniformity in UTP contractions across each major 
experimental group can be appreciated from the combined groups C-R curve in Fig 37. As 
with shams and non-operative controls, a linear relationship between Emax and FD90 was very 
much in evidence (graph not shown); though less close than with shams or non-operative 
controls (r = 0.58, p<0.001: Table 31, Appendix).
3.6.1. SAH sub-group analysis (see Tables 24-30, Appendix)
No significant difference was apparent in either Emax or E C 5 0  values across SAH Groups 1-3: 
indeed, there was a striking degree of uniformity apparent (Table 27). Furthermore, there were 
no significant side differences appaient in UTP contractions within each group (i.e. SAH 
Groups 1-3), suggesting that CCA re-clamping was without significant effect in this study 
(although small n numbers in Group I render this inconclusive: Tables 24-26).
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No significant difference was recorded in either E^ax or EC50 values with increasing survival 
after SAH (Table 29).
No significant difference was recorded in either Emax or E C 5 0  values with acute pressor 
responses after SAH (Table 30).
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Fig 37. Combined non-operative controls, Shams and SAH (Groups 1-3) UTP C-R 
curves.
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
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3.7 HA responses
Responses were recorded in n 54 vessels. The overall SAH (i.e. SAH Groups 1-3) Emax was 
70+4 %. Although Table 28 suggests that this may be significant, the tabulated significance is 
actually across the series: this, in fact, principally reflects the sham/non-operative control 
difference. Thus, no significance is apparent between [overall] SAH and shams (p = 0.093) 
when these are considered in isolation. The overall SAH EC50 was 4.9+0.5 pM. As with Emax 
values, a high degiee of statistical significance was again apparent across the series: again, 
however, this principally related to the sham/non-operative control difference. Thus, no 
significance was apparent between [overall] SAH and shams (p 0.14). In consequence, the 
increased right shift acutely after SAH—additional to that after sham operation—is not 
significant: i.e. most of the shift is due to sham operation (Fig 38). Nevertheless, the 
proportion of MCAs dilated >100% by HA decreased progressively and significantly Ifom 
non-operative controls (52%), through sham operative controls (25%), to SAH Groups (11%) 
[p < 0.001; Table 12 below].
3.7.1. SAH sub-group analysis {see Tables 24-30, Appendix)
Although suggestive, no statistical significance was demonstrated in Emax or E C 5 0  values 
across SAH Groups 1-3 after SAH (Table 27). Furthermore, no significant side differences 
were apparent with either value in SAH Groups 1, 2 or 3 individually (Tables 24-26). These 
results suggest that varying degrees of CCA re-clamping were tolerated without significant 
effect after SAH: however, poor statistical n numbers for SAH Group 1 (n = 4 for each MCA) 
renders this analysis inconclusive.
Although the 3 hour Emax (67±4 %) seemed markedly reduced relative to the 1 hour (87+6 %) 
or 2 hour (77+5 %) values, this difference was—surprisingly—not statistically significant (p = 
0.54: Table 29). No statistical significance was demonstrated in E C 5 0  values across survival 
groups after SAH.
No statistical significance was demonstrated in Emax or E C 5 0  values with acute pressor 
responses after SAH (Table 30).
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
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Fig 38. Combiaed non-operative controls, shams and SAH (Groups 1-3) HA C-R curves.
Only the Emax is reduced—but not significantly—Ifom shams after SAH. The gi'eatest effect 
on non-operative control HA responses—a significant reduction in both Emax and EC50—is 
achieved by sham operation.
T able 6. 2 x A table demonstrating proportions of MCAs with HA E„iax>100%. The
Non-operative
controls
Shams SAH 
(Groups 1-3)
R
Emax >100% 12 4 6 22
Emax <100% 11 12 48 71
N 23 16 54 93
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3.8 PPV responses
Responses were recorded in n = 52 vessels. The overall SAH (i.e. Groups 1-3) Emax was 
104±3 %, the overall SAH E C 5 0  2.3+0.3 pM: neither value differed significantly fiom shams 
or non-operative controls (Table 28). In fact, there was a remaikable degree of uniformity in 
PPV-dilatation across these groups (p = 0.95 and 0.61 respectively) which can be more fully 
appreciated in the combined C-R curves of Fig 39, As with shams and non-operative controls, 
however, C-R curve abnormalities were again prevalent in individual MCAs (^gg Fig 41 
below).
3.8.1 Concentration-response curve abnormalities
As in shams and non-operative controls, a ti’ansient loss of efficacy was occasionally seen in 
SAH responses at 50 pM which soon passed off either with time, or after raising the bath 
[PPV] to 100 pM (Fig 41, A). However, in addition, another distuibance was also 
occasionally obseiwed at 0.5 pM [PPV] wliich appeared unique to SAH responses. It 
amounted to a definite increase of vessel tone that negated the relaxation previously achieved 
(Fig 41, B): again, this appeared transient. Due to its small magnitude (this being within the 
error of baseline PGF2a-induced vasomotion [Fig 19]), the latter abeiTation was not 
quantifiable.
3.8.2. SAH sub-group analysis {see Tables 24-30, Appendix)
Although suggestive, the mean PPV Emax in SAH group 1 did not significantly differ from that 
of SAH Groups 2 and 3 (Table 27): therefore, prolonged CCA re-clamping after SAH did not 
significantly affect PPV responses. Furthermore, no significant side differences were 
demonstrated in SAH Groups 1-3 (Tables 24-26). However, poor statistical n numbers for 
SAH Group 1 (n = 4 for each MCA) renders this analysis inconclusive. No significance was 
apparent with EC50 values either between groups, or between right and left sides within each 
group.
The mean PPV Emax nor the mean PPV EC50 differed significantly with sui’vival following 
SAH (Table 29).
Neither the mean PPV Emax nor the mean PPV EC50 differed significantly with acute pressor 
response following SAH (Table 30).
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F ig  39 . Combined non-operative controls, shams and SAH (Groups 1-3) PPV C-R 
curves. PPV relaxation remains uniform across non-operative controls, shams and overall 
SAH groups.
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F ig  40 . Overall SAH (i.e. Groups 1-3) PPV Emax frequency histogram. The right hand 
tail of the normal distribution (where Emax >100%) reflects the proportion of MCAs where 
dilation of MT must also have occurred.
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F ig 41. PPV C-R curve abnormalities. Representative SAH vessel. Key. A -  transient 
loss of efficacy at 50 pM. B -  paradoxical transient vasoconstriction at 0.5pM
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Fig 42. The relationship of PPV Emax to FD90. Combined responses from control, sham 
and overall SAH groups. No correlation of Emax with diameter is demonstrated (r = 0.04).
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3.8.3. Relationship of Emax to FD9 0
Because o f  the possibility that vasodilators, w ith differential activity related to vessel size, may 
cause TIAs with V SM , it was considered prudent to assess the relationship o f  F D 9 0  to PPV  
Emax- Fig 42  clearly show s that, in fact, no such relationship exists in non-operative controls, 
shams or overall SAH  groups (r =  0.04).
NOTE: N one o f  the results in this section were significantly affected by excluding the two  
anim als that were anaesthetized with hypnorm and hypnovel.
3.9 L-ARG responses
R esponses were recorded in n =  53 vessels. The overall SAH Emax w as 92±5 %, the overall 
SAH E C 5 0  3.410 .6  pM (Table 28, A ppendix). The former value is significantly different Ifom  
shams or non-operative controls (p =  0.01): this is illustrated in the frequency histogram o f  Fig 
43. The E C 5 0 — although not significant in the overall SAH  analysis— was, however, 
significant on sub-group analysis {see below). The general shift in L-ARG responses after 
SAH  can also be appreciated in the C-R curve o f  Fig 44.
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F ig  43 . Combined non-operative controls, shams and SAH (Groups 1-3) L-ARG Emax 
Frequency histogram. Key: white com bined shams and non-operative controls, grey post 
SAH. N ote the significant right-shift in the frequency distribution after SAH. N ote also that 
both distributions are highly representative o f  normal curves.
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3.9.1. SAH sub-group analysis {see Tables 24-30, Appendix)
No significant difference is apparent in Emax values across SAH Groups 1-3 (Table 27): nor is 
any significant side difference demonstrated in Emax in each group individually (Tables 24-26). 
These results suggest that increasing degrees of CCA-clamping did not affect ipsilateral MCA 
reactivity: however, poor statistical n numbers for SAH Group 1 (n = 4 for each MCA) renders 
this analysis inconclusive. Table 27, however, suggests that prolonged CCA-clamping 
significantly obtunded an underlying trend in L-ARG EC50 values to decrease after SAH. This 
is borne out by the fact that the combined E C 5 0  in SAH Groups 2  & 3 significantly differed 
from shams and non-operative controls after exclusion of SAH Group 1 (p = 0.036).
Table 29 suggests a trend toward increasing Emax vdth prolonged survival after SAH.
Although this was not statistically significant, only the Emax in the 2 and 3 hour survival groups 
significantly differed from shams and non-operative controls (p = 0.007 and p = 0.003 
respectively). The E C 5 0  values, however, do significantly differ across this series. 
Paradoxically, it is the 1 and 3 hour survival groups that are decreased relative to shams and 
non-operative controls: the 2  hour group (i.e. the statistically ‘abnormaf group across the 
series in Table 29) appears unchanged after SAH.
No statistically significant trend was demonstrated in either Emax or E C 5 0  values across acute 
pressor response groups (Table 30). However, the trend in Emax is nearly significant and, when 
type II & III acute pressor responses are considered together their combined value (101±5 %) 
is signifieantly different from type I (85+4 %: p = 0.02). Furthennore, the type I acute pressor 
response Emax does not significantly differ from either shams or non-operative controls, 
whereas the type II & III response do with a high degree of statistical significance (p = 0.0001). 
Indeed, this pattern remained significant even when allowing for ‘survivors’ and ‘non­
survivors’ within this sub-group.
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
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3.10 L-NAME responses (Table 28, Appendix)
Responses were recorded in n = 13 vessels. The Emax was 2.4+0.4 mN: this did not differ 
significantly from either control. No EC50 responses were possible because no C-R curves 
were performed.
3.10.1. SAH sub-group analysis (Table 26, Appendix)
L-NAME responses were only recorded in SAH Group 3, therefore no SAIT sub-group 
analysis was possible. However, no significant difference was apparent in right-left MCA 
comparison within SAH Group 3.
No sub-group compai'isons based on either survival or acute pressor response were possible 
due to the small n numbers involved.
NOTE: None of the results in this section were derived from animals that were anaesthetized 
with hypnoim and hypnovel.
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3 .11  SNP responses (see Tables 24-30, Appendix)
R esponses were recorded in n =  52 vessels. The overall SAH  Emax w as 96±4 %, the overall 
SAH  EC50 3 .8+0.7  pM: both values significantly differed from shams and non-operative 
controls (Table 28, Appendix).
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3.11.1. SAH sub-group analysis (see Tables 24-30, Appendix)
Table 27, Appendix, show s that— just as with the L-ARG EC 50— prolonged CCA -clam ping  
(SA H  Group 1) significantly obtunded the increase in SNP Emax that, overall, SAH  (i.e. SAH  
Groups 1-3) otherwise produced. Thus, excluding Group 1 anim als from analysis increased  
the overall remaining SAH group SNP Emax significance (i.e. in SAH  Groups 2 & 3) further 
still [Emax =  99±3 %, p «  0 .0001]. Sim ilarly, the EC50 significance w as also greater in SAH
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Groups 2 & 3, relative to shams and non-operative controls, after excluding SAH Group 1. 
Nevertheless, although suggestive, neither the Emax nor the EC50 were preferentially obtunded 
on the side ipsilateral to the clamping in Group 1 (Table 24, Appendix); nor, indeed, were any 
significant side differences demonstrated in SAH Groups 2 & 3 (Tables 25 & 26, Appendix). 
However, poor statistical n numbers for SAH Group 1 (n = 4 for each MCA) strictly render 
this analysis inconclusive.
Neither the Emax nor the EC50 values significantly differed with increasing survival after SAH 
(Table 29).
The mean Emax did not significantly differ across acute pressor response groups (Table 30). 
However, the mean SNP E C 5 0  in type II & III pressor responses (1.5±0.4 pM) was 
significantly different fiom that in type I (7.1+1.3 pM; p = 0.007); which, in turn, did not 
significantly differ from either non-operative or sham operative controls,
NOTE: None of the results in this section were significantly affected by excluding the two 
animals that were anaesthetized with hypnorm and hypnovel.
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SECTION I 
Whole animal responses 
Chapter 1 
Intracranial and arterial pressor responses
1.1 Background
Blood pressui'e is commonly considered related to SAH only in the elevated state. Thus, 
hypertension may precipitate acute bleeds^ ^^ s and worsens o u t c o m e I t  is also often 
present in the immediate post-SAH period, where some consider it to represent the Cushing 
response (CHR)*^ ,^ 390_ this context, the CHR is considered beneficial, serving to 
maintain CPP against elevated ICPs^ <^ .^ However, as we have already seen (p 14) the ICP 
usually falls to plateau values close to baseline levels within minutes following SAIU^b, 454, 
Thus, a CHR (see below) cannot readily explain any hypertension seen at this time.
Alternatively, post-SAH hypertension may serve to maintain re-expansion of a previously 
collapsed cerebrovasculatiue necessarily incurred during acute SAH. In this context, it 
may thus serve to ‘flush out’ areas of microcirculatory collapse—some perhaps obstructed 
by intravascular clot—in order to subvert no-reflow phenomena (NRP). Notwithstanding, 
perfusion defects frequently persist, perhaps as a result of CBF restoration lagging behind 
ICP restoration^^’ Similar perfusion defects, however, are also seen in spite of
increased MAP after a cardiac aiTest^ ^O; thus, hypertension does not always appear' capable 
of achieving its aim^ ^®. Indeed, especially with SAH, it may even be harmful {see
above)360
1.2 Caveat: BP recording bias
BP recordings may be biased between studies by factors other than observer bias. One 
obvious example is the dichotomy between invasive and non-invasive BP monitoring. The 
majority of experimental models, for example, directly monitor intra-arterial pressure 
(although older experimental studies, of com'se, obviously did employ non-invasive cuff 
monitoring—Cushing’s study being an example). Thus, direct inter-study comparisons of 
absolute BPs may be unreliable here. Furthermore, the site monitored may seriously affect 
the value obtained, since the MAP is increased in peripheral arteries relative to the aorta^ ^^ .^ 
Moreover, almost no study has measured the value that really matters in SAH: i.e. that 
present within the ICA proximal to its entry to the cavernous sinus. Nevertheless, the 
direct inter-study comparison of qualitative changes—such as, for example, the frequency 
of acute hypo- or hyper-tension after SAH—should not be affected by such errors in 
quantification. In the cuiTent study, MAP was assessed from the distal aorta via the 
femoral artery.
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Unfoitunately, the current thesis has highlighted a further—hitherto little explored—error 
that may significantly affect both inter- and intra-study of BP magnitudes; and their 
display. The error discovered relates to the graphical extrapolation of absolute BPs from 
dynamic tracings to statically calibrated scales on a multi-channel, flat bed, pen recorder.
As is demonstrated in Part 5, Section I, 1.1, such extrapolation will always yield eironeous 
systolic and diastolic BP values whenever the animal’s heart rate exceeds the inertial drag 
of the pen on the recorder bed. Thus, the inertial drag of the pen (particularly at the speeds 
encountered with small animal heart rates) results in a slirinkage of the systolic BP—equal 
in magnitude to an inflation of the diastolic BP—when these values are extrapolated to the 
calibrated scale (Figs 7 a & b).
The error is incurred because the graphically calibrated scale is usually derived from 
static BPs via a sphygmomanometer: the pen recorder tracing, however, is produced 
by a dynamic BP.
As a result, the pulse pressui'e becomes aitificially contracted with increasing HR in such 
displays, one possible example fi*om this thesis deriving from the HR change observed with 
a CHR after SAH in Fig 11. In principle, one remedy for this error would involve some 
form of dynamic calibration: however, errors may continue to be incurred with further HR 
fluctuations thioughout the study period. Other remedies are listed in Part 5, Section I, 1.1. 
Whatever the permutations, the quotation of systolic and diastolic BPs from such 
extrapolations ought to be avoided. Fuithermore, the graphical displays—such as those in 
Figs 8, 10 & 11) of this thesis—necessarily provide contradictory information, because the 
systolic and diastolic peaks are uncorrelated to the scale provided. The only satisfactory 
way to overcome these difficulties is to employ a modern electronic digital display, with 
fluctuations recorded in real time and stored to hard disk.
Importantly, the MAP— when this is obtained from the aorta—remains correlated to the 
statically calibrated scale; because the MAP under these circumstances is equal to the 
aritlimetic mean of the pulse pressure^^^ This is important, because it appears that the 
arithmetic mean of the pen recorder tracing—i.e. bandwidth mid-point—can continue to be 
extrapolated to the statically calibrated scale. This axiom simply derives from the fact that 
the pen must always pass thiough the mid-point of the two BP signals (Fig 7), even though 
it may not be able to reach the full extent of the excursion required by them. As a result, 
changes in BP thioughout the study can be reliably assessed only by changes in MAP; lest 
considerable errors may be incurred (Part 5, Section I, 1.1). The magnitude of BP changes 
throughout this thesis, therefore, aie based upon MAP values assessed as the bandwidth 
mid-point on the giaphical display; and—where these were immediately written 
down—corroborated by the digital display fiom the electronic patient monitor.
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1.3 Current experimental findings
In this study, SAH was most frequently heralded by the occurrence of respiratory 
irregularities, blood-pressure disturbances and extensor-posturing; a familiar triad.
The latter was always a transient phenomenon. Respiratory dysfunction, however, 
sometimes persisted, and occasionally required ventilatory support. By far the most major 
disturbance was that of eventual subacute cardiovascular collapse (SCC: 42%). From 
this scenario, it would seem that a considerable SAH had been induced; yet neither a high 
ICPmax nor a CHR were rarely witnessed. In fact, the exact opposite pertained instead: a 
moderate ICPmax (38 mmHg) and an acute hypotension (-AMAP = 30±4 mniHg; p = 
0.03) [Part 5, Section I, 1.3]. In consequence, SCC was often preceded by the exact 
opposite of the sympatho-adienal response ordinarily expectedi^ -^^ "^ ’^ Why was this?
The earliest experimental studies had shown that pressure on the brain could result in 
cardiac^®  ^and r e s p i r a t o r y ^ ^ e  disturbances. Following Rocher’s  previous ideas, Cushing 
presented his classical findings at the Mütter lectuie in 1902* h, 115 Here, in addition to 
noting respiratoiy irregularities and bradycardia, he proposed that an increase in 
intracranial tension “occasions a rise of blood pressure sufficient to overcome the high 
intracranial tension”. Thus, the CHR did not occui” until the ICP had approached the 
MAP: whereafter both pressuies rose paii passu* Cushing emphasized that the CHR
primarily served to maintain flow to the medullaiy respiratory centre (it was not an 
attempt to restore global CBF), and that its occuiTence at lower ICPs could, in fact, prove 
detrimental**\ In contrast, the mean AICP in the cunent study (firom 8±1 to 49±4 
mmHg^^^’ *^25) was clearly fai' short of the MAP 123+5 mmHg. As a result, then, the CHR 
was rarely seen. But why should we have instead observed the opposite (acute 
hypotension)? And why was the AICP only moderate when SAFI itself appeared severe?
In fact, in other studies where a classic CHR eventually supervened, a -AMAP was 
additionally obseived at lower AICPs*^ **’ Unfortunately, intracranial balloon
expansion models were invariably used in these cases: this form of study necessarily 
incurring heterogeneous AICPs** '^ ^^ 4, Nevertheless, others have achieved similar results 
following subarachnoid saline injections (which cause homogenous AICPs)^^ .^ Indeed, 
acute but brief-AM APs clearly followed each subcritical AICP in Cushing’s original 
study* *^ . However, in none of the aforementioned studies was the AICP as rapid as it 
should have been in order to have mimicked acute SAH. Indeed, even in Cushing’s study, 
the AICP was produced gradually in order to mimic the effects of space-occupying lesions 
or haemotomata**^’ **^ . hi consequence, Cushing did not state the CHR in the context of 
acute SAH.
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However, Cushing did indeed refer to such a scenario. In Iris ‘variants’ to the classic 
response, Cushing clearly stated that sudden AICPs resulted in a complete “checking of 
the heart” for “up to thirty seconds”; from which the MAP then gradually recovered* *^ . 
Although often infusing directly into the CM, close to the cardio-respiratory centre, 
Cushing also tried “many other sites” without this influencing the results**^; and hydraulic 
effects would have been experienced homogeneously throughout the subarachnoid space 
anyway. In support of such findings, a more recent model (involving arterial rupture in 
cats) also recorded a -AMAP with ICPmax values of 50 mrnHg^^^—a result similar to that 
observed in the current study. Therefore, it may be that events associated with acute SAH 
are quite distinct fiom those associated with more subacute AICPs, suggesting that the ô 
ICP/ôt may be the determining factor here. Nevertheless, the CHR has been observed in 
some SAH studies following vessel rupture where an acute ÔlCP/Ôt occurred*®» 4^6 
all of the latter, however, the ICPmax approached the MAP. Furthermore, either dogs or 
primates were used (often in small number)^ ***^ » whilst in some cases an initial -AMAP 
was clearly in evidence *®> 4^6 Overall, then, the specific occuiTence of hypotension 
following SAH may depend both upon the ICPmax and the ôlCP/ôt attained. Each of these 
may depend, in turn, upon the species concerned; or even on the individual.
Perhaps, then, a syncopal response may reflect a less severe SAH? The problem here, 
however, is that post-mortem analysis regularly confirmed the general impression of 
extensive SAH (Plates 5, 7, 9). Cleaiiy, then, syncope cannot relate to smaller bleeds; but, 
instead, to paiadoxically moderate AICPs concurrent with severe bleeds. Hydraulic 
failure in the ICP monitoring can be ruled out as subarachnoid injections cause 
homogeneous AICPs* and blood clearly communicated with the CM posteriorly 
(Plates 5 and 7). Fuithermore, the continuous ICP tracings obtained do not suggest 
obstructive interludes in this study (Figs 8, 10 & 11). Thus, the degree of SAH appears 
genuinely disproportionate to the moderate ICPmax, suggesting that the latter poorly reflects 
the volume of blood extravasated (Ve). In fact, the latter disparities have frequently been 
alluded to^ *^» ^57,453, 56i However, these are usually the opposite to that observed here:
the AICPs in these studies is usually gi'eatly out of proportion to the Ve ^ ^*-^^*.  
Nevertheless, the pattern in some has been as that in this thesis^^s. 625 Therefore, these two 
states may represent extieme, opposing variants in the AICP expected from the Ve {see 
below).
1.4 Hypothetical determinants of the AICP after SAH
1.4.1 Small Vg : large AICP
Where one injected fluid produces the same AICP as a larger volume of another, this may 
reflect either inferior pressure-venting mechanisms; or the induced release of another fluid
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into the confined space. The most obvious cause of the latter might seem to be more CSF: 
however, CSF production probably ceases acutely at 25-30 mmHg^^i Another possibility, 
derives from elinical studies in which the cerebral blood volume (CBV) has been shown 
to increase after SAH (Part 1, 1 .1 .1 )222-224, 349, 453,491 These studies suggest an acute 
imbalance in inflow-outflow to the cranium. Cushing drew attention to the early closure of 
veins (including the large venous sinuses) and capillai'ies following AICP** .^ The latter 
probably occurs at ICPs around 30-35 mmHg2*2: but it may occur sooner with SAH, since 
a-receptor affinity is much gieater within cerebral veins237. Such cerebrovascular ‘back- 
damming’, then, would favour a cerebrovascular expansion^^i. A simultaneous 
v a s o p a r a l y s i s 2 4 9 , 454 occuiTing proximally would thus accentuate the engorgement, raising 
the ICP pari passu with the Ve. Such a mechanism much better explains the steep and 
rapid attainment of an ICPmax, up to the level of the MAP, from studies such as those by 
Voldby*^ 22 The rapidity with which a vasoparalysis may occur, and its occuiTence with 
often minimal SAH, suggests a local vascular reflex^^ ,^ 651 since the brain parenchyma is 
virtually incompressible, such a mechanism would as effectively tamponade SAH as any 
other'^ 5*. In consequence, the Ve would be expected to be much smaller with this 
mechanism; the ICPmax and the ôlCP/ôt laige.
A small Ve associated with a large ICP„,ax may therefore he explained by a non-compliant 
subarachnoid space; or by the presence o f an acute cerebrovascular engorgement.
Larger AICPs were significantly conelated with type II (invaiiant: AICP = 50±6 mmHg) 
and type in  (Cushing hypertensive: 73±4 mmHg) responses in the current study.
1.4.2 Large Vg: small AICP
This, of course, is the case in the cuiTent study, and must necessarily preclude any 
aforementioned reflex vascular expansion. It essentially suggests paiticularly efficient 
ICP-venting* *^  *21,453,454 This may involve unusually compliant meninges; or, instead, 
rapid CSF displacements from the subarachnoid space. In support of the latter, Seiro foimd 
it difficult to maintain the ICPmax in his studies as if due to some continuous CSF- 
leakage^4i_ Indeed, Cushing had been warned (by Adamkiewicz) that such leaks, into the 
venous system, might threaten cardiac overload in his m odel*A lthough this did not 
ultimately occur (only 100 mis were expressed in 30 mins in his study!) Cushing readily 
acknowledged this “free communication” * * ^ . This was nowhere more dramatically 
witnessed than following a bm’st of the intracranial balloon, whereupon mercuiy was 
subsequently discovered in the “sinuses, jugulars, right heart and lungs”! **^ . Conceivably, 
such venting may be greater in some individuals than in others243,344 This may, therefore.
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account for the similar failure of other studies (with either rats^ ®^» ^ 25 or cats256) to 
demonstrate an ICPmax approximately equal to the MAP after SAH.
However, another factor may be that of reflex reductions in CBF or CBV—i.e. the opposite 
of the aforementioned cerebrovascular expansion. Any acute fall in the arterial driving 
pressure must necessarily reduce SAH firom an acute jet to more that of an ooze. Such a 
mechanism would be expected to slow down the ôlCP/ôt (Fig 8) as well as—by allowing 
more time for venting mechanisms to take hold—limiting the ICPmax- One mechanism 
here could be that of an acute cerebral vasospasm. This is certainly implied in one study, 
where the injection of subaraclinoid blood yielded greater CBF falls reductions than did 
saline for the same degree of AICP^ ^®. However, another mechanism still would be that 
observed in the current study: i.e. acute hypotension (-AMAP).
A large Ve with a moderate ôlCP/ôt and moderate ICPmax may occur where efficient 
subarachnoid venting mechanisms have combined with cardiovascular mechanisms to limit 
CBF. The latter may involve either an acute cerebrovascular spasm, or an acute systemic 
hypotension.
Smaller AICPs were significantly correlated with a type I (acute hypotensive: AICP = 31+2 
mmHg) responses in the current study.
1.4.3 The ICPmax: MAPf,„a, ratio
The significant -AMAP produced in the current study [-AMAP = 30±4 mmHg] 
significantly elevated the ICPmax-‘MAP ratio fiom a possible 31+3 % (had hypotension not 
occurred) to 41+3% after SAH [p = 0.02]. Importantly, the latter ratio was only slightly 
significantly different from either type II or III pressor ICPmax:MAP ratios (p = 0.46), 
whereas the former value was markedly different (p = 0.001 : Part 5, Section I, 1.3). This 
suggests that relatively modest ICPmax:MAP ratios—perhaps only in the range 40- 
60%—are required to stanch SAH. It may be crucial that this ratio is obtained at lower 
absolute values for both ICPmax and MAP where a syncope (i.e. -AMAP ) has occurred. 
Thus, SAH will not only be stanched with less compressive cerebral strain, but also with 
less shear stress to the supplying cerebrovasculature. Quite clearly, syncope could be 
advantageous with SAH. The correlation between -AMAP and AICP in this study (Fig 
9) suggests that syncope may be especially associated with efficient ICP-venting 
mechanisms: thus, it may serve to aid a naturally ‘weak’ tamponade. Certainly, a CHR 
could prove counterproductive where efficient ICP-venting prevails; this, perhaps, 
explaining its absence where ICPmax«MAP (Fig 9).
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1.5 Mechanisms of arterial pressor responses after SAH
To explain the pathophysiological mechanisms involved some have postulated a 
progressive march of ischaemia cranio-caudally tlrroughout the C N S  with progressive A 
I C P .  In the first phase (IC P m ax < M A P ) ,  the cerebrum alone is ischaemic^ ^®» 343,344,546- this 
resulting in decreases in H R ,  M A P  and in cardiac o u tp u t^ i^ , 533,552  *phe latter effects are 
attributable to ‘vagal activation’: certainly the bradycardia can be prevented by sectioning 
of the vagi^i^. As the pressure wave progresses (IC Pm ax - M A P ) ,  the upper brainstem 
becomes ischaemic, this causing a mixed vago-sympathetic output manifest as the CHR 
(bradycardia, hypertension and respiratory irregularity). Eventually (IC Pm ax > M A P )  the 
lower medulla becomes ischaemic where (somehow) the parasympathetic response is 
singularly lost, this allowing the S N S  alone to dominate. The latter is manifested in a 
general hyperdynamic state of increasing heart rate and M A P :  a common agonal feature 
of brain d e a t h ^ i ^ ,  533,5 5 2  The cui’rent results—i.e. acute hypotension (64%)-invariant 
(30%)-acute hypertension (6%)—certainly suggest that two opposing ‘forces’ (i.e. one 
‘depressor’ [ - A M A P ]  and one ‘pressor’ [ + A M A P ] )  may be in operation such that either 
one may predominate (depressor = hypotension: pressor = hypertension); or that both 
‘forces’ may be in balance (invariant).
The first stage, then, resembles the syncope observed in the cur rent model; where modest A 
ICPs may only have affected hemispheric flow. The term ‘vaso-vagal syncope’ (VVS) was 
coined by Lewis, in 1932, to explain the slow pulse and hypotension accompanying a 
faint229. However, VVS is certainly an autonomic hybrid: the patient is also pale and 
clammy—^frequently with dilated pupils. Indeed, the bradycar dia—as in the current 
study—may even be absent, or replaced by tachycardia^^^. Fuiihermore, VVS can be 
triggered by emotional factors and pain—stimuli which ordinarily activate the sympatho­
adrenal axis229. VVS is characterized by both a sudden hypotension and a failure of 
cerebral autoregulation: thus, cerebral infarcts may accompany mistaken attempts to prop 
the patient up^^c vVS most likely results from excessive dilation in splanchnic and 
skeletal muscle vascular beds^^ ;^ thus implying a loss of sympathetic tone. Certainly the -  
AMAP seen with sympatholysis closely resembles that seen with sympatholysis in cord 
shock (Part 2, 2,6). That Cushing noted the opposite—“anaemic bowels”—with the CHR, 
suggests a fundamental linkage between the two processes''^. The occurrence of VVS 
with emotional shock is of uncertain teleological value^^ :^ its occurrence with SAH, 
however, may be entirely appropriate; serving to augment the stanch of the bleed. It is not 
without relevance that in some cases of SAH, where headache (and therefore ICP-loading) 
appeared minimal, the presentation was actually that of syncope^^. It is important to 
remember that the current experimental findings were recorded in an animal that was 
normothermic, previously cardiovascularly stable, but above all supine: the effects of
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SAH-syncope would clearly be more marked given contrary circumstances— in particular, 
with an animal in the erect position.
1.6 Subacute cardiovascular collapse (SCC) after SAH
s e e  occurred in 42% of animals and resulted in the premature termination of the study 
within the arbritary three hour period. All animals that sur vived into the third hour did not 
suffer SCC. It has been argued above that SAH-syncope (i.e. type I acute pressor response) 
may be theoretically less stressfril both to the cerebrovasculature, as well as less stressful to 
the cerebral parenchyma. Nevertheless, SAH-syncope did not appear capable of protecting 
against a subsequent SCC (Table 20, Appendix). In fact, SCC appeared equally as likely 
irrespective of the acute pressor response that preceded it. The apparent ‘severity’ of 
SAH—as determined by a subsequent SCC—therefore cannot be predicted by the type of 
acute pressor response that precedes it. Indeed, the very fact that SCC supervened—in the 
vast majority of eases—in the absence of the CHR appears contrary to the view that SCC 
(and, therefore, ear ly mortality) necessarily results from activation of the hypothalamo- 
sympatho-adrenal axis^ -^ '^8,3so, 412,446,460,462,485,493, 516,552,602,656,665 However, that a
CHR—and, therefore, a sympathetic “storm”—has been recorded in numerous other 
studies, hints at the likelihood of either species (or even individual) variation. It must be 
remembered, however, that all clinical recordings have necessarily witnessed only 
secondary SAH, which may be an entirely separate ‘statistical’ event.
In many ways the results of the cur rent study accord, then, with those obtained following 
head injury. In some of these studies, an initial -AMAP—with +AMAP rebound—had 
finally given way to one of SCC (modest AICPs occurring throughout)^^’ 214,258  ^ Such 
results, therefore, favour non-cateeholaminergic mechanisms, such as those recently 
proposed involving cytokine-release—  and, possibly, cytokine-mediated inductions of 
NOS (Part 3, 1.8)—within the myocardium. In the latter site, NO has been shown to 
obtund p-mediated adrenergic contractility^^. 9 3 ,125, 242,410  jg  interesting that high levels 
of cytokines have been recorded systemically in cases of SCC^ "^ » 3^5  ^as they have also been 
within the CSF after SAH439,443 The normal findings on routine histopathological (or 
electron microscopic) sectioning of the myocardium (Part 5, Section I, 2.3) are not 
surprising in this context, since others have assessed that at least 6 hours are required for 
their development^^': this was beyond the scope of the present study.
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1.7 Conclusions
• Abrupt ôlCP/ôts after SAH in rats may elicit acute hypertension, acute hypotension, or 
no BP change at all (invariant).
• The most common acute pressor response after SAH in rats is acute hypotension 
(64%): hypertension is rai*e (6%). An invariant pressor response is seen acutely in the 
remainder (30%). These results directly agree with Cushing: hypertension was not 
stated with abrupt ôlCP/ôts—hypotension was stated instead.
• The height of the ICPmax correlates with the acute pressor response seen. Hypotension 
predominates with AICPs < 65 mmHg: hypertension prevails with AICPs > 65 mmHg.
• The ICPmax does not correlate with the Vy.
• Subacute cardiovascular collapse (SCC)—and early mortality—after SAH is equally 
likely (approximately 40%) irrespective of the type of acute pressor response observed.
• The prevalence of acute hypotension with SCC suggests that non-cateeholaminergic 
mechanisms may be primarily responsible.
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S E C T I O N  I I  
I n  v i t r o  v e s s e l  r e s p o n s e s  
Chapter 1 
Normal MCA characteristics
1.1 MCA diameter asymmetry and its effect upon agonist response
1.1.1 Background
When setting about the study of isolated vessel responses, it is usual to restrict 
investigation to a particular branch, such as that of the “proximal middle cerebral artery”. 
This is a statement inferring the ultimate eomparison of Tike with like’ between the 
different groups considered. Usually the diameter-range is given in such studies but, since 
the same branch is used, it is invariably assumed that they will all be comparable; even 
where size differences may be appreciable.
It is frequently the case in small vessel studies, however, that a large variance of agonist 
response is obtained; with correspondingly large standard deviations (SD). This renders 
statistical analysis less atti'active, forcing either large samples or large response differences 
in order to prove statistical significance. Such variance in agonist response may largely be 
due to natural variation in, for example, receptor-density on the vessel wall. However, it 
may also result from a failure to compare Tike with like’.
1.1.2 Kniax varies linearly with FD90
As is commonly the case, the variance of Kmax values within each experimental group 
appeared large and did not very closely approximate to that of a normal distribution (Fig 
16). However, the distribution itself was symmetrical, with similar mean (5.5 mN) and 
median (5.4 mN) values. It was felt tluoughout the study, however, that the diameter had 
appeared important in determining the efficacy of contractile responses obtained. A clue to 
this became appai’ent upon coirelating the FD90 (|un) with the Kmax (mN) in eaeh vessel 
used. Here a fr equency histogram much more closely resembling that of a noimal 
disfribution was obtained (Fig 17). This apparent dependence of agonist response upon 
vessel diameter was demonstrated more clearly still by simply plotting Kmax against FD% 
(Fig 18). Over the range of diameters encountered, this approximated to a linear 
relationship, and conformed to the regiession equation:
Kmax=(0.031),FD9„ + (0.6)
The conelation obtained was highly significant (r = 0.75, n = 34, p<0.001).
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Such a relationship gained further credence upon consideration of other groups and agonist 
responses. For example, for KCl responses in the sham operative group (Fig 28) the 
equation was again quite similar:
Kmax=(0.038).FD9o-(0.2)
and with even less spread about the regression line (r = 0.78, n = 16, p<0.001).
Reeeptor-mediated constrictions also yielded linear relationships to similar degrees of 
statistical significance. Table 31, Appendix lists all such correlations and significance 
values for individual regression plots in each agonist concerned. From this, it can be seen 
that up to 76% of the variation in certain agonist Emax (i.e. PGF2a in shams) may be 
explained merely by variations in FD%. From the above equations it can be noted that, for 
example, the Kmax values predicted at 200 |_im (6.7 mN and 7.4 mN respectively) are both 
nearly twiee that predicted at 100 pm (3.6 mN and 3.6 mN respectively). That is, an MCA 
that is twice the size of another may be expected to produce twice the contractile force in 
response to a membrane depolarization. How might such findings tally with simple 
physical considerations?
1.1.3 Theoretical implications
The tension developed within the walls of elastic structures when subject to intraluminal 
pressures exerted radially is described by the law of Laplace as:
P-a
th
This implies a linearity in tension development in response to passive distension, and is 
demonstrated in the distension-diameter study obtained with pulmonary arteries in Fig 13. 
Such vessels function purely as passive capacitance vessels within the systemic circuit, the 
FD increasing proportionately with increasing luminal pressure (r = 0.98, n = 13, p «  
0.001). A similar background passive tension must necessarily be apparent with the MCAs 
here as these have also been subject to distension. But unlike pulmonary arteries, MCAs 
develop myogenic tone (MT) to distension (Pait 2, 2.2). This was reflected in the 
spontaneous vasomotion of all vessels used, this being a featur e of pre-capillary 
sphincters, and concords with other studies^^. In such vessels, MT increases 
proportionately with increased distending pressure (Fig 14), this serving to maintain stable 
diameters and, tlierefore, stable flow (autoregulation). In consequence, each MCA is likely 
to possess a certain amount of both passive and active tension prior to each KCl 
depolarizing constriction.
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The circumference at 200 pm is, of course, twice that at 100 pm (since this is Tc.diam.). If 
VSMCs are arranged in a predominantly concentric fashion within the tunica media then, 
from first principles, we would expect twice as many to be present at 2 0 0  pm as at 1 0 0  pm. 
This, of course, assumes that eaeh VSMC is approximately similar in length, and that each 
is arranged in series. If this is the case, then one would not be too surprised to find the 
overall constricting force present at 200 pm to be twice that at 100 pm. Fiu’thermore, since 
this will be additive to any passive elements, the overall tension developed at 2 0 0  pm 
ought to be double that at 100 pm, given the appropriate stimulus. Thus, the Kmax at 200 p 
m ought to be twice that at 100 pm. Furthermore, if each VSMC is the same size (and has 
the same properties as any other), then we might expect that it shortens to the same degr'ee 
as its fellows given the same pharniacologieal stimulus. Thus, following appropriate 
stimulation, luminal size will eontinue to be, in the lai'ger vessel, twice that of the smaller- 
one. As a result, it can be seen that the simple relationship between agonist response and 
functional luminal diameter is in accordance with conespondingly simple principles 
based upon a concentric arrangement of the VSMCs present within the arterial walls. 
Indeed, although as a general principle one should not extrapolate outside of the regression 
range obtained, it is clear from the graphs that the regression lines invariably pass close 
through the origin; which, with greater experimental numbers, may possibly become even 
more apparent. If so, then this would again accord with simple physical considerations, as 
a vessel with zero diameter would not be expected to produce any tension.
1.1.4 Practical implications
In most experiments on small vessels, agonist responses between different experimental 
gi’oups are often only compared by virtue of their summaiy statistics, there being little 
attention given to either the diameter or the anatomical side from which the vessel is 
derived. In large samples, and with randomization for side, such errors ought to be 
minimized (as was shown in this study: Part 5, Section II, 3.1) . However, with cerebral 
arteries even this may not be the case. Thus, in a reeent eadaver study of 145 vessels^^? the 
mean right vertebral arteiy diameter (4.5 mm) of the group was some 13% lar ger than the 
left (4.0 mm), with the largest difference being 280% (2.5 nun against 7 mm)! Such 
differences in size (an inerease of xl .3 will result in a x3 increase of flow: Part 2, 2.4) may 
have appreciable effects in vivo. However, they will also have important—and 
unwanted—effects with in vitro experimental studies. Thus, although the mean FD90 
remained remarkably constant across both experimental groups in the current study (Table 
5), this belies the fact that there was significant asymmetry present in up to 50% of the 
animals used. As Table 9, Appendix, shows, a difference in size between right and left
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MCAs was apparent in these cases, similar to that seen in the overall results of the 
aforementioned study^^?.
The importance of the response-diameter association herein established may therefore 
apply to any small vessel study where small numbers are involved. But it especially 
applies, however, to unilateral studies of cerebral vessels in which the contralateral side 
is used to supply the paired control. Such models are paificularly eommon with unilateral 
stroke study, and are cuirently gaining credence with type lib SAH studies using 
craniotomy (Part 4, 1.2.2). For example, from the non-operative controls in Table 9, by 
taking only the combinations where the right MCA exceeded the left by >lxSD (bold type) 
we obtain a mean right MCA of 171+21 pm compared to a left of 111+26 pm. From the 
regiession equation (Fig 18) it can be seen that the Kmax will be significantly larger in the 
right MCA (5.9 mN) than the left at 4.0 mN (p<0.01). Thus, by making the systematic 
error of choosing these animals for a unilateral ‘paired control’ study, we might quite 
wrongly attribute a significantly greater right MCA response to the effects of the procedure 
performed. But in reality, this simply resulted from the fact that the right MCA diameter 
was significantly gieater (p<0.001), the increased Kmax being simply a consequence of this. 
As a result, studies of both in vitro and in vivo vasoreactivity must therefore take into 
account the higlily significant degree of diameter-asymmetiy that is present within the 
cerebral vasculature.
1.1.5 Conclusions
Although the large variance obtained in agonist response with small vessel studies may be 
attributed to such factors as receptor density, this study clearly shows that another factor is 
that of diameter-variance; at least within eerebral arteries. In fact more than half of the 
variance in agonist response obtained with agonists such as KCl, 5HT and PGF2a may 
be explained simply by variance in vessel size. In these cases variance in factors such as 
receptor or ion-channel density appeal" less significant. However in other cases, such as 
responses obtained with 5HT or, especially, NE {see below), receptor-mediated factors 
appear much more significant. In consequence, this study emphasizes the regular 
quotation of diameters in all studies comparing agonist responses (especially those 
involving KCl, 5HT and PGF2a), but in particular with unilateral studies using the 
contralateral vessel as the paired control. However, by obtaining response-diameter 
plots in non-operative contiols, due allowance can be made for diameter-efrects by noting 
deviations in ‘observed from expected’ responses. Indeed, in some cases, such plots 
may indicate diameter effects to be almost disregardable (NE responses, see below). The 
failure to quote diameters in many current SAH small vessel studies might be a critical
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factor in explaining some of their failni'e to explain—or to procure effieacious treatment 
strategies for—either delayed VSM or DCI.
1.2 Heterogeneity of NE response: pathophysiological implications
1.2.1 Introduction
The role of the SNS in governing CBF is largely unknown. Its role in the systemic 
circulation is largely one of redistribution^^s^ although it also serves to maintain MAP. The 
latter is well evidenced upon its sudden removal, as in spinal cord transection, where acute 
decreases in MAP to 40-60 mmHg can occiu’^ 3^ Nevertheless, most have found 
adrenoceptors to mediate much poorer responses within the cerebrovasculature (Part 2,
2.6). Because of the brain’s vital function, a limited role for sympathetie regulation—and, 
therefore, a limited means to divert flow elsewhere—may thus be considered a convenient 
adaptation. Nevertheless, sympathetic regulation may be more prominent with extremes of 
MAP; or with intense tissue metabolism (Part 2, 2.6).
1.2.2 Current experimental findings
The cmrent study confinned relatively poor NEmax values within rat MCAs (Figs 23 & 24; 
Table 31, Appendix). Thus, the mean ‘responder’ NEmax at 3.2+0.3 mN was significantly 
weaker than either the Kmax (5.5±0.3 mN, p == 0.0001) or the PGF2amax (5.1 ±0.4 mN, p 
0.0006). A novel finding fr om this thesis, however, was that NE responses were singularly 
heterogeneous. Thus, whereas a poor Emax to one agonist was invariably associated with 
an equally poor response to other agonists, responses to NE were fi'equently poor despite 
adequate Emax values to other agonists (NE- ‘ subresponders ’ ). The plot of NEmax v FDqq 
initially yielded a wide scatter with minimal linear correlation: indeed, as little as 10% of 
NEmax varianee could be attributable to FDgo.
Clearly, the major factor distorting the E„mx v FD™ correlation was the presence of 
numerous NE-‘ subresponders’ (Figs 23 & 24). Upon their exclusion, a linear 
relationship—with correlation equal significance to that with other agonists—could be 
restored (r = 0.62, p<0.01). It was therefore decided to exclude such ‘subresponders’ from 
analysis of continuous data, but to analyze them instead as categorical data: a manoeuvre 
also justified by ‘subresponder’ NEmax values being within the range of baseline 
vasomotion (Fig 12). NE ‘subresponders’ ai’e clearly discernible in the lower portion of 
Fig 23 where withNEmax^l.O mN. Because ‘subresponders’ could occur contralateral to a 
‘responder’, NE responses could be markedly asymmetrical in some cases; whilst absent 
altogether in others.
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That poor NE responses were genuine, and not the result of a faulty solution, was 
confirmed in thiee ways. Firstly, in nearly a half of these the contralateral vessel displayed 
an adequate response, in the same bath (Tables 10-14, Appendix). Secondly, whenever 
bilaterally poor, a fieshly made up solution also failed to elicit a response. And thirdly, a 
‘poor-response solution’ when kept and subsequently tried again (on another pair of 
vessels) usually produced normal—or even supranormal—responses. Thus, it appeared 
that a genuine subgroup of subresponders was present in this sample.
1.2.3 Theoretical implications
A clue to explaining such heterogeneity was proffered by Tsukahara et al who attributed 
weaker animal NEmax values to a greater preponderance of a2 receptors*^''The more 
efficacious response in human vessels, therefore, related to a greater a l  :a2 ratio—the a l  
receptor allegedly mediating larger responses^"' .^ Unfortunately, the actual explanation may 
be somewhat more complicated, since p adr enoceptors are also present within the 
c e r e b r o v a s c u l a t u r e ' ^ ' ’ 379,5ii t^ct, all three receptor types may be present upon the same 
VSMC (Part 3, 1.3): this alone giving rise to eight possible combinations (with five 
differing types of net effect : Table 7). Indeed, the situation may be further complicated 
still, as NE also elicits the simultaneous release of endothelial-derived constricting and 
relaxing f a c t o r s ^ ^ ? ,  299, 320,321 (^ p^ rt 3, 1.3). It is quite possible, in fact, that a2-EDRF 
release explains diminished responses, as this may be the basis behind similarly reduced 
responses in the coronary resistance circulation^^^.
The ultimate effect in any one target cell thus depends upon the precise combination of 
receptors and effects present, this explaining almost all of the NEmax variance'^'. For 
example, the presence of p receptors may possibly explain asymmetrical NE-responses 
since in one study left-sided P receptors were extraordinarily fickle to minor insults^?^. 
However, P receptors are rare in the proximal MCA, most evidence indicating instead a 
predominance of a l  receptors (in both rats and h u m a n s ) ^ ^ ?  suggests, then, that
more specific factors are important, such as relative a  receptor density and the prevalence 
of receptor u n c o u p l i n g ^ ^ v ,  620 Although there is theoretically greater potential for 5HT 
receptor heterogeneity (Part 3,1.4), it is interesting that in this thesis 5HT responses were 
more closely linear in their Emax v FDgo correlation than NE (Figs 21 & 23).
1.2.4 Conclusions
In addition to the anatomical irregularities and asymmetiy that abound within the 
cerebrovasculature^?’ 253,347, 396  ^the cuiTent study also provides evidence for a similar 
degree occurring at receptor levels. Thus, even after allowing for diameter-effects—and 
even after restricting study to a small segment of a major cerebral artery (thus reducing
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gross receptor-variaiice?3?’ 620 —^considerable variance was obtained in NE-mediated 
responses. Bevan et al have recently demonstrated that such poor responses may relate to 
both a sparse innervation, as well as to a poor receptor-mediated response^".
The current results suggest that in 12.5% of individual rats (i.e. the proportion of bilateral 
‘subresponders’ in non-operative controls: Table 10, Appendix), the regulatory role of the 
SNS on CBF through MCAs may be significantly compromised by a relative failure in 
agonist-receptor response. Furthermore, in a further 12.5%, SNS regulation may only be 
present on one side: a global sympathetic activation producing perversely asymmetrical 
effects. Since the larger part of CBF is conducted through the MCA (Part 2, 1.1), this 
finding could have significant physiological consequences. Eccles & Eccles have 
commented upon autonomic asymmetry in the clinical setting with head and neck 
s t m c t u r 'e s '^ ^  At present, the SNS is thought likely to play its part only at extremes of CBF; 
with myogenic and metabolic regulation controlling the CBF between these limits (Part 2,
2.4 & 2.5). Should the current results extrapolate to humans and to other cerebral arteries, 
it is conceivable that an absence of protective adrenergic constriction (i.e. presence of 
NE-‘ subresponders’) may be responsible for the bounding CBF of an acute migraine, since 
SNS regulation may be more critical in a setting of gross metabolic dilatation (Part 2, 2.6). 
It is interesting that migraine afflicts 15-30% of the population in this regard^''^, since this 
is the proportion of animals possessing either one or both MCAs subresponsive to NE 
(migraine can, of course, be either a unilateral or bilateral affectation; depending on the 
individual).
T able 7. Theoretical adrenergic receptor combinations on VSMCs
Receptor types on V S M C Effect
1. — 0
2 . a l 2+
3 .  a 2 1+
4.p -1
5 . a l . a 2 3+
6 . a l . p 1+
7 . a 2 . p 0
8. a l . a 2 . p 2+
Assuming that a l  receptors mediate more powerful constrictions than a2 receptors^''?, and 
that p receptors mediate dilatory effects comparable in magnitude to a2 constrictions, the 
following ranks of net response can be obtained: a l  ^  +2, a2 = +1, and p = -1. (—) 
denotes an absence of receptors. (NB endothelial-derived relaxing and constricting 
effects have not been considered). Note that, overall, only five differing types of net 
effect are produced.
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The failure to note the presence of diseontinuous agonist responses—herein epitomized by 
NE response heterogeneity—in many current SAH small vessel studies might be a critical 
factor in explaining some of their failure to explain—or to procure efficacious treatment 
strategies for—either delayed VSM or DCI. Such discontinuity precludes normal statistical 
analysis, since this requires that data are normally and continuously distributed. As a 
result, discontinuous data should be analysed separately from continuous data.
1.3 NO responses and auto regulation
NO was assessed in this study both by its endothelial production from L-ARG—and the 
latter’s subsequent inhibition by L-NAME—as well as by its effectiveness as a substrate 
for VSMC GC by analysis of SNP. The fact that in this study the L-ARG Emax ~ SNP Emax 
suggests two major points (Table 28, Appendix). Firstly, it suggests that the endothelium 
was not unduly affected by the mounting procedure, in spite of the risks involved^^f Thus, 
NO released directly into VSMCs by SNP donation achieves the same effect as that 
produced by endothelial release. Secondly, it indirectly supports the concept that agents 
such as SNP do indeed achieve their effects by the direct liberation of NO within the target 
cell (Part 3, 1.10). The fact that the endothelium remained intact may not necessarily relate 
to exquisite handling as the cerebrovascular endothelium (due to the relative importance of 
the BBB: Part 2, 1.3) may eonceivably be more ‘robust’ than it is systemically.
There are numerous reports in the literature concerning the role of NO in governing CBF 
autoregulation. The results of the cun ent study suggest that NO rarely affects baseline MT 
(i.e. Emax>100%, white right hand tails: Fig 43). Since numerous studies have shown that 
NO does influence CBF, tlris suggests that factors other than MT largely control CBF in 
vivo (i.e. AT!). NO is, however, co-released in vivo in submaximal amounts concuiTent 
with both AT and shear stress (Part 3, 1.8 & 1.9). The results of the present thesis suggest 
that L-NAME would elevate the mean PGF2a Emax in normal MCAs from 5.1 to 6.4 rnN, 
producing a value for ‘basal NO release’ at 26% of the total NO MCA release possible 
(Par t 5, Section 11, 1.10). The latter value is well within the range (20-40%) of that seen 
systemically. However, the relative importance of ‘basal NO release’ in vivo will 
obviously depend on the extent to which overall MCA tone is dictated by the AT:MT ratio. 
Since SNS tone may ordinarily be as small as 5% (Part 2, 2.6), ‘basal NO release’ would 
not be likely to influence matters much here. Nevertheless, the role of NO would certainly 
increase as the role of the SNS does under more extr eme circumstances (Part 2, 2.6).
The precise source of AT in CBF regulation in vivo appears to be lar gely unknown. One 
possible factor, however, not entertained in most NO-CBF studies, is that of the anaesthetic 
agent in creating an artefactually abnormal degree of background AT. This would have
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serious implications for the perceived role of NO in autoregulation. This criticism, of 
coui'se, underlines one of the major problems of in vivo studies in general (Part 4, 4.1).
But if VSM after SAH does relate to the inhibition of NO-mediated VSMC relaxation, then 
it would seem from the above that—at least with SAH—considerable AT must also be 
present within the cerebrovasculature. Such AT could, of course, derive fi'om agonists 
within the clot suiTOimding the vessels after SAH. What does seem apparent from the 
cmrent results, however, is that MT alone is not likely to be the major somce of tone, 
simply because NO—even in maximal amounts (e.g. [L-ARG] = 200pM)—rarely appeal's 
to affect it (i.e. L-ARG E„iax<100%): at least not in normal control vessels (Part 5, Section 
11, 1.10).
1.4. Hypoxia, HA, PPV and myogenic tone (MT)
1.4.1 Hypoxia
Of all the factors suggesting that MCAs develop MT to luminal distension, the relaxation 
achieved with at least 15 mins hypoxia provides the most substantive. With this, MCAs 
were progressively dilated ftom baseline conditions without any preconsti'iction from 
PGF2a or any other agonist. Such baseline dilation must ipso facto represent MT dilation. 
Since hypoxia achieves cerebral vessel relaxation via non-NO EDRF release—the agent 
presumably being PGl2'^3—this, then, provides further confirmation for continued 
endothelial function in spite of the perceived risks of the mounting procedure incurred {see 
above). More specifically, it implies that hypoxia may be a powerful effector of 
dysautoregulation within vessels where MT represents a major source of overall tone.
The value obtained by hypoxic dilation also allows us to assess the relative contribution of 
spontaneous MT to that of the overall constricting power extant in MCAs. Thus, taking a 
maximal constrictory power in normal MCAs as that obtained from the KCl Emax (5.5 mN), 
and taking the total MT as being that obtained ftom hypoxic dilation (3.6 mN), MT can be 
seen to represent 40% of the total tone possible. This value for MT is in fact close to 
that obtained (20-40%) in other studies (Part 5, Section II, 1.13). The ratio of MT:AT 
within isolated MCAs is, therefore, approximately 2:3 ftom this study.
1.4.2 HA and PPV
As each respective frequency distribution shows in Figs 25 and 40, both PPV and HA in 
maximal concentrations are likely to risk dysautoregulation in vivo in approximately 35- 
50% of normal MCAs beeause, in such cases, some amount of background MT is dilated in 
addition to the complete abolition of AT. Such a distribution may be reflected, then, in the 
wide variety of responses obtained with such agents across different studies. For example, 
injection of HA has been noted by one group to cause cerebrovasculai' dilatation and
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headache?^: this possibly reflecting dysautoregulation. In similar fashion, one other group 
demonstrated an increased CBF and ICP following a PPV i n f u s i o i f l o o .  hi marked contrast, 
no observable effect was apparent in one other study in which HA was infused directly in 
to the CCA452.
Since HA mainly achieves vasodilation via HA2 receptors, in both rats and humans (Part 3, 
1.11 & Fig 26), this would imply that HA2 blocker therapy, such as with ranitidine or 
cimetidine, might be potentially protective against sudden massive central releases, such as 
may occur with a cerebral anaphylaxis. Thus, HA2 blockers may be conceivably 
prophylactic, for example, with cerebral trauma. Indeed, such therapy may prove 
particularly efficacious in tumour neurosui'geiy, as tumour vessels appeared unusually 
HA2-responsive in one study452. The implications of PPV usage will be considered, in 
turn, in more detail later.
1.5 Interaction between PPV and SNP: evidence for synergism?
PPV and SNP may often be present in significantly high concentiations at around the time 
of aneurysmal clipping. This is because PPV is often administered routinely by some 
groups at craniotomy closure following a successful clipping; and because SNP is often 
administered during aneurysm manipulation (for example, both manoeuvres represent 
standard Neurosurgical practice in the Royal Hallamshire Hospital, Sheffield). SNP and 
PPV both effect relaxation by the two cyelic nucleotide mechanisms possible (Part 2, 3.5). 
Thus, PPV vasodilates via cAMP-PKA mechanisms; whilst SNP dilates via cGMP-PKG 
mechanisms. As both PKA and PKG share homologous biochemical structures and 
catalytic properties, it is not surprising that evidence of a possible interaction between the 
two has increasingly accumulated (Part 2, 3.5).
In the current thesis, it was clearly found that responses obtained with such a PPV-SNP 
combination were more pronounced at each stage, confirming such interaction. Thus, the 
combined C-R curve (Fig 27) was clearly left-shifted relative to either individual control 
curve, with both significantly enhanced efficacy (Ennix) and potency ( E C 5 0 )  [p = 0.01 and
0.014 respectively]. Apart ftom providing some evidence for an interaction at the 
subcellular level, these results also present important clinical ramifications. Most 
importantly, they suggest that combined maximal concentrations seriously threaten 
cerebral dysautoregulation in a manner comparable to that seen with hypoxia. Thus, a 
profound cerebrovascular paralysis may result, the CBV passively expanding to the 
dictates of the MAP. This may threaten the microcirculation, causing cerebral oedema 
formation (Part 2, 2.5).
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Alternatively, however, a PPV-SNP combination could be used, in more moderate 
concentrations, to distinct advantage. Thus, PPV may be used to diminish SNP 
concentrations, so obviating the risks of SNP toxieity. Furthermore, the two may be 
introduced simultaneously into the angiographic catheter to locally reverse VSM. As a 
result, such a combination may potentially have both beneficial as well as deleterious 
effects, clearly dependent upon the concentrations achieved.
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S E C T I O N  I I  
I n  v i t r o  v e s s e l  r e s p o n s e s  
C h a p t e r  2  
E f f e c t  o f  s h a m  o p e r a t i o n  u p o n  M C A  r e s p o n s e s
2.1 The effects of peripheral trauma upon central vasoreactivity: 
current knowledge
Cerebrovascular dysfunction is well recognised following a variety of eerebral insults (Part 
1, 2.6). In particular, alterations in both metabolic regulation (e.g. CO2 regulation) and in 
autoregulation have been documented following acute S A H 224-226, 257,2 8 9 ,307, 453, 590, 615, 632^ 
along with widespread alteration in receptor-mediatedfunction^’ 4 8 ,123, 309,3 6 7 ,3 6 8 ,574, 595,5 9 8 , 
604,635 Little is known, however, regarding the effects of peripheral injury upon 
cerebrovascular' function. In one recent study, clear evidence of cerebral 
dysautoregulation following limb trauma (ischaemia-reperfusion injury) was 
demonstrated, with CO2 regulation remaining intact?^?. This concords with the view that 
metabolic regulation is more ‘robust’ than myogenic autoregulation (Part 1, 2.6). 
Haemorrhagic hypotension, however, whieh often accompanies trauma, does not affect 
either metabolic regulation or autoregulation^?^; suggesting this to be a lesser insult. Yet 
haemorrhagic hypotension is known to cause receptor-mediated dysfunction^^s. Tliis tends 
to suggest that peripheral tiauma, as in the study of Hadfield et aP^? above, may also have 
affected receptor-mediated vascular function. Direct evidence for such conjecture, 
however, is currently lacking.
2.2 Current experimental findings
In the first part of this study, HA responses were analyzed in non-operative control MCAs. 
Because prolonged anaesthesia without adequate monitoring (i.e. without arterial blood gas 
and fluid balance analysis) raises serious ethical issues, a tiue anaesthetic control group 
here was not possible. Following prolonged anaesthesia (4-6 hours) and surgical trauma, 
HA relaxation of AT was significantly reduced. Thus, HAmax was reduced fiom 102+5 to 
82+5% (p = 0.0085), whilst the EC50 increased from 2.3+0.6 to 6.8+1.6 pM (p = 0.0062: 
Figs 29 & 30). The marked decrease in both affinity and efficacy appeared to resemble that 
of low-moderate concentration HA2 blockade (Fig 26), The resultant left-shift in the 
fi'equency distribution (Fig 29) signified that a smaller proportion of MCAs would suffer 
additional dilation of MT following complete abolition of AT (i.e. fewer HA E„,ax>100%:
). Thus, the theoretical risk of dysautoregulation was also significantly reduced in MCAs 
after sham operation.
237
2.3 Theoretical and therapeutic implications
Although urethane is singularly ineffective in affecting cardiovascular physiology 
ordinarily'28, and is not known to release HA from MCs, it remains entirely possible that 
the continued effects of this anaesthetic agent were responsible for the adverse effects 
observed on HA relaxation. Clearly, a future study would be indicated in order to analyze 
further this possibility. However, it would be difficult to maintain anaesthesia for up to 6 
houL'S without direct access to the animal’s circulation; and considerable trauma is applied 
during this manoeuvre,
Sui'gical tiauma was induced in four main areas in this study (Paid 4, 3.3):
1. The left groin and associated neuro-vasculatuie
2. The posterior cervical musculature and cisterna magna (CM)
3. The central anterior neek region (i.e. tracheostomy)
4. The right cai'otid sheath and extra- / intia- cranial ICAs (i.e. thread insertion)
All of these areas could, theoretically, have been individually or collectively responsible 
for the effect observed. It seems unlikely, however, that manipulation of the right carotid 
sheath—with thread insertion intiacranially within the ICA (No. 4 above)—played any 
significant role. Thus, no significant difference was observed in either HA Emax or ECgo 
between right {study side) and left {contralateralpaired control) MCAs. This strongly 
suggests that the manoeuvre:
[Right caiotid sheath manipulation] + [ECA obliteration] + [Intracranial ICA tliread
insertion]
exerted no significant lateralizing effect upon MCA reactivity within the study period. 
Indeed, no significant differences between right and left MCA responses were found
to any of the agonists used in this study; again reinforcing the view that unilateral 
manipulation was without lateralizing effect {see later). Further support for this notion is 
obtained from the “Sheffield Model” of SAH, where rCBF remained unaffected by right
carotid sheath m a n i p u l a t i o n ^ ^ s
The relative significance of factors 1-3 above, however, cannot be further elaborated upon 
here. Although penetration of the CM permits a direct mechanism by which MCA 
responses to HA may be affected, the degree of peripheral trauma suffered in Nos 1-3 
have more evidence to support their possible contribution in this regard. In particular, the 
fact that various degrees of limb ischaemia were incurred following arterial cannulation 
must rank highly. For example, Stoner et al showed in 1984 that limb ischaemia could 
influence central NE pathways via nociceptor afferents ascending in the femoral 
nerve^^^. This, in fact, explained the levels of hypertension frequently seen during limb
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ischaemia, a fact known since 19374. Indeed, hypertension was frequently observed in the 
current study (MAP being 154/96 mmHg), this being abolished by severance of the femoral 
nerve (Part 5, Section I, 1.2 & 1.3). A similai' neurovascular mechanism may thus pertain 
with HA down-regulation. Thus, combined [central and peripheral] surgical trauma plus 
ischaemia may have been the factors involved here; coupled to the possible effects of 
prolonged anaesthesia.
2.4 Conclusions
The results of this study appear to provide evidence that peripheral trauma may play a 
role in the acute down-regulation of cerebral HA-mediated vasodilation. If so, then this 
would be one of the first studies to demonstrate that peripheral injury may affect centrally 
receptor-mediated function. That such an effect might occur ought not necessarily to 
appear surprising, since Kovach et al (1985) demonstrated that haemorrhagic hypotension 
could achieve a similar effect^^s  ^whilst peripheral ischaemia certainly appears to affect 
more robust autoregulation^^?. The possible mechanisms involved (in addition to 
nociceptive afferent activation) will be discussed later (see later).
The fact that no significant differences were found between right and left MCA responses 
in sham operative controls to any of the agonists used in this study suggests that EF-SAH 
models do not introduce any significant ‘side bias’ upon ipsilateral MCA reactivity by 
virtue of the potentially confounding combination: 1) unilateral carotid manipulation, 2) 
unilateral EF insertion or 3) potentially ipsilateral intracranial rupture. Sueh models may 
therefore provide the substrate for post-SAH cerebral vessel study without fear of this 
potentially confounding bias.
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S E C T I O N  I I  
I n  v i t r o  v e s s e l  r e s p o n s e s  
C h a p t e r  3
E f f e c t  o f  a c u t e  S A H  u p o n  a c u t e  M C A  r e s p o n s e s
3.1 FD90 values and KCl responses
Tables 24-30, Appendix, clearly show that in spite of continued individual diameter 
asymmetiy, and in spite of the stresses of surgieal trauma and acute SAH incurred, overall 
mean FD90 values remained remarkably unaltered across all experimental sub-groups 
considered; as well as between right and left MCAs within each sub-group. This, to a first 
approximation, suggests that MT has also remained unimpaired, since MCA diameter at 90 
mmHg internal pressure (FDgo) is dictated by myogenic contraction as well as by ‘passive’ 
anatomical factors. This is an important finding, because it not only confirms the 
comparison of ‘like with like’ MCAs; but it also suggests that MT—the fundamental 
aspect of ‘autoregulation’ that Bayliss hiitially conceived—is a somewhat ‘robust’ entity. 
Its continued presence was also appreciated visually by the continued presence of baseline 
vasomotion (Fig 12) within MCAs after SAFI.
That MT was fundamentally unaffected by SAH is, however, more specifically supported 
still by the invariance of FD in n = 27 MCAs subjected to a range of intraluminal pressures 
from 70-150 mmHg after SAH (Figs 14 & 31). Thus, at least within three hours of SAH, 
the ‘stimulus-response’ ability of MCAs to increase MT in order to counteract increased 
distension appears to have remained largely unaltered. In consequence, it seems likely that 
such vessels ought to be able to ‘autoregulate’ normally in vivo, since this is an intrinsic 
property of such vessels umelated to other physiological inputs (Pai't 2, 2.2-2.4). As a 
result, the current study suggests that the degree of SAH incuired is not likely to have 
affected the basic mechanism of autoregulation in MCAs. This is cleaily contradictoiy 
to the popular view (Pai't 1, 2.6), and appears surprising in view of the appai’ent ease with 
which HA receptor-mediated function was clearly affected following mere sham operation 
(see previous seetion).
A further important finding from the current results is that the ability of MCAs to contract 
to a non-specific depolarizing stimulus (i.e. 120 mM KCl) also remained remarkably 
preserved after acute SAH (Table 28, Appendix: see also Fig 32). Indeed, the same degree 
of linear eorrelation between KCl Emax and FD90 was as apparent after SAH as before in 
shams or non-operative controls. Furthermore, Kmax remained strikingly invariant across 
SAH Groups 1-3 and, thus, despite varying degrees of CCA re-clamping. These findings 
confirm that the basic contractile maehineiy of the MCA wall has remained flmdamentally
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unaffected by the combined stresses of sham operation and acute SAH. It also confirms 
that whatever other effects may be apparent in, for example receptor-mediated function 
after SAH, these have essentially occurred against a background comparison of Tike MCAs 
with like’.
The current results are completely contradictoiy to those that have demonstrated a loss of 
contractile power following acute SAH^4,289,472,599 xhey also, specifically, contradict 
Tsuji and Cook’s finding of reduced KCl responses within 4 hours of SAH '^'  ^ ^  is 
possible that the cuiTent findings may also—along with FDgo invariance—contradict 
evidence that the VSMC membrane becomes acutely depolarized in the early houi's 
following SAH'^ 41 jf the latter was the case, then one might expect in an increase in the 
MT:AT ratio to result; this resulting in reduced contractility (c.f. Tsuji and Cook and 
others (^) ’^ This result derives from Haider’s finding that MT was achieved
lai'gely by way of VSMC membrane depolaiizatioif^o. Waters and Harder proposed in 
1985 that VSMC depolarization was one of the first significant physiological changes to 
occur following the application of blood to the BA^ i^- others have since concuned^'". 
Notwithstanding, the cuiTent findings do not support the view that PSCs within the VSMC 
membrane have been specifically damaged by acute SAH^o^
One exception to the pattern of otheiwise unchanged Kmax after SAH was apparent in one 
sub-gioup analysis of the current study. Thus, the mean Kmax following a type II pressor 
response appealed maikedly reduced in comparison to that following a type I or III 
response (Table 30). Although this did not prove to be statistically significant, it nearly did 
(p = 0.0527); whilst an isolated comparison of the type I Kmax against the type II or against 
a type ÏI/III combination (see Part 5, Section I, 1.3: types II & III acute pressor responses 
appeared similar and distinct in their AICP than type I) did reveal statistical significance (p 
= 0.025 and 0.044 respectively). These findings can be interpreted as demonstrating that, 
in comparison to the type II acute pressor response, the type I response appeared to 
‘protect’ the Kmax ftom the effects of SAH; maintaining its equivalence to either shams or 
non-operative controls. One possible explanation for this finding eould relate to the fact 
that the type I response stanches SAH with less cerebrovascular sheai' stress, and also less 
compressive cerebral strain (Part 6, 1.4.3). Although the Kmax in the type III group alone 
does not support this contention, it must be remembered that this group contained a 
statistically small number (n = 2 animals); and so might not be representative.
Furthermore, other evidence from this study (Part 5, Section I, 1.3) suggests that the type II 
and III response groups can be considered together against type I. Reduced type II acute 
pressor Kmax values after SAH suggest that higher AICPs and higher ICPmax values may 
damage VSMC contractility. If tliis is so, then it would provide some support for similar
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findings with delayed VSM clinically, as observed in the study of Onoue et al discussed 
later [Part 6 , Section III]4?2.
Conclusions
Two basic properties of autoregulatoiy arteries—the ability to develop MT in response to 
intraluminal distension, and the ability to constrict to a non-specific depolarizing 
stimulus—remain remarkably preserved acutely after SAH. These findings suggest that the 
basic mechanism of autoregulation remains intact, and contradicts studies that have 
demonstrated an acute vasopaialysis after SAH. The remarkable degree of uniformity in 
Kmax and FDgo suggest that Tike with like’ comparisons may continue after SAH; and 
further suggest that the Kmax may remain as the ‘gold standard’ against which to compare 
other responses: as in shams or non-operative controls. In comparison to the type II acute 
pressor response, or to type II and III responses together in combination, the type I pressor 
response appeared protective to the Kmax, maintaining its equivalence to shams and non­
operative controls. It is possible that this protective effect in some way relates to the 
decreased cerebrovascular shear and decreased cerebral compressive strain that must 
accompany an acute hypotension with SAH. If proven, this would be a significant finding 
because it supports the possibility that higher AICPs and higher ICPmax values might 
damage VSMC contractility. Future studies utilizing greater group numbers may be 
required to assess this matter further.
The fact that no significant differences were found between right and left MCAs in either 
their diameters or in response to a non-specific depolarizing stimulus suggests that EF- 
SAH models do not introduee any significant ‘side bias’ upon ipsilateral MCA reactivity by 
virtue of the potentially confounding combination: 1) unilateral carotid manipulation, 2) 
unilateral EF insertion or 3) potentially ipsilateral intr acranial rupture.
3.2 PGF2a responses
The majority of previous studies have demonstrated enhanced PG-induced constrictions 
following SAH635. Furthermore, many studies have demonstrated increased PG 
concentrations in SAH CSF, particularly following secondary haemorrhage. Therefore, 
both enhanced concentrations and enhaneed Emax values would make PGs strong 
candidates for agonist-induced VSM. This may be particulariy so with PGF2a, since this 
causes a prolonged constriction (Part 3, 1.5) and is present in elevated coneentrations at 
around the time of clinical DCH? .^ As a result, many studies have isolated PGs as the 
dominant vasoconstrictory force within SAH-CSF (Part 2, Ch 4), this correlating with the 
findings of enhanced PKC mechanisms associated with vessels in spasnY^3
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Neither the PGF2a E^ax or EC50 was significantly altered by SAH when SAH Groups 1-3 
were considered either together or in isolation. Indeed, a remarkable degi’ee of uniformity 
was appar ent in the C-R curves obtained fr om non-operative controls, shams and overall 
SAH groups. This degree of uniformity also extended to the apparent loss of efficacy at 
supramaximal PG concentrations (see Fig 33): a phenomenon that might relate to cross­
reactivity of PGF2a with inhibitory receptors. A closer analysis of Table 29, Appendix, 
however, suggests that a progressive increase in Emax had occrmed with increased survival 
following the acute ictus. Thus, the Emax in the 3 hour group was significantly greater than 
that in the 1 and 2  hour suiwival group; as well as being greater than in shams or non­
operative controls. Some of this effect could have derived from the fact that the FD^ in the 
1 hour group was considerably smaller than in the 2 or 3 hour groups which, by the Emax v 
FDgo relationship, could have distorted this group’s value. Nevertheless, the corresponding 
group Kmax was not reduced. The possibility exists, therefore, that the progression 
observed is genuine, and that it might continue outwith the arbritaiy thr ee hour period—a 
possibility certainly compatible with the findings of others^^ .^ Further studies would be 
required to establish or refute this possibility. Such increased efficacy with sui'vival could 
relate to the continued prolonged effects of some biochemical ‘trigger’ associated with the 
acute ictus: however, it could also reflect a property peculiar to ‘survivors’. To exclude the 
latter, a future study would be required in which one group of animals developing an SCC 
are aitificially kept alive by inotropic support: any significant differences in PGF2a 
efficacy between this group and those naturally surviving would therefore support the 
contention that the ‘efficacy’ effect was peculiar to ‘survivors’. Notwithstanding, PGF2a 
remains at least as efficacious as it was in shams or non-operative controls at three hours 
following acute SAH.
A fui'ther finding on sub-group analysis was that the EC50 in SAH Group 2 was 
significantly smaller than either SAH Groups 1 or 3 (Fig 28). However, it did not differ 
significantly from shams or non-operative controls (although it nearly did: p = 0.058). As a 
significant trend across these groups, this result is difficult to explain. In principle, SAH 
Group 2 represents an intermediate category between the multiple CCA clamp- 
release->ICP re-rise->CCA re-clamping cycles of SAH Group 1, and the ‘ideal’ CCA 
clamp-release-^immediate reperfusion category of SAH Group 3. We are therefore lead to 
the conclusion that any difference between Group 2, and Groups 1 & 3 together 
simultaneously, is not likely to relate to the ipsilateral effects of CCA clamping; nor to 
graded events associated with the ICP re-rise (and what this actually represented!). 
However, SAH Group 1 cleaiiy appeared unique for numerous other reasons in this 
study—not least of all because its small statistical number (see Part 6, Seetion II, 3.8)—so 
that, upon Group 1 exclusion, we may perhaps concentrate upon differences between
243
Groups 2 & 3, The principal difference between the latter two groups was that SAH Group 
2 contained an animal that had sustained a type III acute pressor response [see Table 22]. 
However, since this animal’s mean PGF2a EC50 was 5.9 pM, the observed CHR cannot be 
held responsible for this group’s deviant PGF2a EC50 value.
Conclusions
PGF2a constrictions are at least as potent and efficacious as they are in either shams or 
non-operative controls after SAH. Moreover, the trend suggests that there is a progressive 
increase in efficacy with prolonged survival after SAH. The prolonged and powerftil 
eonstrictions that PGF2a produce, coupled with evidence for its relative abundance within 
the SAH-CSF and the possibility that its efficacy may increase with prolonged survival, 
makes PGF2a a strong candidate for the agonist responsible for reversible VSM. PGF2a 
constrictions appear to be significantly more potent following a reperfasion-induced ICP 
re-rise and subsequent CCA re-clamping for <5 mins, than after immediate reperfusion 
without an ICP re-rise, after acute SAH.
The fact that no significant differences were found between right and left MCAs in 
response to PGF2a suggests that EF-SAH models do not introduce any significant ‘side 
bias’ upon ipsilateral MCA reactivity by virtue of the potentially confounding combination: 
1) unilateral cai'otid manipulation, 2) unilateral EF insertion or 3) potentially ipsilateral 
intracranial rupture.
3.3 5HT responses
5HT may be important in both structural and functional VSM: thus, 5HT may promote 
myoproliferative change within the vessel wall (Part 3, 1.4). Most 5HT in blood is 
contained within platelets which are, of couise, in plentiful supply within the local clot^? ,^ 
323,610 However, 5HT is also present within serotonergic neumnes and mast cells (Part 3, 
1.4). The latter source may be of crucial importance, as these are curiously prevalent 
within blood vessel walls in the local rupture vicinity (Part 2, 1.4.2). A recent study has 
demonstrated that perivascular sympathetic boutons take up and store local accumulations 
of 5HT, metering them out in turn over the ensuing days^ ?®. Furtheiinore, 5HT may be co­
released ftom sympathetic terminals with NE^^?’ and the two may even interact^^?. In 
this context, serotonergic neumnes may feature heavily in the DSS phenomenon (Part 3, 
3.3). Interestingly, the presence of blood can directly augment the 5HT resp o n se^ 3^8^  as 
can also endothelial denudation'
Most studies have demonstrated an increased responsiveness of cerebral vessels to 5HT 
after SAH. Interestingly, Debdi et al (1993) demonstrated—in a type II SAH model—that
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increased 5HT responses could occur' as early as 10 mins after SAH'23. Similarly, Tsuji 
and Cook demonstrated increased responses within 1 hom* which were significantly 
resistant to nimodipine dilation'^ot. Others have demonstrated similar* 
findings—unfortunately all within Bas^?+ 635 The results of the current study, however, do 
not support these findings. In general, 5HT responses remained imiform between non­
operative controls, shams, and overall SAH groups; with no statistically significant 
differences in either Emax or EC50 values. This fact can be appreciated in the eombined 
groups C-R curve of Fig 35. Although sub-group analysis of survival after SAH appears to 
support a trend toward an increase in Emax with survival, this trend was not statistically 
significant (Table 29, Appendix). In fact, the Emax did not significantly differ either 
between SAH Groups 1-3 (Table 27), or between acute pressor response gi’oups (Table 30); 
nor was there any signifieance between right and left MCAs within each sub-group (Tables 
24-26). As in shams or non-operative controls, the 5HT Emax was comparable in 
magnitude to both the KCl and PGF2a values after SAH, but was much lai'ger than either 
the UTPmax or NEmax in ‘responders’. However, the E C 5 0  value was an order of magnitude 
smaller than that of all other agonists excepting UTP (from which it differed by two orders 
of magnitude). In consequence, 5HT responses are especially potent in MCAs: in non­
operative controls, shams and after acute SAH.
Because Emax values were so invariant, it was somewhat surprising to find that the E C 5 0  
values frequently differed signifieantly amongst SAH sub-groups (Table 27). For example, 
the E C 5 0  in SAH Group 1 (0.72+03.1 pM) was significantly larger than that in either 
Groups 2 and 3; or that in shams and non-operative controls (Table 28). No significant 
side difference within SAH Group 1, however, was appaient (Table 24). This suggests that 
SAH Group 1 responses significantly differed by factors not directly related to prolonged 
unilateral CCA clamping per se: however, the small n numbers for side compaiisons make 
this analysis strictly inconclusive. Nevertheless, other factors that could have been 
important include the fact that prolonged re-clamping was employed in response to 
repeated ICP re-rises with each attempted repei'fusion. Thus, Group 1 could have differed 
primarily because of multiple re-bleeds. This factor also ties in with another distinguishing 
feature of this group, namely that of early mortality. Thus, SCC occurred within the 
arbritary three hours after SAH in 4/4 (100%) of tliis group. However, one other important 
factor relating to this group was its statistically small group number: thus, only n = 8 
MCAs were analyzed amongst n = 4 animals [see Part 5, Section II, 1.5; and Part 6 , Section 
II, 3.8].
The 5HT EC50 also appeared markedly inereased in the 2 hour survival group relative to 
the 1 and 3 hour' groups (Table 29), This difference, however, did not prove to be
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statistically significant. The 5HT EC50 in the type III acute pressor response group, 
however, was highly significantly different fiom either the type I and II groups (p = 0.002); 
or fiom shams and non-operative controls (p = 0.0003: Table 30). As with all statistical 
analyses attempted on the type III acute pressor response sub-group, no firm conelusions 
can be drawn simply by virtue of their small group number. Nevertheless, it is certainly 
conceivable that a CHR could have been detrimental to the 5HT receptor-mediated 
response, particularly in view of the greater cerebrovascular shear stress—and greater 
cerebral strain—that this group must necessai'ily have incurred. Further studies with, 
hopefully, greater CHR sub-group numbers, would be required to resolve further this 
important issue.
Conclusions
5HT responses—both Emax and EC50—are, overall, insignificantly altered after SAH. The 
5HT Emax after SAH, as in shams and non-operative controls, is comparable in magnitude 
to that with KCl and PGF2a and, therefore, considerably stronger than that with UTP or 
NE-‘responders’. The EC50 is an order of magnitude more potent than with most other 
agonists. Sub-group analysis suggests that 5HT affinity is significantly decreased in the 
prolonged CCA re-clamped group, this perhaps relating to the repeated ICP re-rises—and 
subsequent early mortality—^suffered by this group: however, it may also represent an 
artefact of this group’s small statistical number. Sub-group analysis also suggested that the 
CHR was detrimental to the affinity of the 5HT response, diminishing this significantly 
fiom either shams and non-operative controls, or fiom acute pressor response types I & II. 
However, as with SAH Group 1, this effect could also have been an artefact of a small 
group number.
The fact that no significant differences were found between right and left MCAs in 
response to 5HT suggests that EF-SAH models do not introduce any significant ‘side bias’ 
upon ipsilateral MCA reactivity by virtue of the potentially confounding combination: 1) 
unilateral carotid manipulation, 2) unilateral EF insertion or 3) potentially ipsilateral 
intracranial rupture.
3.4. UTP responses
UTP, like 5HT and NE, is present in copious amounts within the platelets of the SAH clot. 
It may also be present as neui'otransmitter within the CNS, and is richly present within 
cerebral tissue. Little is known about its role although evidence suggests that this may be 
specific to the CNS (Part 3, 1.6). Few SAH studies have used UTP as a response agonist. 
In those that have, conflicting reports once again abound. For example, Debdi et al 
demonstrated increased UTP responses within 10 mins in a type Ilb SAH modeP^^, whilst
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Kim et al demonstrated diminished responses in a similai* model but with the use of ring 
myography^^^. However, both of these studies employed the BA for analysis.
As Table 31, Appendix shows, UTP responses were singularly different from all other 
contractile agonists in that the Emax v FDgo correlation in non-operative controls was not 
significantly linear. Nevertheless, linearity—with a high degree of correlation and 
significance—was once more restored in shams and overall SAH groups (i.e. all other 
groups). No adequate explanation is offered for the aberrant finding in non-operative 
controls, apart from the somewhat banal one of ‘sporadic receptor heterogeneity’ or, 
possibly, ‘sampling error’.
UTP responses remained singularly unaffected by SAH in this study. Thus, neither the 
Emax nor the EC50 were significantly altered by either the degi'ee of CCA re-clamping (SAH 
Groups 1-3: Tables 27 & 28); the degree of smwival (Table 29); nor the type of acute 
pressor response sustained after SAH (Table 30). These results sti’ongly suggest that the 
receptors involved—and receptor coupling to intracellular second messengers (Part 3,
1 .6 )—have remained imaffected by the acute ictus: at least within the short period after 
SAH analyzed in this study. The UTPmax, like non-operative eontrols (but unlike shams), 
was significantly weaker than the corresponding Kmax after SAH (p 0.0001). In terms of 
scale, the UTPmax ranked more akin to NE than to KCl, PGF2a or 5HT. Therefore, UTP 
eonstrictions are not as powerful as PGF2a or 5HT constrictions. Furthermore, with an 
EC50 value an order of magnitude higher than with these agonists, UTP constrictions are 
also significantly less potent.
Conclusions
UTP responses remained as potent and efficaeious after SAH as in shams or non-operative 
eontrols: however, in both of these parameters, UTP responses are significantly weaker 
than either KCl or PGF2a. SAH sub-group analysis does not reveal any exceptions from 
this rule. If, during delayed VSM, a local increase of [UTP] occurs, then the current 
findings at up to thiee houis — should they persist for several days after SAH—suggest that 
UTP may mediate equally as potent and powerful constrictions as in shams or non­
operative contiols. However, such constrictions are significantly weaker and less potent 
than with other likely agonists.
The fact that no significant differences were found between right and left MCAs in 
response to UTP suggests that EF-SAH models do not introduce any significant ‘side bias’ 
upon ipsilateral MCA reaetivity by vii*tue of the potentially confounding combination: 1)
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unilateral car otid manipulation, 2) unilateral EF insertion or 3) potentially ipsilateral 
intracranial rupture.
3.5 NE responses
3.5.1 Background
One factor involved with VSM may be excessive adrenergic activation^^®. Thus, 
myonecrosis is frequent in the outer medial layers*^ ^^  which represents the most functionally 
active layer adjacent to the adrenergic supply^^Q Furthermore, high local concentrations of 
catecholamines have been shown experimentally to produce a myonecrosis^, as well as to 
produce endothelial denudation^oo, 3 0 i and meningeal reaction*^ ^^  also commonly seen. 
Animals pre-treated with reseipine (RSP), however, do not develop these changes^^ ,^ 555. 
nor do animals treated with blood from a donor similarly pre-treated with RSP (where RSP 
also depletes platelets of NE)^^4
An acute sympathetic activation often accompanies SAH. Hence the CHR (resulting fiom 
activation of resistance vessels^^^ and the myocardium^*^), and the development of cardiac 
dysfunctional^' ^ 3i Indeed, the cardiac lesions incurred with the CHR often resemble those 
of an acute catecholamine o v e r l o a d ^ a n d  surges in catecholamine levels often 
correlate with the height of TCP elevations 1 F u r t h e r m o r e  the wddespread occurrence 
of adrenergic nerves spent of neurotransmitteri , i6 2 ,3 6 7 ,3 6 8 ,434,472  appears testimony to the 
aftermath of such excessive activity. There are varying reports concerning the effect of 
SAH upon NE-responsiveness in cerebral vessels. By far the majority have demonstrated 
that NE efficacy is increased after S A H * 2 3 , 162, 3 6 7 ,3 6 8 ,434,472 Some, though, have shown no 
change at alE^ ;^ whilst others have even demonstrated decreased responses'll '^ 599 
Unfortunately, in most of these studies the model used was either a type lib, or the vessel 
study was umepresentative (either in design, or because of the use of the BA).
3.5.2 Current experimental findings
The distinguishing feature of NE constrictions in non-operative controls—i.e. the mar ked 
heterogeneity of response between ‘responders’ and ‘subresponders’—persisted through 
shams and to all SAH groups. In fact, although the degree of heterogeneity (% NE- 
‘subresponders’) remained statistically invariant across this series, the trend actually 
suggested that it increased (non-operative controls 24%, sham operative controls 12.5%, 
SAH groups 55%: p>0.05). NE heterogeneity also did not significantly vary across:
• SAH Groups 1-3 (38%, 65% and 55% NE-‘subresponders’: p »0 .2 )
• Sui'vival groups (33%-Group 1, 38%-Group 2, 48%-Group 3 NE-‘subresponders’:
p » 0 .2 )
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• Acute pressor response type I (39% NE-‘subresponders’) and type [II & III] (47% NE- 
‘ subresponders’ : p » 0 .2 )
NE heterogeneity therefore appears to have persisted despite SAH or any of its possible 
sub-divisions. The vessels designated ‘subresponders’ were specifically so toward 
NE—responses to other agonists were noimal. The NEmax in ‘responders’ remained 
remarkably uniform between non-operative controls, shams and overall SAH groups; with 
a significance value approaching unity (Table 28, Appendix). This uniformity was even 
greater still across SAH Groups 1-3 (Table 27). Therefore, both the degree of 
heterogeneity and ‘responder’ efficacy remained generally invariant after SAH. 
Furthermore, the other feature of NE responses—i.e. their significantly weaker efficacy 
relative to KCl or PGF2a—also persisted after SAH (Part 5, Section II, 3.5).
SAH sub-group analysis, however, suggested that NE efficacy progressively increased with 
prolonged survival after SAH. Thus, the 3 hour value (4.8±0.6 mN)—impressively similar 
to the corresponding Kmax (4.9+0.4 mN)—significantly differed from either the 1 or 2 hour 
value (p = 0.04); or fi-om shams and non-operative controls (p = 0.026). As with PGF2a 
survival efficacy, some of this effect could have derived from the fact that the FD90 in the 1 
hour gioup was considerably smaller than that in the 2 or 3 hour groups which, by the E^ i^x 
V FD90 relationship, could have distorted group I ’s NEmax- Nevertheless, no such distortion 
was apparent in the coiTesponding group Kmax value. If, then, the progressive increase in 
NEmax with sui’vival is real and does persist—as with the progression in PGF2amax (3.2 
above)—then both of these agonists could appear as key players in the development of 
‘reversible’ VSM: whether acute or delayed. Several studies have demonstrated an 
increased NEmax after SAH consistent with the delayed time course of VSM.
Although no significance was actually demonstrated, a progressive increase in the EC50 
value was also suggested fi'om non-operative controls, thiough shams, to overall SAH 
groups (Table 28: p = 0.08). Analysis of SAH sub-groups, however, revealed that the 
immediate reperfusion group (i.e. SAH Group 3) was largely responsible for this deviation 
(Table 27). Thus, the Group 3 EC50 (9.2±2.3 pM) was significantly greater than that in 
SAH Group 2 (2.4±0.7 pM, p = 0.01); or than that in shams and non-operative controls (p 
= 0.002). Unfortmiately, no EC50 value was obtained fi'om SAH Group 1 for a more 
complete comparison: nevertheless, the difference was quite striking. SAH Groups 3 
differed from Group 2 in that normal reperfusion was restored immediately upon thread 
withdrawal after SAH induction: in SAIT Group 2, however, the clip was repositioned for 
up to 5 mins in response to an ICP re-rise (Part 4, 3.3). The fact that no significant 
right: left side differences were apparent in either group suggests that the difference
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between the two groups’ EC50 value does not relate to CCA re-clamping effects per se (i.e. 
to ipsilateral CCA ischaemia). It would seem more likely, therefore, that the ‘protective’ 
effect in SAH Group 2 related in some way to the vexed issue of the ‘ICP re-rise’, and 
what this actually represented (Part 6, Section I, 1.4). However, in view of the similarly 
increased NE EC50 after a type II pressor response {see below), one other possible 
explanation relates to the fact that SAH Group 3 contained a higher proportion of type II 
acute pressor responses (43%) than did Group 2 (27%): although this difference was not 
statistically significant (Table 22).
As aforementioned, the NE EC50 was also strikingly increased after a type II pressor 
response (15.3+5.0 pM) relative to either type I alone, or to types I & III in combination 
(Table 30); or to shams and non-operative controls (Table 28). If this is so, then it suggests 
that the type II acute pressor response is detrimental to NE responses. One likely 
explanatory factor here could be that of the higher AICP and ICPmax incurred (Pait 5, 
Section I, 1.3). Unfortunately, the experimental numbers from the type II and III groups 
were too small for this hypothesis to be conclusive. Nevertheless, put together, these sub­
group findings suggest that NE affinity in ‘responders’ may, in some cases, be significantly 
reduced after SAH. It is interesting, in this context, that a cadaver study has demonstiated 
specific a2 receptor damage in patients at various stages after SAH<)(i7_ Similar findings 
have also been reported for cerebral a l  receptors following cerebral trauma i^i*. It is 
certainly possible that these effects are the consequence of acute surges in catecholamines 
in response to SAH, since this may result in high-dose receptor uncoupling^'i (Part 3, 3.2). 
Whatever the fate of the EC50, however, it is clear that the NEmax continues to remain 
unaffected: indeed, the cunent evidence suggests that it increases with survival. Thus, 
maximal local NE concentrations will still achieve maximal responses in those vessels still 
capable: this is an important point {see below).
3.5.3 Implications o f NE heterogeneity for VSM
Intracranial adrenergic activation may arise in localized fasliion via two separate 
mechanisms: platelet-borne NE deriving from sequential clot lysis; and ipsilateral 
sympathetic denervation causing a delayed DSS (Part 3, 3.3). Both appear likely 
mechanisms after SAH, since both develop with some delay—the latter often being 
maximal after at least 5 days (Part 3, 3.3). Although functionally ‘denervated’ by being 
bereft of neui otransmitter (NE), copious amounts of NE, of coiu’se, continue to prevail 
locally within clot platelets. Can delayed super-sensitivity (DSS) occur with such a 
scenario? As described in Part 3, 3.3, the neuiotransmitter is not the only substance 
required to ‘subdue’ a target cell. Thus, in many cases, the co-release of a “trophic factor” 
along with the neurotransmitter occui’s to raise target cell threshold. Any depletion of the
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trophic factor, then, will cause DSS to the neurotransmitter in spite of the latter’s 
continued presence. Increased circulating catecholamines occuning 5-7 days after SAH 
would, thus, worsen these prospects^^^; and, furthermore, haemoglobin itself augments the 
NE response by a variety of mechanisms (Paif 1, 1.4 & Part 3, 1.3).
Any animal containing at least one NE-‘responder’ can potentially produce VSM in that 
vessel where VSM is mediated by contractile agonists acting via a  adrenoceptors 190,313,576 
The proportion of animals capable of producing VSM, therefore, includes both 
symmetrical and asymmetrical NE-‘responders’ (Tables 12-14). From the results of tins 
thesis, a maximum of 22/29 (76%) animals could develop VSM in MCAs after SAH under 
this scheme. However, only in those animals where both MCAs unequivocally respond to 
NE may VSM develop irrespective of clot localization (symmetrical responders. Tables 12- 
14)—if subarachnoid clot is assumed to represent the major source of the contractile 
agonist requiredi'^^. Thus, 12/28 (43%) animals could develop VSM irrespective of clot 
localization under this scheme.
VSM does not occur in every patient. Attempts to prognosticate development and severity 
of VSM aie, most commonly, based upon clot site and size^ '^ .^ Nevertheless, widespread 
anecdotal clinical evidence supports published findings that VSM often defies such 
prognosticatioirt^o, 583 x h e  correlation is therefore not perfect^ i^ :^ clot may be present 
without local VSM, and vice versa. As Fisher’s landmark study cleaiiy showed, VSM may 
be witnessed at some distance from the clot (Fisher’s cases 14, 17, 33, and 47) as well as 
being minimal or absent within it (Fisher’s cases 12,13, 16, 18, 25, 28, 29, 31, 34, 36-38, 
40, 42-46) i77_ In fact, VSM only occurs in 43-67% of cases of proven SAHi^^. Such 
disparities have been attributed to “individual differences” in cerebral arteiy 
susceptibility*53; however, no underlying mechanism has yet been proffered.
Clearly, it would be premature to extrapolate the above findings to the clinical scenario of 
delayed VSM. However, if it is assumed that NE heterogeneity—with possibly increased 
NEmax responses in survivors remaining—does persist into the period of delayed VSM after 
SAH; and if one assumes that NE acting at a  receptors is instmmental in VSM aetiology 
313,576. then exceptions to the ‘clot = VSM’ hypothesis can easily be explained. Thus, 
based on the results of this thesis, a maximum only of 75% animals would be capable of 
developing VSM under this scheme, irrespective o f clot size. Since, however, only 
bilateral ‘responders’ exist in 43% animals after SAH, only this proportion could sustain 
VSM irrespective o f  clot lateralization. It is interesting that this range—i.e. 43-76%—is 
comparable to that obtained from large epidemiological studies of clinical VSM^^ .^ 
Although such extrapolations are of dubious scientific merit, the underlying principle—i.e.
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that of a dichotomy of agonist response in MCAs—could easily explain exceptions to 
Fisher’s axiom. Furthermore, the decrease in NE affinity amongst some sub-groups after 
SAH would serve to localize VSM still further: since significant responses would only be 
expected in ar eas of higher agonist concentrations—i.e. within the clot itself.
3.5.4 Conclusions
The degree of NEmax heterogeneity, and NE-‘responder’ efficacy, remained generally 
invariant after SAH, although the NEmax continued to be significantly weaker than either 
the Kmax, 5HT max or the PGF2amax- The significantly increased NEmax at 3 hours, as with 
the similarly increased PGF2amax at this time, suggests that NE responses may be more 
efficacious with prolonged survival after SAH. The significantly increased EC50 in SAH 
Group 3, and the significantly increased EC50 after a type II pressor response, is difficult to 
accoimt for; however, one possibility is that it derives from the greater AICP and ICPmax 
experienced in these groups. Significantly diminished NE affinity in these cases suggests 
that SAH may be detrimental to a  adrenoceptors in some cases. Persistent heterogeneity 
provides a conceptual mechanism to explain exceptions to Fisher’s axiom where VSM may 
be mediated by NE acting at a  adrenoceptors. Diminished affinity in some ‘responders’ 
could explain why VSM is only apparent with high NE concentrations within the clot.
The singular existence of discontinuous response heterogeneity with NE precluded their 
use in demonstrating an absence o f ‘side bias’ in EF-SAH models.
3.6 HA responses
When acute SAH was superimposed against the backgroimd conditions of sham operation 
(Pait 2, Section II, 3.7), HA responses appealed diminished fuither still. This can be 
appreciated visually in the combined C-R curve of Fig 38. Nevertheless, neither the HA 
Emax nor the E C 5 0  significantly differed from sham values. Thus, at up to tliree hours after 
SAH, the major effect upon HA responses continues to relate to the underlying effects of 
‘sham operation’ upon non-operative control responses. It is entirely possible, however, 
that, with time, a fuifher (and perhaps significant) reduction in Emax—or increase in 
E C 5 0 —could ultimately be seen: futuie studies would be indicated to confirm or refute this 
hypothesis. Some support for the latter suggestion may be gleaned from the present thesis, 
where the HA Emax appeared to progressively decrease with survival: however, this did not 
prove to be statistically significant. A similarly insignificantly increased E C 5 0  value at 3 
hours also suggests this possibility (Table 30). Furthermore, the proportion of MCAs 
dilated >100% by HA progressively and significantly decreased from non-operative 
controls (52%), through shams (25%), to SAH Groups (11%) [p < 0.001; Table 6]: 
nevertheless, once again, most of this effect related to the effect of sham operation. Direct
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support for a continued significant reduction in HA responses after SAH is, however, 
already extant from some studies "^^ .^
Conclusion
Despite the trend suggested by the combined C-R cuiwes (Fig 38), and despite the highly 
significant ANOVA values across the control-sham-SAH series, HA responses aie not 
significantly affected by SAH at up to three hours. Furthermore, no significant differences 
were apparent either within SAH sub-groups, or between right and left sides within each 
sub-group. As with sham operative controls, the significant difference in HA Emax and 
EC50 with non-operative controls presumably, in some way, relates to either the trauma 
sustained (with SAH itself being included here) or to the prolonged effects of the 
anaesthetic agent used. Again, as with the ‘sham operative findings’, should it prove—in 
subsequent studies—that trauma represents the unifying mechanism, then this would justify 
analysing the role of HA2 blockers in such a setting in future studies.
The fact that no significant differences were found between right and left MCAs in 
response to HA suggests that EF-SAH models do not introduce any significant ‘side bias’ 
upon ipsilateral MCA reactivity by virtue of the potentially confounding combination: 1) 
unilateral carotid manipulation, 2) unilateral EF insertion or 3) potentially ipsilateral 
intracranial rupture.
* Excluding the two anim al’s anaesthetized by hyp norm and hypnovei did not alter these 
findings
3.7 PPV responses
PPV is being increasingly used locally to reverse VSM, particularly via the catheter at 
angiography^^, with diamatic improvements often being r e p o r t e d ^ ^ B ,  4 0 0 ,5 3 8 ,622, 6O8 
Nevertheless, PPV does not always work^ ,^ 89,365^ suitable responses perhaps being 
obtainable in around 50% of cases^^s Moreover, PPV may even cause adverse effects in 
this settingiii^, 391  ^many with direct relevance to the condition being treated. For example, 
the development of a severe immunologically-mediated thrombocytopenia^i ^  theoretically 
increases the risk of re-rupture in those cases still awaiting definitive surgery. However, it 
is with the development of TIAs that most concern is currently being v o i c e d 391
Detrimental effects with PPV have so far occurred in a total of 9 out of 68 (13%)iii^ VSM 
cases reported: these have included episodes of blindness^^, brainstem depressioirt^i, 
hemipai’esis*ii2,317 and seizure activity^^. In some cases there have been associated 
increases in ICP reported'ioii, this perhaps implying a failure of autoregulation. Although 
VSM may vary from an active vasoconstriction to one of a fibrotic non-
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compliaiice^*^^—thus explaining PPV’s effectiveness in some cases and not in 
others^^^—this hardly seems able to account for iatrogenic TIAs. Instead, it appears that 
intrinsic properties related to PPV itself are implied since other mechanisms, such as those 
related to the mode of administration, appear u n l i k e l y  293
The major featuie of PPV responses in the current study was that they remained as potent 
and efficacious after SAH as they were in either shams or non-operative controls. 
Furthermore, efficacy and potency were not significantly affected by either the degree of 
CCA re-clamping, the degree of survival, or by the type of acute pressor response sustained 
after acute SAH (Tables 24-30). These findings are not likely to surprise the majority of 
neurosurgeons. Thus, in the majority of cases, PPV completely abolished AT without 
disrupting background MT: induced VSMC levels of cAMP are, thus, likely to have 
remained unchanged across each group—irrespective of the procedure performed.
These results, although agieeing with the popular view (and with the recent findings of 
others i^i^), are significantly at variance from studies that have demonstrated a paradoxical 
vasoconstriction at certain PPV concentrations^^s, 521 por example, Jin et aP^  ^
demonstrated such constriction at 50 pM in cortical pial vessels of rats following pre­
constriction with a phorbol ester. At 100 pM, however, PPV caused a vasodilation much 
as expected. Jin et al hypothesized that such a biphasic response could be a possible 
explanation for poor angiographic-clinical correlates with VSM and, potentially, for the 
inadvertent development of aforementioned TIAs^^ .^
One obvious difference between the Jin et al’s study and the current one is that apparently 
smaller vessels were used in that study (30-70 pm). However, since the vessels in the 
former study were not exposed to intraluminal distension they would, of necessity, appear 
smaller anyway. Furthermore, such vessels would also possess little or no MT (Part 2,
2.2). It is also important to note that no ‘true’ SAH-model was utilized in the former study: 
a phorbol ester-induced constriction alone was considered to closely resemble VSM. In 
addition to creating a more physiological SAH, MCAs were pre-constricted in the cuirent 
study with PGF2a. The latter activates PKC in a similar fashion to that of a phorbol ester 
(Part 2, 3.5). Finally, significant differences in the bath temperature were apparent between 
the two studies. The temperatuie of 33°C used by Jin et ap93 was unphysiological: any 
results therefore obtained would therefore not be directly comparable to those produced at 
3TC.
In spite of these shortcomings, it was intriguing to have observed similar distuibances in 
the C-R curve at precisely the same (50 pM) concentration in the current study, both in
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control gi'oups as well as after SAH (Fig 41 A). Thus, a point of inflexion occurred in the 
otherwise sigmoid curve negating some of the relaxation acliieved at preceding, lower 
concentrations. However, in marked contrast to the previous study, the 50 pM anomaly did 
not amount to an actual vasoconstriction, but rather to a transient loss of efficacy. It 
amounted to a loss of about 10-15% of previously-dilated tone. Therefore, since dilation of 
AT was still extant, this disturbance cannot be considered as a possible cause for 
TIAs—although it occurs at intriguingly the same position on the C-R curve.
In support of the previous study, however, a small proportion (10-15%) of MCAs appeared 
to develop a definite—yet similarly transient—potentiation of pre-constricted tone at a 
[PPV] of 0.5 pM (Fig 41 B). The latter anomaly certainly could be classified as a 
‘paradoxical vasoconstriction’. However, the plateau of tone reached following PGF2a- 
induced constriction in many vessels was, like the prior baseline level, fluctuant (Figs 12 & 
19). Therefore, a precise quantification of this phenomenon was not possible. In the few 
cases where the 0.5 pM anomaly may assume some significance—i.e. in terms of 
magnitude and duiation—it is certainly possible that it may produce a TIA. However, it 
must be emphasized that this phenomenon was not widespread and, invariably, was 
extremely transient (i.e. seconds). Furthermore, it did not occur at the concentrations 
observed by Jin et al. In conclusion, then, the current findings do not generally support 
those of the aforementioned study.
Other possible causes for TIAs were, in tiun, considered. One putative mechanism 
concerns a differential dilation achieved dependent on vessel size. For example, where a 
vasodilator specifically acts at the microvascular level—leaving larger arteries 
unaffected—a vascular ‘steal’ may result where there exists an imdistendable, diseased 
segment. Thus, certain nitrosovasodilators such as dipyrhnidole (which specifically dilates 
the smaller coronary arteries) may, in fact, promote an episode of angina rather than 
alleviate it^ "^?. in spite of the fact that only MCAs were studied, a rather large range of 
vessel diameters was obtained; thus providing some scope for such investigation.
However, no definite relationship was, in fact, demonstrated between vessel diameter and 
PPV response obtained (Fig 42). This was also the case with PPV in systemic vessels of 
another s t u d y ^ - i n  consequence, a differential PPV-effect would not appear to be a likely 
mechanism for TIAs following PPV infusion. Interestingly, such differential vasodilation 
has also been observed with nimodipine in cerebral vessels^i- ^ 4^; and a recent case report 
also appears suggest that some degree of this might have occurred with PPV i^i .^
A finding fiom the current study that much more likely explains the occasional episode of 
TIA with PPV concerns the proportion of MCAs where PPV dilated MT in addition to all
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AT (i.e. in those MCAs where Emax>100%). As can be seen from the normal distribution 
of SAH vessels (Fig 40), the right-hand tail reflects those vessels (n = 17, 33%) where—at 
least in principle—a dysautoregulation may occur in vivo: however, this would be 
particularly significant in approximately 15%. The significance obviously depends on the 
relative influence of MT which was, in turn, assessed at 40% in non-operative controls of 
the current study (Pait 5, Section II, 1.13). Thus, in MCAs where PPV dilates >130% of 
pre-constricted tone, a 50% reduction in MT will result, this causing considerable increases 
in flow in vivo (Part 2, 2.4).
Potentially, the effect of PPV on systemic pre-capillary vessels can reveal exactly what 
can be expected within cerebral vessels when such tone is also abolished. The latter 
vessels serve to maintain intiacapillary pressures close to 15 mmHg (Part 2, 2.5),
However, PPV is regularly used experimentally to paralyze such vessels^o?—after which 
intracapillary pressures of up to 36 mmHg may be seen. Under such circumstances, 
large amounts of plasma can be transudated as oedematous fluidio?; whilst high 
intravascular pressures threaten architectural disruption (Part 2, 2.5). It is conceivable, 
therefore, that such a powerful mechanism could easily underlie the precipitation of a TIA 
with PPV were this to also occur within the cerebrovasculature. That PPV infusion has 
caused both excessive vasodilatioiflu as well as I C P - e l e v a t i o n ^ o o  in some studies, is 
supportive of this assertion. Moreover, given the possible interaction with SNP, a PPV- 
SNP combination would seriously threaten this complication when both agonists may be 
present in significant concentration: as, for example, during aneurysm surgeiy.
Conclusion
This study thus re-afftrms PPV as a powerful and potent vasodilator of major cerebral 
arteries such as the MCA. However, when MT is additionally dilated (approximately 15% 
vessels) cerebrovascular dysautoregulation may ensue, and threaten capillaiy perfusion. 
Should the pre-capillary sphincters themselves also prove susceptible (as they aie within 
the systemic circulation), then TIAs could follow systemic surges in MAP. However, since 
in the majority only non-MT is affected (i.e. only superimposed AT), this would explain 
why approximately 50% of patients show clinical improvement with PPV i^i ,^ 4oo- and why 
such improvement occui's without complication (because autoregulation itself remains 
intact). Two other possible mechanisms, however—that of a low-dose (0.5 pM) 
paradoxical vasoconstriction, and that of a vascular ‘steal’—camiot be ruled out from the 
present study; although both appear unlikely. A prolonged and powerful constriction at 50 
pM^^3, as promoted by Jin et al, can be ruled out; since this was not observed in any 
experimental group. Nevertheless, the transient loss of efficacy observed at 50 pM 
requires fuither study and explanation.
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The fact that no significant differences were found between right and left MCAs in 
response to PPV suggests that EF-SAH models do not introduce any significant ‘side bias’ 
upon ipsilateral MCA reactivity by viitue of the potentially confounding combination: 1) 
unilateral carotid manipulation, 2) unilateral EF insertion or 3) potentially ipsilateral 
intracranial rupture.
3.8 L-ARG and L-NAME responses
NO is produced by NOS using L-ARG as substrate. The major form of NOS within the 
vasculatine is the constitutive variety, cNOS, occurring within endothelial cells. However, 
other sources include VSMCs and adventitial nitroxidergic neurones. The NO produced 
acts as the substrate for GC within VSMCs (Part 2, 3.5 & Paif 3, 1.8 ): as a result, VSMC 
relaxation occurs following an increase of intracellular cyclic guanosine 3’,5’ 
monophosphate (cGMP) and subsequent PKG activation.
NO is inferred to be co-released with tonic activity in systemic arteries, both in vivo and in 
vitro75,502 Thus, co-inhibition of NO release during AT results in increased AT. Such co­
inhibition has been used to explain pathologically increased tone, such as that observed in 
h y p e r t e n s i o n ^ 7 2 ^  prinzmetal’s angina and in atherosclerosisi^*’. The common initiator in all 
of these cases is assumed to be that of endothelial dysfunction. It has also been suggested 
that inhibition of ‘basal’ NO release is responsible for the occurrence of VSM following 
SAH. Whilst endothelial dysfunction may similarly be responsible here, another possibility 
would also include NO-scavenging by the surrounding clot^ 44, in, 325 _ Several studies have 
documented evidence for both mechanisms, although most favour the latter^'11. 
Alternatively, some have demonstrated that the smrounding clot directly affects GC 
activity within the VSMCs themselves. Whatever the case, inhibition of basal NO release 
by L-NAME in the current study elevated effective AT by approximately 26% (Part 5, 
Section II, 1.10).
In the current study, L-ARG efficacy was significantly increased after SAH compared to 
shams and non-operative controls. Observation of the C-R curve Fig 44 suggested that the 
EC50 might also be significantly affected: however, no significance was demonstrated on 
ANOVA. Obseiwation of the combined frequency histogram in Fig 43 shows that the 
proportion for which E,nax>100% is significantly greater after SAH (32%) than in shams 
(6%) or non-operative controls (9%: p<0.05). Thus, maximal [L-ARG] may threaten 
dysautoregulation in a proportion of MCAs after SAFI, in a similar fashion to that deduced 
for PPV and HA {see above). Tins is important, because increased NO production has 
frequently been observed following ischaemia and ischaemia-reperfusion insults486. One of 
the perceived raison d'êtres for this effect relates to beneficial vasodilatoiy effects within
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the ischaemic penumbra. The results of the current study suggest that the L- 
ARG-^NOS->NO->GC—>cGMP sequence may be more efficacious in this role after SAH.
Significantly enhanced L-ARG efficacy in overall SAH groups, and significantly enhanced 
affinity in n = 26 animals from SAH Groups 2 & 3 {see below), suggests that the L- 
ARG->NOS—>NO->GC“>cGMP pathway is in some way stimulated acutely after SAH. 
This is a remarkable finding, because it completely contradicts the plethora of reports that 
demonstrate that this pathway is inliibited. This dichotomy of evidence may derive fi om 
the fact that most models used in SAH studies are type II models (Part 4, 1,2); thus, they do 
not create a truly ‘physiological’ ictus. However, another key difference is that such 
studies have not examined responses in the acute period; whilst the current study, in tm*n, 
has not examined the delayed period following a physiological ictus. Thus, it is entirely 
possible that an acute early activation might become translated into a depressed one several 
days after the acute ictus: further studies would be indicated to confirm or refute this.
One possible explanation for L-ARG-^NOS->NO->GC^cGMP pathway activation after 
SAH is that of cNOS activation. The most likely tissue som'ces for increased cNOS 
production or activation would include:
• MCA endothelium
• MCA VSMCs
• MCA adventitia—fibroblasts and/or myofibroblasts
• Perivascular glial tissue
• Perivascular neurones (particularly nitroxidergic neurones)
Numerous studies have confirmed that an early activation of the L- 
ARG—>NOS-^NO—>GC->cGMP pathway with ischaemic or ischaemia-reperfusion 
injuries most frequently relates to cNOS activation. If this is so, then current evidence 
suggests that this ‘early’ response is predominantly ‘neuroprotective’486. Thus, with 
ischaemic or ischaemia-reperfusion injuries, excess consitutively-released NO ameliorates 
penumbral zone ischaemia via vasodilatory and anti-platelet aggregatoiy functionsis^. 
Another neuroprotective mechanism would be that of nitrosoyl inliibition of 
glyceraldehyde-3-phosphate dehydrogenase function, which would lead to a diminished 
lactate production'll^. A further ‘protective’ mechanism still may concern NG’s role in 
stabilizing mast cells^oi- ^ 89 have already noted that such cells are curiously prevalent 
around sites of anemysmal rupture (Part 2, 1.4.2), as they ai-e also within coronary 
atherosclerotic plaques where they are thought to mediate plaque rupture^of NO-mediated 
mast cell stabilization may therefore prevent MC dischar ge of lytic agents; as well as 
ameliorating the effects of MC-induced ischaemia-reperfusion i n j u r y ^ *2,3i3_ Either way.
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cNOS activation is thought to result from ischaemia-induced calcium mobilization, 
although nitroxidergic neuronal activation would also achieve this^^ .^ Whatever the 
mechanism, the current results clearly suggest that greater MCA dilation will result with L- 
ARG acting as substrate. It is interesting, in this regard, that increased CSF L-ARG levels 
are apparent after SAH304 However, for cNOS activation to be tenable, we would have to 
accept that:
• Acute SAH in some way triggers widespread calcium mobilization (c.f. head injury)
• The ‘calcium trigger’ deriving Ifom SAH continues within the MCA wall into and 
throughout the period of myography
Clearly, the current study cannot provide sufficient evidence to speculate further upon 
either of these requisites: future studies would be indicated instead.
Another possible explanation for L-ARG—>>NOS->NO->GC^cGMP pathway activation is 
that of de novo /NOS production within the vessel wall (Part 3, 1.8). Most studies have 
suggested that /NOS activation is characteristically delayed, since changes in genetic 
transcription are implied. However, it must be remembered that MCAs were immediately 
transferred to a bath at normal body temperatures containing PSS: thus, a continued 
incubation of MCAs already genetically ‘switched-on’ is conceivably possible here.
Support for the latter possibly derives, in the current study, from the trend toward increased 
Emax at 2 and 3 hours’ survival—only these values differed significantly from sham 
operative or non-operative controls (Table 29, Appendix). Further support may also derive 
from the fact that L-NAME efficacy remained invariant after SAH; whilst L-ARG efficacy 
was increased (Table 28, Appendix). This result suggests that an alternative source of 
NOS has been created by SAH that is not tonically released. However, in reality this extra 
source may equally as likely represent cNOS as /NOS: in fact, no results from the current 
study can further aid in differentiating this ‘extra’ NO source.
/NOS can only be activated by endotoxin or cytokine stimulation (Part 3, 1.8). It is clearly 
possible that operation could have introduced Gram negative bacteria into the rat’s internal 
milieu, and so elaborated endotoxin. One such source could be that of the plastic camrulae 
used for arterial or intracranial pressure monitoring. Another source is that of the 3/0 
Prolene® thread inserted into the ICA: especially on those occasions where the same 
thread was used in different animals. However, all of these materials were—as with the 
operative instruments—regularly cleaned with detergent and, just prior to surgery, cleaned 
with sterile alcohol wipes and allowed to dry. Furthermore, sham operative animals 
underwent exactly the same manoeuvres excepting intracranial arterial rupture. The 
current results therefore tend to implicate, a priori, cytokines rather than endotoxin as the 
trigger towai'd putative /NOS production. It is interesting in this regard that several studies
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have demonstrated the presence of cytokines within the CSF of SAH patients^^?, 443 
Furthermore, Beasely et al demonstrated that interleukin-1 lead to a prolonged L-arg- 
dependent increase in cGMP production in rat VSMCs^^, whilst Smith et al have directly 
demonstrated interleukin-1 within human cerebral vessels after SAH555. Circumstantial 
evidence for central cytokine liberation is also extant in the form of the prolonged central 
pyrexiai^2, sis ^nd drowsinessi^^, 396 that is frequently observed in SAH patients (Part 1,
1.1.2). Such /NOS activation is usually harmful and delayed (Part 3, 1.8), and will be 
discussed later (Part 6, Section III). However, to reiterate: the current study cannot 
attribute enhanced L-ARG efficacy— in the presence of unchanged L-NAME 
efficacy—to either cNOS or /NOS activation.
SAH sub-group analysis revealed that the failure of SAH L-ARG EC50 to attain overall 
significance was largely due to the confounding effects of SAH Group 1 (Table 27, 
Appendix). Thus, when the remaining overall SAH EC50 from Groups 2 and 3 was re­
assessed—with Group 1 excluded—statistical significance was obtained against shams and 
non-operative controls. It therefore seems that SAH Group 1 in some way obtunded the 
general effect which, overall, SAH had activated in MCAs {see 3.9 below). The possible 
explanation for this confounding effect must relate to one or more of the following factors:
• Prolonged unilateral CCA re-clamping (1-2 hours) and potential unilateral ischaemia
• Repeated ICP re-rises (the raison d ’être for re-clamping)
• Early mortality (100% in Group 1)
• Protective effect of type I acute pressor response (75% in Group 1)
• Small experimental group numbers distorting statistical significance
It is interesting that a procedure normally associated with NOS induction—i.e. carotid 
ischaemia—might be, when combined with acute SAH, conceivably ‘anti-NOS inductive’. 
However, the evidence that CCA clamping—for even 1 -2 hours—in rats necessarily incurs 
ischaemia is not convincing. Thus, studies that use rats as a substrate for car otid ischaemia 
invariably co-administer profound hypoxia in order to achieve this result^io, since the CoW 
in rats is amongst the most completely developed of the animal kingdom. Moreover, the 
Sheffield Model demonstrated that CCA clamping did not significantly affect ipsilateral 
CBF and, more specifically, concluded that “. ..perfusion in the distribution of the 
ipsilateral MCA territory is not affected by clipping the CCA on the ipsilateral side” ^ 25. 
Finally, Rosenblum has demonstrated, in an in vivo pial model, that vasoreactivity to 
agonists similar to those used in the current study was not affected by CCA ligation for 
periods of up to 6 hours^i^ Such findings endorse the findings of insignificant side 
differences in the current study (Tables 24-26, Appendix) and suggest that the degree of 
CCA clamping utilized in SAIT Group 1 did not alter ipsilateral vasoreactivity. It seems
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unlikely, therefore, that carotid ischaemia could have been responsible for the 
‘normalizing’ effect upon SAH-induced increased L-ARG efficacy.
In contrast, the possibility that early mortality was responsible seems—at least 
superficially—more attractive. For example, /NOS activation {see above) probably requires 
changes in genetic transcription, which would take some time to evolve: death within 1-2 
hours could, conceivably, have arrested this process. As a result, no increased L-ARG 
efficacy would have been expected to have been observed, despite the presence of the 
‘adequate stimulus’ in the form of acute SAH. However, as aforementioned, MCAs were 
immediately expropriated to an oxygenated PSS bath that could easily have permitted a 
continued incubation for a period of several hours (Part 4, 6.1).
The possibility that the ‘noimalizing’ effect of SAH Group 1 on L- 
ARG“ >NOS->NO->GC->cGMP pathway activation after SAIT related to repeated ICP re­
rises after attempted reperfusion is also difficult to entertain conceptually. Transient 
disturbances in CBF and CPP notwithstanding, such episodes would hardly be long enough 
to constitute ‘ischaemia-reperfusion’ injuries. However, they may be short enough to have 
constitute ischaemic pre-conditioning: interestingly, NO—from cNOS as source—has 
recently been implicated in this role (Par t 2, 2.6.2). Repeated re-bleeds, on the other hand, 
would more feasibly be detrimental, since these would imply a greatly magnified stimulus 
than that of a solitary SAH-with-reperfusion. However, as is discussed in Part 6, Section I, 
1.4, an ICP re-rise may not necessarily imply a re-bleed: it may also reflect an acute 
cerebrovascular engorgement. The occurrence of the latter phenomenon, in the acute 
setting of SAH at craniotomy, has been succinctly described by West^^i An acute 
cerebrovascular engorgement could be ‘protective’ in SAH by, tamponading SAH with a 
smaller Ve; and by holding vessels ‘open’ thus preventing no-reflow phenomena.
It seems most likely, then, that a small statistical group number—combined with a 100% 
gi’oup mortality—represented the most likely source for the confounding effects of SAH 
Group 1 on a significant increase in L-ARG affinity after SAH. However, one other 
possibility deserves serious consideration: 75% of Group 1 animals experienced an acute 
pressor response type I. Interestingly, this pressor gi'oup yielded an Emax that was 
statistically insignificantly different from shams and non-operative controls: the major 
overall ‘SAH effect’ instead deriving from acute pressor response types II and III (p = 
0.0001 : Table 30). Thus, it is entirely possible that the type I acute pressor response 
represented the ‘protective’ effect of SAH Group 1. If so, then the staunching of SAH at 
lower cerebrovascular shears, and lower cerebral compressive strains, seem somewhat 
convenient explanations.
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L-ARG affinity was significantly increased in the 1 and 3 hour survival gioups, but 
unchanged fiom either shams or non-operative controls in the 2 hour group (Table 29, 
Appendix). The major featm*e of the 2 hour sui’vival group was that 4/8 (50 %) animals 
derived from SAH Group 1. We have already seen that this group presents many features 
of a ‘statistically separate’ group from other SAH sub-groups. It would therefore appear 
that the unchanged affinity of the 2 hour sub-group reflects the undue influence of SAH 
Group 1 upon the general trend toward an increased L-ARG affinity after SAH.
No statistically significant trend was demonstrated in either E,nax or EC50 values across 
acute pressor response groups (Table 30). Nevertheless, the trend in Emax is nearly 
significant and, when type II & III acute pressor responses are considered together their 
combined value (101+5 %) is significantly different fiom type I (85+4 %: p -  0.02). 
Furthermore, the type I Emax does not significantly differ from either shams or controls, 
whereas the type II & III response does so with a high degree of significance (p = 0.00005). 
Because the type II & III arterial pressor response groups suffered a significantly higher 
AICP than those of type I, there is some justification in treating these gi'oups separately. 
With such a high degree of significance, it would seem likely that the increased 
cerebrovascular shear' experienced with the former groups was a factor in their significantly 
increased Emax values. If this is so, then it constitutes a major finding in the cmrent thesis, 
since it strongly suggests that the acute physiological disruption does indeed exert a direct 
and significant effect upon cerebrovascular reactivity that is clearly contradictory to current 
results emanating from ‘clot-VSM’ (i.e. type II) SAH models.
Conclusion
L-ARG efficacy is significantly increased after SAH as compared to shams and non­
operative controls. Furthermore, a significantly greater proportion of MCAs are dilated 
beyond baseline MT after SAH than in shams or non-operative controls. If SAH Group 1 
is excluded, L-ARG affinity is also significantly greater after SAH than in shams or non­
operative controls. A similar effect is seen with survival, where the 2 hour 
group—disproportionately represented by SAH Group 1 (50 %)—does not differ from 
shams or non-operative controls; whilst the 1 and 3 hour group (in which no SAH Group 1 
animals occur ) did so. Overall, such results suggest an activation of the L- 
ARG—>NOS->NO-^GC->cGMP pathway. Such activation could derive from either 
cNOS or /NOS activation. Currently, cNOS activation is thought to be ‘early’ and 
‘neuroprotective’ with cerebral insults; /NOS ‘delayed’ and hamlul. The results from the 
present study suggest that L-ARG will lead to greater vasodilation of MCAs after SAH: 
this may prove beneficial in the reperfusion of ischaemic penumbras, and in offsetting post- 
SAH no-reflow phenomena. Increased L-ARG efficacy, in the presence of unchanged L-
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NAME efficacy, suggests that the alternative soui’ce of NOS produced after SAH is not 
tonically released.
Significantly increased L-arg Emax after SAH appears specifically restricted to 
animals exhibiting a typell/III arterial pressor response. Significantly increased L- 
arg Emax after SAH also appeared more likely in ‘survivors’. If this is so, then it 
constitutes a major finding in the current thesis, since it strongly supports the 
principle hypothesis that the acute physiological disruption exerts a direct and 
significant effect upon cerebrovascular reactivity that is independent of later chronic 
clot lytic effects. Both of these effects were reiterated with SNP (see below).
The fact that no significant differences were found between right and left MCAs in 
response to L-arg also suggests that EF-SAH models do not introduce any significant ‘side 
bias’ upon ipsilateral MCA reactivity by virtue of the potentially confounding combination:
1) unilateral carotid manipulation, 2) unilateral EF insertion or 3) potentially ipsilateral 
intracranial rupture.
3.9 SNP responses
Further evidence from this study that the L-ARG->NOS->NO“ >GC”>cGMP pathway had 
become activated after SAH derives from the results with SNP. Thus, both the efficacy 
and affinity of SNP were significantly increased overall after SAH in relation to either 
shams or non-operative conti'ols (Table 28). This fact can be appreciated in both the 
combined fr equency histogiam of Fig 45, and the combined C-R curves of Fig 46. 
Furthermore, similar to L-ARG, the prolonged CCA re-clamp group (i.e. SAH Group 1) 
appeared to obtund the increase in both efficacy and affinity that, overall, SAFI othei-wise 
produced (Table 27, Appendix). Thus, by excluding SAH Group 1, the significance of 
these values over shams and non-operative controls was increased further still.
Once again, no significant side differences were found within SAH Group 1 (nor, indeed, 
were any side differences demonstrated in either Group 2 or 3 for that matter: Tables 24- 
26, Appendix). This, superficially a least, suggests that the obtunding effect did not relate 
to the unilateral elamping per se. However, the n numbers here were even smaller still (n = 
3 MCAs on each side), so this deduction cannot possibly be conclusive. Nevertheless, it 
does prompt one to sti'ongly consider other explanations, as discussed previously with L- 
ARG (see 3.8 above).
As with L-ARG responses, a trend toward increased SNP efficacy with prolonged sui'vival 
after SAH was apparent, although not of statistical significance (Table 29, Appendix).
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Further studies would be required to confirm whether or not this trend continued to 
significantly increase outwith the arbritary three hour period. SNP affinity, however, was 
significantly increased after a type II or III acute pressor response relative to either a type I 
response, or shams and non-operative controls (Table 30, Appendix). This suggests that 
most of the ‘SAH effect’ upon SNP affinity relates primaiily to the invariant and Cushing 
hypertensive responses: the type I response appears ‘protective’. This is an interesting 
observation because, as was seen above, the type I pressor response also appeared 
‘protective’ toward the L-ARG Emax—maintaining its equivalence to both shams and non­
operative controls. Again, as with the latter finding, we may speculate that the staunching 
of SAH at lower cerebrovascular shears, and lower cerebral compressive strains, were 
important contributors in this regard.
3.9.1 Therapeutic implications for SNP after acute SAH
Hypertension is clinically apparent in the eaiiy post-acute period. This is most likely due to 
either pre-existing hypertension, or to nociceptive afferent stimulation deriving from the 
meninges, in a fashion after Stoner^^  ^ As has already been noted, increased levels of MAP 
at this junctui'e may be detrimental, in spite of the fact that they may represent a mechanism 
to re-open a closed micro vasculature i ^ 2, Several other aspects of SNP’s effects may in fact 
prove beneficial in this context. Firstly, SNP is more efficacious toward cerebral vessels in 
the early hours after SAH. As a result, SNP may augment autoregulatory dilation of the 
cerebro vasculature at the lower limit of the MAP range. Fui’thermore, by virtue of its 
anti-platelet and fibrinolytic effects (Part 3, 1.8 & 1.10), SNP may also serve to protect 
against NRP; whilst its mast cell stabilizing properties may also limit ischaemia- 
reperfusion injuries, as well as—potentially—re-rupture.
T able 8. Therapeutic possibilities for SNP after acute SAH
Pharmacological property Therapeutic protection offered
Antihypertensive Vulnerable microcirculation
Re-rupture
Antiplatelet No-reflow phenomena
Fibrinolytic No-reflow phenomena
Reduce clot size - offset vasospasm
Mast cell stabilizing Ischaemia-reperfusion injury
? Re-rupture
The fact that no significant differences were found between right and left MCAs in 
response to SNP suggests that EF-SAH models do not introduce any significant ‘side bias’ 
upon ipsilateral MCA reactivity by virtue of the potentially confounding combination; 1) 
unilateral carotid manipulation, 2) unilateral EF insertion or 3) potentially ipsilateral 
intracranial rupture.
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S E C T I O N  I I I  
C o n c l u s i o n
The endovascular filament (EF) model used in this study created a SAH that closely 
resembled the clinical scenaiio. This is not the ease with the vast majority of models 
currently employed. Although others have also begun to use similar models^o, 4i, 236,302  ^ no  
EF-SAH study has simultaneously analyzed isolated cerebral vasoreactivity: the 
current study appears to be the first to do so. Moreover, isolated cerebral 
vasoreactivity was analyzed in this study in all cases immediately upon animal 
sacrifice: no vessels were fridge-kept for use on subsequent days. The SAH produced 
in this study was frequently severe, both in terms of Vg as well as in terms of the 
significant mortality (42%) incurred. It is curious that many might see such a mortality as a 
potential weakness of the model used, given that SAH is a significant cause of sudden 
death c l i n i c a l l y  120, 374,472 x^us, between 40-50% patients with SAH may die before 
reaching hospitaF^?, More specifically, Bederson et al recently recorded a similar early 
mortality (57%) in an experimental SAH study using endovascular filament rupture in 21 
rats'll. A similar figure (50%) was also recorded in an earlier study with 22 rats; in that 
study, 25% of early mortality occuired within the first two hours^ .^ In one other study, a 
16% mortality was observed within the first hour following basilar artery rupture in 94 
rats202. Finally, in the previous study from the author’s laboratory—in which the same 
endovascular filament model was used as in the current study—a 53% mortality was 
recorded at three hours in 43 rats^^s xhe plethora of cuiTent SAH models (in reality, ‘clot- 
VSM’ models: Part 4, 1.2), therefore, that deliver survival rates in excess of 90% into the 
first week—whilst certainly being efficient in terms of experimental loss—utterly betray 
the reality of the acute ictus.
The potential devastation of the acute ictus, then, is obviously a factor completely 
overlooked by cun*ent ‘clot-VSM’ (i.e. type II) SAH models. Potentially, then, factors 
associated with the acute ictus might go someway toward explaining why type II models 
fail to deliver clinically usefiil information. By showing that, in the current study, MCAs 
from ‘survivors’ differed significantly Ifom shams and controls—at least In some of their 
physio-pharmacological properties—then at least one possible explanation for the current 
failings of type II models might, therefore, be advanced. Thus, the vessels subjected to 
chronic clot lysis in type II models are indistinguishable fiom controls, when—as the the 
current results clearly suggest—vessels fiom ‘survivors’ of an acute ictus are significantly 
‘altered’ fiom controls. Because it is eminently conceivable that other differences will also 
subsequently be found with other agonists, it seems likely that type II models might be 
fundamentally flawed because they do not commence study from the correct ‘baseline’.
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The current results, therefore, suggest that chronic ‘clot lytic’ effects ought to be 
superimposed upon cerebral vessels that have been significantly altered from controls by 
vitrue o f  ‘acute ictal ’ effects: they should not be merely superimposed on vessels 
indistinguishable from controls. The principle hypothesis of the current thesis is therefore 
endorsed: i.e. that events associated vyith acute SAH elicit changes in MCA physio- 
pharmacology that are independent of chronic clot lytic effects; but which may, 
nevertheless, subsequently interact with the latter effects to potentially explain both 
delayed VSM and DCL
Notwithstanding, by noting that ‘survivors’ significantly differed from shams and controls, 
at least one potential conundrum immediately arises. Thus, it could be reasoned that 
responses obtained from ‘non-survivors’ ought to be even more altered than ‘survivors’; 
because—it could be natuially presumed—the acute ictus in ‘non-survivors’ might have 
been more ‘extreme’ than with ‘survivors’. Notwithstanding, several rational explanations 
can immediately be advanced to counteract this conjecture. Firstly, in animals dying 
acutely, it is conceivable that insufficient time could have elapsed for the processes 
required in generating the physio-pharmacological alterations to have become established. 
Secondly—and probably far more likely—these very processes may subsequently have 
become negated by the secondaiy effects that the acute ictus has subsequently wreaked: in 
particular, the secondary confounding effects of a hypotensive state (i.e. SCC) upon MCA 
reactivity225. Finally, it proved extremely difficult—if not impossible to identify any 
parameter that correlated with the concept of ‘severity’ of SAH in this study. In particular, 
neither the Ve (Part 5, section I, 2.1)—nor the AMAP or AICP (Table 22, Appendix; Part 5, 
section I, 1.4)—appeared to correlate with ‘survival’ or acute mortality in this thesis.
In addition to the potential importance of ictal ‘survivors’ in explaining the current 
scientific failure of type II models, another factor also relates to the dichotomy of acute 
arterial and intracranial pressor response obseiwed after SAH—with it’s subsequent effect 
upon acute cerebrovascular reactvity. Indeed, a major distinction in the current results 
from those described by others relates to the fact that a massive AICP—with a 
correspondingly high ICPmax and a CHR—proved extremely rare (6%). In fact, the 
opposite response—an acute hypotension—was the most fr equent observation (63%): with 
an invariant response making up the remainder. Interestingly, the acute pressor response 
observed conelated with the extent of the ICPmax and, therefore, with the AICP. More 
specifically, acute hypotension correlated with lower AICPs, whilst a CHR was only 
observed at AICPs over 65mmHg. The latter finding, in fact, is compatible with previous 
f i n d i n g s  114, i is, iso ^nd suggests the presence of centml pressure (or mechano-) receptors 
which are only triggered at, or above, such an AICP.
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Of particular' importance to the centr al hypothesis of the current study, however, was the 
correlation of the type of acute AMAP/AICP observed with significantly altered 
vasoreactivity to certain agonists. In particular', significantly increased L-arg Emax after 
SAH appeared restricted to a typell/III aiferial pressor response, whilst the type I response 
did not significantly differ from shams or controls. Impor-tantly, this fact remained so even 
after allowing for ‘survivors’ and ‘non-survivors’ within this category (indeed, there was 
no correlation between the acute pressor response and mortality in this thesis: Table 20, 
Appendix). Thus, the type I response appeared to exert a ‘normalizing’ effect upon an 
otherwise overall ‘drive’ of acute SAH toward eliciting a significantly increased L-arg 
Emax- One potential explanation for this effect relates to the known effect that endothelial 
shear stress has upon the cerebrovasculature under normal circumstances: i.e. the ‘tonic’ 
release of NO basally^^’ Thus, given that the endothelial shear is likely to be much 
greater after a type II/III response (where both MAP and ICP are significantly gr'eater [Part 
5, Section I, 1.3.1; also see Fig 9]) than after a type I response, it is conceivable that this 
mechanism may have been ‘up-graded’—and rendered somewhat more persistent—as a 
result of the acute ictus. Notwithstanding the precise mechanism, however, the dichotomy 
of acute AMAP/AICP after SAH demonstrates another factor—i.e. distinct fiom that 
determining acute mortality—associated with the acute ictus that is able to alter MCA 
reacitivity from that of shams and controls.
Moderate acute AICPs and negative AMAPs—as evidenced with a type I arterial pressor 
response—also appeared to be associated with potentially ‘beneficial’ effects towards other 
agonists. For example, similar ‘normalizing effects’ were also seen with the EC50 values of 
SNP, 5HT and NE (see below) which also significantly differed from controls after SAH 
only with a type II/III pressor response. Nevertheless, as aforementioned, the type I arterial 
pressor response did not appear' prophylactic toward an eventual SCC—and, therefore, 
toward an acute mortality. In fact, SCC was equally as likely irrespective of the precise 
acute pressor change that preceded it (Table 20, Appendix). It would seem, therefore, that 
SAH per se—irrespective of arterial and intracranial tensions created—is peculiarly prone 
to producing cardiovascular dysfunction. Furthermore, the frequent occurrence of SCC in 
the absence of a CHR (94 % in the cuiTent study) must necessarily implicate non- 
adrenergic mechanisms in this response—a conclusion that is clearly contrary to cuiTent 
neurosui'gical dogma (Part 1, 1.3.2.1). It would seem, therefore, that cardiovascular 
dysfunction after SAH may not necessarily coiTelate with cerebrovascular dysfunction.
The finding that L-arg Emax is significantly increased after SAH suggests the L- 
ARG^NOS-^NO-^GC—>cGMP pathway is activated acutely after the acute ictus; this is
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completely contradictory to a majority of extant publications "^ "^ ’^  ^ However, it 
must be remembered that the cuiTent results only pertain to the first tliree hours after SAH: 
thus, it is entirely possible that the acute findings could ultimately become reversed 
clii'onically. Notwithstanding, an acute early activation of the L- 
ARG->NOS->NO-^GC-^cGMP pathway—which most fiequently relates to cNOS 
activation—is currently believed to be ‘n e u r o p r o t e c t i v e ’486_ por example, with ischaemic 
or ischaemia-reperfusion injuries, excess consitutively-released NO ameliorates penumbral 
zone ischaemia via vasodilatoiy and anti-platelet aggregatory effects4S6; diminishes lactate 
production via nitrosoyl inhibition of glyceraldehyde-3-phosphate d e h y d r o g e n a s e 4S6 ; and 
stabilizes mast cells (thereby off-setting reperfusion injmy)20L 389 cNOS activation is 
thought to result from ischaemia-induced calcium mobilization, or to nitroxidergic 
neuronal activation486. By whatever mechanism, the current results suggest that this 
pathway is more efficacious after SAH. The increased proportion of MCAs where L-ARG 
Emax >100% may, in addition, explain the degree of vasoparalysis that is sometimes 
observed after SAH (particularly in the poorer clinical grades)^^?, 453—and the increased
CBY that may be recorded in c o n s e q u e n c e 222-224
Nevertheless, it is not easy to see how such acute findings (i.e. with L-arg Emax) might 
ultimately become reversed chronically; to thus become compatible with results from ‘clot- 
VSM’ models '^*'^ ’ One potential explanation, however, derives fiom
consideration of an alternative explanation for the mechanism of enhanced L-arg Emax in 
the cui'rent study. Thus, one other explanation for L-ARG->NOS-^NO->GC->cGMP 
pathway activation is that of de novo zNOS production within the vessel wall (Part 3, 1.8). 
The combination of /NOS-NO with other toxic agents, such as free radicals (e.g. with 
superoxide leading to peroxynitrite formation^^—a potent liberator of further fiee radical 
formation: Part 3, 1.8), may result in the progressive inhibition of VSMC metabolism. 
Interestingly, haemoglobin—i.e. such as released during chronic clot lysis—can augment 
cytokine-mediated /NOS production within VSMCs^?^, Since VSMC levels of ATP and 
GTP are known to be depleted following the mere application of surface blood to cerebral 
vessels^33  ^the effects of /NOS (Part 3, 1.8) may therefore be exacerbated. If so, then a 
cellular metabolic exhaustion could result, and lead to a ‘rigor-type’ increase in VSMC 
tone566 (Part 2, 3.3). Such a mechanism is clearly compatible with the myonecrosis that 
accompanies VSM204-206 (Part 1, 1.3.1.2). Because, in large numbers of VSMCs in this 
state, acto-myosin bonds would be permanently engaged (Part 2, 3.3), such vessels would 
appear rigid, contracted and h y p o - r e s p o n s i v e 4 2 2 , 6 2 3 , 655  However, because myonecrosis 
is typically patchy, a partial responsiveness to both contractile agonists and vasodilators 
would also be expected422. The production of a ‘ latch-state’ as a consequence of a clot- 
product/NO interaction could, therefore, account for cases of ‘irreversible’ VSM observed
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clinically. Such reasoning therefore provides a mechanism that potentially links acute 
changes in post-SAH MCA reactivity (as found in this thesis) with the subsequent effects o f  
chronic clot lysis (not analyzed in the current thesis).
The current results suggest that relatively modest ICPmax:MAP ratios—perhaps only in the 
range 40-60%—are required to staunch SAH (Part 6, Section I, 1.4.3). If this is correct, 
then it suggests that ratios in excess of this—as are necessarily indicated by a type II & III 
response—may be unnecessary; and, possibly, detrimental. Excessive ICPmax^MAP ratios 
after SAH would certainly encourage a complete cerebrovascular closure: however, they 
would also risk the development of no-reflow phenomena (NRP) upon—and 
despite—reperfusion. The triggering of the CHR at AICPs of approximately 65 
mmHg—as found in the current study—may serve to offset this effect. The CHR may, 
therefore, denote an evolutionary mechanism that serves primarily to ameliorate NRP 
where intracranial pressure venting has, in turn, permitted a rapid and excessive AICP. The 
CHR would not be ‘necessary’, however, where a high ICPmax related to a cerebrovascular 
expansion222-224,349,453,454,491,651 (Part 6, Section 1 ,1.4). Clearly, cerebrovascular 
expansion—by holding vessels open—would per se limit NRP just as effectively as it 
would tamponade SAH. This state of affairs would be analogous to the use of positive- 
end-expiratory-pressure (PEEP) to prevent atelectasis dming pulmonary ventilation. Such 
a mechanism would also serve the expedient of limiting Ve and, therefore, the delivery of 
contractile and myoproliterative agonists into the subarachnoid space. On the debit side, 
however, is the greater cerebrovascular shear—as well as tlie greater cerebral parenchymal 
strain—that a ‘cerebrovascular expansion-with-CHR’ necessarily implies.
Subtle differences in MCA reactivity notwithstanding, it is also worth noting that the 
results from the current study demonstrated that MCA contractility remained largely 
preserved despite the nature and severity of the acute ictus incurred: i.e. there was no gross 
dismption of MCAs consequent upon the acute ictus. For example, the spontaneous 
development of myogenic tone (MT) to intraluminal distension—the basis behind Bayliss’ 
original concept of ‘ a u t o r e g u l a t i o n ’ 35—appeared uniformly intact after SAH; as well as 
remaining remarkably invariant across each SAH sub-group considered. MT was manifest 
in the continued, rhythmic, tonic variation of mounted MCAs; as well as in the invariance 
of functional diameters between sub-groups functional diameters (FDqo). However, it was 
particularly manifest in the invariance of MCA FD with increasing intraluminal distension 
(Figs 14 & 32). In addition, maximum MCA contractile power {contractility) to non­
specific depolarizing stimulation (i.e. KCl) also remained remarkably uniform after SAH; 
as well as between numerous SAH sub-groups. MCAs pre-constricted with AT from 
PGF2a also dilated to drugs, such as PPV, in a manner indistinguishable to those of
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controls. A major conclusion from the cuiTcnt study, therefore, is that whilst vasoreactivity 
to some agonists certainly was altered after SAH, no gross derangement o f  contractile or 
dilatoiy potential was demonstrated.
Ironically, this fact is also at variance with the findings o f  certain others where profoundly 
diminished cerebrovascular function has been found following a type I (i.e. aiferial rupture) 
SAH^T 289, 306, 435, 472, 599_ Fqi* example, most groups studying in vivo responses have 
demonstrated acute alterations in C O 2  reactivity^^^, 306, 4os^ metabolic regulation^o^, 408, 
and/or autoregulation^^^, 306 after SAH from arterial rupture. In particular, some have 
shown an acute v a s o p a r a l y s i s ^ ^ ^  However, as noted in Part 4 ,  4 . 1 ,  all in vivo studies suffer 
from the potential setback o f  the continuing effects o f  the anaesthetic agent: ftirthemrore, 
many o f  these studies were thwarted not only small group numbers^^^, 40s ^^t, in addition, 
by even smaller numbers o f  shams^^ ,^ 4os More specifically, however, other groups have 
demonstrated global vessel hypofunction following a type I SAH on isolated vessels in
Unforfunately, such studies have invariably created arterial rapture via a previous 
craniotomy (with all it’s potential setbacks [Part 4 ,  l . l ] ) ,  as well as having utilized 
decidedly unphysiological small vessel study models (Part 4 ,  4.1)599. in contrast, our 
results were obtained via in vitro myography following non-craniotomy arterial rupture.
It is interesting that Bokowski et al recently recorded a similar preservation o f  acute 
cerebrovascular" contractility after midline, fluid percussion, total brain injury in rats^ .^ The 
limitations o f  the latter study, however, rendered the authors unable to state whether or not 
MT may also have been preserved. Although acute SAH, in principle, resembles a fluid 
percussion injury; it is clearly less severe. The current findings— that both MT and 
maximum constrictory/dilatory potential remained intact after SAH— would not appear, on 
this comparison, to be surprising. What the current findings do imply, however, is that i f  
any acute derangement o f  M CA function is observed in vivo, then this is likely to have 
occurred against a background o f  essentially normal contractile and dilatory potential. In 
this sense, we may therefore conclude— as, indeed, did Bokowski et aP^— that any acute in 
vivo effects are likely to prove reversible: they would not be likely to reflect an inevitable, 
irreversible loss o f  function, as implied by aforementioned type I SAH studies94 289,306, 435, 
472,599 One possible application o f  this principle derives ftrom the findings o f  enhanced L- 
arg Emax in the current thesis: in particular, the significantly increased proportion where L- 
arg E m a x > 1 0 0 %  (Part 6, Section II, 3.8). Thus, should maximal L-arg (i.e. >10'"^  M) be 
released after SAH, then this may threaten dysautoregulation in a proportion o f  MCAs— in 
a fashion similar to that deduced for HA and PPV (Part 5, Section II, 1.8 & 1 . 9  
respectively). Since, however, such hypothetical ‘vasoparalysis’ would be purely ‘agonist- 
induced’— and not due to a fundamental cerebrovascular derangement— it would,
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potentially, be fully reversible (i.e. with L-arg antagonists, such as L-NAME). 
‘Vasoparalysis’ after acute SAH is then, on this scheme, theoretically pharmacologically 
reversible.
There may, of coui*se, be several explanations for the dispairty between the current findings 
of preserved overall contractility and those of other studies suggesting otherwise. One 
piquant explanation, however, relates to the possibility that the results of previous studies 
may have been distorted by a failure to have compared ‘like with like’. The source of such 
error may include deficiencies in either the SAH model (Part 4, Ch 1 & 2), the vessel study 
model (Part 4, Ch 4), or in the aetual vessel chosen for study (usually the basilar artery:
Part 4, 6.8). Some studies have, in fact, suffered from deficiencies in all three d o m a i n s ^ ^ .  
However, one other critical factor—and indeed, one not hitherto refeired to—may derive 
from the relationship herein expounded between contractile Emax and functional diameter 
(Part 6, Section II, 1.1). Thus, it may be that many of the effects observed in certain 
previous studies have, essentially, related to the inter-group comparison of incomparable 
vessels. As the current study has demonstrated, more than half of the variance in response 
efficacy may be attributable—at least with some agonists—simply to a variance in vessel 
functional size. This is important because MCAs demonstrate a wide range of functional 
diameters, which are frequently asymmetrical. Sampling errors may, therefore, be a 
problem with small experimental numbers: but, especially, with paired controls. Sampling 
errors therefore remain a concern in all studies—admittedly the majority—where vessel 
diameters appear" to have gone completely umecorded.
A rather more prosaic explanation for globally reduced cerebrovascular responses after 
SAH in other studies^i, 289,472,599 may relate to the study of chronic VSM per se. In the 
latter situation, vessels have been exposed to clot in vivo for several days. As a result, the 
encased and thickened clot (along with a ‘fibrous’ meningeal reactioni'^4,232,288 [Part 1,
1.3.2.2]) may preclude the careful dissection and manipulation of vessels for in vitro 
analysis. The possibility of potential manipulative trauma is almost never acknowledged 
in SAH-VSM correspondences: yet it is cleaily a likely cause of global hypofunction if tliis 
is found in such vessels. In contrast, because SAH was terminated within three houis in 
the current study, most of the peri-vascular clot could still be inigated away; thus 
permitting a safer dissection. As a result, MCAs could be manipulated with almost as 
much vision as those in controls. Therefore, the fact that MCA ftmction was assessed 
acutely may alone explain the finding of essentially preserved vascular function in the 
current study: in stark contrast to the findings of chronic studies.
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It is certainly possible, however, as aforementioned that preserved cerebrovascular 
contractility in the acute setting might become reversed chronically as a result of the 
progressive effects of clot lysis. In particular, one must pay especial regard to results 
obtained in human vessels harvested from patients dying at some time after SAH. For 
example, in contrast to the present results, Onoue et al demonstiated diminished contractile 
responses to KCl, PGF2a, NE and to 5HT in one cadaveric study^^^! This suggests a 
primaiy dysfunction of VSMCs that may, therefore, only become apparent in the chronic 
situation. If so, then it would certainly tie in with the finding of a myonecrosis—and a 
consequent thinning—of the tunica media observed in so many post mortem studies (Part 
1, 1.3.1.2). Unfortunately, there are several setbacks with cadaveric studies. A 
heterogeneous sample of vessels (ACAs, MCAs etc—each of differing diameter) is often 
obtained fiom a heterogeneous group of patients (in terms of age, sex, operative status, and 
time post ictus); whilst a major problem exists with controls. Furthermore, in the 
aforementioned study, an additional problem related to the use of helical strips—a most 
unphysiological form of vessel study (Part 4, 4.2.1)472.
Vai'iable degrees of unilateral CCA clamping were employed in approximately half the 
animals used in this study. However, prolonged clamping was only employed in 4 animals. 
The motive for CCA clamping largely stemmed fiom the findings emphasized in the 
previous study fiom this l a b o r a t o r y <^ 25 i^ the latter study, prolonged CCA clamping was 
employed from the outset to lessen SAH severity and, a priori, to offset the excess 
mortality that was inevitably encountered when immediate reperfusion was restored in that 
study^25 In the current thesis, CCA clamping was never used electively as a prolonged 
manoeuvre fiom the outset: instead, CCA re-clamping was only employed whenever an 
ICP re-rise was encountered with each attempted reperfusion. CCA re-clamping was 
therefore used in an attempt to offset the confounding effects of a presumed secondary 
haemorrhage. The rationale behind the use of CCA re-clamping in the current study, 
therefore, radically differed from that of the previous study. Such differences presumably 
underlie the sometimes radically different findings between the two studies. For example, 
a 100% mortality was experienced with prolonged CCA clamping (i.e. SAH Group 1) in 
the current study (Table 21, Appendix); whilst the equivalent group from the previous 
study yielded the lowest mortality (33%) of that study<125. in similar fashion, the lowest 
mortality in the current study (29%) was obtained after immediate full, reperfusion; whilst 
a 100% mortality was experienced in the equivalent group fiom the previous study^2s it is 
interesting that such diametiically opposed results were obtained from each study—a fact 
that presumably relates to the profound methodological difference that existed between 
them (i.e. the deliberate ploy of utilizing prolonged c l a m p i n g the outset in the 
previous study—Part 4, Ch3.3).
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Notwithstanding, vaiying degrees of CCA clamping appeared to be tolerated without any 
overt effect in the current thesis. Specifically, no significant right-left side differences were 
found with any agonist employed in this study, despite even prolonged clamping in SAH 
Group 1. However, the combined right and left results from SAH Group 1 did significantly 
differ Ifom SAH Groups 2 & 3 in many agonist responses: in fact, SAH Group 1 was the 
most frequently abnormal SAH sub-group that existed in this study. For example, 
SAH Group 1 5HT affinity was significantly weaker than either SAH Group 2 or 3; or the 
affinity of shams and controls. In contrast, SAH Group 1 SNP affinity, as well as SAH 
Group 1 L-ARG affinity and efficacy—though significantly different from SAH Group 2 
and 3 responses—remained equivalent to shams and controls. Thus, in the latter situation, 
SAH Group 2 and 3 responses were ‘abnormal’: SAH Group 1 responses were similar to 
shams and controls. Insignificant side differences in all of these cases argues against the 
possibility that ‘Group 1 effects’ related per se to unilateral CCA ischaemia. In attempting 
to explain these findings, one important factor that must be considered is that of the 
statistically small group number necessaiily considered (i.e. n = 4). However, thiee other 
factors also distinguish SAH Group 1. Firstly, since CCA re-clamping was only employed 
after an ICP re-rise, SAH Group 1 may be distinguished from the other two groups by the 
possibility that at least two re-bleeds may have occuned. Secondly—and perhaps related 
to the latter—SAH Group 1 animals suffered a 100% mortality rate, with all deaths 
occurring in the 2"  ^hour. Thirdly, since 75% of Group 1 animals sustained a type I acute 
pressor response, the aforementioned ‘normality’ of this group’s findings could also relate 
to the ‘protective effect’ of acute hypotension with its necessarily diminished 
cerebrovascular shears [Part 6, Section I, 1.4.3]. In conclusion, prolonged CCA re­
clamping in response to an ICP re-rise with attempted reperfusion probably does not 
influence ipsilateral vasoreactivity directly: but it may influence bilateral responses as a 
result of some other factor.
The fact that prolonged unilateral CCA re-clamping may be without significant ipsilateral 
effect on MCA reactivity is consistent with several fundamental principles and 
experimental findings. Firstly, the CoW in rats ranks amongst one of the most complete in 
the animal kingdom. This is such that models employing rats as a substrate for unilateral 
carotid ischaemia are invariably required to render the animal simultaneously hypoxic for 
at least 1 hour in addition to persistent CCA clamping^i^. [No additional hypoxia is 
required, for example, in gerbils because the CoW is characteristically deficient here]. 
Secondly, the “Sheffield Model” of SAH clearly showed that ipsilateral regional CBF 
remained unaffected by right carotid sheath manipulation and clamping; the authors 
concluding that “.. .perfusion in the distribution of the ipsilateral MCA territory is not
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affected by clipping the CCA on the ipsilateral side”^^ .^ Although bilaterally reduced CBF 
was recorded after SAH in the latter study, this was largely restricted to their “reperfusion” 
group—and clearly related to a global SCC (i.e. the opposite findings to the cuirent study) 
G25. Finally, in one detailed experimental study of pial vasoreactivity after CCA clamping, 
no significant effect was observed to similar agonists used in the current study—even with 
clamping up to 6 hours^i^ The latter study was in gerbils where CCA clamping invariably 
leads to unilateral ischaemia.
More specifically, an absence of statistically significant side differences between right and 
left MCA reacitivity in the current thesis indicates that EF-SAH models per se do not 
appear to introduce any significant ‘side bias’ upon ipsilateral MCA reactivity by virtue o f 
the potentially confounding combination: 1) unilateral CCA manipulation and clamping (of 
variable duration), 2) unilateral EF insertion or 3) potentially ipsilateral intracranial 
rupture. This proof represented a major preliminary requirement of the current study, since 
no EF-SAH model to date has subsequently assessed cerebrovascular reactivity. Indeed, as 
a result of such proof, futmn studies of delayed (i.e. chronic) VSM using EF-SAH models 
can be performed with greater re-assurance: in particulai*, should any side differences be 
subsequently found in such studies, then these could be more readily attributable to focal 
factors—such as thickened clot lateralization—with somewhat greater confidence than 
would otherwise have been the case.
The novel finding of NE response heterogeneity in control MCAs was further endorsed by 
its inconigible persistence throughout sham operation and SAH. Although a trend existed 
toward increased heterogeneity after SAH, this did not reach statistical significance. The 
ratio of NE- ‘ responders’ : ‘ subresponders’ also remained stable across all SAH sub-groups. 
Although the current study confirmed that NE responses were significantly weaker than 
other agonist responses, the NEmax in ‘responders’ remained remarkably invariant across 
controls, shams, and after SAH. Such uniformity in both heterogeneity and NEmax permits 
a mechanism that is able to account for the inherent deficiencies of Fisher’s hypothesis 
The latter author implied and stated the ‘clot = VSM’ axiom: nevertheless, a cai'eful review 
of the results upon which it was based clearly reveals numerous exceptions. Thus, clot can 
occur without VSM, and vice versa (Paif 6, Section II, 3.5.3). If one assumes that NE 
acting at a  adrenoceptors is instrumental in a e t i o l o g y ^ 3 13,576^ then the current results 
suggest that a maximum only of 75% animals could develop VSM irrespective o f clot site 
or size after SAH. Since, however, only bilateral NE-‘responders’ exist in 43% animals 
after SAH, only this proportion could sustain VSM irrespective o f clot lateralization.
Large epidemiological studies have indeed shown that clinical VSM only occurs in such a 
proportion (43-67%) after SAH^^  ^ Furthermore, decreased NE affinity in some SAH sub-
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groups (Part 6, Section II, 3.5.2) would localize VSM still further, because significant 
responses would only occur in areas of higher concentrations—i.e. within the clot itself.
Such reasoning again provides a mechanism that potentially links acute changes in post- 
SAH MCA reactivity (as found in this thesis) with the subsequent effects of clironic clot 
lysis (not analyzed in the current thesis). Nevertheless, whilst entirely possible, it is 
not—alas—  seriously the author’s intention to use NE heterogeneity to explain clinical 
VSM in one fell swoop! Although the current results imply that NE efficacy may continue 
to increase outside the acute period, the results per se only pertain to the first three hours 
(i.e. this study cannot extrapolate to the delayed situation of DCI). Furthermore, the 
evidence that an agonist, or agonists, acting at a  adrenoceptors is responsible for clinical 
VSM is not in abundance in the scientific literature. Nevertheless, the findings with NE 
permit a generalized mechanism that bases VSM on a dichotomy of response in individual 
cerebral vessels toward a given agonist. Thus, the ability of some vessels to respond—but 
of others to fail to respond—to a given agonist, can clearly explain exceptions to Fisher’s 
hypothesis; and, thus, why clinical VSM does not occur in every patient despite an 
abundance of agonist within the clot. The principle that VSM may relate to the “individual 
nature” of cerebral vessels is, in reality, not new^ :^ however, to the best of the author’s 
knowledge, no actual mechanism has hitherto been proffered. The persistence of NE 
heterogeneity after SAH clearly represents one possible mechanism—however likely or 
unlikely it may subsequently prove to be. The hypothesis that responses of cerebral vessels 
to agonists released as a result of SAH might be discontinuous, and not—as is assumed 
with most, if not all, studies—continuous, may be referred to as ‘Brandt’s hypothesis’ 
(although tliis remained implicit and not explicit in his articles).
Blood in the subarachnoid space is also associated, as a result of its chronic lysis, with the 
copious release of prostaglandins—including PGF2a—as well as 5 HT from platelets. 
Fui’thermore, local cell decomposition may be expected to be associated with increased 
concentrations of K+ ions. The results ftom the cmrent study have shown that all of these 
agonists are potent and efficacious vasoconstrictors of rat MCAs; and, furthermore, that 
they aie all at least as efficacious after SAH as they are in controls. Indeed, responses with 
PGF2a were significantly more efficacious in ‘survivors’ after SAH. Furthermore, these 
agonists also constrict vessels in a predictable and continuous fashion, with neither 
heterogeneity nor discontinuity, and with an efficacy that is largely dependent upon 
functional vessel size. However, of all the agonists tested, 5HT was also the more potent 
by several orders of magnitude (Fig 35). Whilst UTP responses were, in contrast, the least 
potent—and their efficacy weaker, like NE responses (Fig 37)—UTP responses are 
characteristically prolonged, and do not develop tachyphylaxis. Both UTP and NE are also
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present within the clot platelets; whilst NE may also derive from the SNS. In consequence, 
the cui'rent study peimits the hypothesis that locally elevated levels of K^, PGF2a, 5HT, 
UTP and NE may all mediate VSM: either alone, or in combination. The possible 
interaction of such agonists with each other—as well as with other agonists(Part 3, Ch 
2)—may explain the varying severities of VSM that is ultimately seen^^z, 6i6_ %ig 
component of VSM—i.e that resulting from agonists or agonist-interaction—remains 
perfectly reversible (‘reversible’ VSM): as the results with PPV clearly demonstrate.
It was Nagai’s belief that the seeds for VSM and DCI were sewn in the profound 
physiological disturbance that was associated with the acute ictus. In Nagai’s words, “...the 
initial brain damage (caused) by SAFI alters (both) the vasoreactivity and the tolerance of 
the brain itself for cerebral ischaemia...”435, The cmrent study cannot provide any evidence 
that directly relates to the latter assertion although, should /NOS prove to be the cause of L- 
ARG->NOS->NO->GC-->cGMP pathway activation, one could speculate that a similar 
activation might also arise within the cerebral parenchyma. Putative parenchymal /NOS 
activation could, conceivably, produce a similar degree of metabolic disruption as that 
previously proposed with VSMCs. The current results, however, certainly do support 
Nagai’s former assertion that the acute ictus alters cerebral vasoreactivity. Thus, 
significant alterations were appai*ent in receptor-mediated activity to several different 
agonists within the first thi’ee horns of acute SAH in the current study. The principle 
hypothesis of the current study— i.e. that events associated with the acute ictus of 
SAH elicit changes in cerebrovascular physio-pharmacology that are independent of 
any subsequent effects of chronic clot lysis—is therefore endorsed. Because such 
changes might prove crucial to the subsequent development of delayed VSM and DCI they 
may, in consequence, ultimately explain why currently favoured ‘clot-VSM’ fail to 
adequately explain these phenomena (i.e. because demonsti’ating post-ictal alterations 
undermines the assumption of ‘clot-VSM’ models that delayed VSM and DCI merely 
result from the chronic effects of clot lysis upon normal cerebral vessels). Two key factors 
associated with the acute ictus—seemingly independent of each other—have heen 
identified in this regard: firstly, factors related to the determination of acute mortality; and 
secondly, factors related to the effects of the acute intracranial and systemic arterial pressor 
response. It is the current author’s belief that the acute ictus may not only be central to 
early mortality (as demonstrated in the cmTcnt thesis) but also to delayed mortality—via 
DCI—as implied by Nagai. To quote Nagai “...it is with the initial brain damage...” after 
acute SAH that “...clues to the mechanism...” of DCI may “.. .ultimately be sought.. .”435,
In addition, the findings of persistent NE heterogeneity endorse ‘Brandt’s principle’ 
that it “...is with the individual natme of cerebral vessels why VSM ultimately occui’s in 
some cases, and not in others.. And finally, the secondaiy hypothesis of the current
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study—i.e. that EF-SAH models inherently introduce ‘side bias’— is formerly rejected as a 
result of the results so repeatedly obtained, thus endorsing their use for the analysis of 
delayed VSM.
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PART 7 
APPENDIX
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Fig 47. Exponential decay of systolic-diastolic bandwidth with increasing heart 
rate (HR). The box under the curve denotes the approximate range for the normal rat 
HR^ 43, 344 Thus, in the normal rat HR range, bandwidth dimensions have contracted 
to approximately 35-60% the statically calibrated scale, as a result of pen inertia 
artefact. NOTE: The graph is presumed to be exponential because 1) a linear 
relationship would suggest that the bandwidth would become zero at 720 b.p.m., and
2) because of electro-mechanical considerations.
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Table 9. FD 9 0  (pm) Non-operative controls
Right MCA Left MCA
185 137
140 97
132 191
157 81
112 71
164 103
191 147
126 140
174 157
116 213
168 NA
112 187
146 128
145 108
206 237
163 209
217 214
189 99
191 206
158 167
Key: Bold type—animals where marked asymmetry (i.e. >xl SD) was apparent. 
NA—non-viable vessel.
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Table 10. NE E^ ax responses in Non-operative controls
Animal no. Right MCA Left MCA
1. 1.8 2.0
2. 4.3 1.2
3. 3.3 3.8
4. 5.6 1.7
5. 0.8 1.2
6. 0.3 0.7
7. 3.6 4.9
8. 1.9 2.6
9. 1.7 5.8
10. 2.0 4.6
11. 0 ---
12. 0.7 ---
13. 1.7 1.8
14. 0.7 4.3
15. 4.2 3.3
16. 0.7 0.8
17. 4.4 4.9
18. 3.4 3.6
Key. Bold type NE-‘subresponder’, (—) non viable MCA {see Part 4, 6.5 and 7.4).
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Table 11. NE Em»x responses in Sham operative controls
Animal no. Right MCA Left MCA
1. 4.6 3.1
2. 4.8 3.8
3. 2.5 2.8
4. 4 1
5. 0.6 2.1
6. 3.5 5.9
7. 4.7 1.2
8. 2.6 1.1
Key. Bold type NE-‘subresponder’, (—) non viable MCA {see Part 4, 6.5 and 7.4).
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Table 12. NE Eniax responses in SAH Group 1
Animal no. Right MCA Left MCA
1. 4.0 1.0
2. 2.6 4.9
3. 1.9 1.5
4. 0.4 0.5
Table 13. NE Eniax responses in SAH Group 2
Animal no. Right MCA Left MCA
1. 2.5 3.8
2. 5.2 2.8
3. 0.8 0.5
4. 2.0 1.0
5. 0 0
6. 2.3 1.8
7. 6.5 1.0
8. 2.2 4.6
9. 0 1.1
10. 2.2 2.8
Table 14. NE E,„ax responses in SAH Group 3
Animal no. Right MCA Left MCA
1. 1.9 2.4
2. 0 0
3. 1.5 0.6
4. 0 3.8
5. 4.0 4.4
6. 3.3 6.2
7. 3.4 1.3
8. 0.5 1.8
9. 0.4 0.7
10. 1.1 0
11. 1.0 0.5
12. 0.5 2.3
13. 3.3 8.7
14. — 1.5
15. 0.3 0.6
Key. Bold type NE-‘subresponder’, (—) non viable MCA {see Part 4, 6.5 and 7.4).
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Table 15. Arterial blood gases in shams and SAH groups
Shams (n = 8) SAH groups (n = 34)
pH 7.4±0.3 7.38+0.24
pOz (kPa) 12.2+0.8 12.9+0.7
PCO2 4.2+0.3 4.3+0.2
BE (mmol/L) +1+3 +3+2
Key. BE base excess. Values expressed as mean±SE
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No. MAP ICP
1. 113 8
2. 142 3
3. 109 3
4. 83 11
5. 125 9
6. 111 4
7. 102 8
8. 111 8
Mean±SE 112±6 7+1
Table 17. SAH Type I acute pressor responses: Hypotension after SAH. All
pressures recorded in mmHg. Key (—) lost tracing, * SCC (43%). M A P i /  IC P ]  =  
pressures prior to SAH, M A P 2 /I C P 2  = pressures immediately after SAH. [NB IC P 2  
IC Pm ax]
No. MAPi MAP2 -AMAP ICPi ICP2 AICP
1.* 110 72 38 8 33 25
126 98 28 16 37 21
3.:^ 79 71 8 4 39 35
4. 84 79 5 13 40 27
5.* 173 125 48 4 24 20
84 68 16 6 30 24
7. 129 85 44 10 32 22
8. 159 138 21 8 42 34
9.* 139 113 26 2 49 47
10. 183 175 8 10 50 40
11.* 135 65 70 — — —
12. 115 81 34 5 25 20
13.* 170 143 27 6 49 43
14. 133 104 29 — — —
15. 114 96 18 — — —
16. 152 81 71 4 45 41
17. 131 94 37 8 47 39
18.* 104 84 20 — — —
19. 119 — — — —
20. 154 114 40 12 32 20
21. 88 68 20 10 41 31
Mean+SE 128+6 98+7 30+4 8+1 38±2 31+2
NOTE: In animal no. 19, no quantification of pressor change was possible because 
the original pen recorder tracing was subsequently lost; and because the precise values 
from the patient monitor could not be stored onto hard disk. Nevertheless, this was 
faithfully recorded as a hypotension in the notes from the experiment. Note also that 
the ICPmax MAP2 ratio is not as simple as dividing the mean values at the column 
bases, because in five animals there do not exist corresponding ICP and MAP values.
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Table 18. SAH Type H acute pressor responses: Invariant. All pressures 
recorded in minHg. Key (—) lost tracing (see section 3.3), * SCC (40%). ICPi =
No. MAP ICPi ICP2 AICP
1.* 91 10 86 76
2. 104 5 41 36
3. 84 10 77 67
4. 115 12 72 60
5. 115 15 57 42
6. 140 12 41 29
7. 125 — — ----
8.* 156 14 54 40
9.* 97 ..  - -—^ —
10.* 103 6 54 48
Mean+SE 113+7 11+1 60+6 50+6
Table 19. SAH Type HI acute pressor response: Cushing Hypertensive 
response (CHR). All pressures recorded in mmHg. Key ( ~ )  lost tracing (see section 
3.3), * SCC (50%). MAP]/ ICP] = pressures prior to SAH, MAP2/ICP2 = pressures 
immediately after SAH. [NB ICP2 = ICPmax]
No. MAPi MAP: +AMAP ICPi ICP2 AICP
1.* 131 142 11 11 87 76
2. 125 148 23 9 78 69
Mean+SE 128+3 145+3 17+6 10+1 83+5 73+4
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Table 20. The distribution o f Subacute Cardiovascular Collapse (SCC) with 
acute pressor response after SAH. Animals developing subacute cardiovascular 
collapse (SCC; bold type) did so in the and 2 "^  hours of SAH: animals surviving 
into the 3^^^ hour did not develop SCC (SCC is equivalent to mortality in this thesis).
= 1.06 on (3-l)(3“l) degrees of freedom, giving p»0.2. No statistical significance 
is demonstrated.
SCC occurrence after SAH
1  ^Hour 2 ‘^‘^ Hour 3'"^Hour Total
Type I 4 5 1 2 2 1
Type II 2 2 6 1 0
Type III 0 1 1 2
Total 6 8 19 33
NOTE: the total number of animals considered is 33 and not 34: this is because in one animal 
the type of acute pressor response (i.e. hypertension, hypotension or invariant) was not 
recorded on a pen recorder tracing.
Table 21. Contingency table demonstrating CCA re-clamping effect upon 
survival within three hours o f SAH. yf = 6.76 on (2-l)(3-2) 2 degrees of freedom, 
giving p < 0.05. NB expected figures in parenthesis. Prolonged CCA re-clamping is 
significantly associated with premature mortality in this study. Clearly, Groups 2  and 
3 (39% and 29% mortality respectively) were markedly different from Group 1 ( 1 0 0 %
Group 1 Group 2 Group 3 Totals
Non-survival 4(1 ,7) 5 (5.4) 5 (7.0) 14
Survival 0 (2.4) 8 (7.7) 1 2  (1 0 .0 ) 19
Totals 4 13
o r d i _________ n  A T T
17 34
n z - i y i  . - . I  • o t d
hour after SAH. (SCC is equivalent to mortality in this thesis).
Table 22. Contingency table demonstrating the distribution o f acute pressor 
response with CCA re-clamping, yf = 4.99 on (2-l)(3-2) 2 degrees of fteedom, 
sivins n »  0.05 No statistical significance is demonstrated.
Group 1 Group 2 Group 3 Totals
Type I 3 7 8 18
Type II 0 3 6 9
Type III 1 1 0 2
Totals 4 11 14 29
NOTE: the total group number is 29 and not 34. Myography was only performed in n = 30 
animals (Protocols: Part 4, 7.4). However, in one animal myography was performed without 
knowledge of the qualitative acute pressor response (lost tracing). Nevertheless, BP (patient 
monitor) and intermittent arterial blood gas values confirmed that the animal was adequately 
perfused. This Table was only used to provide some explanation for PGF2a and NE EC50 
values discussed in Part 6 , Section II, 3.2 & 3.5.
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Table 23. Sham operative Emax and EC50 values in right and left MCAs. No
significant side difference strongly suggests that unilateral CCA-ICA manipulation
RIGHT MCA n LEFT MCA n p values
FD90 167+35 8 148+46 8 0.36
Agonist Emax EC50 Emax ECso Emax ECso
KCl 6.3+0.7 — 8 5.4+0.7 — 8 0.39 ...........
PGF2a 6.3+0.8 5.0+1.0 8 5.4+0.9 7.5+1.8 8 0.46 0.25
PPV 106+11 3.2+0,2 8 118+17 2.3+0.7 8 0.55 0.35
UTP 4.6+0.6 20+1.7 8 4.8+0.9 20.2+2.4 8 0.90 0.95
SNP 70+2 8.1+3.1 8 81+6 9.5+5.9 8 0.10 0.83
L-ARG 74+4 3.3+0.9 8 69+8 6.1+2.6 8 0.60 0.33
5HT 5.4+0.9 0.09+0.02 8 5.4+1.1 0.08+0.04 8 0.98 0.80
NE 3.4+0.5 3.5+1.5 7 2.6+0.6 2.8+1.2 7 0.33 0.69
HA 84+7 Ô.2+2.4 8 79+6 7.4+2.3 8 0.55 0.72
L-NAME 1.8+0.8 — 3 2.3+0.8 — 3 0.65 —
Key. n = no. MCAs studied, (—) not applicable, Diam± SD measured in pm, +SE
values for KCl, PGF2a, UTP, 5HT, NE and L-NAME measured in mN, E^ ax ±SE 
values for PPV, HA, SNP, L-ARG measured in % pre-constricted agonist-induce tone 
(AT), all EC50 ±SE values measured in pM. NOTE: NE values refer only to 
‘responders’.
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Table 24. SAH Group 1 and ECso values in right and left MCAs. No
significant side differences strongly suggests that prolonged CCA re-clamping does
RIGHT MCA n LEFT MCA n p values
FD,o 152+18 4 157+41 4 0.82
Agonist Emax ECso Emax ECso Emax ECso
KCl 5.0+1.0 4 5.2+0.7 — 4 0.90 ——
FGF2a 5.2+0.7 7.3+1.6 4 6.7+1.3 7.6+1.9 4 0.32 0.90
PPV 86+18 3.4+2.3 4 92+4 2.2+0.8 4 0.80 0.63
UTP 2.8+0.6 23.8+1.8 4 4.3+1.1 23.7+3.3 4 0.25 0.97
SNP 55+23 6.1+4.7 3 88+19 9.7+3.9 3 0.32 0.59
L-ARG 95+12 9 .8+4.0 4 91+6 7.0+5.0 4 0.78 0.68
5HT 3.2+0.8 0.45+0.18 4 5.1+1.2 0.99+0.6 4 0.24 0.42
NE 2.8+0.6 — 3 3.2+1.7 — 2 0.82 —
HA 52+3 3.0+1.6 4 64+12 1.9+0.7 4 0.51 0.55
Key. n = no. MCAs studied, (—) not applicable, Diam ± SD measured in pm,
±SE values for KCl, PGF2a, UTP, 5HT and NE measured in mN, E^ ax ±SE values for 
PPV, HA, SNP, L-ARG measured in % pre-constricted agonist-induce tone (AT), all 
ECso ±SE values measured in pM. NOTE: NE values refer only to ‘responders’.
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Table 25. SAH Group 2 Emax and ECso values in right and left MCAs. No
significant side differences strongly suggests that temporary CCA re-clamping for up
RIGHT MCA n LEFT MCA n P values
FD,o 163+42 11 156+25 11 0.64
Agonist E.,mx ECso E,„ax ECso E„mx ECso
KCl 5.4+0.7 — 10 5.8+0.6 — 10 0.66 ----------
PGF2a 7.6+0.8 3.5+0.5 10 6.9+0.6 3.8+1.1 10 0.52 0.81
PPV 101+4 2.5+0.4 10 109+7 2.1+0.3 10 0.32 0.43
UTP 4.1+0.5 20.5+2.7 10 3.4+0.6 24.1+3.4 10 0.36 0.43
SNP 93+5 5.1+2.7 10 92+7 3.5+1.3 10 0.92 0.60
L-ARG 91+8 4.0+0.9 10 81+7 2.3+0.7 10 0.39 0.16
5HT 6.3+1.0 0,16+0.05 9 5.5+0.6 0.17+0.03 10 0.47 0.78
NE 3.6+0.7 2.1+0.8 7 2.4+0.4 2.7+1.3 6 0.17 0.69
HA 80+9 5.3+1.3 10 77+5 5.6+0.9 10 0.77 0.84
Key. n = no. MCAs studied, (—) not applicable, Diam ± SD measured in pm, Emax 
+SE values for KCl, PGF2a, UTP, 5HT and NE measured in mN, Emax ±SE values for 
PPV, HA, SNP, L-ARG measured in % pre-constricted agonist-induce tone (AT), all 
ECso ±SE values measured in pM. NB There is n = 1 more diameter value tlian corresponding 
agonist value for each MCA because in one animal no agonist responses were obtained. NOTE; NE 
values refer only to ‘responders’.
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Table 26. SAH Group 3 E^ax and EC50 values in right and left MCAs after
SAH No significant side differences strongly suggests that no underlying asymmetry 
is present in MCA reactivity after SAH. [This group effectively acts as a ‘control’ for
RIGHT MCA n LEFT MCA n p values
FD.0 163+49 15 163+44 15 0.99
Agonist E m ax ECso TT-^niax E C s o E ,„ „ x ECso
KCl 4.4+0.5 — 14 4.5+0.7 --- 15 0.86 —
PGF2a 5.6+0.7 7.9+1.4 13 6.7+0.8 6.3+1.6 14 0.38 0.46
PPV 102+5 2.6+0.5 12 111+4 1.8+0.4 12 0.07 0.21
UTP 3.5+0.5 22.1+2.5 13 3.8+0.7 17.9+2.7 14 0.84 0.26
SNP 105+8 3.6+1.0 13 112+5 1.9+0.5 13 0.42 0.12
L-ARG 92+9 1.5+0.4 12 100+17 2.2+0.7 13 0.68 0.39
5HT 4.5+0.8 0.14+0.04 13 5.0+0.8 0.1+0.02 14 0.67 0.41
NE 2.3+0.4 8.8+4.2 8 3.8+0.8 9.4+3.0 8 0.15 0.90
HA 67+9 5.5+1.3 13 67+7 4.5+0.9 13 0.96 0.56
L-NAME 2.0+0.5 — 7 2.9+0.7 — 6 0.31 —
Key. n = no. MCAs studied, (—) not applicable, Diam ± SD measured in pm,
±SE values for KCl, PGF2a, UTP, 5HT, NE and L-NAME measured in mN, E,„  ^±SE 
values for PPV, HA, SNP, L-ARG measured in % pre-constricted agonist-induce tone 
(AT), all EC50 ±SE values measured in pM. NOTE; NE values refer only to 
‘responders’.
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Table 27 , Comparison of SAH Group 1, 2 and 3 responses. Statistically 
significant differences are apparent mainly in ECso values. The ‘abnormal’ group is 
mainly SAH III; however, SAH V NE ECso values clearly differ from SAH IV (SAH
S A H l(n  = 4) SAH 2 (n= 11) SAH 3 (n= 15) P values
FD,o 154+29 159+34 163+45 0.85
Agonist Eiuas ECso Emax ECso Emax ECso IT-■-'max ECso
KCl 5.1+0.6 — 5.6+0.5 — 4.510.4 — 0.52 —
FGF2a 5.9+0.7 7.4+1.5 7.2+0.5 3.7+0.6 6.210.5 7.1+1.1 0.3 0.02
PPV 89+10 2.8+1.1 105+4 2.310.3 10814 2.1+0.3 0.08 0.67
UTP 3.5+0.6 24+2 3.710.4 23+2 3.710.4 20+2 0.98 0.53
SNP 72+15 7.9±2.9 92+4 4.2+1.4 10813 2.610.5 0.003 0.08
L-ARG 93+6 8.4+3.0 86+5 3.1+0.6 96110 1.810.4 0.66 0.0006
5HT 4.1+0.8 0.72+ 5.8+0.5 0.17+ 4.810.5 0.121 0.21 0.0004
0.31 0.03 0.02
NE 3.0+0.6 — 3.1+0.4 2.410.7 3.210.5 9.212.3 0.97 0.002
HA 58+8 2.4+0.8 78+5 5.5+0.8 67+5 5.010.8 0.13 0.18
Key. Bold type statistical significance, (—) not applicable, n = max. no. animals 
studied, Diam ± SD measured in pm, E^ ax +SE values for KCl, PGF2a, UTP, 5HT , 
and NE measured in mN, E^ ax ±SE values for PPV, HA, SNP, L-ARG measured in % 
pre-constricted agonist-induce tone (AT), all ECso ±SE values measured in pM. 
NOTE; NE values refer only to ‘responders’.
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Table 28. Comparison of overall (i.e. Groups 1-3) SAH responses with controls 
and shams
Controls (n = 20) Shams (n = 8) SAH(n = 30) p values
FD90 156+42 157141 161139 0.86
Agonist E„„.x ECso Emax ECso Emax ECso Emax ECso
KCl 5.510.3 — 5.910.5 — 5.210.3 — 0.42 —
PGF2a 5.110.4 6.411.0 5.910.6 6.211.1 6.510.3 5.810.6 0.051 0.88
PPV 10619 2.110.6 107116 2.710.5 10413 2.310.3 0.95 0.61
UTP 3.410.4 16.41 4.710.5 20.11 3.710.3 21.31 0.11 0.17
2.8 1.4 1.3
SNP 7214 10.71 7613 8.813.2 9614 3.810.7 0.0003 0.04
4.3
L-ARG 7214 5.011.3 7215 4.711.4 9215 3.410.6 0 . 0 1 0.37
5HT 4.410.3 0.091 5.410.7 0.081 5.110.4 0.211 0.39 0.10
0.02 0.02 0.06
NE 3.210.3 2.411.0 3.310.4 3.110.9 3.110.3 5.911.4 0.90 0.08
HA 10215 2.310.6 8215 6.811.6 7014 4.910.5 0.0004 0.004
L-NAME 1.310.4 — 2.010.5 — 2.410.4 — 0.20 —
Key. Bold type statistical significance, (—) not applicable, n = max. no. animals 
studied, Diam ± SD measured in pm, Emax ±SE values for KCl, PGF2a, UTP, 5HT, 
NE and L-NAME measured in mN, E^ ax ±SE values for PPV, HA, SNP, L-ARG 
measured in % pre-constricted agonist-induce tone (AT), all ECso ±SE values 
measured in pM. NOTE: NE values refer only to ‘responders’.
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Table 29 . Survival groups Emax and ECso values after SAH.
1 hour (n = 5)_____2 hours (n = 8) 3 hours (n = 17) p values
FD,o 136+31 160135 168141 0.08
Agonist Emax ECso Emax EC50 Emax ECsa Emax ECso
KCl 5.1+0.8 — 5.010.4 — 5.310.4 — 0.88 —
PGF2a 4.6+0.8 7.011.0 6.610.7 6.010.9 7.210.4 5.711.0 0.03 0.78
PPV 106+8 2.910.4 9916 2.610.7 10613 2.110.3 0.52 0.40
UTP 2.610.5 2114 3.810.4 2412 4.010.4 2012 0.18 0.35
SNP 9519 5.313.0 8819 4.711.5 10214 3.310.6 0.30 0.50
L-ARG 76113 2.310.9 9115 6.011.8 10018 2.110.3 0.23 0.01
5HT 4.411.0 0.141 4.510.6 0.381 5.510.5 0.141 0.35 0.06
0.04 0.17 0.02
NE 2.410.5 5.213.4 3.110.6 4.311.4 4.810.6 7.113.5 0.04 0.10
HA 8716 4.110.5 7715 3.910.9 6714 5.610.8 0.54 0.31
Key. Bold type statistical significance, (—) not applicable, n = max. no. animals 
studied, Diam ± SD measured in pm, Emax ±SE values for KCl, PGF2a, UTP, 5HT 
and NE measured in mN, Emax +SE values for PPV, HA, SNP, L-ARG measured in % 
pre-constricted agonist-induce tone (AT), all ECso ±SE values measured in pM. 
NOTE; NE values refer only to responders’
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Table 30. E m a x  and EC50 values with Type I, II and 111 pressor responses after 
SAH
Type I (n = 18) Type H (n = 9) Type HI (n = 2) p values
FD90 161+33 161+52 148+26 0.82
Agonist E,niix ECso Emax ECso Emax ECso Emax ECso
KCl 5.3+0.4 — 3.7+0.5 ---- 5+0.7 ——' 0.05 ---
PGF2a 6 .8+0.4 6.3+0.9 6.1+0.9 4.9+0.8 4.9+0.7 6.3+2.1 0.29 0.64
PPV 104+3 2 .1+0 .2 107+7 2.7+0.3 87+14 3.8+2.3 0.23 0.14
UTP 3.6+0.3 2 0 + 2 3.7+0.5 2 2 ± 2 4.2+1.2 24+2 0.83 0.72
SNP 93+5 7.1±1.3 99+5 1.7+0.4 90+3 0 .6 +0 .1 0.77 0.03
L-ARG 85+4 3.9+0.9 1 0 2 + 6 2 .1+0 .8 94+13 1.7+0.4 0.06 0.40
5HT 5.1+0.5 0.17± 4.6+0.7 0.17+ 4.3+1.0 0.92+ 0.74 0 .0 0 2
0.03 0.05 0.64
NE 3.3+0.3 4.3+1.3 3.6+1.7 15.3+5 2.6+0.7 0 .8 +0 .1 0.67 0.004
HA 66+4 5.0+0.7 77±8 5.2+0.8 71±16 1.9+1.1 0.43 0.48
Key. Bold type statistical significance, (—) not applicable, n = max. no. animals 
studied, Diam ± SD measured in pm, E^ ax ±SE values for KCl, PGF2a, UTP, 5HT 
and NE measured in mN, Emax ±SE values for PPV, HA, SNP, L-ARG measured in % 
pre-constricted agonist-induce tone (AT), all EC50 ±SE values measured in pM.
NOTE; the total no. of animals used is one less than in previous tables (i.e. 29 instead of 30). 
This is because in one animal the acute pressor response was not recorded. Intermittent 
arterial blood gas sampling and continuous BP readouts from the patient monitor, however, 
confirmed its suitability for myography. ICP monitoring and post mortem analysis confirmed 
SAH. NB: NE values refer only to ‘responders’.
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Table 31. Comparison of E,„ax v FD^ correlation coefficients r and their 
statistical significance. Only the r  value for non-operative controls UTP Emax v FDgo 
correlation does not reach statistical significance, NB NE refers only to NE-
‘responders’____________________________________________________________
Non-op Controls Shams ______[overall] SAH
Agonist r p value r p value r p value
KCl 0.75 <0.01* 0.78 <0.001* 0.52 <0.001
PGF2a 0.45 <0.05* 0.87 <0.001* 0.632 <0.001
5HT 0.523 <0.02* 0.64 <0.01* 0.56 <0.01
NE 0.62 <0.01* 0.72 <0.001* 0.47 <0.001
UTP 0.31 >0.1 0.74 <0.01* 0.58 <0.001
Key * statistical significance
296
PART 8 
REFERENCES
297
1 Alabadi JA, Salom JB, Torregrossa G, Miranda FJ, Jover T, Alborch E; Changes 
in the cerebrovascular effects endothelin-1 and nicardipine after experimental 
subarachnoid hemorrhage. Neurosurgery 33(4):707-15, 1993.
2 Alabadi JA, Torregrosa G, Salom JB, Miranda FJ, Barbera MD, Mayordomo F 
Alborch E.: Changes in the adrenergic mechanisms of cerebral arteries after 
subarachnoid haemorrhage in goats. Neurosurgery 34(6): 1027-33, 1994.
3 Alafaci C, Jansen I, Arbab MA, Shiokawa Y, Svendgaard NA, Edvinsson I: 
Enhanced vasoconstrictor effect of endothelin in cerebral arteries from rats with 
subarachnoid haemorrhage. Acta Physiol Scaud 138:317-319, 1990.
4 Alam M, Smirk FH. Observations in man upon blood pressure raising reflex from 
voluntary muscles. J Physiol (Loud.) 89:372-83, 1937.
5 Alexander III E, Black PM, Liszczak TM et al. Delayed CSF lavage does not 
prevent artériographie and morphologic vasospasm after experimental 
subarachnoid haemorrhage. J Neurosurg 63:949-58, 1985.
6 Alexander III E, McL Black P: CBF and artériographie VSM. Effects of delayed 
lavage in an experimental canine model. In Cerebral Vasospasm, Wilkins RH (ed). 
Raven press. New York, 1988, pp 395-401.
7 Alksne IF, Greenhoot JH. Experimental catecholamine-induced chronic chronic 
vasospasm. J Neurosurg 41: 440-445, 1974.
8 Alksne JF, Smith RW. Experimental models of spasm. Clin Neurosurg 24:216- 
227, 1977.
9 Allen GS, Gross CJ: Cerebral arterial spasm. Part 5: In vitro contractile activity 
of vasoactive agents icnluding human CSF on human basilar and anterior cerebral 
arteries. J Neurosurg 44:594-600, 1976.
10 Allen GS: Role of calcium anatagonists in cerebral arterial spasm. Am J Cardiol 
55:149B-153B, 1985.
11 Allen GS,Henderson LM, Chou SN, French LA. Cerebral arterial spasm, Part 1; 
In vivo contractile activity of vasoactive agents on canine basilar and middle 
cerebral arteries. J Neurosurg 40: 433-441, 1974
12 Andreoli A, Pasquale GD, Pinelli G, Grazi P, Tognetti F, Testa C. Subarachnoid 
haemorrhage: frequency and severity of cardiac arrhythmias. Stroke 18:558-564,
1987.
13 Antonaccio MJ (ed). Cardiovascular pharmacology. New York, NY Raven 
press, 1984.
14 Aoki T, Takenaka K, Suzuki S, Kassell NF, Sagher O, Lee KS; The role of 
hemolysate in the facilitation of oxyhemoglobin-induced contraction in rabbit 
basilar arteries. J Neurosurg 81:261-6, 1994.
15 Arnal JF, Warin L, Michel JB. Determinants of aortic cGMP in hypertension 
induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 90:647-52,
1992.
16 Arnold WP, Longnecker DE, Epstein RM et al. Nitroprusside produces cyanide 
poisoning via reaction with haemoglobin. J Pharmacol Exp Ther 191:557-563, 
1974.
17 Arnold WP, Longnecker DE, Epstein RM. Photo degeneration of Sodium 
nitroprusside biological activity and cyanide release. Anesthesiology 61:254-60,
1984.
298
18 Asano T, Sano K: Pathogenetic role of no-reflow phenomena in experimental 
subarachnoid haemorrhage in dogs. J Neurosurg 46:454-466, 1977.
19 Asano T, Tanishima T, Sasaki T et al. Possible participation of free radical 
reactions initiated by clot lysis in the pathogenesis of vasospasm after 
subarachnoid haemorrhage, in Cerebral Vasospasm, RH (ed), Raven press,
New York, 1988, ppl90-201.
20 Asano T, Takakura K, Sano K, Kikachi H, Nagai H, Saito I, Tamura A, Ochiai C, 
Sasaki T. Effects of a hydroxyl scavenger on delayed ischaemic neurological 
deficits following aneurysmal subarachnoid haemorrhage: results of a multi-centre 
placebo-controlled double-blind trial. J Neurosurg 84:792-803, 1996.
21 Aschenbrenner R, Bodechtal G. Ueber EKG-veraenderungen bei 
Hirntumorkvanken. Klin Wochenschrift 17: 298-302, 1938.
22 Auer LM, Gallhofer B. Rhythmic activity of cat pial vessels in vivo. Eur Neurol 
20:448-68, 1981.
23 Badimon L, Badimon JJ, Penny W, Webster MW, Chesebro JH, Fuster V. 
Endothelium and atherosclerosis. J  Hypertension 10(suppl2):S43-50,1992.
24 Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an
intracardiac renin-angiotensin system. Ann Rev Physiol 54: 227-41, 1992.
25 Balligand J-L, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac
muscle cell function by an endogenous nitric oxide signalling system. Pro cl Natl
Acad Sci USA 90:347-351, 1993.
26 Balligand J-L, Ungureanu-Longrois G, Simmons WW, Pimentai D, Malinski TA, 
Kapturczak M, Taha Z, Lowenstein CJ, Davidoff AJ, Kelly RA, Smith TW, 
Michel T. Cytokine - inducible /NOS expression in cardiac myocytes: 
characterization and regulation of /NOS expression and detection of /NOS 
activity single cardiac myocytes in vitro. J Biol Chem 269: 27580-27588, 1994.
27 Balligand JL, Kelly RA, Marsden PA Smith TW, Michel T. Control of cardiac 
muscle cell function by an endogenous nitric oxide signalling system. Proc Natl 
Acad Sci USA 90: 347-51, 1993.
28 Balligand J-L, Kobzik L, Han X, Kaye, DM, Belhassen L, O'Hara DS, Kelly RA, 
Smith TW, Michel T. Nitric oxide dependent parasympathetic signalling is due to 
activation of constitutive (III) NOS in cardiac myocytes. J Biol Chem 270: 
14582-6, 1995.
29 Banerjee A, Lock-Winter C, Rogers KB, Mitchell MB, Brew EC, Cairns CB, 
Bensard DD, Harken AH. Preconditioning against myocardial dysfunction after 
ischaemia and reperfusion by an a l  adrenergic mechanism. Circ Res 73:656-70, 
1993.
30 Barry KJ, Goghan MA, Bennett M, Stein MD. Small animal model for 
investigation of subarachnoid haemorrhage and cerebral vasospasm. Stroke 
10(5):538-541, 1979.
31 Bates JN, Baker MT, Guerra R Jr, Harrison DG: Nitric oxide generation from 
Nitroprusside by vascular tissue: evidence that reduction of the nitroprusside 
anion and cyanide loss are required. Biochem Pharmacol 42:5157-5165, 1991.
32 Baumbach GL, Heistad DD. Heterogeneity of brain blood flow and permeability 
during acute hypertension. Am J Physiol 249: H629-37, 1985.
33 Baumbach GL, Siems JE, Faraci FM, Heistad DD. Mechanics and composition 
of arterioles in brainstem and cerebrum. Am J  Physiol 256:H493-501, 1989.
299
34 Bay down AR, Bogle RG, Pearson JD, Mann GE. Discrimination between 
citrulline and arginine transport in activated murine macrophages; inefficient 
synthesis of nitric oxide from recycling of citrulline to arginine. Br J  Pharm 
112:487-492, 1994.
3 5 Bayliss WM: On the local reactions of the arterial wall to changes of internal 
pressure. J  Physiol (Lond) 28: 230-241, 1902.
36 Beard EF, Robertson JW, Robertson RCL. Spontaneous subarachnoid 
haemorrhage simulating acute myocardial infarction. Am Heart J  58:755-9,
1959.
37 Beasely D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L- 
arginine-dependent cGMP and nitrite production in rat vascular smooth muscle 
cells. J  CLin Invest 87:602-608, 1991.
38 Beckman DL, lams SG. Circulating catecholamines in cats before and after lethal 
head injury. Proc Soc Exp Biol Med 160:200-202, 1979.
39 Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent 
hydroxyl radical production by peroxynitrite: implications for endothelial injury 
from nitric oxide and superoxide. Proc Natl Acad USA 87:1620-1624, 1990.
40 Bederson JB, Germano IM, Gaurino L: Cortical blood flow and cerebral perfusion 
pressure in a new noncraniotomy model of subarachnoid hemorrhage in the rat. 
Stroke 26:1086-92, 1995.
41 Bederson JB, Levy AL, Ding WH, Kahn R, DiPema C, Jenkins AL, 
Vallabhajosyula P: Acute vasoconstriction after subarachnoid hemorrhage. 
Neurosurgery 42(2):352-62, 1998.
42 Beitner R, Haberman S, Cycowitz T. The effect of cGMP on 
phosphofructokinase from rat tissues. Biochem Biophys Acta 482:330-340, 
1977.
43 Bevan JA, Su C. Effectiveness of adrenergic transmitter concentrations in 
synaptic clefts of differing dimensions. In Frontiers in catecholamine research. 
by E. Uschin and S.Snyder (Ed), Pergamon press New York, 1973, pp 575-77.
44 Bevan JA, Osher JV. A direct method for recording tension changes in the wall 
of small blood vessels in vitro. Agents Actions 2:257-260, 1972.
45 Bevan JA, Duckies SP, Lee TJF. Histamine potentiation of nerve and dmg- 
induced response of rabbit cerebral artery. Cir Res 36:647-653, 1975.
46 Bevan JA, Bevan RD, Frazee JG; Functional arterial changes in chronic 
cerebrovasospasm in monkeys: An in vitro assessment of the contribution to 
arterial narrowing. Stroke 18:472-481, 1987.
47 Bevan RD, Bevan JA: Diltiazem protects against functional changes in chronic 
cerebrovasospasm in monkeys. Stroke 19:73-79, 1988.
48 Bevan JA, Bevan RD, Frazee JG. Increased arterial wall stiffness and abnormal 
tone contribute to arterial narrowing in chronic cerebral vascular spasm in the 
monkey: protection by diltiazem pretreatment. In Cerebral Vasospasm, Wilkins 
RH (ed). Raven press. New York, 1988, pp 463-8.
49 Bevan RD, Dodge JT, Wellman T, Walters CL, Bevan JA: Is there a neurogenic 
influence on the diameter of human small pial arteries? In The human brain 
circulation: functional changes in disease, Bevan RD, Bevan JA (Eds), Humana 
press, Totowa, New Jersey, 1994, pp 93-107.
50 Bevan RD, Dodge J, Nichols P, Penar PL, Walters CL, Wellman T, Bevan JA: 
Weakness of sympathetic neural control of human pial compared with superficial
300
temporal arteries reflects low innervation density and poor sympthetic 
responsiveness. Stroke 29:212-221, 1998.
51 Bill A, Linder J: Sympathetic control of cerebral blood flow in acute arterial 
hypertension. Acta Physiol Scand 96:114-121, 1976.
52 Black P McL. Hydrocephalus and vasospasm after subarachnoid haemorrhage 
from ruptured intracranial aneurysms. Neurosurgery 18:12-16, 1986.
53 Blaine EM, Tallman RD, Frolicher D, Jordan MA, Bluth LL, Howie MB. 
Vasopressin supplementation in a porcine model of brain dead potential organ 
donors. Transplantation 38; 459-464, 1984.
54 Bobik A, Campbell JH, Carson V, Campbell GR. Mechanism of isoprenaline- 
induced refractoriness of the P-adrenoceptor-adenyl cyclase system in chick 
embryo cardiac cells. J Cardiovasc Pharmacol 3:541-553, 1981.
55 Bogle RG, Vallance P. Econazole inhibition of the induction of nitric oxide 
synthase in lipopolysaccharide treated rat aorta. Br J Pharmacol 114:13OP,
1995
56 Bukowski RD, Wang SN, Bian K, DeWitt DS: Traumatic brain injury does not 
alter cerebral artery contractility. Am J Physiol 272(Heart Circ. Physiol 
41):H1406-H1411, 1997.
57 Boullin DJ, Mohan J, Grahame-Smith DG. Evidence for the presence of a vaso­
active substance (possibly involved in the aetiology of cerebral arterial spasm) in 
cerebrospinal fluid from patients with subarachnoid haemorrhage. J Neurol 
Neurosrg Psych 39:756-66, 1976.
58 Boullin OJ, Brandt T, Ljungren B Vasoconstrictor activity in cerebrospinal fluid 
from patients subjected to early surgery for ruptured intracranial aneurysms. J 
Neurosurg 55:237-245, 1981.
59 Brackett CE. Systemic complications of central nervous system trauma. In:
CNS trauma research status report, Odom GL ed., 1979, Washington DC:
Public health service 1979: pp 232-263.
60 Brady AJB, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE. Nitric oxide 
attenuates cardiac myocyte contraction. Am J Physiol 265:H176-182, 1993.
61 Brady AJB, Wilson PA, Harding SE, Warren JB. Nitric oxide production 
within cardiac myocytes reduces their contractility in endotoxaemia. Am J 
Physiol 263-.H1963-I966, 1992.
62 Brady AJB, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production 
within cardiac myocytes reduces their contractility in endotoxaemia. AM J 
Physiol 263.H1963-1966, 1992.
63 Brandt L, Ljunggren B, Andersson K-E, Hindfelt B: Individual variations in 
response of human cerebral arterioles to vasoactive substances, human plasma, 
and CSF from patients with aneurysmal SAH. J Neurosurg 55:431-437, 1981.
64 Brandt L, Ljunggren B, Anderson KE et al: Effects of indomethacin and 
prostacyclin on isolated human pial arteries contracted by cerebrospinal fluid from 
patients with aneurysmal subarachnoid haemorrhage. J Neurosurg 55:877-83,
1981.
65 Bray JJ, Cragg PA, MacKnight ADC, Mills RG, Taylor DW. The cardiovascular 
system, m Lecture notes on human physiology, 1986, pp324-417.
66 Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera 
P, Menlove R, Shah P, Jamieson S, Stinson EB. pi and P2 adrenergic 
subpopulations in nonfailing and failing human ventricular myocardium: coupling
301
of both receptor subtypes to muscle contraction and selective pi receptor down 
regulation in heart failure. Cir Res 59:297-309, 1986.
67 Bristow MR, Anderson FL, Port JD, Skeri L, Hershberger RE, Larrabee P, 
O'Connell JB, Renlund DG, Volkmana K, Murray J Feldmana AM. Differences 
in p adrenergic neuroeffector mechanisms in ischaemic versus idiopathic dilated 
cardiomyopahty. Circulation 84:1024-1039,1991.
68 Branston NM, Symon L, Crockard HA et al. Relationship between the cortical 
evoked potential and local cortical blood flow following acute middle cerebral 
artery occlusion in the baboon. Exp Neurol 45: 195-208, 1974.
69 Browder J, Meyers R. Behaviour of the systemic blood pressure, pulse rate, and 
spinal fluid pressure associated with acute changes in intracranial pressure 
artificially produced. Arch Surg (Chic) 36:1-19, 1936.
70 Brown JM, White CW, Terada LS, Grosso MA, Shanley PF, Mulvin DW, 
Banerjee A, Whitman GJR, Harken AH, Repine JE. Interleukin 1 pre-treatmnent 
decreases ischaemia-reperfusion injury. Prod Natl Acad Sci USA 87: 5026- 
5030, 1990.
71 Bülbring E, Torrdta T: Catecholamine action on smooth muscle. Pharm Rev 
29(l);49-96, 1987.
72 Bunemann L, Jensen KA, Riisager S, Thomsen LJ. Cerebral blood flow and 
metabolism during hypotension induced with sodium nitroprusside and 
metoprolol. Eur J Anaesthesiology 8:197-201, 1991
73 Burgen ASV, Mitchell JF. In Gaddum's Pharmacology, 8th ed., Oxford 
university press. New York, Toronto, 1981.
74 Burnstock G, McCullock MW, Story DF, Wright ME. Factors affecting the 
extraneuronal activation of noradrenaline in cardiac and vascular smooth muscle 
cells. Br J Pharm 46:243-53, 1972
75 Busse R, Mulsch A, Fleming I, Hecker M. Mechanisms of nitric oxide release 
from the vascular endothelium. Circulation 87(suppl V ) :  18-25, 1993.
76 Buus NH, VanBavel E, Mulvany MJ. Differences in sensitivity of rat mesenteric 
small arteries to agonists when studied as ring preparations or as cannulated 
preparations. B rJ Pharmacol 112:579-87, 1994.
77 Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman 
KP, Molinoff PB, Ruffolo RR Jr, Trendelenberg U. IV. International union of 
Pharmacology nomenclature of adrenoceptors. Pharm rev 46(2): 121-136, 1994.
78 Campbell JH, Campbell GR. Potential role of heparanase in atherosclerosis. New 
Phys Sci 4; 9-12, 1989.
79 Cannon WB, Rosenbleuth A. The supersensitivity o f denervated structures, 
MacMillan, New York, 1949.
80 Carpenter DA, Grubb RL Jr, Tempel LW et al. Cerebral oxygen metabolism after 
aneurysmal subarachnoid haemorrhage. J Cerebr Blood Flow & Metab 11:837- 
842, 1991.
81 Carruthers ME, Patel S. Reduction of stress/catecholamine induced cardiac 
necrosis by (H selective blockade. Lancet 2:585-9, 1987.
82 Casscelles W, Willesron JT. Endogenous and exogenous nitric oxide protect 
against intracoronary thrombosis and reocclusion after thrombolysis. Circualtion 
92:1005-1010, 1995.
302
83 Casteels R, Kitamura K, Kuriyama H, Suzuki H; The membrane properties of the 
smooth muscle cells of the rabbit main pulmonary artery. J Physiol 271:41-61, 
1977.
84 Castellot JJ Jr, Cochrane DL, Karnovsky MJ. Effect of heparin on vascular 
smooth muscle cells. I Cell metabolism. J Cell Physiol 124:21-28, 1985.
85 Centeno JM, Orti M, Salom JB, Sick TJ, Perez-Pinzen MA: Nitric oxide is 
involved in anoxic preconditioning neuroprotection in rat hippocampal slices. 
Brain Res 836(1-2):62-9, 1999.
86 Charcot JM: Sur un cas de migraine othalmologique (paralysie oculomotrice 
périodique). ProgrMed 18:83, 1890.
87 ChehraziBB, Youmans JR. Cerebral blood flow in clinical neurosurgery. In 
Neurological Surgery 3rd Ed, Youmans JR (ed)WB Saunders Co, Harcourt 
Brace Jovanovich Inc, Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, 
1990, Vol 2, Ch 24, pp 696-740
88 Chen HI, Sun SC, Chai CY Pulmonary oedema and haemorrhage resulting from 
cerebral compression. Am J  Physiol 224:223-29, 1973.
89 Cheng GC, Libby MD, Grodzinsky AJ, Lee RT. Induction of DNA synthesis by a 
single transient mechanical stimulus of human vascular smooth muscle cells: role 
of fibroblast growth factor - 2. Circulation 93:99-105 1996.
90 Chertok VM: [Mast cells of the outer coat of the arteries of the basis cerebri] 
Arkh Anat Gistol Embriol 79:72-79, 1980 (Rus)
91 Chi OZ, Wei HM, Weiss HR. Effects of CAS 754, a new nitric oxide donor, on 
regional cerebral blood flow in focal cerebral ischaemia. Anaesthesia and 
analgesia 80(4): 703-708, 1995.
92 Cirino G, Tigley AW, Wallace JG, Baydown AR. Inhibition of zNOS expression 
in J774 cells by the novel NSATD Flurbiprofen-nitroxybutylester (FNBE). Br J 
Pharmacol 114:13 IP, 1995
93 Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG. Mechanism of 
cytokine inhibition of P adrenergic agonist stimulation of cyclic AMP in rat 
cardiac myocytes: impairment of signal transduction. Cir Res 67:753-753, 1990.
94 Chyatte D, Sundt TM. Cerebral vasospasm: evidence supporting an inflammatory 
aetiology. In Cerebral Vasospasm, Wilkins RH (ed). Raven press. New York, 
1988, pp 357-365.
95 Clarke JA: An X-ray microscopic study of the vasa vasorum of the intracranial 
arteries. Ztsch Anat Entwickl 124:396-400, 1965.
96 Clarkson CW, Eick RE: On the mechanism of lysophosphatidylcholine-induced 
depolarization of cat ventricular myocardium. Circ Res 52:543-556, 1983.
97 Clavier N, Kirsch JR, Hum PD, traystman RJ. Effect of post-ischaemic 
hypoperfusion on vasodilatory mechanisms in cats. Am J Physio 267(5pt2):H 
2012-2028, 1994.
98 Clouse RE. In Gastrointestinal disease: pathophysiology, diagnosis, and 
management, 4th Ed., Sleisenger MH, Fordtran JS (Eds), WB Saunders Co, 
Harcourt Brace Jovanovich, Inc., Philadelphia, London, Toronto, Montreal, 
Sydney, Tokyo, 1989, pp 567-569.
99 Clouston JE, NumagucM Y, Zoarski GH, Aldrich EF, Simard JM, Zitnay KM. 
Intra-arterial papaverine infusion for cerebral vasospasm after subarachnoid 
haemorrhage. Am J Neuroradiology 16(1):27-3 8, 1995
303
100 Glower BR, Smith RR, Haining JL, Lockard J: Constrictive endarteropathy 
following experimental subarachnoid haemorrhage. Stroke 12(4);501-508, 1981.
101 Glower BR, Sullivan DM, Smith RR: Intracranial vessels lack vasa vasorum. J 
Neurosurg 61:44-48, 1984.
102 Clyde BL, Firlik AD, Kaufmann AM, Spearman MP, Yonas H. Paradoxical 
aggravation of vasospasm with papaverine infusion following aneurysmal 
subarachnoid haemorrhage. J Neurosurg 84:690-695, 1996
103 Cockerham LG, Prell GD, Cerveny TJ, O'Brien M, Hampton JD. Effects of 
aminoguanidine on pre- and post- irradiation rCBF, sytemic BP and plasma 
histaminelevels in the primate. Agents and actions 32 (3-4):237-244, 1991.
104 Cohn JN, Levine BT, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, 
Rector T. Plasma norepinephrine as a guide to prognosis in patients with 
congestive cardiac failure. N Eng J Med 311:819-823, 1984.
105 Coleman RA, Smith WL, Narumiya S: VIII. International union of 
pharmacology classification of prostanoid receptors: properties, distribution, and 
stmcture of the receptors and their subtypes. Pharm Rev 46(2):205-229, 1994.
106 Colohan ART, Zuccarello M, Kassell NF, Quaqiarello V, Scheld WM, Nazar G, 
Sasaki T. Permeability changes in the major cerebral arteries in experimental 
meningitis. In Cerebral Vasospasm, Wilkins RH (ed). Raven press. New York, 
1988, p p  367-72.
107 Conway LW, McDonald LW. Structural changes of the intradural arteries 
following subarachnoid haemorrhage. J Neurosurg 37:715-723, 1972.
108 Cook DA. The pharmacology of cerebral vasospasm. Pharmacol 29:1-16, 1984.
109 Cooper Sir AP. Lectures on the principles and practice o f Surgery. Vol 1 300 
Underwood London 1824.
110 Coyle P. Collateral pial arteries. In: The human brain circulation: functional 
changes in disease, Bevan RD, Bevan JA (Eds), Humana press, Totowa, New 
Jersey, 1994, pp 237-246.
111 Crompton MR. Cerebral infarction following the rupture of cerebral berry 
aneurysms. Brain 87:491-510, 1964.
112 Crowe SE, Perdue MH. Gastrointestinal food hypersensitivity: basic mechanisms 
of pathophysiology. Gastroenterology 103:1075-95, 1992.
113 Cruikshank JM, Neil-Dwyer G, Degaute JP, Hayes Y, Kuurne T, Kytta J, Vincent 
JL, Carruthers ME, Patel S. Reduction of stress/catecholamine induced cardiac 
necrosis by (31 selective blockade. Lancet 2:585-589, 1987.
114 Cushing H. Concerning a definite regulatory mechanism of the vasomotor centre 
which controls blood pressure during cerebral compression. Bull John Hopkins 
Hosp 12:290-2, 1901.
115 Cushing H. Some experimental and clinical observations concerning states of 
increased intracranial pressure. Am J  Med Sci 124:375-400, 1902.
116 Cushing H. The blood-pressure reaction of acute cerebral compression, 
illustrated by cases of intracranial haemorrhage. Am J  Med Sci 125:1017-1045, 
1903.
117 Cushing H. Studies in intracranial physiology and Surgery. London Oxford 
university press 1925
118 Cutler RWP, Page L, Galicich J et al. Formation and absorption of cerebrospinal 
fluid in man. Brain 91:707-720, 1968.
304
119 D-Alecy L, Feigl EO. Sympathetic control of cerebral blood flow in dogs. Cir 
Res 31:267-283, 1972.
120 Davis MJ, Gore RW. Capillary pressures in rat intestinal muscle and mucosal villi 
during venous pressure elevation. Am J Physiol 249: H174-187, 1985
121 Davson H, Hollingsworth G, Segal MB. The mechanism of drainage of the 
cerebrospinal fluid. Brain 93:665-678, 1970.
122 Debbage PL, Dwyer D, Meyermann R. In Cerebral vascular spasm Voth D, 
Glees P, deGruyter, 1985, pp 41-48.
123 Debdi M, Seyiaz J, Sercombe R. Early changes in rabbit cerebral artery reactivity 
after subarachnoid haemorrhage. Stroke 23(8): 1154-1162, 1992.
124 Debdi M, Seyiaz J, Sercombe R. Influence of calcium and nicardipine on rabbit 
basilar artery reactivity after brief subarachnoid haemorrhage. J Cardiovasc 
Pharm 21(5):754-759, 1993.
125 De Beider AJ, Radomski M, Why HJF, Richardson PJ, Bucknall CA, Salas E, 
Martin JF, Moncada S. Nitric oxide synthase activities in human myocardium. 
Lancet 341: 84-85, 1993.
126 Delgado TJ, Brismar J, Svengaad NA. Subarachnoid haemorrhage in the rat: 
angiography and fluorescence microscopy of the major cerebral arteries. Stroke 
16(4):595-601, 1985.
127 De Mey JG, Vanhoutte PM. Heterogeneous behaviour of the canine arterial and 
venous wall. Importance of the endothelium. Circ Res 51:439-447, 1982.
128 De Wilt DJ. Etomidate-anaesthesia, with and without fentanyl, compared with 
urethane-anaesthesia in the rat. BJPharm 79:461-9, 1983.
129 Dietrich HH, Dacey RG jr. Effects of extravascular acidification and 
extravascular alkalinization on constriction and depolarization in rat cerebral 
arterioles. J Neurosurg 81:437-442, 1994.
130 Dinning TAR, Falconer MA. Sudden or unexpected natural death due to 
ruptured intracranial aneurysm. Suiwey of 250 forensic cases. Laucet 2:799-810, 
1953.
131 Docherty JR: Functional changes in the aging cerebrovasculature. In: The human 
brain circulation: functional changes in disease, Bevan RD, Bevan JA (Eds), 
Humana press, Totowa, New Jersey, 1994, pp 109-116.
132 Doczi T, Joo F, Sonkodi S, Adam G. Increased vulnerability of the blood brain 
barrier to experimental subarachnoid haemorrhage in spontaneously hypertensive 
rats. Stroke 17(3);498-501, 1986.
133 Doczi T, Joo F, Vecsernyés M, Bodosi M. Increased concentration of atrial 
natriuretic factor in the cerebrospinal fluid of patients with aneuiysmal 
subarachnoid haemorrhage and raised intracranial pressure. Neurosurgery 
23(1): 16-19, 1988
134 Dorsch NWC, King MT. A Review of cerebral vasospasm in aneurysmal 
subarachnoid haemorrhage. J Clin Neurosci 1:19-26, 1994.
135 Downey JM. Ischaemic preconditioning: nature's own cardioprotective 
intervention. Trends Cardiovasc Med 2:170-176, 1992.
136 Draper I. Lecture notes on Neurology, Sixth ed. Blackwell scientific productions 
C hl3 , 1984, p 123.
137 Drapier JC, Hibbs JB Jr. Murine cytotoxic macrophage inhibit aconitase in 
tumour cells. J Clin Invest 78:790-797, 1986.
305
138 Drenth JPH, Nishimura J, Nouailhetas VLA, van Breemen C. Receptor-mediated 
C-kinase activation contributes to alpha-adrenergic tone in rat mesenteric 
resistance artery. JHypertension 7(S4);S41-S45, 1989.
139 Du Boulay GH, Verity PM. In The cranial arteries o f mammals, Heineman, 
London 1973.
140 Duckies SP, Bevan JA. Pharmacological characteristics of adrenergic receptors 
of a rabbit cerebral artery in vitro. J. Pharmacol Exp Ther 197 (2):371-378 
1976.
141 Duckies SP, Rim J, Bevan RD, Bevan JA. Alteration of innervation and reactivity 
of monkey cerebral arteries after subarachnoid haemorrhage, Stroke 8:10, 1977.
142 Duckies SP, Kim J, Bevan RD: In vitro studies of monkey cerebral arteries after 
subarachnoid hemorrhage. Acta Neurol Scand Suppl 64:314-5, 1977.
White RP: Vasodilator proteins: role in delayed cerebral vasopsasm. Stroke 
17(2):207-213, 1986.
143 Duff TA, Feilbach JA, Yusuf Q, McGucken R, Scott G. In Cerebral Vasospasm, 
Wilkins RH (ed). Raven press. New York, 1988, pp 303-9.
144 Duff TA, Feilbach JA, Yusuf Q, McGucken R, Scott G. Bilirubin and the 
induction of intracranial spasm. JNeurosurg:69:593-98, 1988.
145 Eccles R, Eccles KSJ: Asymmetry in the autonomic nervous system with 
reference to the nasal cycle, migraine, anisocoria, and Meniere's syndrome. 
Rhinology 19:121-5, 1981
146 Ecker A, Riemenschneider PA. Artériographie demonstration of spasm of the 
intracranial arteries with special reference to saccular arterial aneurysms. J 
Neurosurg 8:660-667, 1951.
147 Eckly AE, Lugnier C. Role of phosphodiesterase III and IV in the modulation of 
vascular cAMP content by the nitric oxide/cGMP pathway. Br J Pharm 
113:445-450, 1994.
148 Echlin F. Experimental vasospasm, acute and chronic, due to blood in the 
subarachnoid space. J Neurosurg 35:646-656, 1971.
149 Edvinsson L, MacKenzie ET. Amine mechanisms in the cerebral circulation. 
Pharmacol Rev 28; 275-348, 1976.
150 Edvinsson L, Owman C, Sjoberg N-O. Autonomic nerves, mast cells and amine 
receptors in human brain vessels. A histochemical and pharmacological study. 
Brain Res 115:377-393, 1976.
151 Edvinsson L, Owman CH. A Pharmacologic comparison of histamine receptors in 
isolated extracranial and intracranial arteries in vitro. Neurology (Minueap) 
25:271-276, 1975.
152 Edvinsson L, Jansen JR: Perivascular neuropeptides (NPY, VIP, CGRP, and SP) 
in human brain vessels after subarachnoid hemorrhage. Acta Neurol Scand 
90:324-330, 1994.
153 Eisenberg HM, Gray HE Jr, Aldrich EF et al. Initial CT findings in 753 patients 
with severe head injury: a report from NTH traumatic coma database. J 
Neurosurg 73:688-698, 1990.
154 Edvinsson L, Cervos-Navarro, Larsson LI et al. Regional distribution of mast 
cells containing histamine, dopamine, or 5HT in the mammalian brain. Neurology 
27:878-883, 1977.
306
155 Edwards DH, Byrne JV, Griffiflh TM. The effect of chronic subarachnoid 
haemorrhage on basal endothelial derived relaxing activity in intrathecal cerebral 
arteries. J.Neurosurg 76(5): 830-837, 1992.
156 Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of 
impaired endothelial derived coronary vasodilation in patients with angina pectoris 
and normal coronary angiograms. N Eng J Med 328:1659-1664, 1993.
157 Egeman N, Turker RK, Sanlidilek U, Zorlutuna A, Bilgic S, Baskaya M, Unlu A, 
Caglar S, Spetzler RF, McCormick JM. The effect of intrathecal sodium 
nitroprusside on severe chronic vasospasm. Neurological Research 15(5): 310- 
315 1993.
158 Eichbaum FW, Bisetti PC. Effect of head injury and acute intracranial 
hypertension the cardiovascular system. In Third international congt^ess o f 
Neurological surgeiy, Copenhagen 1965, Exceipta med (Amst), International 
congress series, 1965, No 93, pp 163-4.
159 El-Ackad TM, Brody MJ. Fluorescent histochemical localization of non-mast cell 
histamine, m Neuropsychopharmacolgy, Amsterdam: Excerpta Medica, 1974, 
Series 359, pp551-559.
160 Enevoldsen EM, Cold G, Jensen FT et al. Dynamic changes in rCBF, I VP, CSF 
pH and lactate levels during acute phase head injury. Neurosurgery 44:191-215, 
1976.
161 Emery AEH: In Elements o f medical Genetics, Churchill Livingstone, Edinburgh, 
London, Melbourne, New York 1983, p i56.
162 Emmelin N, Trendelenberg U. Degeneration activity after parasympathetic or 
sympathetic deneivation. Erberg Physiol 6:190-211, 1972.
163 Espinosa F, Weir B, Noseworthy T. Non-operative trreatment of subarachnoid 
haemorrhage. In Neurological Surgery, 3rd Ed, Vol 3, Youmans JR, WB 
Saunders Co, 1990 page 1668.
164 Essik CR. Formation of macrophages by the cells lining the subarachnoid cavity 
in response to the stimulus of particulate matter. Contribution 272, Carnegie Inst 
Washington, 1920, pp377-388.
165 Evans HG, Lewis JM, Shah AM. IL-lp modulates myocardial contraction via 
dexamethasone sensitive production of nitric oxide. CardiovascRes 27:1486-90, 
1993.
166 Faleiro LCM, Machado CRS, Gripp A Jr et al : Cerebral vasospasm: presence of 
mast cells in human cerebral arteries after aneurysm rupture. Preliminary note: J 
Neurosurg 54:733-735, 1981.
167 Falloon BJ, Stephens N, Tulip JR, Heagerty AM. Comparison of small artery 
sensitivity and morphology in pressurized and wire-mounted preparations. Am J 
Physiol 268(Heart circ physiol 37): H670-678, 1995.
168 Faraci FM, Mayhan WG, Heistad DD. Segmental vascular responses to acute 
hypertension in cerebrum and brainstem. Am J Physiol 253:H73 8-42, 1987.
169 Feelisch M, Noack E. Nitric oxide (NO) formation from nitrovasodilators occurs 
independently of Hb or non-haeme Fe. Eur J Pharmacol 142:465-9, 1987.
170 Fein JM, Flor WJ, Cohan SL, Parkhurst J. Sequential changes of vascular 
ultrastructure in experimentla vasospasm. Myonecrosis of subarachnoid arteries.
J  Neurosurg 41:49-58, 1974.
171 Ferrendelli JA, Blank AC, Gross RA. Relationships between seizure activity and 
cyclic nucleotide levels in brain. Brain Res 200:93-103, 1980.
307
172 Feldman AM, Cates AE, Veazey WB, Herschberger RE, Bristow MR, Baughman 
KL, Baumgartner WA, Van Dop C Increase of the 40,000 mol-wt pertussis 
toxin substrate (G protein) in the failing human heart. J Clin Invest 82:189-97,
1988.
173 Findlay IM, Weir BKA, Steinke D, Tanabe T, Gordon P, Grace M. Effect of 
intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a 
primate model of subarachnoid haemorrhage. J Neurosurg 69:723-735, 1988.
174 Findlay JM, Weir BKA, Kanamura MD, Espinosa F. Arterial wall changes in 
cerebral vasospasm. Neurosurgery 25(5):736-745, 1989.
175 Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role or platelets 
in smooth muscle proliferation and migration after vascular injury in rat carotid 
artery. Prod Natl Acad Sci USA 86:8412-8416, 1989.
176 Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL.
Negative inotropic effects of cytokines on the heart mediated by nitric oxide. 
Science 257: 387-389, 1992.
177 Fisher MD, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid 
haemorrhage visualized by CT scanning. Neurosurgery 6:1-9, 1980.
178 Fishman JA, Ryan GB, Karnovsky MJ. Endothelial regeneration in the rat carotid 
artery and the significance of endothelial denudation in the pathogenesis of 
myointimal thickening. Lab Invest 32:339-351, 1977.
179 Fitch W, MacKenzie ET, Harper AM. Effects of decreasing arterial blood 
pressure on cerebral blood flow in the baboon. Influence of the sympathetic 
nervous system. Circ Res 37:550-557, 1975.
180 Fitch W, McDowall DG, Keaney MP, Pickerodt VWA. Systemic vascular 
responses to increased ICP. 2. The "Cushing" response in the presence of 
intracranial space occupying lesions; systemic and cerebral heamodynamic studies 
in the dog and the baboon. J Neurol Neurosurg Psychiatry 40:843-852, 1977.
181 Fleming W, Westphal DP: In Catecholamines vol I, Handbook o f experimental 
pharmacology, Springer-Verlag, Berlin, Heidelberg, New York, 90,1989, pp 509- 
559.
182 Foldes FF, Arrowood JG. Changes in cerebrospinal fluid pressure under the 
influence of continuous subarachnoid infusion of normal saline. J din Invest 
27:346-351, 1948.
183 Foley PL, Takenaka K, Kassell NF, Lee KS. Cytotoxic effects of bloody 
cerebrospinal fluid on cerebral endothelial cells in culture. J Neurosurg 81:87- 
92, 1994.
184 FolkowB. Introduction and historical background. J Hypertension 
7(suppl4):Sl-S4, 1989.
185 Folkow B, Neil E. In Circulation, London, Oxford University press, 1971.
186 Forbus WD. On the origin of miliary aneurysms of the superficial cerebral 
arteries. Bull John Hopkins Hosp 47:239-84, 1930.
187 Forstermann U, Muge A, Alheid U, Haverich A, Frolich JF. Selective attenuation 
of endothelial-mediated vasodilation in atherosclerotic human coronary arteries. 
Circ Res 62:185-190, 1988.
188 Fox JL, Ko JP. Cerebral vasospasm: a clinical observation. Surg Neurol 
10:269-275, 1978.
189 Fox JL. In Intracranial aneurysms, Vlev/York, Springer-Verlag, 1983.
308
190 Fraser RA, Stein BM, Barret RE, Pool JL; Noradrenergic mediation of 
experimental cerebrovascular spasm. Stroke 1(5):356-362, 1970.
191 Frazee JG. A primate model of chronic cerebral vasospasm. Stroke 13:612-614, 
1982.
192 Frazee JG, Bevan JA, Bevan RD, Jones KR: Effect of diltiazem on experimental 
chronic cerebral vasospasm in the monkey. J Neurosurg 62:912-17, 1985.
193 Fredericks KT, Liu Y, Rusch NJ, Lombard JH. Role of endothelium and arterial 
potassium channels in mediating hypoxic dilation of middle cerebral arteries. Am  
J  Physiol 267(Heart Circulation physiology 36): H580-586, 1994.
194 Freedman R, Taylor D, Seiger A, Olson L, Hoffer B. Seizures and related 
epileptiform activity in hippocampus transplanted to the anterior chamber in the 
eye. II Modulation by cholinergic and adrenergic input. Ann Neurol 6:281-293, 
1979.
195 Froman C, Smith AC. Metabolic acidosis of the cerebrospinal fluid associated 
with subarachnoid haemorrhage. Lancet 1:965-967, 1967.
196 Fujii S, Fujitsu K. Experimental vasospasm using cultured arterial smooth muscle 
cells. Part 1 : contractile and ultrastructural changes caused by oxyhaemoglobin.
J Neurosurg 69:92-97, 1988.
197 Furchgott RF. The role of endothelium in the response of vascular smooth muscle 
to drugs. Annu Rev Pharmacol Toxicol 24:175-197, 1984.
198 Furlong B, Henderson AH, Lewis MJ, Smith JA. Endothelial derived relaxing 
factor inhibits in vitro platelet aggregation. Br J Pharmacol 90:687-692, 1987.
199 Furuya M, Aisaka K, Miyazaki T, Honbou N, Kawashima K, Ohno T, Tanaka S, 
Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide inhibits intimai 
thickening after vascular injury. Biochem Biophys Res Comm 193(l):248-253,
1993.
200 Fyhrquist F, Sirvio ML, Helin K, Saijonmaa O, Metsarinne K, Paakari I,
Jarvinen A, Tikkanen I. Endothelin antisemm decreases volume-stimulated and 
basal plasma concentration of atrial natriuretic peptide. Circulation 88:1172- 
1176, 1993.
201 Gaboury JP, Niu XF, Rubes P. Nitric oxide inhibits numerous features of mast 
cell-induced inflammation. Circulation 93:318-326, 1996.
202 Galli SJ. New concepts about the mast cell. N Eng J Med.328:257-265, 1993.
203 Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromocycIic 
GMP inhibits mitogenesis and proliferation of cultured rat vascular smooth muscle 
cells. J Clin Invest 83:1774-1777, 1989.
204 Geng Y-J, Hartwig JH, Hansson GK, Libby P. Cytokine-induced apoptosis of 
actin cytoskeletons and nucleolysis. J Cardiovasc Trauma 33(l):abstr 111, p29.
205 Geng Y-J, Wu Q, Hansson GK. Protein Kinase C activation inhibits cytokine- 
induced nitric oxide synthase in vascular smooth muscle cells. Biochem Biophys 
Acta 1223(1) 125-132, 1994.
206 Geng Y-J, Wu Q, Muszynshi M, Hansson GK, Libby P. Apoptosis of vascular 
smooth muscle cells induced by in vitro stimulation with interferon y, tumour 
necrosis factor a , and interleukin-1-(3. Arteriosclerosis, thrombosis, and 
vascular biology 16(1): 19-27, 1996.
207 Gerzer R, Karrenbrock B, Siess W, Heim JM. Direct comparison of the effects of 
nitroprusside, SIN 1 and various nitrates on platelet aggregation and soluble 
guanylate cyclase activity. Thromb Res 52:11-21, 1988.
309
208 Gibbons GH, Dzau VJ. The emerging concept of vascular remodelling. N Eng J 
Med 330:1431-8, 1994.
209 Gibson QH, Roughton FJW. The kinetics and equilibria of the reactions of nitric 
oxide with sheep haemoglobin. J  Physiol 136:507-526,1957.
210 Gilby KL, Armstrong JN, Currie RW, Robertson HA: The effects of hypoxia- 
ischemia on expression of c-Fos, c-Jun and Hsp70 in the young rat hippocampus. 
Brain res 48(l):87-96, 1997.
211 Giller CA, Purdy P, Giller A, Batjer HH, Kopitnik T. Elevated transcranial 
doppler ultrasound velocities following therapeutic arterial dilation. Stroke 
26(1): 123-127, 1995.
212 Goluboff B, Shenkin HA, Haft H. The effects of mannitol and urea on cerebral 
haemodynamics and cerebrospinal fluid pressure. Neurology (minneapolis) 14: 
891-898, 1964.
213 Gonzalez NC, Oberman J and Maxwell JA. Circulatory effects of moderately and 
severely increased intracranial pressure in the dog. J  Neurosurg 6:721-726,
1972.
214 Graf CJ, Rossi NP. Catecholamine response to intracranial hypertension. J 
Neurosurg 49: 862-868, 1968.
215 Grady MS, Cooper GW, Kassell NF, Login IS: Profound cerebral vasospasm 
without radiological evidence of subarachnoid haemorrhage; case report. 
Neurosurgery 18:653-659, 1986.
216 Granger DL, Lehninger AL. Sites of inhibition of mitochondrial electron 
tranpsort in macrophage-injured neoplastic cells. J Cell Biol 95:527-535, 1982.
217 Graser T, Leisner H, Tiedt N. Absence of a role of endothelium in the response 
of isolated porcine coronary arteries to acetylcholine. Cardiovasc Res 20:299- 
302, 1986.
218 Grennhoot JH, Reichenbach DD. Cardiac injury and subarachnoid haemorrhage: 
a clinical, pathological, and physiological correlation. J Neurosurg 30:521-531, 
1969.
219 Grifftfth TM, Edwards DH, Lewis MJ et al. The nature of the endothelial derived 
relaxing factor. Nature 308:645-647, 1984 (letter).
220 Gross PM. Cerebral histamine; indications for neuronal and vascular regulation.
J Cereb Blood Flow & M etab 2:3-23, 1982
221 Grote E, Hassler W. The critical first few minutes after subarachnoid 
haemorrhage. Neurosurgery 22:654-661, 1988.
222 Grubb RL Jr, Phelps ME, Raichle ME et al: The effects of arterial blood 
pressureon the regional cerebral blood volume by X-Ray fluorescence. Stroke 4: 
390-399, 1973.
223 Grubb RL Jr, Raichle ME, Phelps ME et al. Effects of increased intracranial 
pressure on cerebral blood volume, cerebral blood flow and oxygen utilization in 
monkeys. J Neurosurg 43 385-398, 1975.
224 Grubb RL Jr, Raichle ME, Eichling JO Gado MH Effects of subarachnoid 
haemorrhage on cerebral blood volume, cerebral blood flow and oxygen 
utilization in humans. J Neurosurg 46:446-453, 1977.
225 Gulick T, Pieper SJ, Murphy MA, Lange LG, Schreiner GF. A new method for 
assessment of cultured cardiac myocyte contractility detects immune facto- 
mediated inhibition of (3-adrenergic responses. Circulation 84:313-321, 1991.
310
226 Gustafsson H, Mulvany MJ, Nilsson H. Rhythmic contractions of isolated small 
arteries from rats; influence of the endothelium. Acta Physiologica Scand 
148(2);153-163, 1993.
227 Hadfield JM, Yates DW, Kirkman E, Little RA. Regional cerebral blood flow and 
carbon dioxide reactivity after non-cerebral injury in the rat. Circ Shock
39(2); 100-106, 1993.
228 Hagar JM, Hale SL, Kloner RA. Effect of preconditioning ischaemia on 
reperfusion arrhythmias after coronary artery occclusion and reperfusion in the 
rat. Circ Res 68(l):61-68, 1991.
229 Hains worth R. Syncope and fainting. In: Autonomic failure: a textbook o f 
clinical disorders o f the autonomic nervous system, Bannister R, Mathias CJ 
(Eds) Oxford university press, Oxford, New York, Tokyo, 1992, 761-781.
230 Halpern W, Kelly M. In vitro methodology for resistance arteries. Blood 
vessels28:245-251, 1991.
231 Hamer J. The significance of cerebral vasospasm with regard to early and delayed 
aneurysmal surgery; preliminary results of early surgery. Acta Neurochir (Wien) 
63:209-213, 1982.
232 Hammes EM. Reaction of the meninges to blood. Arch Neurol Psychiatry 52: 
505-514, 1944.
234 Hamon M, Vallet B, Banters C, Wernert N, McFadden EP, Lablanche JM,
Dupuis B, Bertrand ME. Long term oral administration of L-arginine reduces 
intimai thickening and enhances neo-endothelial-dependent acetylcholine-induced 
relaxation after arterial injury. Circulation 90:1357-1362, 1994.
235 Handa Y, Kubota T, Kaneko M, Tsuchids A, KObayashi H, Kawano H, Kubota 
T. Expression of intercellular adhesion molecule 1 (ICAM-1) on the cerebral 
artery following subarachnoid haemorrhage in rats. Acta Neurochirurgien 
132(l-3):92-97, 1995.
236 Harada S, Kamiya K, Masago A, Iwata A, Yamada K: Subarachnoid hemorrhage 
induces c-fos, c-jun and hsp70 mRNA expression in rat brain. Neuroreport 
8(15)13399-3404, 1997.
237 Hardebo JE, Owman C: Autonomic receptors in human brain arteries. In: The 
human brain circulation: functional changes in disease, Bevan RD, Bevan JA 
(Eds), Humana press, Totowa, New Jersey, 1994, pp 109-116.
238 Harder DR, Brann L, Halpern W. Altered membrane electrical properties of 
smooth muscle cells from small cerebral arteries of hypertensive rats. Blood 
Vessels 20:154-160, 1983.
239 Harder DR. Pressure-dependent depolarization in cat middle cerebral artery.
Circ Res 55:197-202, 1984.
240 Harder DR, Gilbert R, Lombard JH. Vascular muscle cell depolarization and 
activation in renal arteries on elevation of transmural pressure. Am J Physiol 
253:F778-781, 1987.
241 Harder DR. Pressure-induced myogenic activation of cat cerebral arteries is 
dependent on intact endothelium. Circ Res 60:102-107, 1987.
242 Hare JM, Keaney JF Jr, Kelly RA, Loscalzo J, Smith TW, Colucci WS. Inhibition 
of nitric oxide synthase potentiates the postive inotropic response to p adrenergic 
stimulation in normal dogs. Circulation 88(suppl I):1 1905 Abstract, 1993.
243 Hare JM, Colucci WS. Role of nitric oxide in the regulation of myocardial 
function. Prog Cardiovasc Dis 38:155-166, 1995.
311
244 Hare JM, Loh E, Creager MA, Wilson S, Colucci S. Nitric oxide inhibits the 
positive inotropic response to p adrenergic stimulation in humans with left 
ventricular dysfunction. Circulation 92:2198-2203, 1995.
245 Hare JM, Keaney JF Jr, Balligand J-L, Loscalzo J, Smith TW, Colucci WS. Role 
of nitric oxide in parasympathetic modulation of P adrenergic myocardial 
contractility in normal dogs. J Clin Invest 95:360-366 1995.
246 Harper AM, Deskmukh VD, Rowan JO et al. The influence of the sympathetic on 
cerebral blood flow. Arch Neurol 27:1-6, 1972.
247 Harrison DG, and Bates JN 1993. The nitrovasodilators. New ideas about old 
drugs. Ciculation 87:1461-1467, 1993.
248 Hart MN. Morphometry of brain parenchymal vessels following subarachnoid 
haemorrhage. Stroke 11:653-655, 1980.
249 Hartmann B, Udenfriend S. The use of dopamine P hydroxylase as a marker for 
the central noradrenergic nervous system in rat brain. Proc Natl acad Sci USA  
69:2722-2726, 1972.
250 Hartzell H, Fischmeister R. Opposite effects of cGMP and cAMP on calcium 
current in single heart cells. Nature 323:273-275, 1986.
251 Hasebe N, Shen YT, Vatner SF. Inhibition of endothelial derived relaxing factor 
enhances myocardial stunning in conscious dogs. Circulation 64:1101-1107,
1993.
252 Hashi K, Nin K, Shimotake K. Surgery in the prevasospastic interval. Acta 
Neurochir (W ien)63:141-145, 1982.
253 Hassler O. Morphological studies on the large cerebral arteries, with reference to 
the aetiology of subarachnoid haemorrhage. Acta Psychiat Neurol Scand 
(suppl)154:1-145, 1961.
254 Hatake K, Wakabayashi I, Kakishita E, Hishida S. Impairment of endothelium- 
dependent relaxation in human basilar artery after subarachnoid haemorrhage. 
Stroke 23(8): 1116-1117, 1992
255 Hawkins WF, Glower BR. Myocardial damage after trauma and simulated 
intracranial haemorrhage in mice; the role of the autonomic nervous system. 
Cardiovasc Res 5:524-529, 1971.
256 Hayakawa T, Waltz AG. Experimental subarachnoid haemorrhage fi*om a middle 
cerebral artery. Neurologic defects, intracranial pressures, blood pressuresand 
pulse rates. Stroke 8:421-426, 1977.
257 Hayashi M, Marukawa S, Fujh H, Kitano T, Kobayashi H, Yamamoto S. 
Intracranial hypertension in patients with ruptured aneurysms. J Neurosurg 46: 
584-590, 1977.
258 Hayreh SS, Edwards J. Vascular responses to acute intracranial hypertension. J 
Neurol Neurosurg Psych 34:587-601, 1971.
259 Hergstrand LR, KanofPD, Greengard P. Histamine-sensitive adenyl cyclase in 
mamalian brain. Nature 260:163-165, 1976.
260 Heistad DD, Marcus ML. Effect of sympathetic stimulation on permeability of 
the blood brain barrier to albumin during acute hypertension in cats. Circ Res 
45:331-338, 1979.
261 Heller R, Bussolino F, F, Ghigo D, Garbarino G, Pescarmona G, Till U, Bosia 
A. Nitrovasodilators inhibit thrombin-induced platelet activating factor synthesis 
in human endothelial cells. Biochem Pharmacol 44:223-229, 1992.
312
262 Hendrix LE, Dion JE, Jensen ME, Phillips CD, Newman SA. Papaverine-induced 
mydriasis. Am J Neuroradiolog 15(4):716-718, 1994
263 Hermann L. Ueber die wirkungen des stickoxydulgases auf das blut. Arch Anat 
Physiol, Lpz: 469-481, 1865.
264 Hernandez MJ, Brennan RW, Bowman GS. Cerebral blood flow autoregulation 
in the rats. Stroke 9:150-155, 1978.
265 Heros RC, Zervas NT, Lavyne MH et al. Reversal of experimental cerebral 
vasospasm by intravenous nitroprusside therapy. Surg Neurol 6:227-229, 1976.
266 Herz DA, Baez S, Shulman K. Pial microcirculation in subarachnoid 
haemorrhage. Stroke 6:417-424, 1975.
267 Hillman J, Saveland H, Jakobsson, KE, Edner G, Zygmunt S, Fridriksson S, 
Brandt L. Overall management outcome of ruptured posterior fossa aneurysms.
J Neurosurg 85:33-38, 1996.
268 Hirsh LF. Intra-arterial nitroprusside treatment of acute experimental vasospasm. 
Stroke 11(6)601-605, 1980.
269 Hodgson JS. The relation between increased intracranial and increased interstitial 
pressure. Changes in the cerebrospinal fluid in increased intracranial pressure.
Res PubI Assoc Res Nerve Ment Dis 8:182-188, 1927.
270 Hoenpud JD, Campbell SM, Mendelsohn DJ. Interleukin-1 induced myocardial 
depression in an isolated beating heart preparation. J Heart Transplant 8:460- 
464 ,1989.
271 Hogie M, Clozel M, Loftier B-M, Thuillez C. In Vivo evidence of an endothelin- 
induced vasopressor tone after inhibition of nitric oxide synthesis in rats. 
Ciculation 91:771-775, 1995.
272 Hongo K, Nakagomi T, Tsukahara T, Ogawa H, Lehman RM, Sasaki T, Kasselll 
NF. Inhibition of spontaneously released endothelial derived relaxaing factor after 
subarachnoid haemorrhage in the rabbit basilar artery. In Cerebral Vasospasm, 
Wilkins RH (ed). Raven press. New York, 1988, pp 155-168.
273 Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ,
Saxena PR, Humphrey PPA. VII. International union of pharmacology 
classification of receptors for 5-hydroxytryptamine (serotonin). Pharm Rev 
46(2):157-203, 1994.
274 Hubschmann OR, Kornhauser D. Effect of subarachnoid haemorrhage on the 
extracellular environment. J Neurosurg 56:216-221, 1982.
275 Hughes JT, Schianchi PM. Cerebral artery spasm. A histological study at 
necorpsy of the blood vessels in cases of subarachnoid haeomorrhage. J  
Neurosurg 48:515-525, 1978.
276 Humphrey JH, Toh CC. Absorption of serotonin and histamine by dog platelets.
J Physiol 124:300-304, 1954.
277 Huszti Z, Deli MA, Joo F. Carrier-mediated uptake and release of histamine by 
cultrured rat cerebral endothelial cells. Neuroscience letters 184(3): 185-188, 
1995.
278 Hutcheson IR, Griffifth TM. Release of endothelial derived relaxing factor is 
modulated both by fi-equency and amplitude of pulsatile flow. AmJ Physiol 261: 
H257-262, 1991.
279 Hutchings M, Weller RO. Anatomical relationships of the pia mater to cerebral 
vessels in man. J Neurosurg 65:316-325, 1986.
280 Huxley HE. The mechanism of muscular contraction. Science 164:1356, 1969.
313
281 ladecola C, Pelligrino DA, Moskowitz MA, Lassen NA. Nitric oxide synthase 
inhibition and cerebrovascular regulation. J Cereb Blood Flow & Metab 
14(2): 175-192, 1994.
282 Indolfi C, Esposito G, Di LorenzoE, Rapacciuolo A, Feliciello A, Porcellini A, 
Awedimento VE, COndorelli M, Chiarello M. Smooth muscle cell proliferation 
is proportional to the degree of balloon injury in a rat model of angioplasty. 
Circulation 92:1230-1235, 1995
283 Isotani E, Suzuki R, Tomita K, Hokeri M, Monma S, Marumo F, Hirakawa R. 
Alterations in plasma concentrations of natriuretic peptides and ADH after 
subarachnoid haemorrhage. Stroke 25: 2198-2203, 1994.
284 Isotani E, Azuma H, Suzuki R, Hamasaki H, Sato J, Hirakawa K: Impaired 
endothelium-dependent relaxation in rabbit pulmonary artery after subaracnoid 
hemorrahge. J Cardiovasc Pharm 28:639-644, 1996.
285 Ito U, Ohno K, Yamaguchi T, Takei H, Tomita H, Inaba Y. Effect of 
hypertension on blood brain barrier change after restoration of blood flow in post- 
ischaemia in gerbil brains. An EM study. Stroke (11)6:606-611, 1980.
286 Ito A, Egashira K, Kadokami T, Fukumoto Y, Takanyanagi T, Nakaike R, Kuga 
T, Sueishi K, Shimokawa H, Takeshita T: Chronic inihibtion of endothelial 
derived NO synthesis causes coronary microvascular structural changes and 
hyperreactivity to serotonin in pigs. Circulation 92:2636-2644, 1995
287 Iwai A, Sakano T, Uenishi M, Sugimoto H, Yoshioka T, Sugimoto T. The effects 
of vasopressin and catecholamines on the maintenance of circulatory stability in 
brain dead patients. Transplantation 48:613-617, 1989.
288 Jackson IJ. Aseptic haemogenic meningitis: an experimental study of aseptic 
meningeal reactions due to blood and its breakdown products. Arch Neurol 
Psychiat 65 572-589, 1949.
289 Jakubowski J, Bell BA, Symon L, Zawirski MB, Francis DM. A primate model of 
subarachnoid haemorrhage: change in regional cerebral blood flow, autoregulation 
carbon dioxide reactivity, and central conduction time. Stroke 13(5): 601-611,
1982.
290 Jancar S, Schultz R, Krueger CA, Cook DA. Role of cyclo-oxygenase and 
lipoxygenase products in arachidonic acid-induced contraction of cerebral artery: 
relevance to cerebral vasospasm. In Cerebral Vasospasm Wilkins RH (ed) Raven 
Press, New York, 1988, pp 259-264.
291 Jawad K, Miller JD, Wyper DJ, Rowan JO: Measurement of CBF and carotid 
artery pressure compared with cerebral angiography in assessing collateral blood 
supply after carotid ligation. J  Neurosurgery 46:185-196, 1977.
292 Jensen PE, Mulvany MJ, Aaljaar C. Endogenous and exogenous agonist-induced 
changes in the coupling between intracellular calcium and force in rat resistance 
arteries. Pflugers Arch-Europ J Physiol 420(5-6):536-543, 1992.
293 Jin Y, Sagher O, Thai QA, Kassell NF, Lee KS. The effects of papaverine on 
phorbol dibutyrate-induced vasocnstriction in brain slice micorvessls. J 
Neurosurg 81:574-578, 1994.
294 Johansson B. Myogenic tone and reactivity: definitions based on muscle 
physiology. J Hypertension 7:(suppl 4):S5-8, 1989.
295 Johnson G, Tsao PS, Lefer AM. Cardioprotective effects of authentic nitric oxide 
in other control systems. J Hypertension 7(suppl 4): S33-39, 1989.
314
296 Johnson PC, Wayland H. Regulation of blood flow in single capillaries. Am J  
Physiol 212:1405-1415, 1967.
297 Joly GA, Narayanan K, Griffifth OW, Kilbourn RG. Characterization of the 
effecst of two new arginine/ citrulline analogues on cNOS and iNOS in rat aorta. 
B rJ Pharm 115:491-497, 1995.
298 Jones CJH, DeFily DV, Patterson JL, Chilian WM. Circulation 87(4): 1264- 
1274, 1993.
299 Jones CJH, Kuo L, Davis MJ, DeFily DV, Cilian WM. Role of nitric oxide in the 
coronary microvascular responses to adenosine and increased metabolic demand. 
Circulation 91:1807-1813, 1995.
300 Joris I, Majno G. Endothelial changes induced by arterial spasm. AM J Pathol 
102:346-352, 1981.
301 Joris I, Zand T, Majno G: Hydrodynamic injury of the endothelium in acute aortic 
stenosis. Am J  Pathol 106:394-408, 1982.
302 Kader A, Krauss WE, Onesti ST, Elliot JP, Solomon RA: Chronic cerebral blood 
flow changes following experimental subarachnoid hemonhage in rats. Stroke 
21:577-581, 1990.
303 Kahn AJ. Effects of variations in intracranial pressure. Arch Neurol Psychiatry 
51:508-527, 1944.
304 Kajita Y, Suzuki Y, Oyama H, Tanazawa T, Takayasu M, Shibuya M, Sugita K. 
Combined effect of L-arginine and superoxide dismutase on the spastic basilar 
artery after subarachnoid haemorrhage in dogs. J Neurosurg 80:476-483, 1994.
305 Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K. Superselective intra-arterial 
infusion of papaverine for the treatment of vasospasm after subarachnoid 
haemorrhage. J Neurosurg 77(6): 842-847, 1992
306 Kamiya K, Kuyama H, Symon L An experimental study of the acute stage of 
subarachnoid haemorrhage. J Neurosurg 59:917-924, 1983.
307 Kamiya K, Yamashita N, Sugiyama N, Ono M, Nagai H. Does vasospasm alone 
cause delayed ischaemic neurological deficits after subarachnoid haemorrhage?
In Cerebral vasospasm, Findlay JM (ed), Amsterdam: Elsevier 1993, pp 63-66.
308 Kanamura K, Waga S, Kojima T, Fujimoto K, Niwa S. Endothelial dependent 
relaxation of canine basilar arteries. II inhibition by haemoglobin and 
cerebrospinal fluid fi'om patients with aneurysmal subarachnoid haemorrhage. 
Stroke 18:938-943, 1987.
309 Kanamura K, Weir BKA, Findlay JM, Krueger CA, Cook DA. Pharmacological 
studies on relaxation of spastic primate cerebral arteries in subarachnoid 
haemorrhage. J Neurosurg 71:909-915, 1989
310 Kanamaru K, Weir BK, Simpson I, Witbeck T, Grace M. Effect of 21- 
amniosteroid U-74006f on lipid peroxidation in SA clot. J Neurosurgery 74(3): 
454-459, 1991.
311 Kanwar S, Kubes P. Mast cells contribute to ischaemia-repeiffision-induced 
granulocyte infiltraion and intestinal dysfucntion. Am J Physiol 267:G316-321,
1994.
312 Kanwar S, Kubes P. Ischaemia-reperfusion-induced granulocyte influx is a 
multistep process mediated by mast cells. Microcirculatioii 1:175-182, 1994.
313 Kapp JP, Neill WR, Neill CL, Hodge LR, Smith RR The 3 phases of spasm. 
Surgical neurol 18:40-45, 1982.
315
314 Karliner JS, Simpson PC, Honbo N, Woloszyn W. Mechanisms and time course 
of P adrenoceptor desensitiaztion in mamalian cardiac myocytes. Cardiovasc Res 
20:221-228, 1986.
315 Kassel NF, Torner JC. Aneurysmal rebleeding. A preliminary report from the 
co-operative aneurysm study. Neurosurgery 13:479-481, 1983.
316 Kassell NF, Sasaki T, Colohan ART et al. Cerebral vasospasm following 
aneurysmal subarachnoid haemorrhage. Stroke 16:562-572, 1985.
317 Kassell NF, Helm G, Simmons N et al. Treatment of cerebral vasospasm with 
intra-arterial papaverine. J Neurosurg 77:848-852, 1992.
318 Kasuya H, Weir BKA, Nakane M, Pollock JS, Johns L, Marton S, Stefansson K. 
Nitric oxide synthase and guanylate cyclase levels in canine basilar arteries after 
subarchnoid haemorrhage. J Neurosurg 82:250-255, 1995.
319 Kataoka K, Niiyama K, Uejima T, Kuroda R, loka M, Yamada K, Taneda M, 
Hayakawa T. Treatment of severe localized cerebral vasospasm following 
recurrent haemorrhage from middle cerebral artery aneurysm. Neurologica 
Medico Chirurgien 33(12): 830-832, 1993
320 Katusic ZS, Shepherd JT, Vanhoutte PM. Endothelial dependent contractions to 
stretch in canine basilar arteries. Am J Physio! 252:H671-673, 1987.
321 Katusic ZS, Shepherd JT, Vanhoutte PM. Endothelial dependent contractions to 
calcium ionophore A23187, arachidonic acid and acetylacholine in canine basilar 
arteries. Stroke 19:476-479, 1988.
322 Kelly PAT, Ritchie IM. Local cerebral blood flow following repeated exposure to 
No-nitro-L-arginine-Methyl ester. Br J Pharm 113:78P, 1994.
323 Keyp JP, Neill WR, Neill CL, Hodge LR, Smith RR The 3 phases of vasospasm. 
Surg Neurol 18:40-45, 1982.
324 Kikuchi T, Okuda Y, Kaito N, Abe T. Cytokine production in cerebrospinal fluid 
after subarachnoid haemorrhage. Neurol Res 17(2): 106-108, 1995.
325 Kim P, Sundt TM, Vanhoutt PM. Loss of endothelial dependent relaxations and 
maintenace of endothelial dependent contractions in chronic vasospasm following 
subarachnoid haemorrhage. In Cerebral Vasospasm Wilkins RH (ed) Raven 
Press, New York, 1988, ppl45-154.
326 Kim P, Sundt TM Jr, Vanhoutte PM. Alterations of mechanical properties in 
canine basilar arteries after subarachnoid haemorrhage. J Neurosurg 71:430-436, 
1989.
327 Knuckley NW, Fox RA, Surveyor I et al. Early cerebral blood flow and CT in 
predicting ischaemia after cerebral aneurysm rupture. J Neurosurg 62:850-855, 
1985.
328 Kobrine Al, Doyle TF, Martins AN. Local spinal cord blood flow in experimental 
traumatic myelopathy. J Neurosurg 42:144-149, 1975.
329 Kohno K, Takeda S. Impairment of vascular reactivity and changes in 
intraccellular calcium and calmodulin levels of smooth muscle cells in canine 
basilar arteries after subarachnoid haemorrhage. Neurosurgery 25(5):753-761,
1989.
330 Kojima M, Handa H, Hashimoto N, Kim C, Hazama F. Early changes of 
experimentally induced cerebral aneurysms in rats: scanning electron microscopic 
study. Stroke 17(5):835-841, 1985.
331 Kolin A, Norris JW. Myocardial damage from acute cerebral lesions. Stroke 15: 
990-993, 1984.
316
332 Kontos HA, Wei EP, Navari RM et a. Respnses of cerebral arteries and arterioles 
to acute hypotension and hypertension. Am J Physiol 234:H371-H383, 1978.
333 Kooy NW, Royall JA, Ye YZ, Kelly DR, Beckman JS. Nitration of myocardial 
protein tyrosines; evidence for peroxynitrate production in myocardial 
inflammation. Circulation 90(suppl I);1-627 Abstract.
334 Korbut R, Lidbury P, Vane JR. Prolongation of fibrinolytic activity of tissue 
plasminogen activator by nitrovasodilators. Lancet 335:669-675, 1990.
335 Kovach AGB, Szabo C, Farago M, Lohinai Z, Fehér E. Effect of haemorrhagic 
hypotension on cerebrovascular reactiovity and ultrastructure in the cat. Stroke 
22:1541-1547, 1991.
336 Krahn V. The pia mater at the site of entry of blood vessels into the central 
nervous system. Anat Embryol 164:257-263, 1982.
337 Krueger C, Weir B, Nosko M et al. Nimodipine and chronic vasospasm in 
monkeys. Part2 Pharmacological studies of vessels in spasm. Neurosurgeiy 16: 
137-140, 1985.
338 Kronholm V, Lintrup J. Spectrophotometric investigations of the cerebrospinal 
fluid in the near ultraviolet region: a possible diagnostic aid in diseases of the 
central nervous system. Acta Psychiatr Scand 35:314-329, 1960
339 KuD, Caufield JB. Human coroanry aortic bypass grafts, but not coronary 
arteries respond to acetylcholine with endothelial dependent relaxation [Abstract] 
Circulation 76 (supplIV):382,1987
340 Kuo JF, Shojh M. Handbook Exp Pharm Chl2 pp 393- 1985
341 Kurose I, Wolf R, Grisham MB, Granger DN. Modualtion of isch/reper induced 
microvascular dysfunction by nitric oxide. Circ Res 74:376-382, 1994.
342 Kuwayama A, Zervas NT, Shintani A. Papaverine hydrochloride and 
experimental haemorrhagic arterial spasm. Stroke 3:27-33, 1972.
343 Lacey PS, Earle AM. A small animal model for EGG abnormalities observed after 
an experimentla subarachnoid haemorrhage. Stroke 14:3; 1983.
344 Lacey PS, Earle AM. Central neural cotnrol of blood pressure and cardiac 
arrhythmias during subarachnoid haemorrhage in rats. Stroke 16(6): 998-1002,
1985.
345 Laher I, Bevan JA. Stretch of vascular smooth muscle activates tone and 45Ca '^*‘ 
influx. J Hypertension 7 (suppl 4):SI7-20, 1989.
346 Lamontagne D, Pohl U, Busse R. Mechanical deformation of vessel wall and 
shear stress determine the basal endothelial dependent relaxing factor release in 
the intact coronary vascular bed. Circ Res 70:123-130, 1992.
347 Lang J. In Clinical anatomy o f the posterior fossa and its foramina, Thieme 
Verlag, Stuttgart, New York, 1991 p 30.
348 Langer SZ, Shepperson NB. Recent developments in vasospasm pharmacology: 
the post-synaptic a2 adrenoreceptor. Trends Pharmacol Sci 3:440-444, 1982.
349 Langfitt TW, Weinstein JD, Kassell NF, Simeone FA. Transmission of increased 
intracranial pressure. I Within the craniospinal axis. J Neurosurg 21:989-997, 
1964.
350 Langfitt TW, Weinstein JD, Kassell NF. Cerebral vasomotor paralysis produced 
by intracranial hypertension. Neurology 15:622-641, 1965.
351 Lanzino G, Kongable GL, Kassell NF. Electrocardiographic abnormalities after 
nontraumatic subarachnoid haemorrhage. J Neurosurg Anaesth 6(3): 156-162,
1994.
317
352 Lassen NA; Brain extracellular pH: the main factor controlling cerebral blood 
flow. Scand J Clin Lab Invest 22:247-251, 1968
353 Leblanc R. Familial cerebral aneurysms: a bias for women. Neurosurgery 
27:1050-1054, 1996
354 Lee TJF, Mcllhany M, Sarwinski S: Erythrocyte extracts enhance neurogenic 
vasoconstriction of dog cerebral arteries in vitro. J Cerebr Blood Flow &
Metab 4:474-6, 1984.
355 Lehman RM, Kassell NF, Nazar GB, Weir BK, Joshita H, Nosko M, Duling BR, 
Owens GK. Morphometric methods in the study of vasospasm. In Cerebral 
Vasospasm Wilkins RH (ed) Raven Press, New York, 1988, ppl 13-117.
356 Levy WJ, Bay JW, Sawhny B et al. Aminophylline plus nitroprusside and 
dopamine for treatment of cerebral vasospasm: a preliminary report. J 
Neurosurg 56:646-649, 1982.
357 Lewis NP, Tsao PS, Rickenbacher PR, Haywood GA, Leyen HVD, Valantine 
HA, Hunt SA, Gillingham ME, Cooke JP, Fowler MB. Induction of iNOS 
mRNA in the human cardiac allograft is associated with impaired left ventricular 
contractile function. Circulation 90(suppl I):I-193 Abstract 1994.
358 Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for 
restenosis: a special case of atherosclerosis progression. Circulation 86(suppl 
m ): III 47-52 1992.
359 Limas CJ, Cohn JN. Stimulation of vascular smooth muscle sodium, potassium- 
adenosinetriphosphate by vasodilators, Circ Res 35:601-607, 1974.
360 Lin SR, O'Connor MJ, King A, Hamish P, Fischer HW. Effect of dextran on 
cerebral function and blood flow after cardiac arrest. An experimental study in 
he dog. Stroke 10(1): 13-20, 1979
361 Lindpainter K, Ganten D. The cardiac renin-angiotensin system. Circ Res 
68:905-921, 1991.
362 LiszczakTM, Varsos VG, Black PML et al. Cerebral artreial constriction after 
experimental subarachnoid haemorrhage is associated with blood components 
within the arterial wall. J Neurosurg 58:18-26, 1983.
363 Livingston K, Guterman LR, Hopkins LN. Intra-arterial papaverine as adjunct to 
transluminal angioplasty for vasospasm induced by subarachnoid haemorrhage. 
Am J Neuroradiol 14(2):346-347, 1993.
364 Liu Y, Downey JM. Ischaemic preconditioning protects against in farction in rat 
heart. Am J Physiol 263:H1107-1112, 1992.
365 Ljusegren ME, Axelsson KL. Lactate accumulation in isolated hypoxic rat 
ventricular myocardium: effect of different modulators of the cGMP system. 
Pharmacol Toxicol 72:56-60, 1993.
366 Ljunggren B, Brandt L, Kagstrom E et al. Results of early operations for 
rutptured aneurysms. J Neurosurg 54:473-479, 1981.
367 Lobato R, Marin J, Salaices M et al. Effect of experimental subarachnoid 
haemorrhage on the adrenergic innerevation of cerebral artreies. J Neurosurg 
53:477-479^ 1980.
368 Lobato R, Marin J, Salaices M et al. Cerebrovascular reactivity to norepinephrine 
and 5-hyroxytryptamine following experimental subarachnoid haemorrhage. J 
Neurosurg S3: 480-485, 1980.
369 Locksley HB. Report on the cooperative study of intracranial aneurysms and 
subarachnoid haemorrhage. Section V, part II. Natural history of subarachnoid
318
haemorrhage, intracranial aneurysms and arterio-venous malformations based on 
6368 cases in the co-operative study. J Neurosurg 25:321-368, 1966.
370 Lu GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial protection with 
pre-conditioning. Circulation 82:609-619, 1990.
371 Luscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelial derived contracting 
factors. Hypertension 19:117-130, 1992.
372 Luscher TF, Boulanger CM, Yang Z, Noll G, Dohi Y. Interactions between 
endothelial derived relaxing and endothelial derived contracting factors in health 
and cardiovascular disease. Circulation 87 (suppl V):V-36~44, 1993.
373 Luscher TF, Noll G. Endothelial dysfunction in the coromary circulation. J 
Cardiovasc Pharmacol 24(suppl3):S16-S26, 1994.
374 Lynch P. Soldiers, sport, and sudden death. Lancet 1:1235-1237, 1980.
375 MacDonald RL, Wier BKA. A reveiw of haemoglobin and the pathogenesis of 
cerebral vasospasm. Stroke 22:971-982, 1991.
376 Macdonald RL, Weir BK, Grace MG. Mechanism of cerebral vasospasm 
following subarachnoid haemorrhage in monkeys. Can J Neurol Sci 19(4):419- 
427, 1992.
377 Macdonald RL, Weir BK, Young JD, Gi ace MG. Cytoskeletal and extracellular 
matrix proteins in cerebral arteries following subarachnoid hameorrhage in 
monkeys. J Neurosurgery 76(1):81-90, 1992.
378 MacKenzie ET, Farrar JK, Fitch W, Graham DI, Gregory PC, Harper M. Effects 
of haemorrhagic hypotension on the cerebral circulation. 1. Cerebral blood flow 
and pial arteriolar caliber. Stroke 10(6): 711-718, 1979
379 Magnoni MS, Kobayashi H, Frattola L, Spano PF, Trabucchi M. Effect of 
common carotid occlusion on p-adrenergic receptor function in cerebral 
micro vessels. Stroke 16(3): 505-509, 1985.
380 Mallov S. Role of calcium and free fatty acids in epipnephrine-induced 
myocardial necrosis. Toxicol Appl Pharmacol 71:280-287, 1983.
381 Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology 
of the adult mamalian cardiocyte. Circulation 84:2091-2100, 1991.
382 Marion DW, Segal R, Thompson ME Subarachnoid hameorrhage and the heart. 
Neurosurgery 18 (1): 101-106, 1986.
383 Marks MP Steinberg GK, Lane B Intra-arterial papaverine for the treatment of 
vasospasm. Am J Neuroradiol 14(4): 822-826, 1993.
384 Marshman LAG: Elastin degradation in the superficial temporal arteries of 
patients with intracranial aneurysms reflects changes in plasma elastase. Letter to 
the Editor. Neurosurgery 43(4):982, 1998.
385 Marshman LAG, Ward PJ, Walter PH, Dossetor RS: The progression of an 
infundibulum to aneurysm formation and rupture. Case report and literature 
review. Neurosurgery 43(6): 1445-9, 1998.
386 Martin W, Villani GM, Jothianandan D et al. Selective blockade of endothelial- 
dependent and GTN-induced relaxation by haemoglobin and by methylene blue in 
the rabbit aorta. J Pharmacol Exp Ther 232:708-716, 1985.
387 Martin NA, Doberstein C, Zane C, Caron MJ, Thomas K, Becker DP. 
Posttraumatic cerebral arterila spasm: transcranial doppler ultrasound, cerebral 
blood flow, and angiographic findimgs. J Neurosurg 77(4):575-583, 1992.
388 Martins AN, Doyle TF, Wright SJ, Bass BG. Response of cerebral circulation to 
topical histamine. Stroke ll(5):469-476, 1980.
319
389 Masini E, Gambassi F, Di Bello MG, Mugnai L, Raspanti S, Manaioni PF. Nitric 
oxide modulates cardiac and mast cell anaphylaxis. Agents Actions (Suppl) 
41:C89-90, 1994.
390 Mathiesen T, Andersson B, Loftenius A, von Holst H. Increased interleukin-6 
levels in cerebrospinal fluid following subarachnoid haemorrhage. J Neurosurg 
78:562-567, 1993,
391 Mathis JM, De Nardo A, Jensen ME, Scott J, Dion JE. Transient neurologic 
events associated with intra-arterial papaverine infusion for subarachnoid 
haemorrhage-induced vasospasm. Am J Neuroradiolog 15(9): 1671 -1674, 1994
392 Mathis JM, De Nardo A, Jensen ME, Scott J, Dion JE. Transient severe brain 
stem depression during intra-arterial papaverine infusion for cerebral vasospasm. 
Am J Neuroradiolog 15(4);719-723, 1994.
393 Matsui T, Sugawa M, Johshita H, Takuwa Y, Asano T: Activation of the protein 
kinase C-mediated contractile system in canine basilar arteiy undergoing chronic 
vasospasm. Stroke 22:1183-87, 1991.
394 Matta BF, Lam AM, Mayberg TS, Eng CC, Strebel S. Cerebrovascular response 
to CO2 during SNP and isoflurane-induced hypotension. Br J Anaesth 74(3): 
296-300, 1995.
395 Maulik N, Engelman RM, Wei Z, Lu D, Rousou JA, Das DK. Interleukin l a  
preconditioning reduces myocardial ischaemia-reperfusion injruy. Circulation 
88(pt2):387-394, 1993.
396 Maurice-Williams RS. In Suharachnoid haemorrhage. Aneurysms and vascular 
malformations o f the central nervous system, Wright, Bristol, 1987.
397 Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet 
function by nitrovasodilators and activators of adenylate cyclase: inhibition of 
cAMP breakdown by cGMP. Br J Pharm 113:671-681, 1994
398 Mayberg MR, Liszczack TM, Black PMcL, Zervas NT. Acute structural changes 
in feline cerebral arteries after subarachnoid haemorrhage. In Cerebral 
Vasospasm Wilkins RH (ed) Raven Press, New York, 1988, pp231-246.
399 Mayberg MR, Okada T, Bark DH The significance of morphological changes in 
cerebral arteries after subarachnoid haemorrhage. J Neurosurg 72:626-633,
1990.
400 Me AulifFe W, Townsend M, Eskridge JM , Newel DW, Grady MS, Winn Hr. 
Intracranial pressure changes induced during papaverine infusion for treatment of 
vasospasm. J Neurosurg 83(3):430-434, 1995.
401 McCall TB, Feelisch M, Palmer RMJ, Moncada S. Identification of N- 
iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in 
phagocytic lines. Br J Pharmacol 102:234-238, 1991.
402 McCormick JM, McCOrmick PW, Zabramski JM, Spetzler RF. Intracranial 
pressure reduction by a central a2 adrenoceptor agonist after subarachnoid 
haemorrhage. J Autonom Nerv Sys 32(6):974-979, 1993.
403 McHenry LC, Jaffe ME, Kawamura J et al. Effect of papaverine on regional 
blood flow in focal vascular disease of brain. New Eng J Med 282:1167-1170, 
1970.
404 McNair JL, Clower BR, Sanford RA. The effect of reserpine pre-treatment on 
myocardial damage associated with simulated intracranial haemorrhage in mice. 
Eur J Pharmacol 9(1): 1-6, 1970
320
405 Mehta P, Mehta J, Miale TS. Nitroprusside lowers platelet count. NEJM 299; 
1134,1978.
406 Mellander S, JohanssonB. Control of resistance, exchange, and capacitance 
fiinctions in the peripheral circulation. Pharmacol rev 20:117-196, 1968
407 Mellander S. Functional aspects of myogenic vascular control. J Hypertension 
7(suppl4):S21-S30, 1989.
408 Mendelow AD, Me Calden TA, Hattingh J, Coull A, Rosendorff C, Eidelman 
BH. Cerebrovascular reactivity and metabolism after subarachnoid haemorrhage 
in baboons. Stroke 12(1): 58-65, 1981
409 Mendelow AD. Pathophysiology of delayed ischaemic dysfunction after 
subarachnoid haemorrhage: experimental and clinical data. Acta Neurochir 
S45:7-10, 1988.
410 Mery PF, Pavoine C, Belhassen L, Pecker F, Fisclimeister R Nitric oxide 
regulates cardiac calcium current: involvement of cGMP-inhibited and cGMP- 
stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 
268: 26286-26295, 1993.
411 Meyer JS, Gotoh F. Interaction of cerebral haemodynamics and metabolism. 
Neurology ll(2):46-65, 1961.
412 Meyer JS, Stoica E, Pascu I, Shimazu K, Hartmann A. Catecholamine 
concentrations in cerebrospinal fluid and plasma of patients with cerebral 
infarction and haemorrhage. Brain 96:277-288, 1973.
413 Meyer CHA, Lowe D, Meyer M et al. Progressive change in cerebral blood flow 
during the first three weeks after subarachnoid haemorrhage. Neurosurgery 
12:58-76, 1983.
414 Meurice T, Banters C, Aufifray JL, Vallet B, Hamon M, Valero F, Van Belle E, 
Lablanche JM, Bertrand ME. Basic fibroblast growth factor restores endothelial- 
dependent responses after balloon injury of rabbit arteries. Circulation 93:18-22, 
1996.
415 Meyers R. Systemic vascular and respiratory effects of experimentally induced 
alterations in intraventricular pressure. J Neuropathl Exp Neurol 1:241-264, 
1942.
416 Michenfelder JD, Tinker JH. Cyanide toxicity and thiosulphate protection during 
chronic administration of sodium nitroprusside in the dog; correlation with a 
human case. Anesthesiology 47(5):441-448, 1977.
417 Miller CA, Yashon D, Locke G et al. Autonomous activity in the human basilar 
artery: relationship to cerebral vasospasm. Neurology 21:1249-1254, 1971.
418 Miller JA,Cross DT, Moran CJ, Dacey RG Jr,McFarland JG, Diringer MN.
Severe thrombocytopenia following intra-arterial papaverine administration for 
treatment of vasospasm. J. Neurosurg 83:435-457, 1995.
419 Miller VM, Komori K, Burnett JC, Vanhoutte PM Differential sensitivity to 
endothelin in canine arteries and veins. AM J Physiol 257:H1127-1131, 1989.
420 Minc-Golomb D, Tarsafaty I, Schwartz JP. Expression of inducible nitric oxide 
synthase by neuroines following exposure to endotoxin and cytokine. Br J 
Pharm 111:720-722, 1994.
421 Minneman KP. a-adrenergic receptor subtypes, inositol phosphates, and sources 
of cell calcium. Pharm rev 40(2):87-117, 1988.
321
422 Miranda FJ, Alabadi JA, Torregrosa G, Salom JB, Jover T, Barbera MD, Alborch 
E; Modulatory role of endothelial and nonendothelial nitric oxide in 5- 
Hydroxytryptamine-induced contraction in cerebral arteries after subarachnoid 
hemorrhage. Neurosurgery 39(5):998-1004, 1996.
423 Misra HP, Fridovich I. The generation of superoxide radical during the 
autoxidation of haemoglobin. J Biol Chem 247:6960-6962, 1972.
424 Mizukami M, Kim H, Araki G, et al. Is angiographic spasm real? Acta 
Neurochir (Wien) 34:247-257, 1976.
425 Mizukami M, Kawase T, Usami T et al. Prevention of vasospasm by early 
operation with removal of subarachnoid blood. Neurosurgery 10:301-307, 1982.
426 Moncada S, Palmer RMJ, Higgs EA. Nitric oxide;physiology, pathophysiology 
and pharmacology. Pharmacol Rev 43:109-142,1991.
427 Moss E. Cerebral blood flow during induced hypotension. Br J Anaesthes 
74(6):635-637, 1995.
428 Mueller SM, Heistad DD, Marcus ML. Total and regional cerebral blood flow 
during hypotension, hypertension and hypocapnia. Circ Res 41:350-356, 1977.
429 Mulvany MJ, Halpern W. Mechanical properties of vascular smooth muscle cells 
in situ. Nature 260(5552):617-619, 1976.
430 Mulvany MJ, Halpern W. Contractile properties of small arterial resistance 
arteries in spontaneously hypertensive and normotensive rats. Circ Res 41(1): 19- 
26, 1972.
431 Mulvany MJ, Kelley M. In vitro methodology for resistance arteries. Blood 
Vessels 28:245-251, 1991.
432 Murray CE, Jennings RB, Reimer KA. Preconditioning with ischaemia; a delay of 
lethal cell injury in ischaemic myocardium. Circulation 74:1124-1136, 1986.
433 Muscholl E, Vogt M. The action of reserpine on peripheral sympathetic nervous 
system. J Physiol 141:132-155, 1958.
434 Nagai H, Noda S, Mabe H. Experimental cerebral vasospasm, eflects of 
vasoactive drugs and sympathectomy on early and late spasm. J Neurosurg 42: 
420-428, 1975.
435 Nagai H, Kamiya K, Sugiyama N, Ueda Y. Change of ischaemic threshold after 
subarachnoid haemorrhage. In Cerebral Vasospasm, Wilkins RH (ed). Raven 
press. New York, 1988, pp 57-61.
436 Nakagawa Y, Yamamoto YL, Meyer E, Hodge CP, Feindel W. Effects of 
hypercapnia on enhancement of decreased perfiision flow in non-infarcted brain 
tissues. Stroke 12(1): 85-92, 1981.
437 Nakagomi T, Kassell NF, Sasaki T, Fujiwara S, Lehman RM, Torner JC: 
Impairment of ednothelium-dependent vasodilation induced by acetylcholine and 
adeonsine triphosphate following experimental subarachnoid hemorrhage. Stroke 
18:482-489, 1987.
438 Nakashima T, Takenaka K, Fukazawa S, Yano K, Nishimura Y, Andoh T, Sakai 
N, Yamada H. Cytosolic free calcium elevation in vascular smooth muscle cells 
induced by cerebrospinal fluid from patients with subarachnoid haemorrhage - 
biochemical nature of the calcium-mobilising factor. Neurologica Medico- 
Chirurgica 35(1) 8-12, 1995.
439 Nagata K, Sasaki T, Iwama J Mori, T, Iwamoto S, Nirei H, Kaori H, Kirino T. 
Failure of FK-506, a new immunosuppressant, to prevent cerebral vasospasm in a 
canine 2- haem model. J Neurosurg 79:710-715, 1993.
322
440 Nagata K, Nikaido H, Kobayashi E et al. Cisternal talc injection can induce a 
delayed and prolonged basilar artery constriction resembling vasospasm after 
subarachnoid haemorrhage in the dog. In Cerebral vasospasm, Findlay JM (ed) 
Amstredam; Elsevier 1993, pp281-284.
441 Nagatani K, Masciopinto JE, Letarte PB, Haworth RA, Duff TA. The effect of 
haemoglobin and its metabolites on energy metabolism in cultured cerebrovascular 
smooth-muscle cells. J Neurosurg 82:244-249, 1995.
442 Nakane M, Saheki S, Kuno T et al. Molecular cloning of cDNA coding for 70 
kilodalton subunit of sol GC from rat lung. Biochem Biophys Res Comm 157: 
1139-1147, 1988.
443 Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 
6:3051-3064, 1992.
444 Nazar GB, Kassell NF, Povlishock JT, Lee J, Hudson S. Subarachnoid 
haemorrhage causes adherence of white blood cells to the cerebral arterial luminal 
surface. In Cerebral Vasospasm, Wilkins RH (ed). Raven press. New York, 1988, 
pp343-356.
445 Neil-Dwyer G, Cruikshank J. The blood leucocyte count and its prognostic 
significance in subarachnoid haemorrhage. Brain 97:79-86, 1974.
446 Neil-Dwyer G, Cruikshank J, Stott A, Brice J. The urinary catecholamine and 
plasma cortisol levels in patients with subarachnoid haemorrhage. J Neurol Sci 
22:375-382, 1974.
447 Nielsen KG, Owman CH. Contractile response and amine receptor mechanisms in 
isolated middle cerebral arteiy if the cat. Brain Res 27:33-42, 1971
448 Nelson PB, Seif S, Gutai J, Robinson AG. Hyponatraemia and natriuresis 
following subarachnoid haemorrhage in a monkey model. J Neurosurg 60:233- 
237, 1984.
449 Newell DW, Eskridge JM, Mayberg MR et al. Angioplasty for the treatment of 
symptomatic vasospasm following subarachnoid haemorrhage. J Neurosurg 
71:654-660 1989.
450 Niroomand F, Bangert M, Beyer T, Rauch B, Reduced adenyl cyclase inhibition 
by carbachol and GTP during acute myocardial ischaemia. J Moll Cell Cardiol. 
24:471-475, 1992.
451 Node K, Kitakaze M, Kosaka H, Komamura K, Minamino T, Inoue M, Tada M, 
Hori M, Kamada T. Increased release of nitric oxide during ischaemia reduces 
myocardial contractility and improves metabolic dysfunction. Circulation 
93:356-364, 1996.
452 Nomura T, Ikezaki K, Natori Y, Fukui M. Altered response to histamine in brain 
tumour vessels: the selective increase of regional cerebral blood flow in 
transplanted rat brain tumour. J Neurosurg 79(5):722-728, 1993.
453 Nornes H, Magnaes B. Intra cranial pressure in patients with ruptured sacular 
aneurysms. J Neurosurg 36:537-547, 1972.
454 Nomes H. The role of intracranial pressure in the arrest of haemorrhage in 
patients with ruptured intracranial aneurysm. J Neurosurg 39:226-234, 1973.
455 Norris JW. Cardiovascular manifestations of acute neurological lesions, in 
Neurology and general medicine, AminoffMJ (ed). New York, Churchill 
Livingstone, 1981, pp 159-67.
456 Norris JW. The effects of cardiovascular lesions upon the heart. Neurol Clin N 
America 49:862-868, 1983.
323
457 Nosko M, Handa Y, Weir B, Grace M, Lunt A, Allen P, Mielke B, Mosewich R, 
Tsuji T. The effect of subarachnoid clot removal on the development of chronic 
vasospasm in a primate model. In Cerebral Vasospasm, Wilkins RH (ed). Raven 
press. New York, 1988, pp389-94.
458 Novitsky D, Wicomb WN, Cooper DKC, Rose AG, Fraser RC, Barnard CN.
ECG, haemodynamic and endocrine changes occurring during experimental brain 
death in the chacma baboon. J Heart Transplant 4:63-69, 1984.
459 Novitsky D, Wicomb WN, Cooper DKC, Reichart B. Haemodynamic changes 
myocardial injury and pulmonary oedema induced by sympathetic activity during 
the development of brain death in the baboon. Transplant Proc 18:609-612,
1986.
460 Novitsky D, Wicomb WN, Cooper DKC, Tjaalgard MA. Improved cardiac 
function following hormonal therapy in brain dead pigs. Relevance to organ 
donation. Cryobiology 24:1-10, 1987.
461 Novitsky D, Cooper DKC, Morrell D, Isaacs S. Change from aerobic to 
anaerobic metabolism after brain death and reversal following triiodothyronine 
therapy. Transplantation 45:32-36, 1988.
462 O'Donnel SR, Saar N. A histochemical study of extraneuronal accumulation of 
norepinephrine in the gineau pig trachea. Br J  Fharm 49:267-278, 1973.
463 Ogata M, Marshall BM, Lougheed WM. Observations on the effects of 
intrathecal papaverine in experimental vasospasm. J Neurosurg 38:20-25, 1973.
464 Ohgushi N. Adrenergic fibres to the brain and spinal cord vessels in the dog.
Arcg Jap Chir 37:294-303, 1968.
465 Ohta H, Ito Z, Yasui N et al. Extensive evacuation of subarachnoid clot for 
prevention of vasospasm: effective or not? Acta Neurochir (Wien) 63:111-116, 
1982.
466 Ohlstein EH, Storer BL. Oxyhaemoglobin stimulation of endothelin production in 
cultured endothelial cells. J Neurosurg 77:274-278, 1992.
467 Ohta T, Kuroiwa T, Shimizu K, Shigma M, Yamada K, Yasuda A, Sato G. 
Exaggerated permeability via the adventitia of the spastic vessel wall in 
experimental cerebral vasospasm. In Cerebral Vasospasm, Wilkins RH (ed). 
Raven press, New York, 1988, pp 219-230.
468 Ohta T, Satoh G, Kuroiwa T. The permeability change of major cerebral arteries 
in experimental vasospasm. Neurosurgery 30(3):331-335 discussion 335-6 1992.
469 Okada T, Bark DH, Mayberg MR Localized release of perivascular heparin 
inhibits intimai proliferation after endothelial injury without systemic 
anticoagulation. Neurosurgery 25(6): 892-898, 1989.
470 Olesen J, Skinhoj E. The influence of certain vasoactive amines on the rCBF of 
man. Proceedings o f the international headaches symposium. Elsinore, 
Denmark, May 16-18, 1971, Basel Sandoz, 1971, pi 45-52.
471 Olesen J, Paulson OB. The effect of intra-arterial papaverine on the regional 
cerebral blood flow in patients with stroke on intracranial tumour. Stroke 2:148- 
159,1971.
472 Onoue H, Kaito N, Akiyama M, Tomii M, Tokudome S, Abe T. Altered 
reactivity of human cerebral arteries after subarachnoid haemorrhage. J 
Neurosurg 83(3): 510-515, 1995.
324
473 Onoue H, Katusic Z; The effect of subarachnoid hemorrhage on mechanisms of 
vasodilation mediated by cyclic adenosine monophosphate. J Neurosurg 89:111- 
117, 1998.
474 Osol G, Halpern W. Myogenic properties of cerebral blood vessels from 
normotensive and hypertensive rats. Am J Physiol 249:H 914-921, 1985.
475 Osol G, Osol R, Halpern W. Pre-existing level of tone is an important 
determinant of cerebral artery autoregulatory responsiveness. J Hypertension 
7(suppl4):S67-69, 1989.
476 Ostroumoff A. Experiments on the inhibitory nerves of skin blood vessels 
(inGerman). Pflugers Arch 12:219-277, 1868
477 Pakarinen S. Incidence, aetiology, and prognosis of primary subarachnoid 
haemorrhage. Acta Neurol Scand 43: S29:1967.
478 Palmer RM, Ferridge AG, Moncada S. Nitric oxide release accounts for the 
biological activity of endothelial derived relaxing factor. Nature 327:524-526,
1987.
479 Parfenova H, Shibata M, Leffler CW. Subarachnoid haemorrhage causes pial 
arteriolar constriction in newborn pigs. Stroke 24(11): 1729-1734, 1993
480 Pasqualin A, DaPian R. An analysis of vasospasm following early surgery for 
intracranial aneurysms. Acat Neurochir(Wien) 63:153-159, 1982.
481 Pearce WJ, D'Alecy LG. Haemorrhage-induced cerebral vasoconstriction in 
dogs. Stroke 11(2): 190-196, 1980.
482 Pearce WJ, Ashwal S, Cuevas J. Direct effects of graded hypoxia on intact and 
denuded rabbit cranial arteries. Am J Physiol (Heart Circ Physiol 26):H824- 
H833, 1989.
483 Peerless SJ, Yasargil MG. Adrenergic innervation of the cerebral blood vessels in 
the rabbit. J Neurosurg 35:148-154, 1971.
484 Peerless SJ, Kendall MJ. The significance of the perivascular innervation of the 
brain, in The cerebral vessel wall, Cervas-Navarro J, Betz E, Matakas F, et al 
(eds), New York, Raven press, 1975, ppl75-82.
485 Peerless SJ, Griffifths JC. Plasma catecholamines following subarachnoid 
haemorrhage. In Subarachnoid haemorrhage and cerebral vasospasm. Smith 
RR, Robertson JT (eds), Springfield III, Charles C Thomas, 1975, ppl48-156.
486 Pelligrino DA. Saying NO to cerebral ischaemia. J Neurosurg Anaesth 
5(4):221-231, 1993.
487 Persson L, Valtysson J, Enblad P, Warme P-E, Cesarini K, Lewén A, Hillered L. 
Neurochemical monitoring using intracerebral microdialysis in patients with 
subarachnoid haemorrhage. J Neurosurg 84: 606-616, 1996.
488 Peterson EW, Cardoso ER. The blood-brain barrier following experimental 
subarachnoid haemorrhage. Part 1 and 2: J Neurosurg 58:338-351, 1983
489 Pfister H-W, Feiden W, Einhaupl K-M. Spectrum of complications during 
bacterial meningitis in adults. Results of a prospective study. Arch NeurOl 50: 
575-581, 1993.
490 Phillips SF. In Gastrointestinal disease: pathophysiology, diagnosis, and 
management, 4 thE d, Sleisenger MH, Fordtran JS (Eds) WB Saunders Co, 
Harcourt Brace Jovanovich, Inc., Philadelphia, London, Toronto, Montreal, 
Sydney, Tokyo, 1989, pp 1391-1392.
325
491 Pickard JD, Lovick AHJ, Read DH. Evidence for brain engorgement as the initial 
cause of brain swelling following intraoperative aneurysm rupture in man after 
subarachnoid haemorrhage. Acta Physiol Scan d Suppl 552:94-95, 1986.
492 Pickard JD, Murray GD, Illingworth R et al: Effect of oral nimodipine on cerebral 
infarction and outcome after subarachnoid hemorrhage: British aneurysm 
nimodipine trial. BMJ 298(6674):636-42, 1989.
493 Pilati CF, Clark RS, Gilloteaux J, Bosso FJ, Holcomb P, Maron MB. Excessive 
sympathetic nervous system activity decreases myocardial contractility. Proc Soc 
Exp Biol Med 193.225-231, 1990
494 Pluta RM, Zauner A, Morgan JK, Muraszko KM, Oldfield EH. Is vasospasm 
related to proliferative arteriopathy? J Neurosurg 77:740-748, 1992.
495 Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the 
vasodilator response to increased flow in vivo. Hypertension 8:37-44, 1986.
496 Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. 
Circulation 87(5): 1435-1441, 1993.
497 Pool JL, Potts DG. In Anemysms and arterio-venous anomalies o f the brain: 
diagnosis and treatment. New York, Harper & Row, 1965, p201
498 Prasad MR, Tzigaret CM, Smith D et a l . Decreased a l  adrenergic receptors 
after experimental brain injury. J Neurotrauma 9:269-279, 1992.
499 Quigley MR, Bailes JE, Kwaan HC, Cerullo LJ, Brown JT. Aneurysm formation 
after low power carbon dioxide laser-assisted vascular anastomosis.
Neurosurgery 18(3):292-298, 1986.
500 Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of 
vascular endothelium; interactions between prostacyclin and nitric oxide. Br J 
Pharmacol 92:639-646, 1987 .
501 Raper AJ, Kontos EP, Wei P, Patterson JL. Unresponsiveness of pial pre­
capillary vessels to catecholamines and sympathetic nervous stimulation. Circ 
Res 31:257-266, 1972.
502 Rees DD, Celler S, Palmer RMJ, Moncada S. Dexamethasone inhibits the 
induction by endotoxin of a nitric oxide synthase and the associated effects on 
vascular tone. An insight into endotoxic shock. Biochem Biophys Res 
Commun 173:541-547, 1990.
503 Rees DD, Palmer RMJ, Schultz R, Hodson HF, Moncada S. Characterization of 
three inhibitors of endothelial nitric oxide synthase in vitt'o and in vivo. Br J 
Pharmacol 336:897-900, 1990.
504 Rennels ML, Nelson E. Capillary innervation of the mammalian central nervous 
system: an electron microscopic demonstration. Am J Anat 144:233-234, 1975.
505 Revest PA, Abbott NJ, Gillespie JI. RM changes in intracellular calcium in 
cultured rat brain capillary endothelial cells. Brain Research 549(1): 159-161 
1991.
506 Rhodin JAG. Architecture of the vessel wall. In Handbook o f physiology, 
section 2, The cardiovascular system, vol III, Vascular Smooth Muscle, Bohr DF, 
Somlyo AP, Sparks HV Jr, Geiger SR (eds) Betheseda, Maryland: American 
physiological society, 1980, pp 1-31.
507 Roberts AB, Roche NS, Winokur TS, Burmester JK, Sporn MB. Role of 
transforming growth factor-)) in maintenance of function of cultured neonatal 
cardiac myocytes. J Clin Invest 90; 2056-2062, 1992.
326
508 Roberts A, Vodovotz BY, Roche NS, Sorn MB, Nathan CF. Role of nitric oxide 
in antagonistic effects of TGFp and IL-ip on the beating rate of cultured cardiac 
myocytes. Mol Endocrinol 6:1921-1930,1992.
509 Rodriguez Y, Baena R, Giaetani P et al. Cisternal lumbar cerebrospinal fluid 
concentration of araehidonate metabolism in vasospasm following subarachnoid 
haemorrhage from ruptured aneurysm: biochemical and clinical considerations, 
Surg Neurol 24:428-432, 1985.
510 Rona G. Editorial review: catecholamine cardiotoxocity. J  Mol Cell Cardiol 17: 
291-306, 1985.
511 Rosenblum WI. Cerebral arteriolar spasm inhibit by adrenergic blocking 
agenst. Arch Neurol 21:296-302, 1969.
512 Rosenblum WI. Pial arteriiolar responses in mouse brain revisited. Stroke 7:283- 
286, 1976
513 Rosenblum WI: Contractile responses of pial arterioles in gerbils with unilateral 
carotid ligation. Stroke 12(1) 83-85, 1981.
514 Rosenblum WI. Endothelial dependent relaxation demonstrated in vivo in 
cerebral arterioles. Stroke 17:494-497, 1986.
515 Rosenblum WI, Nelson GH, Povlishock. Laser induced endothelial damage 
inhibits endothelial dependent relaxation in the cerebral microcircualtion of the 
mouse. Circ Res 60(2): 169-176, 1987.
516 Rosner MJ, Newsome HH, Becker DP. Mechanical brain injury: the 
sympathoadrenal response. J Neurosurg 61:76-86, 1984.
517 Rothwell NJ, Hopkins SJ. Cytokines and the nervous system II: actions and 
mechanisms of action. Trends Neurosci 18:130-136, 1995.
518 Rousseaux P, Scherpereel B, Bernard MH, et al. Fever and cerebral vasospasm 
in ruptured intracranial aneurysms. Surg Neurol 14:459-65, 1980.
519 Rüegg JC. In Human Physiology 20th Ed, Schmidt RF, Thews G (eds) Springer- 
Verlag, Berlin, Heidelberg, New York, 1983, Ch 2, pp32-51.
520 Ruskoaho H, Lang RE, Toth M, Ganten D, Unger T. Release and regulation of 
atrial natriuretic peptide. Eur Heart J 8(SB):99~109, 1987.
521 Sagher O, Zhang XQ, Szeto W et al. Live computerized videomicroscopy of 
cerebral microvessels in brain slices. J Cereb Blood Flow & Metab 13:676-682, 
1993.
522 Sahar A. The effect of pressure on the production of cerebrospinal fluid by the 
choroid plexus. J  Neurol Sci 16:49-58, 1972.
523 Sahlin CH, Owman CH, Chang JY, Delgado T, Salford LG, Svendgaard NA: 
Changes in contractile response and effect of a calcium antagonist, nimodipine, in 
isolated intracranial arteries of baboon following experimental subarachnoid 
haemorrhage. Brain Res Bull 24(3):355-361, 1990.
524 Sakaki S, Ohue S, Kohno K, Takeda S. Impairment of vascular reactivity and 
changes in intracellular calcium and calmodulin levels of smooth muscle cells in 
canine basilar arteries after subarachnoid haemorrhage. Neurosurgery 25(5):753- 
761, 1989.
525 Sakakibara Y, Fugiwara M, Muramatsu I. Pharmacological characterization of 
the a  adrenoreceptors dog basilar artery. Naunyn-Schmiederbergs Arch 
Pharmacol 319:1-7, 1981
327
526 Sano K, saito I. Early operation and washout of blood clots for prevention of 
cerebral vasospasm. In Cerebral arterial spasm, Wilkins RH (ed), Baltimore, 
Williams and Wilkins, 1980, pp 510-513.
527 Sano K. Cerebral vasospasm as a deficiency syndrome: In Cerebral Vasospasm, 
Wilkins RH (ed), Raven press. New York, 1988, pp 285-295.
528 Sasaki T, Asano T, takakura K, et al. Nature of the vasoactive substance in 
cerebrospinal fluid firom patients with subarachnoid haemorrhage. J Neurosurg 
60:1186-1191, 1984.
529 Sasaki S, Ohue S, Kohno K, Takeda S. Impairment of vascular reactivity and 
changes in intracellullar calcium and calmodulin levels of smooth muscle cells in 
canine arteries after subarachnoid haemorrhage. Neurosurgery 25(5):753-761, 
1989.
530 Schaller C, Rohde V, Meyer B, Hassler W: Amount of subarachnoid blood and 
vasospasm: current aspects. A transcranial Doppler study. Acta Neurochir 
136(l-2):67-71, 1995.
531 Schievink WI, Schaid DJ, Michels W, Piepgras DG. Familial aneurysmal 
subarachnoid haemorrhage. A community based study. J Neurosurg 83(3):426- 
429, 1995.
532 Schrader H, Krogness K, Aakvaag A, Sortland O, Purvis K. Changes of pituitary 
hormones in brain death. Acta Neurochir (Wien) 52:239-248, 1980.
533 Schrader H, Hall C, Zetnow NN. Effects of prolonged supratentorial mass 
expansion on regional blood flow and cardiovascular parameters during the 
Cushing response. Acta Neurol Scand 72:283-294, 1985.
534 Schrader H, Zetnow NN, Morkid L. Regional cerebral blood flow and 
cerebrospinal fluid pressures during Cushing response induced by a supratentorial 
expanding mass. Acta Neurol Scand 71:453-463, 1985.
535 Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a 
calcium independent nitric oxide synthase in the myocardium. Br J Pharmacol 
105:575-80, 1992.
536 Segal MB, Zlokovic BV. In The blood-brain barrier, amino acids and peptides, 
Kluwer academic publishers, Dordrecht, Boston, London, 1990.
537 Segawa H, Saito I, Okada T, Nagayama I, Kitamura K, Takakura K, Sano K. 
Efficacy of intracistemal papaverine on symptomatic vasospasm. In Cerebral 
Vasospasm, Wilkins RH (ed). Raven press. New York, 1988, pp 433-441.
538 Seiler RW, Grolimund P, Auslid R et al. Relation of cerebral vasospasm 
evaluated by trans-cranial doppler ultrasound to clinical grade and CT-visualized 
subarachnoid haemorrhage. J Neurosurg 64:594-600, 1986.
539 Seifert V, Stolke D, Kuntz U, Resch K. Influence of blood volume on 
cerebrospinal fluid levels of arachidonic acid metabolites after subarachnoid 
haemorrhage: experimental study on the pathogenesis of cerebral vasospasm. 
Neurosurgery 23(3);313-321, 1988.
540 Seifert V, Eisert WG, Stolke D, Goetz C. Efldcacy of single intracistemal bolus 
injection of recombinant tissue plasminogen activator to prevent delayed cerebral 
vasospasm after experimental subarachnoid haemorrhage. Neurosurgery 
25(4): 590-598, 1989.
541 SeiroV. Über die Messung des intraduralen reserveraums. Acta Chir Scand 89: 
139,1943.
328
542 Sellke FW, Shafique T, Johnson RG, Daj H-B, Banitt PF, Schoen FJ, Weintraub 
RM. Blood- and albumin-cardioplegia preserve endothelial dependent 
microvascular responses. Ann Thorac Surg 55:977-985, 1993.
543 Shabo AL, Maxwell DS. Electron microscopic observations of particulate matter 
in the cerebrospinal fluid. J  Neurosurg 29:464-474, 1968.
544 Shah AM, Spurgeon H, Sollot SJ, Talo A, Lakatta EG. 8-Bromo cGMP reduces 
the myofilament response to calcium in intact cardiac myocytes. Circ Res 
74:970-978, 1994.
545 Shigeno T. Norepinephrine in cerebrospinal fluid patients with cerebral 
vasospasm. J  Neurosurg 56:344-349, 1982.
546 Shigeno T, Fritschka E, Brock M, Schramm J, Shigeno S, Cervos-Navarro J: 
Cerebral oedema following experimental subarachnoid haemorrhage. Stroke 13 
(3):368-379, 1982.
547 Shigeno T, Mori K, Saito I, Sano K, BrockM. Early operation of ruptured 
cerebral aneuiysms: the role of norepinephrine in subarachnoid haemorrhage and 
experimental vasospasm. In Advances in Neurosurgery vol 9, Schiefer M. Klinger 
M BrockM (eds) Berlin-Heidelberg-New York, Springer, 1981, pp 189-96.
548 Shiguma M. Change in the ionic environment of cerebral arteries after 
subarachnoid haemorrhage. Neurol Med Chir (Tokyo)22:805-812, 1982.
549 Shiki K, Hearse DJ. Preconditioning of ischaemic myocardium-reperfusion- 
induced arrhythmias. Am J  Physiol 253:H1470-1476, 1987.
550 Shimokawa H, Flavahan NA, Lorenz RR, Vanhutte PM Prostacyclin releases 
endothelial derived relaxaing factor and potentiates its action in the coronary 
arteries of the pig. Br J  Pharmacol 95:1197-1203, 1988.
551 Shirahase H, Fujiwara M, Usui H, Kurahashi K. A possible role of thromboxane 
A2 in endothelium in maintaining resting tone and producing contractile 
response to acetylcholine and arachidonic acid in canine cerebral arteries. Blood 
Vessels 24:117-119, 1987.
552 Shivalkar B, Van Loon J, Wieland W, Tjandra-Maga TB, Borgers M, Piets C, 
Flameng W. Variable effects of explosive or gradual increase of intracranial 
pressure on myocardial structure and function. Circulation 87:230-239, 1993.
553 Sivakumar V, Rajshekhar V, Chandy MJ. Management of neurosurgical patients 
with hyponatraemia and natriuresis. Neurosurgery 34(2):269-273, 1994.
554 Smith RR, Glower BR, Grotendorst GM, Yabuno N, Cruse JM. Arterial wall 
changes in early human vasospasm. Neurosurgery 16(2): 171-176, 1985.
555 Smith RR, Glower BR, Honma Y, Gruse JM. The constrictive angiopathy of 
subarachnoid haemorrhage: an immunopathological approach. In Cerebral 
Vasospasm, Wilkins RH (ed). Raven press. New York, 1988, pp 247-252.
556 Smith RR, Miller JD. Pathophysiology and clinical evaluation of subarachnoid 
haemorrhage. In Neurological Surgery 3rd Ed, Youmans JR (ed), WB Saunders 
Go, Harcourt Brace Jovanovich, Inc, Philadelphia, London, Toronto, Montreal, 
Sydney, Tokyo,1990 Vol 2, Gh 53, pp 1644-60.
557 SolokoffL. The action of drugs on the cerebral circulation. Pharm Rev 11:1-85, 
1959.
558 Solomon RA, Antunes JL, Ghen RYZ, Bland L, Ghien S. Decrease in cerebral 
blood flow in rats after experimental subarachnoid haemorrhage: a new animal 
model. Stroke 16:1,1985.
329
559 Soloman RA, Post KD, Me Murty JG. Depression of circulating blood volume in 
patients after subarachnoid haemorrhage. Implications for the management of 
symptomatic vasospasm. Neurosurgery 15:354-365, 1984.
560 Stehbens WE: The role of plasma elastase in elastin degeneration in the 
superficial temporal arteries and cerebral aneurysms. Letter to the Editor. 
Neurosurgery (Unpublished).
561 Steiner L, Lofgren J, ZwetnowNM. Characteristics and limits of tolerance in 
repeated subarachnoid haemorrhage in dogs. Acta Neurol Scand 52:241-267, 
1975.
562 Stoner HB. A role for the central nervous system in the response to trauma. In 
The scientific basis for the care o f the critically ill. Little RA and Frayn KN 
(eds) Biddles Ltd, Guildford and Kings Lynn, 1986 Ch 14 pp 215-229.
563 Stromberg DD, Fox JR. Pressures in the pial arterial microcirculation of the cat 
during changes in systemic arterial pressure. Circ Res 31:229-239, 1972.
564 StryerL. \n Biochemistry, 2nd Ed, W.H. Freeman and Co., San Fransisco,
565 Summerville LE, Hartsthorne DJ. Intracellular calcium and smooth muscle 
contraction. Cell calcium 7:353-364, 1986.
566 Sun H, Kanamura K, Ito M, Suzuki H, Kojima T, Waga S, Kureishi Y, Nakano T: 
Mysoin light chain phosphorylation and contractile proteins in a canine two- 
hemorrhage model of subarachnoid hemorrhage. Stroke 29:2149-2154, 1998.
567 Sunbarget G, Ponten U. Intracranial pressure and cerebrospinal fluid absorption 
impairmnent after subarachnoid haemorrhage. In Intracranial pressure III Becks 
JWF, Bosch DA, Brock M(eds), Springer Berlin, Heidelberg New York, 1976, pp 
139-146.
568 Sundt TM Jr, Winkelmann RK. Humoral responses of smooth muscle from rabbit 
subarachnoid arteries compared to kidney, mesenteric, lung, heart and skin 
vasospasm. Stroke 3:717-725, 1972.
569 Sutter B, Suzuki S, Arthur AS, Kassell NF, Lee KS. Effects of subarachnoid 
haemorrhage on vascular responses to calcitonin gene-related peptide and its 
second messengers. J  Neurosurg 83(3):516-521, 1995.
570 Suzuki J, Onuma T, Yoshimoto T. Results or early operations on cerebral 
aneurysms. Surg Neurol 11:407-412, 1979.
571 Suzuki Y, McMaster D, Lederis K et al. Characterization of the relaxant effects 
of vasoactive intestinal peptide (VIP); and PHI on isolated brain arteries. Brain 
Res 322:9-16, 1984.
572 Suzuki Y, Satoh S, Lederis K, Rorstad O. Cardiovascular effects of peptide 
histidine methionine in canine and bovine species. Pharmacolcogy 42(5):241-245
1991.
573 Suzuki S, Takenaka K, Kassell NF, Lee KS. Haemoglobin augmentation of 
interleukin-ip-induced production of nitric oxide in smooth-muscle cells. J  
Neurosurg 81:895-901, 1994.
574 Svengaad NA, Edvinsson L, Owman CH, Sahlin CH. Increased sensitivity of the 
basilar artery to norepinephrine and SHydroxytryptamine following experimental 
subarachnoid haemorrhage. Surg Neurol 8:191-195, 1977.
575 Svendgaard NA, Brismar J, Delgado TJ, Rosengren E. Subarachnoid 
haemorrhage in the rat: effect on the development of vasospasm of selective 
lesions of the catecholamine systems in the lower brain stem. Stroke 16(4): 602- 
608, 1985.
330
576 Symon L An experimental study of traumatic cerebral vasospasm. J Neurol 
Neurosurg Psy 30:497-505, 1967
577 Symon L. Experimental features and therapeutic implications of "intracerebral 
steal". In Research on the cerebral circulation, Meyer JA, Reivich M, Lechner 
H, Eichorn O (Eds). Springfield, 111, Charles C thomas, 1970, p 80-5.
578 Szabo C, Emils son K, Hardebo IE, Nystedt S, Owman C. Uptake and release of 
serotonin in rat cerebrovascular nerves after subarachnoid haemorrhage. Stroke 
23(10):54-61, 1992.
579 Tagashira Y, Matsuda M, Welch KMA, Chabi E, Meyer JS. Effects of cyclic 
AMP and dibutyryl cyclic AMP on cerebral haemodynamics and metabolism in the 
baboon. J Neurosurg 46:484-493, 1977.
580 Takahashi I, Abumiya T, Imamura H, Saitoh H, Nomura M, Hokin K,Abe H. A 
case of posttraumatic delayed cerebral arterial spasm: case report and review of 
the literature on the pathogenesis. No Shink Geka. Neurological surgery 20(2): 
161-164, 1992.
581 Takayasu M, Dacey RG Jr. Spontaneous tone of cerebral parenchymal arterioles: 
a role in cerebral hyperemic phenomena. J Neurosurg 71:711-717, 1989.
582 Takenaka K, Kishino J, Yamada H, Sakai N, Arita H, Okano Y, Nozawa Y.
DNA synthesis and intracellular calcium elevation in porcine cerebral arterial 
smooth muscle cells by cerebrospinal fluid from patients with subarachnoid 
haemorrhage. Neurol res 14(4) 330-334, 1992.
583 Talacchi A. Sequential measurements of cerebral blood flow in the acute phase of 
subarachnoid haemorrhage. J Neurol Sci 37(1):9-18, 1993.
584 Tanabe Y, Sakata K, Yamada H, Ito T, Takada M. Cerebral vasospasm and 
ultrastructural changes in cerebral arterial wall. J Neurosurg 49:229-238, 1978.
585 Tanaka Y, Kassel NT, Machi T, Toshima M, Dougherty DA. Effect of bilimbin 
on rabbit cerebral arteries in vivo and in vitro. Neurosurgery 30(2): 195-201 
1992
586 Tanaka Y, Kassell NF, Machi T, Toshima M, Dougherty DA. Effect of bilirubin 
on rabbit cerebral arteries in vivo and in vitro. Neurosurgery 30(2): 195-201,
1992.
587 Tani E, Yamagata S, Ito Y. Intercellular granules and vesicle in prolonged 
cerebral vasospasm. JNeurosurg 48:179-189, 1978.
588 Tanishima T. Cerebral vasopsasm: comparison of contractile responses in isolated 
human and canine basilar arteries. Brain and nerve 35:323-329, 1983.
589 Tatemichi TK, Mohr JP. In: Stroke: pathophysiology, diagnosis, and 
management, Barnet HIM, Mohr JP, Stein BM, Yatsu FM (Eds) Churchill 
Livingstone, New York, Edinburgh, London, Melbourne, Tokyo, 1992, pp 761- 
785.
590 Tenjin H, Hirakawa K, Mizukawa N, Yano I, Ohta T, UchiboriM, Hino A. 
Dysautoregulation in patients with ruptured aneurysms: CBF measurements 
obtained during surgery by a temp-controlled thermo-electric method. 
Neurosurgery 23(6):705-709, 1988.
591 Thelen KI, Dembinska-Kiec A, Pallapies D, Simmet T, Peskar BA. Effect of 3- 
morphlinosydnonimine (SIN-1) and Ng-nitro-L-argining (NNA) in isolated 
perfused anaphylactic guinea pig hearts. Nauny Scmiedebergs Arch Pharmcol 
345(l):93-99, 1992.
331
592 Thomas D, Crockard A. In Neurosurgery: the scientific basis o f clinical 
practice, Crockard A, Hayward R, Hoff IT, Blackwell scientific publications, 
Oxford, London, Edinburgh, Boston, Palo Alto, Melbourne, 1985, Ch 13: pp 
223-308..
593 Thomas VH, Hopkins II. Artériographie demonstration of vascular lesions in the 
study of neurological deficit in advanced Haemohpilus influenzae meningitis. 
Develop Med Child Neurol 14:783-787, 1972.
594 Thornton JD, Daly JP, Cohen MV, Yang XM, Downey JM. Catecholamines can 
induce adenosine receptor-mediated protection of the myocardium but do not 
participate in ischaemic preconditioning in the rabbit. Circ Res 73:649-655,
1993.
595 Tindall GG, Greenfield JC. The effects of intra arterial histamine on blood flow in 
the internal and external carotid artery of man. Stroke 4:46-49, 1973.
596 TodaN, Fujita Y. Responsiveness of isolated cerebral and peripheral arteries to 
serotonin, NE, and transmural electrical stimulation. Cir Res 33:98-104, 1973.
597 Toda N. The action of vasodilatory drugs on isolated basilar, coronary and 
mesenteries arteries of the dog. J Pharm Exp Ther 191:139-146, 1974.
598 TodaN, Ozaki T, Ohta T. Cerebrovascular sensitivity to vasoconstricting agents 
induced by subarachnoid haemorrhage and vasospasms in dogs. J Neurosurg 46: 
296-303, 1977.
599 TodaN, Ozaki T, Ohta T, Cerebrovascular sensitivity to vasoconstricting agents 
induced by subarachnoid haemorrhage and vasospasm in dogs. J Neurosurg 46. 
296-303, 1977.
600 Toda N. Alpha adrenergic receptor subtypes in human, monkey and dog cerebral 
arteries. J Pharmacol Exp Ther 226:861-868, 1983.
601 Toda N. Mechanisms of contracting action of oxyhaemoglobin in isolated 
monkey and dog cerebral arteries. AM J Physiol 258;H57-63, 1990
602 Todd GL, Baroldi G, Pieper GM, Clayton FC, Eliot RS. Experimental 
catecholamine induced myocardial necrosis, I Morphological, quantification and 
regional distribution of acute contraction band lesions. J Mol Cell Cardiol 
7:317-338,1985.
603 Torner JC, Kassell NF, Wallace RB, Adams HP Jr. Pre-operative prognostic 
factors for rebleeding and survival in aneurysm patients receiving antifibrinolytic 
therapy: report of the cooperative aneurysm study. Neurosurgeiy 9:506-513, 
1981.
604 Tsuji T, Cook DA. Mechanism of vascular responses to 5HT in isolated and 
perfused canine basilar arteries during the early stage of experimental 
subarachnoid haemorrhage. In Cerebral Vasospasm, Wilkins RH (ed). Raven 
press. New York, 1988, pp 105- 111.
605 Tsuji T, Cook DA, Weir BKA, Handa Y: Effect of clot removal on 
cerebrovascular contraction afl;er subarachnoid hemorrhage in the monkey: 
pharmacological study. Heart & Vessels 11:69-79,1996.
606 Tsujino M, Hirata Y, Imai T, Kanno K, Eguchi S, Ito H, Marumo F. Induction of 
NOS gene by 11-1(3 in cultured rat cardiocytes. Circulation 90:375-383, 1994.
607 Tsukahara T, Taniguchi T, Fujiwara M, Handa H, Nishikawa M. Alterations in 
Alpha adrenergic receptors in human cerebral arteries after subarachnoid 
haemorrhage. Stroke 16(1) 53-58, 1985.
332
608 Tsukahara T, Yoshimura S, Kazekawa K, Hashimoto N. Intra-arterial papaverine 
for the treatment of cerebral vasospasm after subarachnoid haemorrhage. J 
Auton Nerv Sys 49(suppl s): 163-166, 1994.
609 Tsutsui T, Maekawa T, Goodchild C, Jones JG. Cerebral blood flow distribution 
during hypotension with haemorrhage, trimethaphan or nitroprusside in rats. Br J 
Anaesth 74(6);686-690, 1995.
610 Udenfriend S, Weissbach H. Studies in serotonin (5HT) in platelets. Fed Proc 
13:412-413, 1954.
611 Ueno M, Lee TJ-F. Endotoxin decreases the contractile responses of the porcine 
basilar artery to vasoactive substances. J Cerebr Blood Flow & Metab 13:712- 
719, 1993.
612 Urabe K, Miura TM, Iwamoto TI, Ogawa T, Goto M, Sakamoto J, Limura O. 
Preconditioning enhances myocardial resistance to post-ischaemic myocardial 
stunning via adenosine receptor activation. Cardiovasc Res 27:657-662, 1993.
613 Urquilla PR, Marco EJ, Lluch S. Pharmacological receptors of the cerebral 
arteries of the goat. Blood Vessels 12:53-67, 1975.
614 Urquilla PR. Prolonged contraction of isolated human and canine cerebral 
arteries induced by UTP, Stroke 9:133-136, 1978.
615 Ursino M. Regulation of the circulation of the brain, in: The human brain 
circulation: functional changes in disease, Bevan RD, Bevan JA (Eds), Humana 
press, Totowa, New Jersey, 1994, pp 291-318.
616 Usui H, Kurahashi K, Shirahase H, Fukui K, Fujiwara M. Endothelial dependent 
vasoconstriction in response to NE in the canine cerebral artery. Jpn J 
Pharmacol 44:228-231, 1987
617 van Gelderen EM, De Bruijne EL, Agteresch HJ, Saxena PR The effect of NO 
donors on haemodynamics and blood flow distribution in the porcine carotid 
circulation. Br J Pharm 114(6): 1303-1309, 1995
618 Vanhoutte PM, Rubanyi GM, Miller VM et a l . Modulation of vascular smooth 
muscle contraction by the endothelium. Ann Rev Physiol 48:307-320, 1986.
619 Vanhoutte PM, Houston DS. Platelets, endothelium and vasospasm. Circulation 
72:728-734,1985.
620 Van Riper DA. Norepinephrine and neuropeptide Y as neurotransmitters to 
cerebral arteries. In: The human brain circulation: functional changes in disease, 
Bevan RD, Bevan JA (Eds), Humana press, Totowa, New Jersey, 1994, pp 61-72.
621 Van Vliet PD, Burchell HB, Titus JL. Focal myocarditis associated with 
phaeochromocytoma. N Eng J Med 274:1102-1108, 1966.
622 Vardiman AB, Kopitnik TA, Purdy PD, Batjer HH, Samson DS. Treatment of 
traumatic arterial vasospasm with intra-arterial papaverine infusion. AM J 
Neuroradiology. 16(2):319-321, 1995
623 Varsos VG, Liszczak TM, Han DH, et al. Delayed cerebral vasospasm is not 
reversible by aminophylline nifedipine or papaverine in a "two haemorrhage" 
canine model. JNeurosurg 58:11-17, 1983.
624 Vatner DE, Vatner SF, Nejima J, Uemura N, Susanni EE, Hintze TH, Homey CJ. 
Chronic NE elicits desensitization by uncoupling the P receptor. J Clin Invest 
84:1741-1748, 1989.
625 Veelken JA, Laing RJ, Jakubowski J. The Sheffield Model of subarachnoid 
haemorrhage in rats. Stroke 26(7): 1279-1283, 1995.
333
626 Verstraete M. New thrombolytic drugs in acute myocardial infarction; theoretical 
and practical considerations. Circulation 76(suppl II): 31-38, 1987
627 Vicaut E. Hypertension and the microcirculation: a brief overview of 
experimental studies. J Hypertension 10(S5):S59-S68, 1992.
628 Villamor E, Perez-Vizcaino F, Ruiz T, Leza JC, Moro M, Tamargo J. Group B 
streptococcus and E. Coli lipopolysaccharide-induced NO-dependent 
hyporesponsiveness to norepinephrine in isolated intrapulmonary arteries of 
neonatal piglets. Br J Pharm 115:261-266, 1995.
629 Vinall PE, Simeone FA. A pressurized cannulated in vitio model for the study of 
cerebral arterial mechanics. In Cerebral Vasospasm, Wilkins RH (ed). Raven 
press. New York, 1988, pp 449-445.
630 Vincent FM. Hypoglycorrhachia after subarachnoid haemorrhage.
Neurosurgery 8:7-9, 1981.
631 Viquerat CE, Daly P, Swedberg K, Evers C, Curran D, Parmely WW, Chaterjee 
K. Endogenous catecholamine levels in chronic heart failure Relation to the 
severity of haemodynamic abnormalities. Am JMed 78:455-460, 1985.
632 Voldby B. Pathophysiology of subarachnoid haemorrhage. Experimental and 
Clinical data. Acta Neurochir suppl 45:1-6, 1988.
633 Vollrath BAM, Weir BKA, MacDonald RL, Cook DA. Intracellular 
mechanisms involved in the responses of cerebrovascular smooth-muscle cells 
to haemoglobin. J Neurosurg 80:261-268, 1994.
634 Vollmer DG, Jane S, Torner JC, Kassell NF. Intracistemal papavevrine reverses 
experimental cerebral vasospasm in a rabbit model. In Cerebral Vasospasm, 
Wilkins RH (ed). Raven press. New York, 1988, pp425-431.
635 Vollmer DG, Takayasu M, Dacey RG Jr. An in viti'o comparative study of 
conducting vessels and penetrating arterioles after experimental subarachnoid 
haemorrhage in the rabbit. JNeurosurg 77(1): 113-119, 1992.
636 von Bergmann E. In Die Lehre von de Kopfuerletzungen 1880. F. Erike 
Stuttgart.
637 Vorkapic P, Bevan JA, Bevan RD: Clentiazem protects against chronic cerebral 
vasospasm in rabbit basilar artery. Stroke 22:1409-1413, 1991.
638 Vorkapic P, Bevan JA, Bevan RD. Two indicies of functional damage of the 
artery wall parallell the time course of irreversible narrowing in experimental 
vasospasm in the rabbit. Blood Vessels 28(1-3): 179-182, 1991
639 Walmsley JG, Campling MR, Chertkow HM. Interrelationships among wall 
structure, smooth muscle orientation, and contraction in human major cerebral 
arteries. Stroke 14(5):781-790, 1983.
640 Wang J, Ohta S, Sasaki S, Araki N, Matsuda S, Sakanaka M. Changes in Ca"*^ - 
ATPase activity in smooth-muscle cell membranes of the canine basilar artery with 
experimental subarachnoid haemorrhage. J Neurosurg 80:269-275, 1994.
641 Waters A, Harder DR. Altered membrane properties of cerebral vascular smooth 
muscle following subarachnoid haemorrhage: an electrophysiological study. I 
Changes in resting membrane potential (Em) and effect on the electrogenic pump 
potential contribution to Em. Stroke 16(6): 990-997, 1985.
642 Waters VE, O'Connor PJ. Prevalence of migraine. J Neurol Neurosurg Psych 
38:613, 1975.
643 Watters JW. The effects of bradykinin and histamine on cerebral arteries of 
monkeys. Radiology 98:299-304, 1971
334
644 Weaver DD, Winn HR, Jane JA. Differential intracranial pressure in patients with 
unilateral mass lesions. J  Neurosurg 56:660-665, 1982.
645 Weinberg JB, Hibbs JB Jr. Endocytosis of red cells or haemoglobin by activated 
macrophages inhibited their tumorcidal effect. Nature (Loud) 269:245-247, 
1977.
646 Weinand ME, O'Boynick PL, Goetz KL. A study of serum anti-diuretic hormone 
and atrial natriuretic peptide levels in a series of patients with intracranial disease 
and hyponatraemia. Neurosurgery 25(5):781-785, 1989.
647 Weir B, Grace M, Hansen J et al. Time course of vasospasm in man. J 
Neurosurg 48:173-8, 1978.
648 Weisensee D, Bereiter-Hahn J, Schoeppe W, Low-Friedrich I. Effects of 
cytokines on the contractility of cultured cardiac myocytes. lut J 
Immunopharmacol 51:581-587, 1993.
649 Weissbach H, Bogdanski DF, Undenfriend S. Binding of serotonin and other 
amines by blood platelets. Arch Biochem Biophys 73:492-499, 1958.
650 Wellum GR, Irvine TW, Zervas NT. Dose responses of cerebral arteries of the 
dog, rabbit and man to human haemoglobin in vitro. J Neurosurg 53:486-490, 
1980.
651 West CGH: Intra-operative brain swelling: letter to the Editor. Br J Neurosurg 
4(4):358, 1990.
652 White RP, Hagen AA, Morgan H et al. Experimental study on the genesis of 
cerebral vasospasm. Stroke 6:52-57, 1975.
653 White RP. Vasospasm II. Clinical considerations. In Intracranial aneurysms. 
Fox JL (ed) New York, Springer-Verlag, 1983, pp250-271.
654 White RP, MacLeod RM, Muhlbauer MS. Evaluation of the role haemoglobin in 
cerebrospinal fluid plays in producing contraction of cerebral arteries. Surg 
Neurol 27:237-242, 1987.
655 White RP. Pharmacodynamic features of delayed cerebral vasospasm. In 
Cerebral Vasospasm, Wilkins RH (ed). Raven press. New York, pp373-382,
1988.
656 White M, Wiechmann RJ, Roden RL, Hagan MB, Wollmering MM, Port JD, 
Hammond E, Abraham WT, Wolfel EE, Lindenfield J, Fullerton D, Bristow MR. 
Cardiac (3 adrenergic neuroeffector systems in acute myocardial dysfunction 
related to brain injury. Evidence for catecholamine mediated myocardial damage. 
Circulation 92:2183-2189, 1995.
657 Wiebers DO: Unruptured intracranial aneurysms -  risk of rupture and risks of 
surgical intervention. The international study of unruptured intracranial 
aneurysms investigators. NE JM 339(24): 1725-33, 1998.
658 Wilkins RH, Levitt P. Potassium and the pathogenesis of cerebral arterial spasm 
in dog and man. J Neurosurg 35:45-50, 1971.
659 Wilkinson HA. In Neurological Surgery 3rd Ed, Youmans JR (ed) 1990, WB 
Saunders Co, Harcourt Brace Jovanovich, Inc, Philadelphia, London, Toronto, 
Montreal, Sydney, Tokyo Vol 2 Ch 23 pp 661-695, 1990.
660 Wilkonson HA, Wilson RB, Patel PP et al. Corticosteroid therapy of 
experimental hydrocephalus afl:er intraventricular subarachnoid haemorrhage. J 
Neurol Neurosurg Psychiatry 37:224-229, 1974.
335
661 Willette RN, Zhang H, Mitchell MP; Nonpeptide endothelin antagonist. 
Cerebrovascular characterization and effects on delayed cerebral vasospasm. 
Stroke 25:2450-6, 1994.
662 Willette RN, Shiloh AO, Sauermelch CF: Identification, characterization, and 
fimctional role of phosphodiesterase type IV in cerebral vessels: effects of 
selective phosphodiesterase inhibitors. J Cereb Blood Flow & Metab 17:210- 
219, 1997.
663 Witzleb E; In Schmidt RF, Thews G (eds). In Human Physiology 20th Ed. Ch 18 
p 404, 1984.
664 Wolfe BB, Molinoff PB. In Catecholamines vol /, Handbook of experimental 
pharmacology, Springer-Verlag, Berlin, Heidelberg, New York, 90, pp 376- 
392,1989.
665 Woolf PD, Hamill RW, Lee LA, Cox C, MacDonald IV. The predictive value of 
catecholamines in assessing outcome in traumatic brain injury. J Neurosurg 
66:872-882, 1987.
666 Wright IK, Armichetty-Rao S, Kendall DA. Forskolin potentiates both SNP and 
ANP-stimulated cGMP accumulation in porcine isolated palmar lateral veins. Br 
J Pharm 112. 542P, 1994
667 Yakubu MA, Shibata M, Leffler CW. Subarachnoid haematoma attenuates 
vasodilation and potentiates vasoconstriction induced by vasoactive agents in 
new-born pigs. Paediatric research 36(5): 589-594, 1994.
668 Yamamoto Y, Bemanke DH, Smith RR Accelerated non-muscle contraction 
after subarachnoid haemorrhage: cerebrospinal fluid testing in a culture model. 
Neurosurgery 27(6):921-928, 1990
669 Yamashima T, Yamamoto S. Cerebral arterial pathology in experimental 
subarachnoid haemorrhage. J Neurosurg 58:843-850, 1983.
670 Yamashima T, Kashihara K, Kawano H et al. Myonecrosis following cerebral 
arterial spasm in meningitis: Case report. Neurol Med Chir (Tokyo) 25:818- 
825, 1985.
671 Yanigasawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, 
Yatsaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced 
by vascular endothelial cells. Nature 332:411-415, 1988.
672 Yao S-K, Akhtar S, Scott-Burden T, Ober JC, Golino P, Buja M, Casscelles W, 
Willesron JT. Endogenous and Exogenous NO protect against intracoronary 
thrombosis and reocclusion after thrombolysis. Circulation 92:1005-1010, 1995.
673 Yoshimoto H, Uozumi T. Anterior pituitary dysfunction in cerebrovascular 
disease. Ruptured cerebral aneurysm cases. Neurol Med Chir (Tokyo):25:433- 
439, 1985.
674 Yoshimoto Y, Kim P, Sasaki T, Kirino T, Takakura K: Functional changes in 
cultured strips of canine cerebral arteries after prolonged exposure to 
oxyhemoglobin. JNeurosurg 83:867-74, 1995.
675 Zabramski JM, Spetzler RF, Bonstelle C. Chronic cerebral vasospasm: effect of 
volume and timing of haemorrhage in a canine model. Neurosurgery 18(1): 1-6,
1986.
676 Zervas NT, Liszczak TM, Mayberg MR et al. Cerebrospinal fluid may nourish 
cerebral vessels through pathways in the adventitia that may be analogous to 
systemic vasa vasorum. J  Neurosurg 56:475-481, 1982.
336
677 Zhang F, White JG, ladecola C. NO donors increase blood flow and reduce 
brain damage in focal ischaemia: evidence that NO is beneficial in the early stages 
of cerebral ischaemia. J Cerebr Blood Flow & Metab 14:217-226, 1994
678 Ziche M, Morbidelli L, Parenti S, Amorini HJ, Granger and Ledda P. Nitric 
oxide modulates substance P-induced mobilization of coronary capillary 
endothelial cells. Br J Pharm 111: 103P, 1994.
679 Zweifach BW. In The scientific basis fo r  the care o f the critically ill. Little RA, 
Frayn KN (Eds), Biddles Ltd, Guildford and King's Lynn, 1986, Ch 3, pp 15-32.
680 Zwetnow NN. Effects of increased intracranial pressure on the blood flow and 
energy metabolism of the brain. Acta physiol Scand 79(suppl 339): 1-31, 1970
681 Zuccarello M, Bonasso CL, Sperelakis N, Rappaport RM. Role of membrane 
potential in cerebral vasospasm after sub arachnoid haemorrhage. In Cerebral 
vasospasm, Findlay JM (ed), Amstredam; Elsevier 1993, pp 229-233.
682 Zuccarello M, Romano A, Passalacqua M, Rapoport RM: Decreased 
endothelium-dependent relaxation in subarachnoid hemorrhage-induced 
vasospasm: role of ET-1. Am J Physiol 269(Heart circulation 38):H1009- 
H1015, 1995.
337
r
PUBLICATIONS FROM THIS THESIS
Marshman LAG: Cushing’s variant response (acute hypotension) following 
subarachnoid haemorrhage. Association with moderate intracranial tensions and 
subacute cardiovascular collapse in rats. Stroke 28(7): 1445-1450, 1997.
Marshman LAG, Thompson JS, Morice AH: Increased efficacy of Sodium 
nitroprusside in middle cerebral arteries following acute subarachnoid haemorrhage. J 
Neurosurg Anaesth 10(3): 171-177, 1998.
Marshman LAG: Preserved Contractility without Side Bias in Endovascular 
Filament Models for Subarachnoid Haemorrhage. J Neurosci Meth 117:193-200, 
2002
